LIGAND INFORMATION,,,,,IN VITRO ASSAYS,,,,,,,,,CELL-BASED ASSAYS,,,,,,,,ANIMAL MODELS,,,,,,,,,,,,,,,,,,,,,,,,,,
#,Previous ID #,SMILES,Name,DOI/PMC,Control,Assay Target(s) ,Observation,Ligand Concentration,Buffer,Category,Assay,Method/Notes,Control/Validation,Control,Cell Line,Observation,Ligand Concentration,Category,Assay,Method/Notes,Control/Validation,Control,Organism,Observation,Ligand Concentration/Administration,Category,Assay,Method/Notes,Control/Validation,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,"165 ribD FMN Riboswitch Aptamer, B. subtilis ",T50 = 0.5 µM,"Ligand = 6 nM - 100 µM, 4-fold intervals","80 mM Tris-HCl (pH = 8.0), 20 mM NaCl, 5 mM MgCl2, 0.1 mM EDTA, and 0.01 mg/ml BSA",Activity,Transcription Termination,T50 = concentration of compound to induce half-maximal transcription termination,Compared to native ligand FMN,,C. difficile VPI 10463 (ATCC 43255),"99.9% reduction in viable density to 1.7 X10^3 and 8.0 X10^3 CFU/mL at 4 hours; Reduced levels below 200 CFU/mL, limit of quantitation, at 6 hours",Ligand = 4- or 8-fold higher than MIC,Antimicrobial Activity,Time-Kill,-,Compared to Fidaxomicin and Vancomycin,,CDI mouse model (C57BL/6 mice),Prevented any weight loss,Oral; 10mg/kg twice a day for five days,Antimicrobial Activity,Weight Loss,Mice were administered an antibiotic cocktail to disrupt intestinal flora; Oral dose of C. difficile VPI 10463 spores were administered; Compound suspended in aqueous 0.5% methylcellulose,Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,"165 ribD FMN Riboswitch Aptamer, B. subtilis ",Kd = 7.5 nM,-,NR,Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1; Apparent Kd was derived from quantifying RNA cleaved at each nucleotide position,Compared to native ligand FMN,,C. difficile (21 strains),MIC50 and MIC90 = 1 ug/mL,-,Antimicrobial Activity,Broth Microdilution,Included four hyper-virulent North American pulsed-field gel electrophoresis type 1 (NAP1) ribotype 027 strains and 14 isolates from hospital patients,Compared to Fidaxomicin,,CDI mouse model (C57BL/6 mice),Prevented any mortality,Oral; 10mg/kg twice a day for five days,Antimicrobial Activity,Mortality,Mice were administered an antibiotic cocktail to disrupt intestinal flora; Oral dose of C. difficile VPI 10463 spores were administered; Compound suspended in aqueous 0.5% methylcellulose,Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,,C. difficile 630,Similar to C. difficile VPI 10463 (ATCC 43255),Ligand = 4- or 8-fold higher than MIC,Antimicrobial Activity,Time-Kill,Data not shown,-,,CDI mouse model (C57BL/6 mice),"Severe diarrhea developed in one mouse, resolved by day 3",Oral; 10mg/kg twice a day for five days,Antimicrobial Activity,Symptoms,Mice were administered an antibiotic cocktail to disrupt intestinal flora; Oral dose of C. difficile VPI 10463 spores were administered; Compound suspended in aqueous 0.5% methylcellulose,Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,C,"Diverse panel of anaerobic and aerobic bacteria, including common intestinal flora species","No appreciable activity again B. frailis group, Bifidobacterium, Lactobacillus, and Actinomyces species; Little to no activity against other anaerobic Gram-negative rods and aerobic pathogens; Activity against some strains of E. faecalis ",-,Antimicrobial Activity,Broth Microdilution,-,"Compared to fidaxomicin, metronidazole, and vancomycin; Superior to current marketed DCI therapeutic compounds",C,"Female C57BL/6 mice, weight of 18-21 g","Cecal content levels = 192, 204, 174, 86, 82, and 0.3 µg/g at 1, 2, 4, 6, 7, and 24 h after dosing",Oral; 10 mg/kg single dose,Pharmacokinetics,LC-MS,Compound suspended in aqueous 0.5% methylcellulose,Compared to Fidaxomicin  ,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,C,C. difficile,No isolates with a stably increased MIC; Frequency of resistance development is < 1 X 10 ^-9,NR,On-Target Effect,Serial-Passage ,Data not shown,-,C,"Female C57BL/6 mice, weight of 18-21 g",Plasma content level = 23 ng/mL at 1 h and below limit of quantitation at remaining time points,Oral; 10 mg/kg single dose,Pharmacokinetics,LC-MS,Compound suspended in aqueous 0.5% methylcellulose,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,,,,,,,,,C,"Female C57BL/6 mice, weight of 18-21 g",Very little effect on density of cultured cecal flora groups,"Oral; 10, 50 mg/kg single dose",Cecal Flora Disruption,Microbroth Dilution,"C. spiroforme was identified by colony morphology on egg yolk agar, Gram stain, ability to form spores, a unique helical shape, and antimicrobial susceptibility pattern including rifampin resistance",Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,,,,,,,,,C,"Female C57BL/6 mice, weight of 18-21 g",No effect on visible morphology,"Oral; 10, 50 mg/kg single dose",Fecal Flora Disruption,Visible Morphology,-,Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0001,R-BIND (SM) 0001,CC(CCN1C2=CC(C)=C(C)C=C2N=C2C(=O)[N-]C(=O)N=C12)C1=CC=C(F)C=C1,5FDQD,10.1128/AAC.01282-15,,,,,,,,,,,,,,,,,,C,"Female C57BL/6 mice, weight of 18-21 g","5-fold increase in Enterobacteriaceae family; No effect observed for B. fragilis, bifidobacteria, lactobacilli, enterococci, and staphylococci","Oral; 10, 50 mg/kg single dose",Fecal Flora Disruption,Microbroth Dilution,Media selective for each bacterial taxa; Grown at 35 ºC for an appropriate number of days for each medium and bacteria type,Compared to Fidaxomicin and Vancomycin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,"FMN Riboswitch Aptamer, E. coli",Kd = 6.6 ± 2 nM; Kon = 7.5 ± 4 X 10^5 1/M*sec; Koff = 4.4 ± 1.1 X 10^-3 1/sec,-,"50 mM Tris-HCl (pH = 7.4), 100 mM KCl and 2 mM MgCl2 with 0.2% DMSO",Binding,Competitive Binding,Displacement of native ligand FMN,Compared to FMN,,E. coli MB5746,IC50 = 0.013 ± 0.007 µM,-,Metabolic Activity,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,"FMN Riboswitch Aptamer, F. nucleatum",Adopts a U-shaped conformation like FMN and is positioned inside the junctional region of the six RNA stems,Ligand = 1 mM,"1:1 solution of 10 mM cacodylic acid (pH = 6.8), 100 mM acetate, and 4 mM MgCl2 and 0.1 M Na acetate (pH = 5.0), 0.2 M MgCl2, and 7 to 11% v/v PEG 4K",Structure Determination,X-Ray Crystallography,PDB = 5C45,Compared to X-ray co-structures of F. nucleatum riboswitch aptamer with FMN,,E. coli MB5746,MIC = 01 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5008 lpxC,MIC = 8 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5747 tolC::tn10,MIC = 1 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746 tolC::tn10,MIC = 1 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-WT,MIC = 8 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-2 -193 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-17 -317 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-WT,MIC = 1 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-14 -57 mutant,MIC = 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-17 -9 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MSSA RN4220,MIC = 4 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL,MIC = 4 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL ?ribD,No growth,-,Antimicrobial Activity,Broth Microdilution,?ribD is a strain deficient in de novo RF biosynthesis—gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch; Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,E. faecalis,No growth,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,S. pyogenes,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MSSA RN4220, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL ?ribD, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,"Supplemented with riboflavin; ?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch",Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. faecalis, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"S. pyogenes, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0002,R-BIND (SM) 0002,CNC1=NC=C(C[NH+]2CCC[C@@H](C2)C2=NC(=CC(=O)N2)C2=CC=CS2)C=N1,Ribocil-B,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL,IC50 = 0.44 µM,-,Metabolic Activity,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,"FMN Riboswitch Aptamer SA1, S. aureus",Kd = 58 nM,-,"4 mM KH2PO4 (pH = 7.4), 16 mM K2HPO4, 64 mM KCl, and 0.1 mM EDTA",Binding,Competitive Binding,Displacement of native ligand FMN; Determined by dose-dependent changes in FMN fluorescence signal,-,,MSSA RN4220,MIC = 0.5 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,"FMN Riboswitch Aptamer SA2, S. aureus",Kd = 33 nM,-,"4 mM KH2PO4 (pH = 7.4), 16 mM K2HPO4, 64 mM KCl, and 0.1 mM EDTA",Binding,Competitive Binding,Displacement of native ligand FMN; Determined by dose-dependent changes in FMN fluorescence signal,-,,MRSA COL,MIC = 0.5 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,"FMN Riboswitch Aptamer, E. coli",Kd < 1 nM; Kon > 1.3 X 10^5 1/M*sec; Koff > 1.5 X 10^-4 1/sec,-,"50 mM Tris-HCl (pH = 7.4), 100 mM KCl and 2 mM MgCl2 with 0.2% DMSO",Binding,Competitive Binding,Displacement of native ligand FMN,Compared to FMN,,E. coli MB5746,IC50 = 0.023 ± 0.012 µM,-,Metabolic Activity,HPLC,Measured depletion of cellular riboflavin levels,-,,DBA2/J mice; Inoculated with E. coli MB5746,Comparable to sham-treated mice; 9-9.5 log10 CFU/g spleen,Subcutaneous; 30 mg/kg,Antimicrobial Activity,Bacterial Burden,"Broth Microdilution method - spleens removed, weighed, homogenized, serially diluted, and plated; Colony-forming units (CFU)/g determined",Compared to ciprofloxacin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,"FMN Riboswitch, S. aureus SA1 and SA2 and E. coli",Ribocil-C displays a similar binding mode as Ribocil-B; Clear molecular basis for similarity in binding potency,-,-,Structure Determination,Homology Modeling,Modeled using X-ray crystal structure of the F. nucleatum FMN riboswitch complexed with Ribocil-B,,,MRSA COL ?ribD,No growth,-,Antimicrobial Activity,Broth Microdilution,"?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch; Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin",Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746,MIC = 0.25 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,DBA2/J mice; Inoculated with E. coli MB5746,Dose-dependent reduction in bacterial burden; 1.87 and 3.29 log10 CFU/g spleen,"Subcutaneous; 60, 120 mg/kg",Antimicrobial Activity,Bacterial Burden,"Broth Microdilution method - spleens removed, weighed, homogenized, serially diluted, and plated; Colony-forming units (CFU)/g determined",Compared to ciprofloxacin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5008 lpxC,MIC = 2 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",C,DBA2/J mice; Inoculated with E. coli MB5746,No mortality ,"Subcutaneous; 30, 60, 120 mg/kg",Pharmacokinetics,Mortality,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5747 tolC::tn10,MIC = 0.25 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",C,DBA2/J mice; Inoculated with E. coli MB5746,No gross effects of toxicity,"Subcutaneous; 30, 60, 120 mg/kg",Pharmacokinetics,Symptoms,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746 tolC::tn10,MIC = 0.25 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-WT,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-2 -193 mutant,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-17 -317 mutant,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-WT,MIC ? 0.063 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-14 -57 mutant,MIC = 4 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-17 -9 mutant,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,P. aeruginosa ATCC35151 Z61,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,P. aeruginosa MB5890 Multi-efflux,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,A. baumannii ATCC12457 ?lpxA,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,A. baumannii ATCC19606 ?lpxC,MIC > 64 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,S. cerevisiae S288c,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,S. cerevisiae Sc ?pdr5,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,C. albicans CAF2-1 CDR1/CDR1 CDR2/CDR2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,C. albicans DSY448 ?cdr1/?cdr1 CDR2/CDR2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1038/nature15542,,,,,,,,,,,C. albicans DS654 ?cdr1/?cdr1 ?cdr2/?cdr2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,E. faecalis,No growth,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,S. pyogenes,MIC = 8 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MSSA RN4220, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL ?ribD, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,"Supplemented with riboflavin; ?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch",Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. faecalis, riboflavin supplement",MIC = 32 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"S. pyogenes, riboflavin supplement",MIC > 64 µg/mL,Riboflavin = 12.5 nM,Antimicrobial Activity,Broth Microdilution,Supplemented with riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL,IC50 = 0.04 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL mutant WTM6 (SA1),IC50 = 4.6 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL mutant WTM22 (Azo1),IC50 = 0.08 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, riboflavin supplement",0.2 µM Riboflavin sufficient to suppress activity,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAMH agar plates seeded with bacteria and/or riboflavin supplement,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. coli, riboflavin supplement",20 µM Riboflavin required to suppress activity,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAMH agar plates seeded with bacteria and/or riboflavin supplement,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. coli pnuX, riboflavin supplement",No change in susceptibility compared to vector,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAMH agar plates seeded with bacteria and/or riboflavin supplement; Heterologous expression of the C. clutamicum RF transporter,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, 13 resistant isolates",All 11 distinct Roseoflavin-resistant FMN isolates displayed high level resistance with MIC shifts > 32-fold; No cross-resistance to Azo1 or P139S mutants,-,On-Target Effect,Broth Microdilution,"As ribocil-C does not completely inhibit MRSA growth on agar plates, Roseoflavin- resistant MRSA isolates were first characterized and cross-resistance was assessed; Utilized whole genome sequencing",Compared to Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL ?ribD, 23 resistant isolates",Substantial cross-resistance observed,Ligand = 20 µM,On-Target Effect,Broth Microdilution,"As ribocil-C does should poor growth-inhibitory activity against MRSA ?ribD strain in liquid medium, Roseoflavin-resistant MRSA isolates were first characterized and cross-resistance was assessed; The mutants were spotted on cation-adjusted Mueller Hinton (CAMH) agar plates with ligand; Utilized whole genome sequencing; ?ribD is a strain deficient in de novo RF biosynthesis—gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch",Compared to Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0003,R-BIND (SM) 0003,O=C1NC(=NC(=C1)C1=CC=CS1)[C@H]1CCCN(CC2=CN(C=N2)C2=NC=CC=N2)C1,Ribocil-C,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, 13 resistant isolates",Immunodeficient NOD/SCID+Q72,Ligand = 1 µM,On-Target Effect,HPLC,"No more than 2-fold greater levels of FMN and FAD without ligand, concluding resistance does not lead to a striking upregulation of riboflavin synthesis",Compared to DMSO-treated and wild-type expression levels,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.4161/rna.6.2.7727,,"FMN Riboswitch, B. subtilis",Kd = ~100 nM,-,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, 100 mM KCl",Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1,Compared to native ligand FMN and riboflavin,,B. subtilis,Decreased expression to one-fifth of bacteria grown without supplementation,Ligand = 100 µM,Translational Activity,Gene Reporter,Fused to E. coli lacZ gene and clone into the B. subtilis amyE locus; Activity of constructs were very low; Enhanced reporter gene expression by replacing ribD operon promoter of the reporter with B. subtilis lysC gene,Compared to riboflavin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.4161/rna.6.2.7727,,"FMN Riboswitch, S. davawensis",Kd = 10 nM,-,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, 100 mM KCl",Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1,Compared to native ligand FMN and riboflavin,C,"B. subtilis, Mutant 1",Decreased to approximately half the maximum expression level,Ligand = 100 µM,Translational Activity,Gene Reporter,Fused to E. coli lacZ gene and clone into the B. subtilis amyE locus; Activity of constructs were very low; Enhanced reporter gene expression by replacing ribD operon promoter of the reporter with B. subtilis lysC gene; Mutant 1 is a guanosine to adenosine point mutation at position 41,Compared to riboflavin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.4161/rna.6.2.7727,C,"ribD FMN Riboswitch, B. subtilis, Roseoflavin-resistant Mutant 1",Little to no measurable modulation of all 3 sites,Ligand = 10 µM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, 100 mM KCl",Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1,Compared to native ligand FMN and riboflavin,C,"B. subtilis, Mutant 2",Decreased to approximately half the maximum expression level,Ligand = 100 µM,Translational Activity,Gene Reporter,Fused to E. coli lacZ gene and clone into the B. subtilis amyE locus; Activity of constructs were very low; Enhanced reporter gene expression by replacing ribD operon promoter of the reporter with B. subtilis lysC gene; Mutant 2 is a guanosine to adenosine point mutation at position 60,Compared to riboflavin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.4161/rna.6.2.7727,C,"ribD FMN Riboswitch, B. subtilis, Roseoflavin-resistant Mutant 2",Little to no measurable modulation of all 3 sites,Ligand = 10 µM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, 100 mM KCl",Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1,Compared to native ligand FMN and riboflavin,C,"B. subtilis, Mutant 3",No suppression observed,Ligand = 100 µM,Translational Activity,Gene Reporter,Fused to E. coli lacZ gene and clone into the B. subtilis amyE locus; Activity of constructs were very low; Enhanced reporter gene expression by replacing ribD operon promoter of the reporter with B. subtilis lysC gene; Mutant 3 is a guanosine to adenosine point mutation at position 133,Compared to riboflavin,, ,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.4161/rna.6.2.7727,C,"ribD FMN Riboswitch, B. subtilis, Roseoflavin-resistant Mutant 3",Little to no measurable modulation of sites 1 and 3; Near wild-type modulation at site 2,Ligand = 10 µM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, 100 mM KCl",Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1,Compared to native ligand FMN and riboflavin,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,"FMN Riboswitch, S. aureus SA1 and SA2 and E. coli",Regions of hydrogen bonding interactions between ligand and FMN riboswitch are broadly conserved; Clear molecular basis for similarity in binding potency,-,-,Structure Determination,Homology Modeling,Modeled using X-ray structures of the F. nucleatum FMN riboswitch complexed with Ribocil-C and Roseoflavin,,,MSSA RN4220,MIC = 0.06 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,"BALB/c mice, MRSA COL",2 log10 dose-dependent reduction at 24 hours,"Subcutaneous; 50, 100 mg/kg",Antimicrobial Activity,Bacterial Burden,Intraperitoneal injection of bacteria,Compared to DMSO and Linezolid,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature07642,,"impX RFN Element, F. nucleatum",Riboswitch adopts a similar conformation to riboflavin-bound structure with additional spatial adjustments to accommodate the dimethylamino group,Ligand = 0.7 mM,"100 mM potassium acetate (pH = 6.8), 4 mM MgCl2",Structure Determination,X-Ray Crystallography,PDB: 3F4H,Compared to FMN and riboflavin bound structures,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL,MIC = 0.06 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,"BALB/c mice, MRSA COL ?ribD",2 log10 dose-dependent reduction at 24 hours,"Subcutaneous; 50, 100 mg/kg",Antimicrobial Activity,Bacterial Burden,"?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch; Intraperitoneal injection of bacteria",Compared to DMSO and Linezolid,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL ?ribD,No growth ,-,Antimicrobial Activity,Broth Microdilution,?ribD is a strain deficient in de novo RF biosynthesis—gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch; Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,"BALB/c mice, MRSA COL ?ribD",One animal succumbed to infection with side effects of lethargy and ruffled fur,Subcutaneous; 50 mg/kg,Antimicrobial Activity,Bacterial Burden,"?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch; Intraperitoneal injection of bacteria",Compared to DMSO and Linezolid,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,E. faecalis,No growth ,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,S. pyogenes,MIC = 0.06 µg/mL,-,Antimicrobial Activity,Broth Microdilution,Tested in cation-adjusted Mueller Hinton broth (CAMHB) containing trace levels of riboflavin,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MSSA RN4220, riboflavin or human serum supplement",MIC = 0.5 µg/mL; 8 µg/mL; 4 µg/mL,"Riboflavin = 12.5, 200 nM; Human serum = 50%",Antimicrobial Activity,Broth Microdilution,Supplemented with two concentrations of riboflavin or 50% human serum,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, riboflavin or human serum supplement",MIC = 0.5 µg/mL; 16 µg/mL; 4 µg/mL,"Riboflavin = 12.5, 200 nM; Human serum = 50%",Antimicrobial Activity,Broth Microdilution,Supplemented with two concentrations of riboflavin or 50% human serum,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL ?ribD, riboflavin or human serum supplement",MIC = 0.5 µg/mL; 8 µg/mL; 4 µg/mL,"Riboflavin = 12.5, 200 nM; Human serum = 50%",Antimicrobial Activity,Broth Microdilution,Supplemented with two concentrations of riboflavin or 50% human serum; ?ribD is a strain deficient in de novo RF biosynthesis—gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. faecalis, riboflavin or human serum supplement",MIC = 1 µg/mL; 4 µg/mL; 8 µg/mL,"Riboflavin = 12.5, 200 nM; Human serum = 50%",Antimicrobial Activity,Broth Microdilution,Supplemented with two concentrations of riboflavin or 50% human serum,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"S. pyogenes, riboflavin or human serum supplement",MIC = 0.5 µg/mL; 8 µg/mL; 64 µg/mL,"Riboflavin = 12.5, 200 nM; Human serum = 50%",Antimicrobial Activity,Broth Microdilution,Supplemented with two concentrations of riboflavin or 50% human serum,Compared to Linezolid,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5008 lpxC,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5747 tolC::tn10,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746 tolC::tn10,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-WT,MIC = 4 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-2 -193 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Pa-17 -317 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-WT,MIC = 4 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-14 -57 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,E. coli MB5746/P. aeruginosa RFN ribB Ab-17 -9 mutant,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,P. aeruginosa ATCC35151 Z61,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,P. aeruginosa MB5890 Multi-efflux,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,A. baumannii ATCC12457 ?lpxA,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,A. baumannii ATCC19606 ?lpxC,MIC > 128 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Penicillin G, Novobiocin, Chloramphenicol, and Nalidixic Acid",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,S. cerevisiae S288c,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,S. cerevisiae Sc ?pdr5,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,C. albicans CAF2-1 CDR1/CDR1 CDR2/CDR2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,C. albicans DSY448 ?cdr1/?cdr1 CDR2/CDR2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1038/nature15542,,,,,,,,,,,C. albicans DS654 ?cdr1/?cdr1 ?cdr2/?cdr2,MIC > 32 µg/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to Fluconazole, Amphotericin B and Caspofungin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,,MRSA COL,IC50 = 0.04 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL mutant WTM6 (SA1),IC50 = 11.2 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL mutant WTM22 (Azo1),IC50 > 40 µM,-,Metabolite Synthesis Inhibition,HPLC,Measured depletion of cellular riboflavin levels,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, riboflavin supplement",0.2 µM Riboflavin sufficient to suppress activity,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAHM agar plates seeded with bacteria and/or riboflavin supplement,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. coli, riboflavin supplement",20 µM Riboflavin required to suppress activity,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAHM agar plates seeded with bacteria and/or riboflavin supplement,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. coli pnuX, riboflavin supplement",Increased sensitivity to Roseoflavin,"Riboflavin = 0, 0.2, 20 µM",On-Target Effect,Broth Microdilution,Spotted on the surface of CAHM agar plates seeded with bacteria and/or riboflavin supplement; Heterologous expression of the C. clutamicum RF transporter,Compared to Nargenicin and Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL,Thirty-one isolates sequenced; Twenty-nine (eleven unique) contain a single base substitution in SA1 riboswitch; Two contain missense mutations to Azo1,-,On-Target Effect,Serial-Passage ,Utilized whole genome sequencing,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,MRSA COL ?ribD,Thirty isolates sequenced; Twenty-seven contain a single base substitution or deletion in SA2 riboswitch; Three isolates have single mutations to a histidine kinase or efflux transporter,-,On-Target Effect,Serial-Passage ,"Utilized whole genome sequencing; ?ribD is a strain deficient in de novo RF biosynthesis, gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, 13 resistant isolates","MIC = 16 (n = 1), 32 (n = 3), > 64 (n = 9) µg/mL",-,On-Target Effect,Broth Microdilution,-,Compared to Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL ?ribD, 23 resistant isolates",MIC = 4 (n = 3) and 8 (n = 20) µg/mL; 4- to 8-fold less susceptible,-,On-Target Effect,Broth Microdilution,?ribD is a strain deficient in de novo RF biosynthesis—gene encodes an RF-specific deaminase and directly regulates the SA1 FMN riboswitch,Compared to Novobiocin,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"MRSA COL, 13 resistant isolates",FMN and FAD levels were comparable or less than DMSO control except for a small increase in isolate WTM5,Ligand = 1 µM,On-Target Effect,HPLC,"No more than 2-fold greater levels of FMN and FAD without ligand, concluding resistance does not lead to a striking upregulation of riboflavin synthesis",Compared to DMSO-treated and wild-type expression levels,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,E. faecalis,"Four isolates sequenced; None map to FMN riboswitch controlling ribU expression; Mutations were to ribU open-reading frame, intergenic region upstream of exodeoxyribonuclease III (EF2734), downstream of Gfo/Idh/MocA family oxidoreductase (EF2735), and flavoenzyme EF1586",-,On-Target Effect,Serial-Passage ,Utilized whole genome sequencing,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0004,R-BIND (SM) 0004,CN(C)C1=CC2=C(C=C1C)N=C1C(=O)[N-]C(=O)N=C1N2C[C@H](O)[C@H](O)[C@H](O)CO,Roseoflavin,10.1016/j.chembiol.2017.03.014,,,,,,,,,,C,"E. faecalis, 4 resistant isolates",8- to 16-fold reduced susceptibility,-,On-Target Effect,Broth Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1021/bi051008u,,PbuE Riboswitch,Kd = 25 nM; Kon = 8.6 X 10^4 1/M*s; Koff = 2.2 X 10^3 1/s,RNA = 100 nM; 2AP = 500 nM,NR,Binding,Competitive Binding,Fluorescence based - kinetic competition between 2-aminopurine (2-AP) and the molecule were conducted then modeled,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1021/bi051008u,,70 pbuE Riboswitch,Tm = 60 ºC,Ligand = 5.0 µM; RNA = 5.0 µM,NR,Binding,Optical Melting,-,"Compared to value with 2-AP, Tm = 55, 65 ºC; Value lies below the main structural transition but above the shoulder of the curve; Authors conclude destruction of essential tertiary structure and delicate secondary structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1021/bi051008u,C,70S pbuE Riboswitch Mutant,Tm = 59 ºC,Ligand = 5.0 µM; RNA = 5.0 µM,NR,Binding,Optical Melting,-,"Compared to value with 2-AP, Tm = 57, 67, 74 ºC; Value lies below the main structural transition but above the shoulder of the curve; Authors conclude destruction of essential tertiary structure and delicate secondary structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1021/bi051008u,C,70W pbuE Riboswitch Mutant,"Tm = 42, 57 ºC",Ligand = 5.0 µM; RNA = 5.0 µM,NR,Binding,Optical Melting,-,"Compared to value with 2-AP, Tm = 52, 62 ºC; Value lies below the main structural transition but above the shoulder of the curve; Authors conclude destruction of essential tertiary structure and delicate secondary structure",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,,"Guanine riboswitch, B. subtilis xpt-pbuX","The superimpositions of structures extracted from main clusters indicate that the ligand produces obvious slide and rotation in the binding pocket of the mutated riboswitches relative to the WT, which may affect the binding activity.",N/A,NR,In Silico,Molecular Dynamics,Atomic coordinates of the ligand complexed with mutated riboswitches (U25A/A46G/C74U and A24U/U25A/A46G/C74U) were taken from protein data bank (PDB ID: 4FEO and 4FEP). The initio structure of the ligand wt riboswitch complex was constructed based on the complex structure of hypoxanthone with WT riboswitch.,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant U25A/A46G/C74U","The superimpositions of structures extracted from main clusters indicate that the ligand produces obvious slide and rotation in the binding pocket of the mutated riboswitches relative to the WT, which may affect the binding activity.",N/A,NR,In Silico,Molecular Dynamics,Atomic coordinates of the ligand complexed with mutated riboswitches (U25A/A46G/C74U and A24U/U25A/A46G/C74U) were taken from protein data bank (PDB ID: 4FEO and 4FEP). The initio structure of the ligand wt riboswitch complex was constructed based on the complex structure of hypoxanthone with WT riboswitch.,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant A24U/U25A/A46G/C74U","The superimpositions of structures extracted from main clusters indicate that the ligand produces obvious slide and rotation in the binding pocket of the mutated riboswitches relative to the WT, which may affect the binding activity.",N/A,NR,In Silico,Molecular Dynamics,Atomic coordinates of the ligand complexed with mutated riboswitches (U25A/A46G/C74U and A24U/U25A/A46G/C74U) were taken from protein data bank (PDB ID: 4FEO and 4FEP). The initio structure of the ligand wt riboswitch complex was constructed based on the complex structure of hypoxanthone with WT riboswitch.,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,,"Guanine riboswitch, B. subtilis xpt-pbuX",?G3 = -21.09 ± 0.14 kcal/mol; ?G1 = -33.46 ± 0.47 kcal/mol; ?Gbind = -12.37 ± 0.31 kcal/mol,N/A,NR,In Silico,Free Energy Perturbations,"?G1 and ?G3 represents the changes of free energies in decoupling ligands from GRs and water, respectively. ?Gbind = ?G1 - ?G3. ??G = ?Gmutant - ?Gwild.The last snapshot taken from the first 200 ns of the conventional MD simulation of each system was used as the starting conformation of FEP calculation. The temperature was controlled at 300K.",Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant U25A/A46G/C74U",?G3 = -21.09 ± 0.14 kcal/mol; ?G1 = -36.55 ± 0.58 kcal/mol; ?Gbind = -15.46 ± 0.36 kcal/mol; ??G = -3.09 kcal/mol,N/A,NR,In Silico,Free Energy Perturbations,"?G1 and ?G3 represents the changes of free energies in decoupling ligands from GRs and water, respectively. ?Gbind = ?G1 - ?G3. ??G = ?Gmutant - ?Gwild.The last snapshot taken from the first 200 ns of the conventional MD simulation of each system was used as the starting conformation of FEP calculation. The temperature was controlled at 300K.",Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant A24U/U25A/A46G/C74U",?G3 = -21.09 ± 0.14 kcal/mol; ?G1 = -34.60 ± 0.36 kcal/mol; ?Gbind = -13.51 ± 0.25 kcal/mol; ??G = -1.14 kcal/mol,N/A,NR,In Silico,Free Energy Perturbations,"?G1 and ?G3 represents the changes of free energies in decoupling ligands from GRs and water, respectively. ?Gbind = ?G1 - ?G3. ??G = ?Gmutant - ?Gwild.The last snapshot taken from the first 200 ns of the conventional MD simulation of each system was used as the starting conformation of FEP calculation. The temperature was controlled at 300K.",Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,,"Guanine riboswitch, B. subtilis xpt-pbuX",?EvdW = -25.56 ± 0.27 kcal/mol; ?Eele = -36.47 ± 0.30 kcal/mol; ?Gegb = 37.12 ± 0.23 kcal/mol; ?Gesurf = -2.27 ± 0.01 kcal/mol; ?Gele+egb = 0.65 ± 0.21 kcal/mol; ?H = -27.18 ± 0.22 kcal/mol; -T?S = 19.82 ± 0.68 kcal/mol; ?Gbind = -7.36 kcal/mol,N/A,NR,In Silico,Molecular Mechanics-Generalized Born Surface Area,?Gele+egb = ?Eele + ?Gegb. ??G = ?Gmutant - ?Gwild. ?H = ?EvdW + ?Eele + ?Gegb + ?Gsurf. ,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant U25A/A46G/C74U",?EvdW = -24.75 ± 0.31 kcal/mol; ?Eele = -38.88 ± 0.53 kcal/mol; ?Gegb = 35.53 ± 0.44 kcal/mol; ?Gesurf = -2.28 ± 0.01 kcal/mol; ?Gele+egb = -3.35 ± 0.49 kcal/mol; ?H = -30.38 ± 0.34 kcal/mol; -T?S = 18.41 ± 0.61 kcal/mol; ?Gbind = -11.97 kcal/mol; ??G = -4.61 kcal/mol,N/A,NR,In Silico,Molecular Mechanics-Generalized Born Surface Area,?Gele+egb = ?Eele + ?Gegb. ??G = ?Gmutant - ?Gwild. ?H = ?EvdW + ?Eele + ?Gegb + ?Gsurf. ,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1093/nar/gkz499,C,"Guanine riboswitch, B. subtilis xpt-pbuX  mutant A24U/U25A/A46G/C74U",?EvdW = -27.12 ± 0.21 kcal/mol; ?Eele = -35.98 ± 0.41 kcal/mol; ?Gegb = 35.09 ± 0.38 kcal/mol; ?Gesurf = -2.34 ± 0.01 kcal/mol; ?Gele+egb = -0.89 ± 0.38 kcal/mol; ?H = -30.35 ± 0.26 kcal/mol; -T?S = 19.10 ± 0.88 kcal/mol; ?Gbind = -11.25 kcal/mol; ??G = -3.89 kcal/mol,N/A,NR,In Silico,Molecular Mechanics-Generalized Born Surface Area,?Gele+egb = ?Eele + ?Gegb. ??G = ?Gmutant - ?Gwild. ?H = ?EvdW + ?Eele + ?Gegb + ?Gsurf. ,Compared to hypoxanthine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0005,R-BIND (SM) 0005,NC1=NC(N)=C2NC=NC2=N1,"2,6-Diaminopurine",10.1074/jbc.M114.613497,,,,,,,,,,,E. coli K12 strain BW25113,15-fold increase in fluorescence,Ligand = 500 µM,Translational Activity,Reporter,Reporter plasmid containing wild-type pbuE (purine) riboswitch of B. subtilis with a fluorescent protein reporter (gfpuv),"Compared to adenine, which had 10-fold increase",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,"TPP Riboswitch, B. subtilis ",Kd = 6 µM,-,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,-,"Compared to TPP, native coenzyme",,"B. subtilis strain 1A40, PT sensitive",7.5-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,,"B. subtilis, PT sensitive",All strains had mutations; Most were point mutation but one close has an insertion,Ligand = 100 µM,On-Target Effect,Serial Passage,Sequenced tenA TPP riboswitch,Authors concluded it was most likely the primary cellular target,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,,"E. coli, PT sensitive",Only 7/23 clones carried mutation in thiC riboswitch; One clone had an insertion in thiM-thiD riboswitch; One close had an insertion into the tbpA-yabK-yabJ riboswitch; Other 14 clones did not carry riboswitch mutation,Ligand = 100 µM,On-Target Effect,Serial Passage,Sequenced thiC TPP riboswitch,Authors concluded mutants gained resistance by another mechanism,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,C,"B. subtilis strain 1A40 Mutant, PT sensitive",1.5-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,C,"B. subtilis strain 1A481, PT resistant",10.1-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,C,"B. subtilis strain 1A481 Mutant, PT resistant",1.7-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,,"E. coli, PT sensitive",3.9-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0006,R-BIND (SM) 0006,CC1=NC(N)=C(C[N+]2=CC=CC(CCO)=C2C)C=N1,Pyrithiamine,10.1016/j.chembiol.2005.10.007,,,,,,,,,,C,"E. coli, PT sensitive Mutant",1.3-fold decrease in lacZ expression,Ligand = 10 µM,Translational Activity,Beta-Galactosidase,Reporter gene constructs by fusing an appropriate 5'-UTR sequence with a lacZ gene,"Compared to TPP, native coenzyme",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1021/cb900146k,,"xpt-pbuX Guanine Riboswitch, B. subtilis",Kd = 20 nM,-,NR,Binding,In-Line Probing,"In vitro transcription, dephosphorylation and 5' 32P labeling of RNA for in-line probing; Denaturing PAGE followed by MD Phosphorimager were used to establish RNA spontaneous cleavage patterns",-,,"B. subtilis 168 strain 1A1, GMM Media",MIC = 260 µM,-,Antimicrobial Activity,Broth Microdilution,"Glucose-minimal medium (GMM); MIC was determined by growing a 1A1 strain overnight in LB, then diluted into an OD6000 of 0.1; Compound was added at various concentrations, and MIC was calculated using CLSI guidelines",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,,L. monocytogenes ,Decrease in relative transcription of lmo0573 (5) and lmo1885 (1) genes compared to control (10),Ligand = 100 µM,Activity,Northern Blot,Strain was grown in minimal media to OD600 = 0.25; Small molecule was added until ~1.5 generations before RNA extraction and Northern blot was used to quantify PCR of RNA extract,"Compared to guanine, NaOH, and DMSO; Levels of riboswitch fragments Rli70 and Rli95 increased, supporting riboswitch-mediated termination; tmRNA used as control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,"L. monocytogenes, M1-M6 double mutant",Transcription proceeded similar to wild-type,Ligand = 100 µM,Activity,Northern Blot,"Carried mutations in front of both guanine riboswitches, lmo0573 and lmo1885; Strain was grown in media to OD600 = 0.25; Small molecule was added until ~1.5 generations before RNA extraction and northern blot was used to quantify PCR of RNA extract","Compared to guanine, NaOH, and DMSO; Levels of riboswitch fragments Rli70 and Rli95 decreased, supporting formation of the anti-terminator structure; tmRNA used as control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1021/cb900146k,,,,,,,,,,,"B. subtilis 168 strain 1A1, GMM Media, G6 resistant",MIC = 260 µM,-,Antimicrobial Activity,Broth Microdilution,"Glucose-minimal medium (GMM); Resistant strain for G6 analog, a variant carrying near complete deletion of the terminator stem of the pbuE riboswitch; MIC was determined by growing a 1A1 strain overnight in LB, then diluted into an OD6000 of 0.1; Compound was added at various concentrations, and MIC was calculated using CLSI guidelines",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1021/cb900146k,,,,,,,,,,,"B. subtilis 168 strain 1A1, LB Media",MIC > 1 mM,-,Antimicrobial Activity,Broth Microdilution,"Rich Medium (LB(; MIC was determined by growing a 1A1 strain overnight in LB, then diluted into an OD6000 of 0.1; Compound was added at various concentrations, and MIC was calculated using CLSI guidelines",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,,L. monocytogenes ,Reduction in bacterial growth,"Ligand = 10, 33, 100 µM",Antimicrobial Activity,Broth Microdilution,Bacterial cultures grown in minimal medium for 10 h at 37 ºC; The bacteria were challenged and viable counts were measured,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,,L. monocytogenes ,Bactericidal-like effect; ~100-fold decrease in the number of bacteria compared to inoculum,Ligand = 100 µM,Antimicrobial Activity,Broth Microdilution,Bacterial cultures grown in minimal medium for 10 h at 37 ºC; The bacteria were challenged and viable counts were measured,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,"L. monocytogenes, M1-M6 double mutant",Bacterial growth inhibition similar to wild-type,"Ligand = 10, 100 µM",Antimicrobial Activity,Broth Microdilution,"Carried mutations in front of both guanine riboswitches, lmo0573 and lmo1885; Bacterial cultures grown in minimal medium for 10 h at 37 ºC; The bacteria were challenged and viable counts were measured",Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,"L. monocytogenes, M1-M6 double mutant",Bacterial growth inhibition similar to wild-type at every time point,"Ligand = 10, 100 µM",Antimicrobial Activity,Broth Microdilution,"Carried mutations in front of both guanine riboswitches, lmo0573 and lmo1885; Compound was added at early logarithmic growth phase and samples were taken at different time points to determine survival",Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,,L. monocytogenes ,"Inhibition is not dose-dependent; Bacterial survival at 10 µM is marginally different than 100, 500 µM","Ligand = 0, 10, 100, 500 µM",Antimicrobial Activity,Broth Microdilution,"Bacterial cultures grown to an OD600 = ~0.15, compounds were added, and incubated for 1.5 generations; Bacterial survival scored as colony forming units",Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,Adenine abolished antimicrobial effect; Guanine slightly but reproducibly reversed antimicrobial effect; Cytosine and thymine had no effect,Ligand = 100 µM; Nucleoside = 100 µM,Antimicrobial Activity,Broth Microdilution,Bacterial cultures grown to an OD600 = ~0.15 then compounds were added; Growth was scored as OD600 after 10 h,"Compared to IMM, NaOH, HCl, DMSO, adenine, cytosine, guanine, and thymine; Adenine did not reduce lmo0573 expression, rather a slight upregulation was observed",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,1000-fold higher occurrence of rifampicin resistant mutants; Ligand increased level of mutagenesis,Ligand = 100 µM,Antimicrobial Activity,Broth Microdilution,Bacteria grown in the presence of compound for 10 h; Determined colony forming units and rifampicin resistant mutants by plating on plain LB plates or LB plates containing rifampicin; Read-out is spontaneous rifampicin resistance,"Compared to guanine and DMSO; Sequenced rpoB gene, the rifampicin target site, for sensitive and resistant mutants, revealed mutations",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1021/cb900146k,,,,,,,,,,,B. subtilis 168 strain 1A1,No resistant mutants were isolated,NR,On-Target Effect,Serial-Passage ,Ligand becomes insoluble at concentration slightly higher than MIC,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,No effect on expression of purine biosynthesis operon purEKBCSLQFMNHD,NR,Transcriptional Activity,NR,NR,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,Increased expression of lmo1975 and lmo2676; Ligand induces SOS response,Ligand = 100 µM,Transcriptional Activity,Northern Blot,"Bacteria grown in minimal medium to an OD600 = 0.25 and ligand was added for ~1.5 generations; RNA was extracted, PCR-generated, and radiolabeled DNA probes were used to detect RNA",Compared to adenine and guanine; tmRNA used as control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,Dramatically reduces expression of virulence-related genes hly and actA; Reduces expression of plcA-prfA and from ?B-dependent prfA promoter,Ligand = 100 µM,Transcriptional Activity,Northern Blot,"Bacteria grown in minimal medium to an OD600 = 0.25 and ligand was added for ~1.5 generations; RNA was extracted, PCR-generated, and radiolabeled DNA probes were used to detect RNA","PrfA controls expression of hly and actA; Compared to NaOH, guanine, DMSO; tmRNA used as control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,"L. monocytogenes, M1-M6 double mutant",Dramatically reduces expression of virulence-related genes hly and actA; Reduces expression of plcA-prfA and from ?B-dependent prfA promoter,Ligand = 100 ?M,Transcriptional Activity,Northern Blot,"Bacteria grown in minimal medium to an OD600 = 0.25 and ligand was added for ~1.5 generations; RNA was extracted, PCR-generated, and radiolabeled DNA probes were used to detect RNA","PrfA controls expression of hly and actA; Compared to NaOH, guanine, DMSO; tmRNA used as control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1021/cb900146k,,,,,,,,,,,B. subtilis 168 strain 1A1,Full repression at MIC concentration,Ligand = 250 µM,Translational Activity,Beta-Galactosidase,Gene regulation assay with lacZ reporter gene,"Compared to inactive riboswitch variant, where little repression is observed",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,L. monocytogenes ,Reduced levels of virulence-related proteins LLO and ActA as well as regulator PrfA,Ligand = 100 ?M,Translational Activity,Western Blot,"Bacteria grown in minimal medium to an OD600 = 0.25 and ligand was added; After 3.5 h, proteins were extracted","PrfA controls expression of hly and actAl, experiments were repeated with constitutively active prfA or a strain lacking prfA; Compared to DMSO",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0007,R-BIND (SM) 0007,NC1=N\C(=N/[O-])C2=C(NC=N2)[NH2+]1,2-Amino-N6-Hydroxyadenine,10.1093/nar/gkw1308,,,,,,,,,,C,"L. monocytogenes, M1-M6 double mutant",Reduced levels of virulence-related proteins LLO and ActA as well as regulator PrfA,Ligand = 100 ?M,Translational Activity,Western Blot,"Bacteria grown in minimal medium to an OD600 = 0.25 and ligand was added; After 3.5 h, proteins were extracted","PrfA controls expression of hly and actAl, experiments were repeated with constitutively active prfA or a strain lacking prfA; Compared to DMSO",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,Guanine Riboswitch,Kd = ~100 nM,-,"50 mM Tris-HCl (pH = 8.5), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,-,-,,S. aureus strain ATCC 29213,MIC = 625 ug/mL,-,Antimicrobial Activity,Broth Microdilution,-,"Compared to PC2, a less potent analog",,"S. aureus in CD-1 lactating mice, ATCC 29213","Drastic, dose-dependent reduction in viable bacteria","10, 50, 100 µg/gland",Antimicrobial Activity,Serial Logarithmic Dilutions on Agar,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to amoxicillin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,S. aureus strain ATCC 29213,6.67 ± 0.58 log reduction in CFU/mL,Ligand = 600 µg/mL,Antimicrobial Activity,Time-Kill,Measure bactericidal activity,"Compared to untreated, known antibiotics (ciprofloxin, erythromycin, and vancomycin) and PC2, a less potent analog",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,C,S. aureus strain ATCC 29213,Dose-dependent and 10^3 factor GMP rescue in PC1-treated cells,Ligand = 600 µg/mL; GMP = 100 µM,Antimicrobial Activity,Time-Kill,Low solubility of GMP prevented higher doses and full recovery,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,C,S. aureus strain ATCC 29213,Partial AMP rescue observed in PC1-treated cells,Ligand = 600 µg/mL; AMP = 100 µM,Antimicrobial Activity,Time-Kill,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,C. difficile CD6,5.42  ± 1.02 log reduction in CFU/mL,Ligand = 600 µg/mL,Antimicrobial Activity,Time-Kill,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,B. subtilis,MIC = 1250 ug/mL in minimum growth media; No inhibition observed in cation-adjusted Muller Hinton broth (CAMHB),-,Antimicrobial Activity,Broth Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,15 Gram-positive species,"9/15 showed cellular growth inhibition, which had guaA-controlled riboswitch",-,Antimicrobial Activity,Broth Microdilution,Other 6 strains lacked guaA-riboswitch,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,C,E. coli ATCC 35695,No growth inhibition,-,Antimicrobial Activity,Broth Microdilution,"Strain lacks guanine riboswitches; Repeated using strains deficient for AcrAC efflux system or having increase cell permeability, no change observed",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,"S. aureus, Newbould 305",Fold reduction = 4.86 ± 1.42 log10 CFU/mL,"10, 50, 100 µg/gland",Antimicrobial Activity,Time-Kill,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to untreated,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,"S. aureus, SHY97-3906",Fold reduction = 6.35 ± 1.26 log10 CFU/mL,"10, 50, 100 µg/gland",Antimicrobial Activity,Time-Kill,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to untreated,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,"S. aureus, Chronic #3",Fold reduction = 5.11 ± 1.25 log10 CFU/mL,"10, 50, 100 µg/gland",Antimicrobial Activity,Time-Kill,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to untreated,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,"S. aureus, Chronic #557",Fold reduction = 4.38 ± 1.86 log10 CFU/mL,"10, 50, 100 µg/gland",Antimicrobial Activity,Time-Kill,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to untreated,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,"S. aureus, Chronic #1290",Fold reduction = 5.42 ± 1.56 log10 CFU/mL,"10, 50, 100 µg/gland",Antimicrobial Activity,Time-Kill,"Mammary glands were inoculated, and four hours after infection were treated with PBS or PBS with PC1; Six hours later, they were sacrificed; Detection limit of assay was 100 CFU/g of gland",Compared to untreated,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,C,S. aureus,No resistant mutants developed after 30 passages,Sub-inhibitory concentration,On-Target Effect,Serial-Passage ,-,"Compared to ciprofloxacin and rifampicin, where resistance was observed",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,S. aureus,72% of genes were repressed by two-fold; Results were consistent with guanine riboswitch inhibition; Revealed a potential activation of stress response,Ligand = 600 µg/mL,RNA Abundance,Transcriptomic Microarray Analysis,"S. aureus genes involved in virulence, secretion, general stress responses, sensory/regulatory systems, antibiotic resistance, iron transport and general biosynthesis ","Consistent with GMP cellular depletion and RNA synthesis inhibition, particularly the low expression of guanine riboswitch operon and DNA gyrase subunits; Only two genes ahpF and ahpC were activated and related to stress response; Repeated with GMP and only partial rescue observed with 21% of genes still repressed most in virulence and cell wall synthesis",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0008,R-BIND (SM) 0008,NC1=NC(=O)C(N)=C(N)N1,PC1,10.1371/journal.ppat.1000865,,,,,,,,,,,B. subtilis,Dose-dependent inhibition of beta-galactosidase activity,"Ligand = 0.1, 0.3, 0.6, 1.2 mg/mL",Translational Activity,Beta-Galactosidase,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. subtilis",Kd = 2.4 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,Compared to Proflavine,,B. subtilis,Triggered gene expression,NR,Translational Activity,Biolog Phenotype MicroArray,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; The resulting reporter strain was used to reveal gene expression changes caused by different growth media additives",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 1","Similar to Proflavine, reduced Kd but did not alter bands",-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 1 disrupts base-pairing of P1,-,,B. subtilis,Triggered gene expression,Ligand = 1 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 2","Similar to Proflavine, restored Kd to wild-type",-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 2 restores base-pairing of P1 disrupted in Mutant 1,-,,B. subtilis,~ 6-fold increase in gene expression (5 µM),"Ligand = 1, 3, 5 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Induced toxicity at higher levels; Compared to Proflavine,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 3","Similar to Proflavine, eliminates binding",-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 3 alters the conserved A nucleotide in P2 loop,-,C,"B. subtilis, Mutant 1",Slight increase in gene expression observed (5 µM),"Ligand = 1, 3, 5 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 1 disrupts base-pairing of P1",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. cereus",Strong binding exhibited,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,C,"B. subtilis, Mutant 2",~ 6-fold increase in gene expression (5 µM); Similar to wild-type,"Ligand = 1, 3, 5 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 2 restores base-pairing of P1 disrupted in Mutant 1",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, R. gauvreauii",Strong binding exhibited,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,C,"B. subtilis, Mutant 3",Slight increase in gene expression observed (5 µM),"Ligand = 1, 3, 5 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 3 alters the conserved A nucleotide in P2 loop",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, L. plantarum",Strong binding exhibited,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,C,"B. subtilis, YjdF KO",Similar to wild-type,Ligand = 1 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; KO was achieved by homologous recombination ",Protein KO confirms the effect is not dependent upon the protein,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0009,R-BIND (SM) 0009,COC1=CC=C2C(C=[N+](C)C3=C2C=CC2=CC4=C(OCO4)C=C32)=C1OC,Chelerythrine,10.1261/rna.054890.115,C,"161 nt FMN Riboswitch Construct, B. subtilis",No binding observed,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0010,R-BIND (SM) 0010,CC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=CC=CC=C12,Dequalinium,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. subtilis",Kd = 10 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,,B. subtilis,Triggered gene expression,NR,Translational Activity,Biolog Phenotype MicroArray,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; The resulting reporter strain was used to reveal gene expression changes caused by different growth media additives",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0011,R-BIND (SM) 0011,CC1=NC=CC2=C1NC1=C2C=CC=C1,Harmane,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. subtilis",Kd = 100 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,,B. subtilis,Triggered gene expression,NR,Translational Activity,Biolog Phenotype MicroArray,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; The resulting reporter strain was used to reveal gene expression changes caused by different growth media additives",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0011,R-BIND (SM) 0011,CC1=NC=CC2=C1NC1=C2C=CC=C1,Harmane,10.1261/rna.054890.115,,,,,,,,,,,B. subtilis,Triggered gene expression,Ligand = 100 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0011,R-BIND (SM) 0011,CC1=NC=CC2=C1NC1=C2C=CC=C1,Harmane,10.1261/rna.054890.115,,,,,,,,,,C,"B. subtilis, YjdF KO",Similar to wild-type,Ligand = 100 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; KO was achieved by homologous recombination ",Protein KO confirms the effect is not dependent upon the protein,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0012,R-BIND (SM) 0012,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,Harmine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. subtilis",Kd = 100 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,,B. subtilis,Triggered gene expression,Ligand = 100 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0012,R-BIND (SM) 0012,COC1=CC2=C(C=C1)C1=C(N2)C(C)=NC=C1,Harmine,10.1261/rna.054890.115,,,,,,,,,,C,"B. subtilis, YjdF KO",Similar to wild-type,Ligand = 100 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; KO was achieved by homologous recombination ",Protein KO confirms the effect is not dependent upon the protein,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,,"108 nt yjdF Riboswitch Construct, B. subtilis",Kd = 6.1 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,,B. subtilis,Triggered gene expression,Ligand = 10 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 1",Reduced Kd but did not alter bands,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 1 disrupts base-pairing of P1,-,,B. subtilis,~ 25-fold increase in gene expression (10 µM),"Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Induced toxicity at higher levels; Compared to Proflavine,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 2",Restored Kd to wild-type,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 2 restores base-pairing of P1 disrupted in Mutant 1,-,C,"B. subtilis, Mutant 1","Slight increase in gene expression observed (5, 10 µM)","Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 1 disrupts base-pairing of P1",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 3",Eliminates binding,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 3 alters the A nucleotide in P2 loop,-,C,"B. subtilis, Mutant 2",~ 25-fold increase in gene expression (10 µM); Similar to wild-type,"Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 2 restores base-pairing of P1 disrupted in Mutant 1",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,C,"108 nt yjdF Riboswitch Construct, B. subtilis, Mutant 4",Eliminates binding,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,Mutant 4 alters the G nucleotide in P2 loop,-,C,"B. subtilis, Mutant 3","Slight increase in gene expression observed (5, 10 µM)","Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; Mutant 3 alters the conserved A nucleotide in P2 loop",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,C,"161 nt FMN Riboswitch Construct, B. subtilis",No binding observed,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,C,"B. subtilis, YjdF KO",Similar to wild-type,Ligand = 10 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; KO was achieved by homologous recombination ",Protein KO confirms the effect is not dependent upon the protein,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,,,,,,,,,,C,"B. subtilis, crcB (fluoride riboswitch)",No increase in gene expression observed,"Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the crcB (fluoride riboswitch) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0013,R-BIND (SM) 0013,NC1=CC2=[NH+]C3=CC(N)=CC=C3C=C2C=C1,Proflavine,10.1261/rna.054890.115,,,,,,,,,,C,"B. subtilis, ykkC (orphan riboswitch)",No increase in gene expression observed,"Ligand = 1, 5, 10 µM",Translational Activity,Agar-Diffusion,"DNA corresponding to the  ykkC (orphan riboswitch) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0014,R-BIND (SM) 0014,C[NH2+][C@H]1CC2OC(C)([C@H]1OC)N1C3=CC=CC=C3C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,10.1261/rna.054890.115,,108 nt yjdF Riboswitch Construct,Kd = 100 nM,-,"50 mM Tris–HCl (pH = 8.3), 100 mM KCl, and 20 mM MgCl2",Binding,In-Line Probing,-,-,,B. subtilis,Triggered gene expression,Ligand = 10 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells",Compared to Proflavine ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0014,R-BIND (SM) 0014,C[NH2+][C@H]1CC2OC(C)([C@H]1OC)N1C3=CC=CC=C3C3=C1C1=C(C4=C(C=CC=C4)N21)C1=C3CNC1=O,Staurosporine,10.1261/rna.054890.115,,,,,,,,,,C,"B. subtilis, YjdF KO",Similar to wild-type,Ligand = 10 mM,Translational Activity,Agar-Diffusion,"DNA corresponding to the yjdF motif RNA (108) from B. subtilis was fused in-frame to the lacZ gene from E. coli, which was inserted into a plasmid and transformed into cells; KO was achieved by homologous recombination ",Protein KO confirms the effect is not dependent upon the protein,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),Complete splicing inhibition,Ligand = 200 µM,"50 mM Tris-HCl (pH = 7.5), 1.25 mM MgCl2, 0.4 mM spermidine, 4 U of RNasin (Promega), and 10 mM GTP",Activity,Splicing Inhibition,Used in vitro transcribed rRNA precursor from C. albicans strain 4-1; Gel electrophoresis identified the extent of splicing; Authors suggest Pentamidine inhibits RNA folding,Compared to reported inhibitors BBE and DIMP,,"C. albicans strain 4-1, YPG medium",MIC80 = 0.78 µM;  4-fold increase in susceptibility,Ligand = 0.19 - 100 µM,Antimicrobial Activity,Broth Microdilution,Intron-containing strain,Susceptibility compared to intronless strain 62-1; Compared to small molecule modulator amphotericin B; Confirmed using disk assay (data not shown),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1093/nar/gkf394,,Self-Splicing Group I Intron (Ca.LSU),Complete inhibition at 200 µM at 2 min,Ligand = 200 µM,"50 mM Tris-HCl (pH = 7.5), 1.25 mM MgCl2, 0.4 mM spermidine, 10 µM GTP and 10 U Rnasin (Promega)",Activity,PAGE,Measured by the rate of conversion of radioactive precursor (E1-I-E2) to the splicing intermediates (I-E2 and E1) and product (I and E1-E2) of the splicing reaction,No inhibition observed at 150 µM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1093/nar/gkf394,,Self-Splicing Group I Intron (Ca.LSU),Significant inhibition (25 µM); Greater inhibition (100 - 150 µM); Complete inhibition (200 µM),Ligand = 25 - 200 µM,"50 mM Tris-HCl (pH = 7.5), 1.25 mM MgCl2, 0.4 mM spermidine, 10 µM GTP and 10 U Rnasin (Promega)",Activity,PAGE,"Preincubation of pentamidine with the RNA followed by addition of MgCl2, spermidine, and GTP; Measured by the rate of conversion of radioactive precursor (E1-I-E2) to the splicing intermediates (I-E2 and E1) and product (I and E1-E2) of the splicing reaction",Authors suggest splicing components may compete with pentamidine for binding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1093/nar/gkf394,,Self-Splicing Group I Intron (Ca.LSU),"Shifted RNA into predominately S band; Effect is similar to addition of MgCl2, CaCl2 or spermidine",Ligand = 25 µM,62.5 mM Tris-HCl (pH = 7.5),Binding,Native Gel Electrophoresis,"Preincubation of pentamidine with the RNA; At 0 ºC, the RNA has two bands and is predominately in the S band; At 37 ºC, the RNA is predominately in the F band",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1093/nar/gkf394,,Self-Splicing Group I Intron (Ca.LSU),Many accessible G sites cleaved; Most inaccessible G sites remained inaccessible; Altered cleavable G sites in P5abc in the catalytic domain,Ligand = 25,62.5 mM Tris-HCl (pH = 7.5) and 10 U Rnasin (Promega),Structure Determination,Ribonuclease T1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1093/nar/gkf394,,Self-Splicing Group I Intron (Ca.LSU),Cleavage at all G sites and some U sites,Ligand = 100 µM,62.5 mM Tris-HCl (pH = 7.5) and 10 U Rnasin (Promega),Structure Determination,Ribonuclease T1,-,Authors suggest multiple pentamidine molecules bind in a cooperative fashion at higher concentration,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,,"C. albicans strain 4-1, YPD medium",MIC80 = 12.5 µM; 16-fold increase in susceptibility,Ligand = 0.19 - 100 µM,Antimicrobial Activity,Broth Microdilution,Intron-containing strain,Susceptibility compared to intronless strain 62-1; Compared to small molecule modulator amphotericin B; Confirmed using disk assay (data not shown),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,C,"C. albicans strain 62-1, YPG medium",MIC80 = 3.13 µM,Ligand = 0.19 - 100 µM,Antimicrobial Activity,Broth Microdilution,Intronless strain,Compared to small molecule modulator amphotericin B,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,C,"C. albicans strain 62-1, YPD medium",MIC80 > 100 µM,Ligand = 0.19 - 100 µM,Antimicrobial Activity,Broth Microdilution,Intronless strain,Compared to small molecule modulator amphotericin B,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,,C. albicans isolates,"7/13 isolated contained introns, which were the strains more sensitive to pentamidine",-,On-Target Effect,PCR,-,"High concentrations of pentamidine act equivalently on strains with and without the intro, indicating a second, less sensitive target",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,,"C. albicans isolates, intron containing",MICs < 100 µM for 4 strains,-,On-Target Effect,PCR,Solubility issues prevented further testing of the strains,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,C,"C. albicans isolates, intronless",MICs > 100 µM for all 6 strains,-,On-Target Effect,PCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0015,R-BIND (SM) 0015,NC(=[NH2+])C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=[NH2+])C=C1,Pentamidine,10.1128/aac.44.4.958-966.2000,,Self-Splicing Group I Intron (Ca.LSU),,,,,,,,,C. albicans strain 4-1,14.3-fold increase in pre-rRNA after 1 min of treatment; Sustained increase over 90 minutes,Ligand = 1 µM,RNA Splicing,RT-PCR,-,Compared to levels of actin mRNA and mature rRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0016,R-BIND (SM) 0016,C[N+]1=C2C=CC=CC2=CC=C1C=CC1=CC2=CC=CC=C2N1,Methylquinolinium 15,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 3.4 µM,,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,,HeLa Cells,118.9 ± 2.7% enhancement,Ligand = 2 µM,Translational Activity,Reporter,"Transfected with the A10-WT plasmid and incubated with ligand; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0016,R-BIND (SM) 0016,C[N+]1=C2C=CC=CC2=CC=C1C=CC1=CC2=CC=CC=C2N1,Methylquinolinium 15,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HeLa Cells,IC50 > 50 µM,-,Cytotoxicity,MTT,Measured at 24 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0016,R-BIND (SM) 0016,C[N+]1=C2C=CC=CC2=CC=C1C=CC1=CC2=CC=CC=C2N1,Methylquinolinium 15,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,IC50 = 12.4 ± 2.8,-,Cytotoxicity,MTT,Measured at 28 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0017,R-BIND (SM) 0017,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 16,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 19.2 µM,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,,HeLa Cells,116.3 ± 5.2% enhancement,Ligand = 2 µM,Translational Activity,Reporter,"Transfected with the A10-WT plasmid and incubated with ligand; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0017,R-BIND (SM) 0017,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 16,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HeLa Cells,IC50 = 37.1 ± 1.3 µM,-,Cytotoxicity,MTT,Measured at 24 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0017,R-BIND (SM) 0017,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 16,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,IC50 = 11.2 ± 1.4,-,Cytotoxicity,MTT,Measured at 28 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0018,R-BIND (SM) 0018,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC=C(C=C2)N2CCOCC2)=C1,Methylquinolinium 22,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 2.6 µM,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,,HeLa Cells,137.1 ± 0.2% enhancement,Ligand = 2 µM,Translational Activity,Reporter,"Transfected with the A10-WT plasmid and incubated with ligand; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0018,R-BIND (SM) 0018,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC=C(C=C2)N2CCOCC2)=C1,Methylquinolinium 22,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HeLa Cells,IC50 > 50 µM,-,Cytotoxicity,MTT,Measured at 24 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0018,R-BIND (SM) 0018,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC=C(C=C2)N2CCOCC2)=C1,Methylquinolinium 22,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,IC50 = 29.3 ± 3.3,-,Cytotoxicity,MTT,Measured at 28 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0019,R-BIND (SM) 0019,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC3=CC=CC=C3N2)=C1,Methylquinolinium 23,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA Mutant,NR,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",Data only recorded as RU in graph,,HeLa Cells,IC50 > 50 µM,-,Cytotoxicity,MTT,Measured at 24 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0019,R-BIND (SM) 0019,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC3=CC=CC=C3N2)=C1,Methylquinolinium 23,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 1.8 µM,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,,HeLa Cells,115.8 ± 4.3% enhancement,Ligand = 2 µM,Translational Activity,Reporter,"Dual Luciferase Assay. HeLa cells were transfected with the A10-Wt, A10-Mut, or A10-Del plasmid; The cells were then incubated with 2uM of the compounds; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase; ± not reported. ",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0019,R-BIND (SM) 0019,C[NH+]1CCN(CC1)C1=C2C=CC=CC2=[N+](C)C(C=CC2=CC3=CC=CC=C3N2)=C1,Methylquinolinium 23,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,IC50 = 18.6 ± 1.7,-,Cytotoxicity,MTT,Measured at 28 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 6.1 µM,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,,HeLa Cells,"114.1 - 187.3% enhancement; Statistically significant enhancement, 2.5 µM","Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with the A10-Wt or A10-Del plasmid and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",Ensured mRNA expression levels were not altered at all concentrations for both plasmids; Compared to inactive compound 6,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA Mutant,Kd = 0.7 M,-,50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Surface Plasmon Resonance,"Biotinylated RNA was immobilized on a sensor chip, ligands were serially diluted in running buffer, then injected during the association phase, followed by a dissociation phase; Equilibrium dissociation constants (Kd) were determined with ProteOnmanager software",-,C,HeLa Cells,No obvious effect,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with the A10-Wt mutant plasmid and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",Ensured mRNA expression levels were not altered at all concentrations for both plasmids; Compared to inactive compound 6,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Kd = 4.9 ± 0.3 µM,,"10 mM Tris-HCl (pH = 7.5), 100 mM KCl, and 0.1 mM EDTA",Binding,Microscale Thermophoresis,-,-,,HeLa Cells,109.7 - 144.8% enhancement,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with entire 5'UTR and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",Ensured mRNA expression levels were not altered at all concentrations,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Decrease in the quantity of the RNA G-quad band; Increase in RNA-ligand complex band,"Ligand = 0.5, 1, 5, 10 equiv","10 mM Tris-HCl (pH = 7.5), 100 mM KCl, and 0.1 mM EDTA",Binding,Native Gel Electrophoresis,Sequence was labeled with Cy3 and Cy5,-,C,HeLa Cells,No obvious effect,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with entire mutant 5'UTR and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",Ensured mRNA expression levels were not altered at all concentrations,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,A10-RNA-WT QGRS in ADAM10 mRNA,Little decrease in quadruplex secondary structure at 263 nm,"Ligand = 2.5, 5, 7.5 µM; RNA = 2 µM",50 mM Tris-HCl (pH = 7.5) and 100 mM KCl,Binding,Circular Dichroism,-,-,,HEK-APP Cells,20.2 - 92.9% increase in ADAM10 protein,"Ligand = 0.5, 0.75, 1, 1.5 µM",Translational Activity,Western Blot,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HeLa Cells,IC50 = 20.9 ± 2.7 µM,-,Cytotoxicity,MTT,Measured at 24 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,IC50 = 10.7 ± 1.3 µM,-,Cytotoxicity,MTT,Measured at 28 hours,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,Localizes to cytoplasm,Ligand = 2 µM,Localization,Confocal Microscopy,Observed by measuring the intrinsic fluorescence of the small molecule,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,,HEK-APP Cells,7.7 - 40.8% decrease in A?40 production,"Ligand = 0.5, 0.75, 1, 1.5 µM",Protein Abundance,ELISA,90% of A? secretion is A?40 in Alzheimer's disease,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HEK-APP Cells,Small changes detected,"Ligand = 0.5, 0.75, 1, 1.5 µM",RNA Abundance,RT-PCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,No changes detected,"Ligand = 0.5, 1, 2 µM",RNA Abundance,RT-PCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,~ 20% enhancement; Three-fold selectivity,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with NRAS and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,Small changes detected,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with NRAS mutant and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,~ 20% enhancement; Three-fold selectivity,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with BCL-2 and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,Small changes detected,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with BCL-2 mutant and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,No effect observed,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with VEGF and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,No effect observed,"Ligand = 0.5, 1, 2.5 µM",Translational Activity,Reporter,"Transfected with plasmid with VEGF mutant and then incubated with compound; After 24 hours, luciferase Translational Activity was measured; Values represent % enhancement of Renilla luciferase",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0020,R-BIND (SM) 0020,CCN1C2=C(C=CC=C2)C2=C1C=CC(C=CC1=CC(N3CC[NH+](C)CC3)=C3C=CC=CC3=[N+]1C)=C2,Methylquinolinium 24,10.1021/acs.jmedchem.5b00139,,,,,,,,,,C,HeLa Cells,"Statistically significant increase in ADAM10 protein (1, 2 µM)","Ligand = 0.5, 1, 2 µM",Translational Activity,Western Blot,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0021,R-BIND (SM) 0021,NC1=CC=C(C=C1)C1=CC2=CC=C(C=C2N1)C1=[NH+]CCN1,Compound 1,10.1002/cbic.201402069,,DDPAC MAPT A Bulge,Kd = 14 ± 2 µM,NR,NR,Binding,Fluorescence-Based Titration (Intrinsic) ,-,-,,HeLa Cells,~40% reduction in luciferase,Ligand = 80 µM,RNA Splicing,Reporter,"Transfected cells with DDPAC mini-gene plasmid DNA containing luciferase, then added growth medium containing compound; Exon skipping was quantified by RT-PCR","Compared to untreated control and compound 3, which did not bind in vitro",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022A,R-BIND (SM) 0022A,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1002/cbic.201402069,,DDPAC MAPT A Bulge,Kd = 10 ± 1 µM,NR,NR,Binding,Fluorescence-Based Titration (Intrinsic) ,-,-,,HeLa Cells,~45% and 60% reduction in luciferase,"Ligand = 30, 60 µM",RNA Splicing,Reporter,"Transfected cells with DDPAC mini-gene plasmid DNA containing luciferase, then added growth medium containing compound; Exon skipping was quantified by RT-PCR",Compared to untreated control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022A,R-BIND (SM) 0022A,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1002/cbic.201402069,C,DDPAC + I17T Mutant,Kd = > 100 µM,NR,NR,Binding,Fluorescence-Based Titration (Intrinsic) ,-,-,,HeLa Cells,"Statistically significant reduction in luciferase (30, 60 µM)","Ligand = 20, 30, 60 µM",RNA Splicing,Dual Luciferase,"Co-transfected with plasmids encoding DDPAC-firefly luciferase where exon 10 is in-frame with luciferase and Renilla luciferase, which was used for normalization",Compared to untreated control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022A,R-BIND (SM) 0022A,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1002/cbic.201402069,C,MAPT A WT,Kd = 14 ± 2 µM,NR,NR,Binding,Fluorescence-Based Titration (Intrinsic) ,-,-,,HeLa Cells,Dose-response and statistically significant changes in splicing ratio (60 µM),"Ligand = 20, 30, 60 µM",RNA Splicing,Reporter,RT-PCR analysis of the 4R (exon 10 inclusion)/3 R (exon 10 exclusion) ratio,Compared to untreated control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022A,R-BIND (SM) 0022A,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1002/cbic.201402069,,DDPAC MAPT A Bulge,?Tm = 1 ºC; ?H = -66 ± 4 kcal/mol; ?S = -193 ± 13 eu; ?G = -6.3 ± 0.4 kcal/mol; ,Ligand = 1.25 equiv,NR,Binding,Optical Melting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022A,R-BIND (SM) 0022A,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1002/cbic.201402069,C,DDPAC MAPT Mutant,?Tm = 1 ºC; ?H = -78 ± 3 kcal/mol; ?S = -240 ± 11 eu; ?G = -3.9 ± 0.1 kcal/mol; ,Ligand = 1.25 equiv,NR,Binding,Optical Melting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,C,Hairpin,Kd > 40 µM,-,NR,Binding,Biolayer Interferometry,-,-,,HEK293 Cells,Statistically significant decrease percentage of foci-positive cells,NR,Nuclear Foci Dispersion,RNA Fluorescence In Situ Hybridization ,-,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,C,r(CGG)12,Kd = 10 ± 2 µM,-,NR,Binding,Biolayer Interferometry,-,-,,COS7 Cells,1a-CA-biotin-RNA adduct formation was significantly depleted,NR,On-Target Effect,Competitive Chem-CLIP,"Transfected to express (GGGGCC)66 with no upstream ATG; Synthesized 2-CA-biotin, a ligand conjugate with chlorambucil (CA) and biotin attached",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,C,r(GGCC)4,Kd = 7.2 ± 2.0 µM,-,NR,Binding,Biolayer Interferometry,-,-,,HEK293 Cells,Significantly decreased protein levels,Ligand = 100 µM,Translational Activity,Western Blot,Repeat Associated non-ATG (RAN) Translation; Transfected with (GGGGCC)66; Cells were treated with compound and poly(GP) and poly(GA) proteins translation was monitored,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,,Hairpin Conformation of r(GGGGCC)8,Kd = 15 ± 1 µM,-,100 mM NaCl,Binding,Biolayer Interferometry,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,,G-Quadruplex Conformation of r(GGGGCC)8,Kd > 100 µM,-,100 mM KCl,Binding,Biolayer Interferometry,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0022B,R-BIND (SM) 0022B,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 2,10.1016/j.neuron.2014.07.041,,r(GGGGCC)8,0.63 kcal/mol stabilization; Tm increase of 1.9 ºC; ?H = -73.6 ± 0.4 kcal/mol; ?S = -206 ± 1 cal/K*mol; ?G = -9.61 ± 0.07 kcal/mol ,Ligand = 1 µM; RNA = 3 µM,10 mM Tris HCl (pH = 7.4) and 100 mM NaCl,Binding,Optical Melting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0023,R-BIND (SM) 0023,NC(=[NH2+])C1=CC=C(NC2=CC=C(C=C2)C2=CC3=CC=C(C=C3N2)C(N)=[NH2+])C=C1,Compound 4,10.1002/cbic.201402069,,DDPAC MAPT A Bulge,Kd = 53 ± 8 µM,NR,NR,Binding,Fluorescence-Based Titration (Intrinsic) ,-,-,,HeLa Cells,~20% reduction in luciferase,Ligand = 100 µM,RNA Splicing,Reporter,"Transfected cells with DDPAC mini-gene plasmid DNA containing luciferase, then added growth medium containing compound; Exon skipping was quantified by RT-PCR","Compared to untreated control and compound 3, which did not bind in vitro",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,,NRAS RNA G-Quadruplex,Reduced translational efficiency of luciferase,Ligand = 10 µM,Cell-free protein expression mixture (RTS 100 Wheat Germ CECF Kit),Activity,Luciferase,Firefly luciferase-containing mRNAs,"Compared to NRAS 5-UTR with a G-quadraplex mutation, which was suppressed equally. Using an in vitro RTase assay, an additional G-quad structure was discovered; The double mutant did not respond to RGB-1",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,TERRA G-Quadruplex,Reduced translational efficiency of luciferase,Ligand = 10 µM,Cell-free protein expression mixture (RTS 100 Wheat Germ CECF Kit),Activity,Luciferase,Firefly luciferase-containing mRNAs,"Compared to molecule 2, a fragment of RGB-1, which had no effect as well as a promiscuous G-quad inhibitor TMYPyP4, which decreased translational efficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,Non-Structured RNA,No effect on translational efficiency of luciferase,Ligand = 10 µM,Cell-free protein expression mixture (RTS 100 Wheat Germ CECF Kit),Activity,Luciferase,Firefly luciferase-containing mRNAs,"Compared to molecule 2, a fragment of RGB-1, which had no effect as well as a promiscuous G-quad inhibitor TMYPyP4, which decreased translational efficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,Hairpin-Stem RNA,No effect on translational efficiency of luciferase,Ligand = 10 µM,Cell-free protein expression mixture (RTS 100 Wheat Germ CECF Kit),Activity,Luciferase,Firefly luciferase-containing mRNAs,"Compared to molecule 2, a fragment of RGB-1, which had no effect as well as a promiscuous G-quad inhibitor TMYPyP4, which decreased translational efficiency",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,,NRAS RNA G-Quadruplex,Increased melting temperature,Ligand = 5 µM; RNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,MCF-7 Cells,Dose-dependent suppression of NRAS protein,"Ligand = 5, 10, 20 µM",Protein Abundance,Western Blot,-,"Checked expression of actin and GAPDH, which had fewer effects; Compared to molecule 2 (RGB-1 fragment), which had no effect",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,TERRA G-Quadruplex,?Tm ? 5 ºC; Kd = 8.8 µM,Ligand = 5 µM; RNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,MCF-7 Cells,No effect on NRAS mRNA levels,"Ligand = 5, 10, 20 µM",Target Engagement,RT-qPCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,DNA Parallel G-Quadruplex,?Tm = 0 ºC,Ligand = 5 µM; DNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,DNA Anti-Parallel G-Quadruplex,?Tm = 0.1 ºC,Ligand = 5 µM; DNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,DNA [3+1] Type 1 G-Quadruplex,?Tm = 0.4 ºC,Ligand = 5 µM; DNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,DNA [3+1] Type 2 G-Quadruplex,?Tm = 0.6 ºC,Ligand = 5 µM; DNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,DNA [3+1] Type 3 G-Quadruplex,?Tm = -0.5 ºC,Ligand = 5 µM; DNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,Stem-Loop RNA,?Tm = 0 ºC,Ligand = 5 µM; RNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0024,R-BIND (SM) 0024,O=C1N2CC3=NC4=C(C(=CS4)C4=CC=CO4)C(=O)N3CC2=NC2=C1C(=CS2)C1=CC=CO1,RGB-1,10.1021/jacs.6b04506,C,Double-Stranded RNA,?Tm = 0 ºC,Ligand = 5 µM; RNA = 5 and/or 2.5 µM,10 mM Tris-HCl (pH = 7.6) and 10 mM KCl,Binding,Circular Dichroism,-,"Compared to molecule 2, a fragment of RGB-1, which had no effect on Tm; Also synthesized ligand and compared activity to ensure integrity of purchased ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,C,"5'GUA/3'UCU, pre-miR-449c",NR,-,"8 mM Na2HPO4 (pH = 7.0), 190 mM NaCl, 1 mM EDTA and 40 ?g/mL BSA",Binding,Fluorescence-Based Titration (Labeled Small Molecule),Ligand was labeled with fluorescein and serially diluted,-,,MCF7 Cells,~2.5-fold increase in FOXO1 protein,Ligand = 40 µM,Protein Abundance,Western Blot,Western Blot to assess endogenous levels of FOXO1 protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,"5'UUU/3'AUA, miR-96 Precursor Processing Site",Kd = 1.3 ± 0.1 µM,-,"8 mM Na2HPO4 (pH = 7.0), 190 mM NaCl, 1 mM EDTA and 40 ?g/mL BSA",Binding,Fluorescence-Based Titration (Labeled Small Molecule),Ligand was labeled with fluorescein and serially diluted,-,,MCF7 Cells,Statistically significant increase in pre- and mature miRNA-96; Statistically significant increase in pri-miRNA-96; 90% decrease in mature miRNA-96 level,Ligand = 40 µM,RNA Abundance,qRT-PCR,-,"Compared to LNA and chemically similar, not active benzimidazole ligands 2, 4, and 5; Similar levels of silencing at 50 nM LNA",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,"5'CGAUUU/3'GGUAUA, Expanded miR-96 Precursor Processing Site",Kd = 3.4 ± 0.1 µM,-,"8 mM Na2HPO4 (pH = 7.0), 190 mM NaCl, 1 mM EDTA and 40 ?g/mL BSA",Binding,Fluorescence-Based Titration (Labeled Small Molecule),Ligand was labeled with fluorescein and serially diluted,-,,MCF7 Cells,15% decrease on miRNA-182 and no effect on miRNA-183 levels,Ligand = 40 µM,RNA Abundance,qRT-PCR,miRNA-182 and -183 are transcribed endogenously in the same transcript as miRNA-96,"Compared to LNA and chemically similar, not active benzimidazole ligands 2, 4, and 5; LNA only modestly discriminated between miR-96 and miR-183 at all of the concentrations tested (1–200 nm); The LNA silenced  ~50% of miR-183 expression (50 nM)",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,C,C1 Hairpin Cassette,NR,-,"8 mM Na2HPO4 (pH = 7.0), 190 mM NaCl, 1 mM EDTA and 40 ?g/mL BSA",Binding,Fluorescence-Based Titration (Labeled Small Molecule),Ligand was labeled with fluorescein and serially diluted,-,,MCF7 Cells,~1.7-fold increase in luciferase production,Ligand = 40 µM,Translational Activity,Reporter,Luciferase model system to assess expression levels of FOXO1 protein,"Compared to plasmid encoding FOXO1 3' UTR, which was not affected; Compared to chemically similar compounds benzimidazole 2, 4, and 5, which were not bioactive. ",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,,,,,,,,,,MCF7 Cells,40% of cells TUNEL positive ,Ligand = 40 µM,Apoptosis,TUNEL,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,,,,,,,,,,MCF7 Cells,Stimulated apoptosis not necrosis,Ligand = 40 µM,Apoptosis,Annexin V/Propidium Iodide,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,,,,,,,,,,MCF7 Cells,70% reduction in cells undergoing apoptosis,Ligand = 40 µM,On-Target Effect,Protein Knockdown,FOXO1 knockdown should reduce effect of small molecule,"Compared to cells transfected with an siRNA against GAPDH; Compared to chemically similar compounds benzimidazole 2, 4, and 5, which were not bioactive",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0025,R-BIND (SM) 0025,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Benzimidazole 1 (2014),10.1038/nchembio.1452,,,,,,,,,,,MCF7 Cells,Only miRNA-96 expression was affected by ~19 fold,Ligand = 40 µM,RNA Abundance,qRT-PCR,Tested modulation of 149 disease-associated and highly abundant miRNAs,"Compared to a full-length antagomir, which affected expression of 12 miRNAs by at least 2.5-fold",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0026,R-BIND (SM) 0026,NC(=[NH2+])NC1=CC=C(OC(=O)C2=CC=C(NC(N)=[NH2+])C=C2)C=C1,D6,10.1021/cb200413a,,5'CAG/3'GAC,?Tm = 3 ºC; 9 ºC,"Ligand = 1, 2 equiv","20 mM HEPES (pH = 7.5), 5 mM KCl, 150 mM NaCl, and 1 mM MgCl2",Binding,Optical Melting,Optical melting experiments to assess thermal stability ,-,,Huntington's Disease Patient Fibroblasts,Does not significantly affect the number or intensity of nuclear foci,Ligand = 200 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0026,R-BIND (SM) 0026,NC(=[NH2+])NC1=CC=C(OC(=O)C2=CC=C(NC(N)=[NH2+])C=C2)C=C1,D6,10.1021/cb200413a,,5'CAG/3'GAC,Kd = 0.06 ± 0.03 µM,D2 = 50 nM,"20 mM HEPES (pH = 7.5), 5 mM KCl, 150 mM NaCl, and 1 mM MgCl2",Binding,Fluorescence Displacement,Assay used D2 (a related compound) as a fluorescent indicator,-,,Huntington's Disease Patient Fibroblasts,Statistically significant improvements for NCOR2 (? 50 µM) and ATP2A1 (? 100 µM); Statistically significant shifts toward MD phenotype for MAPT (? 50 µM),"Ligand = 50, 100, 200, 300 µM",RNA Splicing,RT-PCR,HD fibroblasts expresses r(CAG)69,Does not alter splicing of ATP2A1 in normal cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0026,R-BIND (SM) 0026,NC(=[NH2+])NC1=CC=C(OC(=O)C2=CC=C(NC(N)=[NH2+])C=C2)C=C1,D6,10.1021/cb200413a,,r(CAG)12-MBNL1 Complex,IC50 = 3 µM,-,"20 mM HEPES, (pH = 7.5), 110 mM KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1% BSA, and 0.5% Tween-20",Protein Displacement,TR-FRET,-,-,,SK-N-MC Neuroblastoma,Statistically significant improvements for NCOR2 and ATP2A1 (? 100 µM); Statistically significant shifts toward MD phenotype for MAPT (? 50 µM),"Ligand = 50, 100, 200, 300 µM",RNA Splicing,RT-PCR,Model system expresses r(CAG)74,Does not alter splicing of ATP2A1 in normal cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/cb300135h,,Mixture of RNAs,Preferentially binds to r(CGG)12; Very little binding observed to protein; Less than half of observed binding to r(CGG)12 for hairpin RNAs,Ligand = 0.7 µM,NR,Binding,Competition Dialysis,"Two base-paired RNAs, r(CGG)12 and DGCR8? protein",,,COS7 Cells,Statistically significant improvements are observed for Bcl-x splicing (100 µM); Bcl-x splicing is restored to wild-type (500 µM),"Ligand = 100, 500 µM",RNA Splicing,Reporter,"Transfected with equal amounts of plasmid expressing 60 CGG repeats and a Bcl-x mini-gene; Compound was added, then RNA was extracted and subject to RT-PCR",Compared to cells that do not express r(CGG)60,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/cb300135h,,5'CGG/3'GGC Loop,Kd = 76 ± 4 nM,RNA = 1 µM; Hoechst 33258 = 1 µM,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Binding,Fluorescence Displacement,Hoechst 33258 was utilized as dye,,C,COS7 Cells,Did not affect alternative splicing of PLEKHH2 and cTNT,Ligand = 500 µM,RNA Splicing,Reporter,Splicing of PLEKHH2 and cTNT not regulated by the sequestered splicing protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,r(CGG)12,"Kd = 800 nM, 55 µM ",-,1 X Kinetics Buffer (ForteBio),Binding,Biolayer Interferometry,Two binding modes were reported,-,,COS7 Cells,80% inhibition of RANT,Ligand = 50 µM,Translational Activity,Western Blot,"Cells transfected with (CGG)88-GFP17, then grown in medium with compound; Cells were lysed and cellular proteins were separated by SDS-PAGE",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,r(CGG)12,?Tm = 3 ºC; ??G37º = 1.4 kcal/mol; ?H = -77.1 ± 0.1 kcal/mol; ?S = -225 ± 1 kcal/K*mol; ?G = -7.48 ± 0.02 kcal/mol,"Ligand = 1, 2.5, 5 µM; RNA = 1 µM","2 mM Na2HPO4 (pH = 7.0), 45 mM NaCl, and 25 ?M Na2EDTA",Binding,Optical Melting,-,-,,COS7 Cells,"Dose-dependent effect; Statistically significant reduction of inclusions (10, 100 µM); Maximal decrease is ~ 40%","Ligand = 1, 10, 100 µM",Translational Activity,Fluorescence Microscopy,RANT translation product FMRpolyG-GFP inclusions,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/cb300135h,,"r(CGG)12-DGCR8? Complex, 5 µM tRNA",IC50 = 12 ± 0.4 µM,-,"20 mM HEPES (pH = 7.5), 110 mM KCl, 110 mM NaCl, 0.1% (w/v) BSA, 2 mM MgCl2, 2 mM CaCl2, 0.05% (v/v) Tween-20, and 5 mM DTT",Protein Displacement,TR-FRET,-,-,,COS7 Cells,Improvements in SMN2 pre-mRNA splicing defects observed (20 µM); Improves SMN2 splicing levels to ~70% of wild-type (100 µM); SMN 2 splicing is restored to wild-type (500 µM),Ligand = 1 - 500 µM,RNA Splicing,Reporter,"Transfected with equal amounts of plasmid expressing 60 CGG repeats and a SMN2 mini-gene; Compound was added, then RNA was extracted and subject to RT-PCR",Compared to cells that do not express r(CGG)60,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,r(CGG)12-DGCR8? Complex,IC50 = 3.8 ± 0.3 µM; 20.1 ± 1.2 µM (tRNA),-,NR,Protein Displacement,TR-FRET,-,-,,COS7 Cells,5-fold enrichment of r(CGG)88-GFP,Ligand = 2.5 µM,Target Engagement,Chem-CLIP,Cells were transfected with a plasmid encoding (CGG)88-GFP17; Compound 1a was appended with a reactive module (CA) and biotin tag to synthesize 1a-CA-biotin,Measured enrichment of high abundant cellular RNAs and RNAs with at least five consecutive r(CGG) repeats; Modest enrichment was observed (> 2 fold) for RNAs containing r(CGG) repeats,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,"r(CGG)12-DGCR8? Complex, 62-fold Excess tRNA",IC50 = 20.1 ± 1.2 µM,-,NR,Protein Displacement,TR-FRET,-,-,,COS7 Cells,IC50 = 420 nM,Ligand (1a-CA-Biotin) = 2.5 µM,Target Engagement,Competitive Chem-CLIP,Cells were transfected with a plasmid encoding (CGG)88-GFP17; Cotreatment of cells with Compound 1a and 1a-CA-Biotin inhibited the probe from binding to the RNA target,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,,,,,,,,,,COS7 Cells,No toxicity observed,Ligand = 50 µM,Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/cb300135h,,,,,,,,,,,COS7 Cells,Reduced size and number of foci,Ligand = 1 - 20 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,Transfected with equal amounts of plasmid expressing 60 CGG repeats and a GFP mini-gene,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,,,,,,,,,,COS7 Cells,Reduced ribosome occupancy from 75% to 50%,Ligand = 50 µM,Ribosome Loading,NR,Cells transfected with RNA construct without a start codon (ATG),Compared to compound untreated cells; Checked abundance of ?-actin mRNA and no change observed,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027A,R-BIND (SM) 0027A,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1021/acschembio.6b00147,,,,,,,,,,,COS7 Cells,~ 70% inhibition of RANT,Ligand = 50 µM,Translational Activity,Western Blot,Cells transfected with RNA construct without a start codon (ATG),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,,G-Quadruplex Conformation of r(GGGGCC)8,Kd = 82 ± 8 µM,-,100 mM KCl,Binding,Biolayer Interferometry,-,-,,HEK293 Cells,Statistically significant decrease percentage of foci-positive cells,NR,Nuclear Foci Dispersion,RNA Fluorescence In Situ Hybridization ,-,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,,r(GGGGCC)8,0.95 kcal/mol stabilization; Tm increase of 3.1 ºC; ?H = -74.4 ± 1.0 kcal/mol; ?S = -208 ± 3 cal/K*mol; ?G = -9.93 ± 0.15 kcal/mol ,Ligand = 1 µM; RNA = 3 µM,10 mM Tris HCl (pH = 7.4) and 100 mM NaCl,Binding,Optical Melting,-,-,,C9ORF72 iNeurons (Three patient derived),Statistically significant decrease in percentage of cells with RNA foci,Ligand = 2 µM,Nuclear Foci Dispersion,RNA Fluorescence In Situ Hybridization ,Fibroblasts derived from patient skin samples were converted to iNeurons by transduction with pLKO.1 coding for shPTB1,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,C,r(CGG)12,Kd = 9.7 ± 1.0 µM,-,NR,Binding,Biolayer Interferometry,-,-,,COS7 Cells,80-fold enrichment in r(GGGGCC)66,NR,Target Engagement,Chem-CLIP,"Transfected to express (GGGGCC)66 with no upstream ATG; Synthesized 1a-CA-biotin, a ligand conjugate with chlorambucil (CA) and biotin attached",Compared to 18S rRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,C,r(GGCC)4,Kd = 8.4 ± 3.2 µM,-,NR,Binding,Biolayer Interferometry,-,-,,COS7 Cells,1a-CA-biotin-RNA adduct formation was significantly depleted upon addition of 1a,NR,Target Engagement,Competitive Chem-CLIP,Transfected to express (GGGGCC)66 with no upstream ATG; Performed a competitive binding experiment with 1a and 1a-CA-biotin,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,C,Hairpin,Kd > 50 µM,-,NR,Binding,Biolayer Interferometry,-,-,,HEK293 Cells,Significantly decreased protein levels,Ligand = 100 µM,Translational Activity,Western Blot,Repeat Associated non-ATG (RAN) Translation; Transfected with (GGGGCC)66; Cells were treated with compound and poly(GP) and poly(GA) proteins translation was monitored,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,,Hairpin Conformation of r(GGGGCC)8,Kd = 71 ± 7 µM,-,100 mM NaCl,Binding,Biolayer Interferometry,-,-,,HEK293 Cells,"Dose-dependent and statistically significant response; Decreased levels by 10, 18, and 47%, respectively","Ligand = 25, 50, 100 µM",Translational Activity,ELISA,Repeat Associated non-ATG (RAN) Translation; Transfected with (GGGGCC)66; Cells were treated with compound and poly(GP) and poly(GA) proteins translation was monitored,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,,,,,,,,,,C,C9ORF72 iNeurons (Three patient derived),No change in C9ORF72 transcript levels,Ligand = 4 µM,RNA Abundance,qRT-PCR,Fibroblasts derived from patient skin samples were converted to iNeurons by transduction with pLKO.1 coding for shPTB1,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0027B,R-BIND (SM) 0027B,CC1=C2C=C[N+](CC[NH+]3CCCCC3)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Hydroxyellipticine 1a,10.1016/j.neuron.2014.07.041,,,,,,,,,,,C9ORF72 iNeurons (Three patient derived),Statistically significant decrease in percentage of cells with inclusions of and dose-dependent decrease in RAN translation of poly(GP) but not poly(PR) ,"Ligand = 2, 4 µM",Translational Activity,ELISA,Repeat Associated non-ATG (RAN) Translation; Transfected with (GGGGCC)66; Fibroblasts derived from patient skin samples were converted to iNeurons by transduction with pLKO.1 coding for shPTB1,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0028,R-BIND (SM) 0028,[O-][N+](=O)C1=CC=C2NC(CCCC3=NC4=CC(=CC=C4N3)[N+]([O-])=O)=NC2=C1,Benzimidazole 1 (2015),10.1021/acschembio.5b00430,,Mixture of RNAs,Bound to r(CUG)109 to greatest extent,Ligand = 5 µM,"8 mM NaH2PO4 (pH = 7.2), 185 mM NaCl, and 1 mM EDTA",Binding,Competition Dialysis,"Human rRNA A-site, MBNL1-binding site in cTNT pre-mRNA, RNA with GC base-pairs, and RNAs with different numbers of r(CUG) repeats (1X2, 6X2, and 109); Binding was also evaluated to MBNL1",-,C,HeLa Cells,40% reduction in DMPK mRNA,Ligand = 100 µM,RNA Abundance,qRT-PCR,Off-target effect,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0028,R-BIND (SM) 0028,[O-][N+](=O)C1=CC=C2NC(CCCC3=NC4=CC(=CC=C4N3)[N+]([O-])=O)=NC2=C1,Benzimidazole 1 (2015),10.1021/acschembio.5b00430,,r(CUG)12-MBNL1 Complex,IC50 = 63.8 ± 3.2 µM,-,"20 mM HEPES (pH = 7.5), 100 M KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1 % BSA, and 0.05 % Tween 20",Protein Displacement,TR-FRET,Biotinylated r(CUG)12 or MBNL1-His6 was incubated with compound; The RNA/protein were combined and incubated,-,,HeLa Cells,Significantly improved DM1 pre-mRNA splicing defects while not altering cTNTpre-mRNA splicing in the absence of r(CUG)960,Ligand = 100 µM,RNA Splicing,Reporter,Cells were transfected with a plasmid containing Lipofectamine 2000; Equal amounts of plasmid expressing a DM1 mini-gene with 960 CTG repeats and mini-gene that reports on cTNT alternative splicing (regulated by MBNL1) were used; Cells were lysed and RNA harvested then subjected to RT-PCR; Compounds were evaluated at 100 µM,Compared to cells that do not express r(CUG)960 mini-gene,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0028,R-BIND (SM) 0028,[O-][N+](=O)C1=CC=C2NC(CCCC3=NC4=CC(=CC=C4N3)[N+]([O-])=O)=NC2=C1,Benzimidazole 1 (2015),10.1021/acschembio.5b00430,,,,,,,,,,,HeLa Cells,Little to no effect on cell viability,"Ligand = 25, 50, 100 µM",Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0028,R-BIND (SM) 0028,[O-][N+](=O)C1=CC=C2NC(CCCC3=NC4=CC(=CC=C4N3)[N+]([O-])=O)=NC2=C1,Benzimidazole 1 (2015),10.1021/acschembio.5b00430,,,,,,,,,,,HeLa Cells,Significant reduction in r(CUG)exp pulled down by 2H-4-CA,Ligand = 10 µM; 2H-4-CA = 100 nM,On-Target Effect,Competitive Chem-CLIP,2H-4-CA-Biotin is a compound that bind and crosslinks to r(CUG) in cellulo; The amount of r(CUG)exp pulled down with 2H-4-CA-Biotin in presence of compound was measured,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0029,R-BIND (SM) 0029,O=C(NC1=CC=C(C=C1)C1=NC2=CC(NC(=O)C3=CC=CO3)=CC=C2N1)C1=CC=CO1,Benzimidazole 16 (2015),10.1021/acschembio.5b00430,,Mixture of RNAs,Bound to r(CUG)109 to greatest extent,Ligand = 5 µM,"8 mM NaH2PO4 (pH = 7.2), 185 mM NaCl, and 1 mM EDTA",Binding,Competition Dialysis,"Human rRNA A-site, MBNL1-binding site in cTNT pre-mRNA, RNA with GC base-pairs, and RNAs with different numbers of r(CUG) repeats (1X2, 6X2, and 109); Binding was also evaluated to MBNL1",-,,HeLa Cells,Significant reduction in r(CUG)exp pulled down by 2H-4-CA,Ligand = 10 µM; 2H-4-CA = 100 nM,On-Target Effect,Competitive Chem-CLIP,2H-4-CA-Biotin is a compound that bind and crosslinks to r(CUG) in cellulo; The amount of r(CUG)exp pulled down with 2H-4-CA-Biotin in presence of compound was measured,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0029,R-BIND (SM) 0029,O=C(NC1=CC=C(C=C1)C1=NC2=CC(NC(=O)C3=CC=CO3)=CC=C2N1)C1=CC=CO1,Benzimidazole 16 (2015),10.1021/acschembio.5b00430,,r(CUG)12-MBNL1 Complex,IC50 = 92.0 ± 6.0 µM,-,"20 mM HEPES (pH = 7.5), 100 M KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1 % BSA, and 0.05 % Tween 20",Protein Displacement,TR-FRET,Biotinylated r(CUG)12 or MBNL1-His6 was incubated with compound; The RNA/protein were combined and incubated,-,,HeLa Cells,Significantly improved DM1 pre-mRNA splicing defects while not altering cTNTpre-mRNA splicing in the absence of r(CUG)960,Ligand = 100 µM,RNA Splicing,Reporter,Cells were transfected with a plasmid containing Lipofectamine 2000; Equal amounts of plasmid expressing a DM1 mini-gene with 960 CTG repeats and mini-gene that reports on cTNT alternative splicing (regulated by MBNL1) were used; Cells were lysed and RNA harvested then subjected to RT-PCR; Compounds were evaluated at 100 µM,Compared to cells that do not express r(CUG)960 mini-gene,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0029,R-BIND (SM) 0029,O=C(NC1=CC=C(C=C1)C1=NC2=CC(NC(=O)C3=CC=CO3)=CC=C2N1)C1=CC=CO1,Benzimidazole 16 (2015),10.1021/acschembio.5b00430,,,,,,,,,,,HeLa Cells,Little to no effect on cell viability,"Ligand = 25, 50, 100 µM",Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0029,R-BIND (SM) 0029,O=C(NC1=CC=C(C=C1)C1=NC2=CC(NC(=O)C3=CC=CO3)=CC=C2N1)C1=CC=CO1,Benzimidazole 16 (2015),10.1021/acschembio.5b00430,,,,,,,,,,C,HeLa Cells,No change in DMPK mRNA,Ligand = 100 µM,RNA Abundance,qRT-PCR,Off-target effect,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0030,R-BIND (SM) 0030,ClC1=CC=C(C=C1)C1=CC=C(O1)C(=O)NC1=CC=C(C=C1)C1=NC2=CC=CC=C2N1,Benzimidazole 17 (2015),10.1021/acschembio.5b00430,,Mixture of RNAs,Bound to r(CUG)109 to greatest extent,Ligand = 5 µM,"8 mM NaH2PO4 (pH = 7.2), 185 mM NaCl, and 1 mM EDTA",Binding,Competition Dialysis,"Human rRNA A-site, MBNL1-binding site in cTNT pre-mRNA, RNA with GC base-pairs, and RNAs with different numbers of r(CUG) repeats (1X2, 6X2, and 109); Binding was also evaluated to MBNL1",-,,HeLa Cells,Significant reduction in r(CUG)exp pulled down by 2H-4-CA,Ligand = 10 µM; 2H-4-CA = 100 nM,On-Target Effect,Competitive Chem-CLIP,2H-4-CA-Biotin is a compound that bind and crosslinks to r(CUG) in cellulo; The amount of r(CUG)exp pulled down with 2H-4-CA-Biotin in presence of compound was measured,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0030,R-BIND (SM) 0030,ClC1=CC=C(C=C1)C1=CC=C(O1)C(=O)NC1=CC=C(C=C1)C1=NC2=CC=CC=C2N1,Benzimidazole 17 (2015),10.1021/acschembio.5b00430,,r(CUG)12-MBNL1 Complex,IC50 = 128.7 ± 1.4 µM,-,"20 mM HEPES (pH = 7.5), 100 M KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1 % BSA, and 0.05 % Tween 20",Protein Displacement,TR-FRET,Biotinylated r(CUG)12 or MBNL1-His6 was incubated with compound; The RNA/protein were combined and incubated,-,,HeLa Cells,Significantly improved DM1 pre-mRNA splicing defects while not altering cTNTpre-mRNA splicing in the absence of r(CUG)960,Ligand = 100 µM,RNA Splicing,Reporter,Cells were transfected with a plasmid containing Lipofectamine 2000; Equal amounts of plasmid expressing a DM1 mini-gene with 960 CTG repeats and mini-gene that reports on cTNT alternative splicing (regulated by MBNL1) were used; Cells were lysed and RNA harvested then subjected to RT-PCR; Compounds were evaluated at 100 µM,Compared to cells that do not express r(CUG)960 mini-gene,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0030,R-BIND (SM) 0030,ClC1=CC=C(C=C1)C1=CC=C(O1)C(=O)NC1=CC=C(C=C1)C1=NC2=CC=CC=C2N1,Benzimidazole 17 (2015),10.1021/acschembio.5b00430,,,,,,,,,,,HeLa Cells,Little to no effect on cell viability,"Ligand = 25, 50, 100 µM",Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0030,R-BIND (SM) 0030,ClC1=CC=C(C=C1)C1=CC=C(O1)C(=O)NC1=CC=C(C=C1)C1=NC2=CC=CC=C2N1,Benzimidazole 17 (2015),10.1021/acschembio.5b00430,,,,,,,,,,C,HeLa Cells,No change in DMPK mRNA,Ligand = 100 µM,RNA Abundance,qRT-PCR,Off-target effect,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,,"5'CUG/3'GUC, DM1 Motif",Kd = 70 ± 32 nM,-,"8 mM Na2PO4 (pH = 7.0), 185 mM NaCl, and 0.1 mM EDTA",Binding,Fluorescence Anisotropy,-,-,,C2C12L Mouse Myoblast,Modest increase in the fraction of cells expressing DsRed,Ligand = 20 µM,RNA Splicing,Reporter,Analysis by flow cytometry; ~ 55% of transfected cells alone express DsRed or a combination of DsRed and EGFP; ~70% of co-transfected cells with MBNL1 coding sequence express DsRed or a combination of DsRed and EGFP; ~0% of the cells with co-transfected with a mini-gene containing 960 CUG repeats in the DMPK content express DsRed,"Compared to the absence of DT960, which led to a slight decrease in the fraction of cells expressing DsRed; One mouse myoblast line contains a stably transfected shRNA hairpin control",,DM1 HSALR mouse model (Clcn1),"Statistically significant, partial rescue of Clcn1exon 7a exclusion, 54 ± 1.4% to 69 ± 1.4%",Intraperitoneal; 100 mg/kg once a day for seven days,RNA Splicing,PCR,"Mice were sacrificed one day after the last injection; Vastus muscle was obtained, RNA extracted, and cDNA synthesized; PCR amplification allowed quantification of the mis-splicing of Clcn1",Normal exclusion rate is 96 ± 0.2%,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,C,Fully Paired RNA,Kd = 190 ± 61 nM,-,"8 mM Na2PO4 (pH = 7.0), 185 mM NaCl, and 0.1 mM EDTA",Binding,Fluorescence Anisotropy,-,-,,C2C12E5 Mouse Myoblast,Modest increase in the fraction of cells expressing DsRed,Ligand = 20 µM,RNA Splicing,Reporter,Analysis by flow cytometry; ~ 55% of transfected cells alone express DsRed or a combination of DsRed and EGFP; ~70% of co-transfected cells with MBNL1 coding sequence express DsRed or a combination of DsRed and EGFP; ~0% of the cells with co-transfected with a mini-gene containing 960 CUG repeats in the DMPK content express DsRed,"Compared to the absence of DT960, which led to a slight decrease in the fraction of cells expressing DsRed; One mouse myoblast line contains a stably transfected shRNA hairpin control",,DM1 HSALR mouse model (Serca1),"Statistically significant, partial rescue of Serca1mis-splicing, 30 ± 0.6 % to 41 ± 4.0%",Intraperitoneal; 80 mg/kg once a day for seven days,RNA Splicing,PCR,"Mice were sacrificed one day after the last injection; Vastus muscle was obtained, RNA extracted, and cDNA synthesized; PCR amplification allowed quantification of the mis-splicing of Atp2a1/Serca1",Normal exclusion rate is 99.8 ± 0.1%,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,C,Mixture of RNAs,"Greatest amount of binding observed for DM1 motif; Significant binding also observed to 5?CUG/3?GCC, 5?CGG/3?GGC, and 5?CAG/3?GACT",Ligand = 1 µM,-,Binding,Competition Dialysis,"RNAs with DM1 motif, fully paired RNA, RNAs displaying other 1 X 1 nucleotide internal loops, a A-site mimic, and a cTNT pre-mRNA mimic",-,,HeLa Cells,"Modest improvement of splicing (500 µM;) Nearly restored to wild-type, where difference in inclusion between r(CUG)exp treated and untreated cells was determined to not be statistically significant (1 or 2 mM)",-,RNA Splicing,Reporter,"Co-transfected with plasmids containing a DM1 mini-gene, containing 960 CTG repeats in a 3'UTR of cTNT pre-mRNA; Control experiments verified that H1 does not globally affect RNA splicing","Compared to Hoechst 33258; Control experiments to determine global effects on splicing - Cotransfection of (CTG)5 mini-gene in 3' UTR and cTNT mini-gene - no effect observed. No splicing observed for non-MBNL1 regulated transcripts PLEKHH2 (mini-gene), TTC8 (endogenous), and CAMKK2 (endogenous)",,DM1 HSALR mouse model (Serca1),"Statistically significant, partial rescue of Serca1mis-splicing, 30 ± 0.6 % to 42 ± 3.0%",Intraperitoneal; 100 mg/kg once a day for seven days,RNA Splicing,PCR,"Mice were sacrificed one day after the last injection; Vastus muscle was obtained, RNA extracted, and cDNA synthesized; PCR amplification allowed quantification of the mis-splicing of Atp2a1/Serca1",Normal exclusion rate is 99.8 ± 0.1%,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,C,Mixture of RNAs,"Stoichiometric binding observed; Binding increased with the number of repeats of DM1 motif, and preference was observed for DM1 motifs",Ligand = 1 µM,-,Binding,Competition Dialysis,"RNAs containing 1-6 copies of DM1 repeat, A-site mimic, cTNT pre-mRNA mimic, and MBNL1 ",-,C,HeLa Cells,No effect of PLEKHH2 splicing,Ligand = 2 mM,RNA Splicing,Reporter,PLEKHH2 splicing not regulated by MBNL1,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,,r(CUG)12-MBNL1 Complex,IC50 = 50 µM,-,"20 mM HEPES (pH = 7.5), 110 mM KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1% BSA, and 0.5% Tween-20",Protein Displacement,qTR-FRET,-,Compared to no ligand and no RNA,,HeLa Cells,Modest increase in the fraction of cells expressing DsRed,Ligand = 20 µM,RNA Splicing,Reporter,Analysis by flow cytometry; ~ 55% of transfected cells alone express DsRed or a combination of DsRed and EGFP; ~70% of co-transfected cells with MBNL1 coding sequence express DsRed or a combination of DsRed and EGFP; ~0% of the cells with co-transfected with a mini-gene containing 960 CUG repeats in the DMPK content express DsRed,"Compared to the absence of DT960, which led to a slight decrease in the fraction of cells expressing DsRed",,DM1 HSALR mouse model (Clcn1),"Statistically significant, partial rescue of Clcn1exon 7a exclusion, 54 ± 1.4% to 66 ± 0.6%",Intraperitoneal; 80 mg/kg once a day for seven days,RNA Splicing,PCR,"Mice were sacrificed one day after the last injection; Vastus muscle was obtained, RNA extracted, and cDNA synthesized; PCR amplification allowed quantification of the mis-splicing of Clcn1",Normal exclusion rate is 96 ± 0.2%,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,,,,,,,,,,,HeLa Cells,Cell integrity is largely preserved,Ligand = 500 µM,Cytotoxicity,Propidium Iodide Stain,Analyzed by flow cytometry,Compared to DMSO and growth medium,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,,,,,,,,,,,HeLa Cells,Decreased percentage of cells with nuclear foci when dosed with 1mM or 2mM compound,"Ligand = 1, 2 mM",Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"Co-transfected cells with a DM1 minigene plasmid; After incubation with H1, cells were fixed, permeabilized, and incubated with DY547-labeled 2'Ome oligonucleotide complementary to rCUG repeats",No effect observed at 500 µM,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0031,R-BIND (SM) 0031,NC1=CC(=CC=C1)C1=NC2=CC(=CC=C2N1)C1=CC=C2NC(=NC2=C1)C1=CC(N)=CC=C1,H1,10.1021/ja210088v,,,,,,,,,,C,HeLa Cells,No effect on endogenous TTC8 or CAMKK2 splicing,NR,RNA Splicing,NR,TTC8 and CAMKK2 not regulated by MBNL1,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0032,R-BIND (SM) 0032,COC(=O)C1=C2[NH+]=C3C([O-])=CC(=O)C(C=O)=C3[N-]C2=C([O-])C=C1,Lomofungin,10.1093/nar/gku275,,r(CUG)10,Kd = 998 ± 180 nM,-,1 X HEPES buffered saline with 0.5% DMSO and 0.005% Tween-20,Binding,Fluorescence-Based Titration (Labeled RNA),Cy3-labeled RNA,,,C2C12 Myogenic,3.7 fold increase in luciferase,Ligand = 10 µM,Translational Activity,Reporter,Transfected with flu caused to a DMPK3' UTR that contained either 0 or 800 CTG repeats; Luciferase activity was monitored after addition of compound,Compared to construct with 0 CTG repeats and a 25-mer morpholino antisense oligonucleotide; Levels were similar to vehicle alone,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0032,R-BIND (SM) 0032,COC(=O)C1=C2[NH+]=C3C([O-])=CC(=O)C(C=O)=C3[N-]C2=C([O-])C=C1,Lomofungin,10.1093/nar/gku275,,r(CUG)12-MBNL1 Complex,"IC50 = 717 nM; 95% confidence interval, 533 - 964 nM",-,"20 mM HEPES, 110 mM KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1 % BSA, and 0.05 % Tween 20",Protein Displacement,AlphaScreen,Biotinylated RNA and an MBNL1-?105-His6 protein were used; AlphaScreen donor beads coupled with AlphaScreen acceptor beads were used to detect a close proximity between the RNA/protein complex,,,C2C12 Myogenic,No change in foci,Ligand = 10 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,Measured levels of fluc-CUGxp; Experiment conducted three days after addition of compound,Compared to DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0032,R-BIND (SM) 0032,COC(=O)C1=C2[NH+]=C3C([O-])=CC(=O)C(C=O)=C3[N-]C2=C([O-])C=C1,Lomofungin,10.1093/nar/gku275,,,,,,,,,,,C2C12 Myogenic,IC50 = 7.5 µM,-,Cytotoxicity,WST-1,Experiment conducted three days after addition of compound,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0032,R-BIND (SM) 0032,COC(=O)C1=C2[NH+]=C3C([O-])=CC(=O)C(C=O)=C3[N-]C2=C([O-])C=C1,Lomofungin,10.1093/nar/gku275,,,,,,,,,,,C2C12 Myogenic,Increased diffuse nucleoplasmic staining,Ligand = 10 µM,Localization,Immunofluorescence,Fluc800 cells stained for MBNL1; Experiment conducted three days after addition of compound; Consistent with partial alleviation of MBNL1 sequestration,Compared to vehicle,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0032,R-BIND (SM) 0032,COC(=O)C1=C2[NH+]=C3C([O-])=CC(=O)C(C=O)=C3[N-]C2=C([O-])C=C1,Lomofungin,10.1093/nar/gku275,,,,,,,,,,,C2C12 Myogenic,Promoted inclusion of Serca1ex22 to 71 ± 3%,Ligand = 10 µM,RNA Splicing,RT-PCR,Transfected with pLC16 for conditional expression of expanded CUG repeats; Transcription blocked by a floxed transcription terminator element (TTE); TTE was upstream of a hygromycin selectable marker fused to the DMPK3' UTR containing 800 CUG repeats,Background level of Serca1ex22 inclusion was 54 ± 3%,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,,r(CUG)12,Kd = 125 ± 0.052 nM; Stoichiometry = 6 ± 0.4,-,1 X PBS,Binding,Fluorescence Anisotropy,-,-,,HeLa Cells,Less MBNL1 in foci,Ligand = 100 µM,Nuclear Foci Dispersion,Immunohistochemistry,MB1a antibody,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,MBNL1,Kd >> 2000 nM,-,1 X PBS,Binding,Fluorescence Anisotropy,Weak protein binding,-,C,HeLa Cells,"No change in PLEKHH2, SMN2, and BCL-x splicing",Ligand = 500 µM,RNA Splicing,Reporter,Mini-genes whose splicing is not regulated by MBNL1,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,BSA,Kd >> 2000 nM,-,1 X PBS,Binding,Fluorescence Anisotropy,Weak protein binding,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,r(CAG)12,Kd = 1400 ± 0.2 nM; Stoichiometry = 1.2 ± 0.1,-,1 X PBS,Binding,Fluorescence Anisotropy,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,1 X 1 UU Hairpin,Kd = 530 ± 0.1 nM; Stoichiometry = 1.0 ± 0.1,-,1 X PBS,Binding,Fluorescence Anisotropy,Suggest positive cooperativity with longer RNAs,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,AU Stem,Kd >> 25000 nM,-,1 X PBS,Binding,Fluorescence Anisotropy,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,,r(CCGCUGCGG)2,Ligand stacks on closing GC pair and form three hydrogen bonds with the uridine bases; Pathway for binding is via the minor groove side,-,-,In Silico,Docking,NMR-informed structure (PDB #218C); Generated 50 random RNA:ligand complexes and refined with implicit solvent MD simulations,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,r(CCUG)12-MBNL1 Complex,IC50 = 29 ± 3 µM; 15-fold selectivity,-,NR,Protein Displacement,TR-FRET,Biotinylated r(CCUG)12 was incubated with compound and MBNL1-His6 was added; Fluorescently-labeled anti-His6 antibody and streptavidin are used as FRET pair,-,,HeLa Cells,Foci are more dispersed,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,,r(CUG)12-MBNL1 Complex,IC50 = 2 ± 0.4 µM,-,NR,Protein Displacement,TR-FRET,Biotinylated r(CUG)12 was incubated with compound and MBNL1-His6 was added; Fluorescently-labeled anti-His6 antibody and streptavidin are used as FRET pair,-,,HeLa Cells,Restored IR and cTNT pre-mRNA splicing to normal levels,Ligand = 125 µM,RNA Splicing,Reporter,Mini-gene expressed 960 r(CUG) repeats; Cells were co-transfected with the mini-gene or an empty vector; Percentage of splicing isoform was determined using RT-PCR,Compared to cells that lack r(CUG)exp,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,r(CAG)12-MBNL1 Complex,IC50 = 37 ± 5 µM; 20-fold selectivity,-,NR,Protein Displacement,TR-FRET,Biotinylated r(CAG)12 was incubated with compound and MBNL1-His6 was added; Fluorescently-labeled anti-His6 antibody and streptavidin are used as FRET pair,-,,HeLa Cells,Completely restored splicing levels; Statistically indistinguishable,Ligand = 300 µM,RNA Splicing,Reporter,Mini-gene expressed 960 r(CUG) repeats; Cells were co-transfected with the mini-gene or an empty vector; Percentage of splicing isoform was determined using RT-PCR,Compared to cells that lack r(CUG)exp,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033A,R-BIND (SM) 0033A,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1038/ncomms3044,C,r(CGG)12-MBNL1 Complex,IC50 = 45 ± 5 µM; 24-fold selectivity,-,NR,Protein Displacement,TR-FRET,Biotinylated r(CGG)12 was incubated with compound and MBNL1-His6 was added; Fluorescently-labeled anti-His6 antibody and streptavidin are used as FRET pair,-,,HEK 293T Cells,Dysregulation of cTNT alternative splicing is improved; Less for MBNL2 protein,Ligand = 300 µM,RNA Splicing,Reporter,HEK cells express MBNL proteins at low levels; Tested effect of MBNL2 sequestration; Cells co-transfected with the DM1 cTNT mini-gene and increasing amounts of a plasmid encoding MBNL1 or MBNL2,Compared to untreated cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,miR-544,Dose-dependent and nanomolar inhibition of nuclease processing; 50% inhibition at 20 nM,Ligand = 0.02 - 20 µM,1 X Reaction buffer (Genlantis),Activity,Dicer Protection,-,Compared to RNase T1,,MCF-10A (hypoxic),"Decreased miR-544, HIF-1?, and ATM transcripts and increased mTOR transcripts; Antagomir failed to significantly alter HIF-1? and ATM transcripts",Ligand = 20 nM,RNA Abundance,qRT-PCR,qRT-PCR analysis for cells under hypoxic conditions,Compared to miR-544 antagomir and normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,C,Dicer UA Hairpin,No binding; > 50-fold selectivity,Ligand = 1.25 µM,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,C,MDA-MB-231 (hypoxic),"Pearson correlation coefficient, r = 0.9980",Ligand = 20 nM,Global mRNA Abundance,Microarray,Confirmed few if any off-target events,Compared to untreated cells and miR-544 antagomir,,Immunodeficient NOD/SCID mice,2 of 3 mice had no detectable tumors,Intraperitoneal; 100 µL of 40 µM,Tumor Burden,Bioluminescent Imaging,MDA-MB-231-GFP-luc cells implanted subcutaneously followed by a single IP injection of compound after 24 h; Tumor growth was assessed after 3 weeks; No side effects observed,Compared to miR-544 antagomir and untreated mice as well,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,C,DNA 650 Basepair,No binding,Ligand = 30 µM; DNA = 20 nM,NR,Binding,Electrophoretic Mobility Shift Assay,-,Compared to 5 µM DAPI,,MDA-MB-231 (hypoxic),Prevented growth arrest of tumor cell lines under hypoxic conditions,Ligand = 20 nM,Proliferation,Flow Cytometry,Carboxyfluorescein succinimidyl ester (CFSE) stain,Compared to miR-544 antagomir; Did not affect immortalized epithelial cells in normoxia or hypoxia,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,Drosha UU Hairpin,Kd in mid-nanomolar range,Ligand = 1.25 µM,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,MDA-MB-231 (hypoxic),"Decreased miR-544, HIF-1?, and ATM transcripts and increased mTOR transcripts; Similar to antagomir but at 25-fold lower concentration",Ligand = 20 nM,RNA Abundance,qRT-PCR,qRT-PCR analysis for cells under hypoxic conditions,Compared to miR-544 antagomir and normoxic conditions,,Immunodeficient NOD/SCID mice,"Decreased levels of miR-544, HIF-1?, and ATM and increased levels of mTOR",Intraperitoneal; 100 µL of 40 µM,RNA Abundance,qRT-PCR,MDA-MB-231-GFP-luc cells implanted subcutaneously followed by a single IP injection of compound after 24 h; RNA abundance was assessed after 3 weeks; No side effects observed,Compared to miR-544 antagomir and untreated mice as well,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,Dicer UU Hairpin,Kd in mid-nanomolar range,Ligand = 1.25 µM,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,MDA-MB-231 (hypoxic),"Pearson correlation coefficient, r = 0.9896; Largest downregulation was miR-544",Ligand = 20 nM,RNA Abundance,Microarray,-,Compared to untreated cells and miR-544 antagomir,,Immunodeficient NOD/SCID mice,Significant reduction of tumor growth,Pretreated; 20 nM,Tumor Burden,Bioluminescent Imaging,MDA-MB-231-GFP-luc cells were pretreated and implanted subcutaneously into mice; Tumor progression was monitored after 3 weeks,Compared to miR-544 Antagomir and untreated cells,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,C,Drosha UA Hairpin,No binding,Ligand = 1.25 µM,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,MCF-7 (hypoxic),"Decreased miR-544, HIF-1?, and ATM transcripts and increased mTOR transcripts; Similar to antagomir but at 25-fold lower concentration",Ligand = 20 nM,RNA Abundance,qRT-PCR,qRT-PCR analysis for cells under hypoxic conditions,Compared to miR-544 antagomir and normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MDA-MB-231 (hypoxic),Induced apoptosis,Ligand = 20 nM,Apoptosis,Flow Cytometry,Annexin V Stain,Compared to miR-544 antagomir; Did not affect cells in normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MDA-MB-231 (hypoxic),Induced apoptosis by approximately 5-fold,Ligand = 20 nM; Rapamycin = 100 nM,Apoptosis,Flow Cytometry,Annexin V Stain,"Compared to miR-544 antagomir; Did not affect cells in normoxic conditions; Rapamycin is an inhibitor of the mTOR signaling pathway, probing the effect of mTOR expression level on the phenotype",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MCF-7 (hypoxic),Induced apoptosis,Ligand = 20 nM,Apoptosis,Flow Cytometry,Annexin V Stain,Compared to miR-544 antagomir; Did not affect cells in normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MCF-10A (hypoxic),Did not induce apoptosis,Ligand = 20 nM,Apoptosis,Flow Cytometry,Annexin V Stain,Compared to miR-544 antagomir; Did not affect cells in normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MDA-MB-231 (hypoxic),Significantly reduced chemoresistance to 5-fluorouracil under hypoxic conditions,Ligand = 20 nM; 5-Fluorouracil = 10 - 80 µM,Chemoresistance,MTT,Hypoxia selects tumor cells with drug resistant chemotypes with reduced sensitivity to chemotherapeutic agents,Compared to miR-544 antagomir,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MCF-7 (hypoxic),Significantly reduced chemoresistance to 5-fluorouracil under hypoxic conditions,Ligand = 20 nM; 5-Fluorouracil = 10 - 80 µM,Chemoresistance,MTT,Hypoxia selects tumor cells with drug resistant chemotypes with reduced sensitivity to chemotherapeutic agents,Compared to miR-544 antagomir,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MCF-7 (hypoxic),Prevented growth arrest of tumor cell lines under hypoxic conditions,Ligand = 20 nM,Proliferation,Flow Cytometry,Carboxyfluorescein succinimidyl ester (CFSE) stain,Compared to miR-544 antagomir; Did not affect immortalized epithelial cells in normoxia or hypoxia,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0033B,R-BIND (SM) 0033B,NC1=NC(N2CCCC2)=C(C#N)C2=CC(=NC(N)=C12)N1CCCC1,Naphthyridine 2,10.1021/acschembio.5b00265,,,,,,,,,,,MCF-10A (hypoxic),Prevented growth arrest of tumor cell lines under hypoxic conditions,Ligand = 20 nM,Proliferation,Flow Cytometry,Carboxyfluorescein succinimidyl ester (CFSE) stain,Compared to miR-544 antagomir; Did not affect immortalized epithelial cells in normoxia or hypoxia,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0034,R-BIND (SM) 0034,O=C(NC1=CC=CC=N1)C1=CC(OCC2=CSC=N2)=CC=C1,p1,10.1016/j.bmcl.2016.10.037,,r(CUG)12-MBNL1 Complex,> 20% disruption,Ligand = 50 µM,"20 mM HEPES (pH = 7.5), 100 mM KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1% (w/v) BSA, and 0.05% (v/v) Tween-20",Protein Displacement,TR-FRET,-,Compared to the untreated complex,,C2C12 Cells,"Statistically significant Increase in luciferase (25, 50 µM)","Ligand = 50, 25, 12.5 µM",Transport Activity,Reporter,"Luciferase-encoding mRNA w/ 800 CUG repeats in 3'' UTR. Tested at 50, 25, and 12.5 µM",Compared to same cell line infected with plasmid with no CUG repeats ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0034,R-BIND (SM) 0034,O=C(NC1=CC=CC=N1)C1=CC(OCC2=CSC=N2)=CC=C1,p1,10.1016/j.bmcl.2016.10.037,,,,,,,,,,,NR,No change,Ligand = 100 µM,Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0034,R-BIND (SM) 0034,O=C(NC1=CC=CC=N1)C1=CC(OCC2=CSC=N2)=CC=C1,p1,10.1016/j.bmcl.2016.10.037,,,,,,,,,,C,HeLa Cells,Slightly increased DMPK levels,Ligand = 100 µM,RNA Abundance,RT-qPCR,DM1/DMPK mini gene was transfected into cells and then treated with compound,Compared to untreated control; Indicates the ligand may alter the transcription of the gene,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0034,R-BIND (SM) 0034,O=C(NC1=CC=CC=N1)C1=CC(OCC2=CSC=N2)=CC=C1,p1,10.1016/j.bmcl.2016.10.037,,,,,,,,,,,HeLa Cells,Statistically significant Improvement in cRNR alternative splicing defect,"Ligand = 10, 100 µM",RNA Splicing,Reporter,"Cells transfected with DM1 minigene and 960 CTG repeats, and a minigene reporter for cTNT; Performed TR-PCR after cell growth in compound (1-100 µM)",Compared to same cell line infected with mini-gene with no CUG repeats ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0035,R-BIND (SM) 0035,FC1=CC=C(C=C1)C(=O)NC1=CC=C(NC(=O)C2=CC=NC=C2)C=N1,p7,10.1016/j.bmcl.2016.10.037,C,AT Hairpin DNA,Kd >> 50 µM,Ligand = 5 µM,"8 mM Na2HPO4, pH 7.0, 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,NR,No change,Ligand = 100 µM,Cytotoxicity,WST-1,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0035,R-BIND (SM) 0035,FC1=CC=C(C=C1)C(=O)NC1=CC=C(NC(=O)C2=CC=NC=C2)C=N1,p7,10.1016/j.bmcl.2016.10.037,C,GC Stem Loop,Kd >> 30 µM,Ligand = 5 µM,"8 mM Na2HPO4, pH 7.0, 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,C,HeLa Cells,No change in DMPK levels,Ligand = 100 µM,RNA Abundance,RT-qPCR,DM1/DMPK mini gene was transfected into cells and then treated with compound,Compared to untreated control; Indicates the ligand does not alter the transcription of the gene,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0035,R-BIND (SM) 0035,FC1=CC=C(C=C1)C(=O)NC1=CC=C(NC(=O)C2=CC=NC=C2)C=N1,p7,10.1016/j.bmcl.2016.10.037,,5' CUG/3' GUC Internal Loop,Kd = 4.6 ± 0.5 µM,Ligand = 5 µM,"8 mM Na2HPO4, pH 7.0, 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,HeLa Cells,Statistically significant Improvement in cRNR alternative splicing defect,"Ligand = 10, 100 µM",RNA Splicing,Reporter,"Cells transfected with DM1 minigene and 960 CTG repeats, and a minigene reporter for cTNT; Performed RT-PCR after cell growth",Compared to same cell line infected with mini-gene with no CUG repeats ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0035,R-BIND (SM) 0035,FC1=CC=C(C=C1)C(=O)NC1=CC=C(NC(=O)C2=CC=NC=C2)C=N1,p7,10.1016/j.bmcl.2016.10.037,C,tRNA,Kd >> 50 µM,Ligand = 5 µM,"8 mM Na2HPO4, pH 7.0, 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0035,R-BIND (SM) 0035,FC1=CC=C(C=C1)C(=O)NC1=CC=C(NC(=O)C2=CC=NC=C2)C=N1,p7,10.1016/j.bmcl.2016.10.037,,r(CUG)12-MBNL1 Complex,> 20% disruption,Ligand = 50 µM,"20 mM HEPES (pH = 7.5), 100 mM KCl, 10 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM DTT, 0.1% (w/v) BSA, and 0.05% (v/v) Tween-20",Protein Displacement,TR-FRET,-,Compared to the untreated complex,,C2C12 Cells,Statistically significant Increase in luciferase (50 µM),"Ligand = 50, 25, 12.5 µM",Transport Activity,Reporter,"Luciferase-encoding mRNA w/ 800 CUG repeats in 3' UTR; Tested at 50, 25, and 12.5 µM",Compared to same cell line infected with plasmid with no CUG repeats ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,,Serotonin Receptor 2C (HTR2c) pre-mRNA 200 nt,Changed CD spectrum; Maximum change ~ 265 nM,"Ligand = 20, 200 µM; RNA = 2.5 µM","10 mM Tris (pH = 7), 100 mM KCl and 10 mM MgCl2",Binding,Circular Dichroism,-,-,,HEK-293 Cells,Promoted exon Vb inclusion greater than 3 times the standard deviation of the total data,Ligand = 6 µM,RNA Splicing,Reporter,High-throughput screen; Generated a reporter construct in the HTR2c gene that expresses GFP when exon Vb is included in pre-mRNA; RFP is expressed downstream in the absence of GFP; Measuring the ratio between GFP/RFP measured splicing-dependent exon Vb inclusion,Validated using the HBII-52 snoRNA expression construct (positive control) and then selected two cell lines; Removed all hits containing known transcriptional activators and fluorescent compounds and concentrated on hits common to both cell lines,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,C,dsRNA GC,~ 20% intensity change,"Ligand = 2, 10 µM; RNA = 10 µM",NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic) ,Measured at 620 nM,-,,HEK-293 Cells,Serotonin receptor mRNA peaks with the supraspliceosomes containing splicing factor hnRNP G,Ligand = 10 µM,On-Target Effect,Western Blot,hnRNP G is a regulatory splicing factor in the supraspliceosome; Transfected with serotonin receptor expression construct pRSR-5HTcons and then treated; Nuclear supernatants enriched in supraspliceosomes were prepared and fractioned in 10-45% glycerol gradients,Indicates the ligand does not alter the stability or transcription of one isoform,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,C,PolyU RNA,No change,"Ligand = 20, 200 µM; RNA = 2.5 µM","10 mM Tris (pH = 7), 100 mM KCl and 10 mM MgCl2",Off-Target Effect,Circular Dichroism,-,-,,HEK-293 Cells,Increased Firefly/Renilla ratio from ~ 0.2 to ~ 0.45; Ratio of exon inclusion/skipping = 0.43 (DMSO control = 0.13),Ligand = 5 µM,RNA Splicing,Reporter,Dual Renilla and luciferase construct used; Measured fluorescence after incubation overnight,DMSO control = 0.22,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,C,dsRNA AU,~ 15% intensity change,"Ligand = 2, 10 µM; RNA = 10 µM",NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic) ,Measured at 620 nM,-,,HEK-293 Cells,Change in pre-mRNA splicing within fractions containing splicing components,Ligand = 10 µM,RNA Splicing,RT-PCR,"Transfected with serotonin receptor expression construct pRSR-5HTcons, then treated; Nuclear supernatants enriched in supraspliceosomes were prepped and fractioned in 10-45% glycerol gradients",Indicates the ligand does not alter the stability or transcription of one isoform,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,C,dsRNA A18 and U18,~ 30 to 40% intensity change,"Ligand = 2, 10 µM; RNA = 10 µM",NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic) ,Measured at 620 nM,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,C,ssRNA U18,No change,"Ligand = 2, 10 µM; RNA = 10 µM",NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic) ,Measured at 620 nM,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,,Serotonin receptor 2C (HTR2c) pre-mRNA 200 nt,~ 50% increase of snRNA occupancy,Ligand = 100 nM; RNA = 10 nM,"44% (vol/vol) HeLa nuclear extract, 2 mM adenosine triphosphate, 20 mM creatine phosphate, 3 mM MgCl2 and 1 mM DTT",On-Target Effect,RNA Pull-Down,"Biotinylated RNA was refolded with compound, incubated with nuclear extract and cross-linked; RNA was released and purified, and U1 snRNA was detected by RT-PCR",DMSO control; Used a non-cross-linking control,,HEK-293 Cells,IC50 = 6 µM,Ligand = 0.5 - 12.5 µM,RNA Splicing,Reporter,"Used a reporter minigene that contains all coding exons and their introns; Intron 5 was been shortened from 50 kb to 3000 nt, leaving 1500 nt from the 50 and 30 intronic region, respectively; Gene was transfected, and the switch from exon skipping to predominant inclusion was measured",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0036,R-BIND (SM) 0036,CN(C)C1=CC2=CC=C(C=CC3=C(C)N(C(C)=C3)C3=CC=CC=C3)[N+](C)=C2C=C1,Pyrvinium,10.1093/nar/gkt063,,Serotonin receptor 2C (HTR2c) pre-mRNA 200 nt,Compound promotes a rearrangement of the RNA structure,"Ligand = 1, 2, 5 µM",NR,Structure Determination,SHAPE,"RNA was denatured then renatured in the presence or absence of compound, then incubated with NMIA SHAPE reagent",Subtracted background; Normalized nucleotides U45-A121 to refine the prediction of secondary structure,,HEK-293 Cells,Ratio of exon inclusion/skipping = 0.43,Ligand = 5 µM,RNA Splicing,Reporter,"Used a reporter minigene that contains all coding exons and their introns; Intron 5 was been shortened from 50 kb to 3000 nt, leaving 1500 nt from the 50 and 30 intronic region, respectively",DMSO control = 0.13,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,U1 snRNP:SMN2 pre-mRNA Complex,Analog of NVS-SM1 which binds in vitro to the U1 snRNP/SMN2pre-mRNA complex,-,-,-,-,-,-,,SMN?7 Mouse Myoblast,EC50 = 20 nM,-,Protein Abundance,ELISA,SMN Protein,Compared to two inactive analogs,,C/+ SMA mice,Dose-dependent increase,Oral; 3 - 30 mg/kg,Protein Abundance,TR-FRET,SMN2 full-length transcript and SMN protein in the brain/spinal cord increased,Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/s41467-017-01559-4,C,SMN2 pre-mRNA:U1 snRNA,Changes in the resonance of the [5? U1 snRNA:5?ss SMN2 pre-mRNA] RNA duplex; Preferential binding downstream of the consecutive pseudouridine:adenine pairs in the RNA duplex,Ligand = 0.2 - 2 mM; RNA = 400 µM,"10 mM MES (pH = 5.5), 50 mM NaCl, and 10% D20",Binding,Nuclear Magnetic Resonance,"Proton; The 5?ss in the SMN2 gene has been reported to be inherently weak at interacting with the U1 snRNA component of U1 snRNP23; Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7",-,,SMA Type I Patient Fibroblasts,Observed 36 transcriptome-wide splicing event changes; Expression changes in 229 genes,Ligand = 24 nM,RNA Abundance,RT-qPCR,A database of alternative splicing events was generated based on the human RefSeq database of transcripts; Recently published data suggested that the ligand increases the binding affinity of U1 snRNP for the 5?ss of exon 7,Treatment at ~5x EC50, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,C,hERG,IC50 = 6.3 µM,"Ligand = 0.003, 0.03, 0.1, 0.3, 1, 3, 10, 30 µM. Protein = ca. 15 µg","20 mM HEPES (pH = 7.4 at r.t.), 10 mM KCl, 1 mM MgCl2",Off-Target Effect,Ligand Titration (Radiolabeled),Cell membranes were prepared from CHO cells expressing functional hERG channels. [3H] dofetilide used as radioligand.,"Terfenadine, tested in a range from 10 µM to 0.6 nM. Non-specific ligand binding was defined as the binding remaining in the presence of 25 µM terfenadine.",,,,,,,,,,Male Sprague-Dawley rats,Area Under the Curve = 3.03 µM*h,"Intravenous, 1 mg/kg; po at 3 mg/kg",Pharmacokinetics,Plasma Drug Concentration over Time,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,,N/A,logPAMPA = -4.9 cm/s,Ligand = 5 µM,"Purchased from Fluka (pH = 4.0, 6.8 and 8.0), prepared with 100 mM KCl and 5% DMSO",Permeability,Parallel Artificial Membrane Permeability Assay (PAMPA),Analyzed by LCMS,-,,,,,,,,,,Male Sprague-Dawley rats,25 mL min-1kg-1,"Intravenous, 1 mg/kg; po at 3 mg/kg",Pharmacokinetics,Clearance,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,,N/A,5.5 BL-AP/AP-BL,NR,NR,Permeability,MDCK-MDR1 Assay,Measured efflux potential,-,,,,,,,,,,Male Sprague-Dawley rats,Fraction absorbed = 63 %,"Intravenous, 1 mg/kg; po at 3 mg/kg",Pharmacokinetics,Bioavailability,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,iPSc-Derived Neurons (GM00232 and GM09677),Dose-dependent response increase,-,Protein Abundance,ELISA,SMN protein; Induced pluripotent stem cells,ELISA relative to DMSO control,,SMN?7 mice,Dose-dependent increase,Oral; 0.3 - 3 mg/kg,Protein Abundance,TR-FRET,SMN2 full-length transcript and SMN protein in the brain/spinal cord increased,Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,iPSc-Derived Neurons (GM00232 and GM09677),Dose-dependent decrease,-,RNA Abundance,qPCR,SMN?7 transcript; Induced pluripotent stem cells,,,SMN?7 mice,Improved body weight,"Oral; 1, 3 mg/kg",Body Weight,-,Oral administration improved body weight and extended lifespan (increased survival by 50-62%),Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,iPSc-Derived Neurons (GM00232 and GM09677),Dose-dependent increase,-,RNA Abundance,qPCR,Full length (FL) transcript; Induced pluripotent stem cells,,,SMN?7 mice,Increased lifespan in 50 or 62% of animals,"Oral; 1, 3 mg/kg",Lifespan,-,Oral administration improved body weight and extended lifespan (increased survival by 50-62%),Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,SMA-type III Patient Peripheral Blood Mononuclear,Dose-dependent decrease,-,RNA Abundance,qPCR,SMN?7 transcript,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,SMA-type III Patient Peripheral Blood Mononuclear,Dose-dependent increase,-,RNA Abundance,qPCR,Full length (FL) transcript,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,C,Human Fibroblasts,175 genes had 2-fold or greater change in levels; Little to no changes for splicing factors or RNA-binding proteins,Ligand = 100 nM,RNA Abundance,RNAseq,Absolute fold change > ± 2 with a multiple testing correction and adjusted p value < 0.05,Compared to inactive analog NVS-SM3,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,C,Human Fibroblasts,39 splicing events in 35 genes,Ligand = 100 nM,RNA Splicing,RNAseq,Scanned exons and exon-exon junctions that were differentially regulated across conditions when compared to overall expression; 11 of 39 were correlated with RNAseq and qPCR experiments,Compared to inactive analog NVS-SM3,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1038/nchembio.1837,,,,,,,,,,,NSC34 Motor Neuron,Dose response,Ligand = 10 µM,RNA Splicing,Reporter,High-throughput screen,Active or superior to Resveratrol,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,,,,,,,,,,,,,,,,,,,Male Sprague-Dawley rats,Brain concentration = 0.914 µM,"Intravenous, 1 mg/kg; po at 3 mg/kg",Pharmacokinetics,Brain Concentration,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,,,,,,,,,,,,,,,,,,,Male Sprague-Dawley rats,Protein binding = 73%,"Intravenous, 1 mg/kg; po at 3 mg/kg",Pharmacokinetics,Protein Binding in Plasma,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0037,R-BIND (SM) 0037,CC1(C)CC(CC(C)(C)[NH2+]1)OC1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM1,10.1021/acs.jmedchem.8b01291,,,,,,,,,,,,,,,,,,,C/+ SMA mice,Statistically significant increase in SMN protein levels in the brain,"Oral; 3, 10, and 30 mg/kg",Protein Abundance,TR-FRET,-,Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0038,R-BIND (SM) 0038,CN(C1CC(C)(C)[NH2+]C(C)(C)C1)C1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM2,10.1038/nchembio.1837,,U1 snRNP:SMN2 pre-mRNA Complex,Observed chemical shift changes and resonance broadening; Detected shifts in particular residues,Varies with experiment,"20 mM potassium phosphate (pH = 6.2), 100 mM KCl, and 0.1 mM EDTA",Binding,Nuclear Magnetic Resonance ,Proton and TOCSY NMR,Compared to an inactive analog,,SMN?7 Mouse Myoblast,EC50 = 5 nM,-,Protein Abundance,ELISA,SMN Protein,Compared to two inactive analogs,,C/+ SMA mice,Dose-dependent increase,Oral; 3 - 30 mg/kg,Protein Abundance,TR-FRET,SMN2 full-length transcript and SMN protein in the brain/spinal cord increased,Statistical comparisons between treatment doses,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0038,R-BIND (SM) 0038,CN(C1CC(C)(C)[NH2+]C(C)(C)C1)C1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM2,10.1038/nchembio.1837,,U1 snRNP:SMN2 pre-mRNA Complex,Bound to complex but not components alone,Ligand = 10 µM; RNA = 1 µM,"38 mM HEPES (pH = 7.6), 60 mM KCl, 0.12 mM EDTA, and 3.2 MgCl2",Binding,Size Exclusion Chromatography-Mass Spectrometry,-,-,,NSC34 Motor Neuron,Dose response,Ligand = 10 µM,RNA Splicing,Reporter,High-throughput screen,Active or superior to Resveratrol,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0038,R-BIND (SM) 0038,CN(C1CC(C)(C)[NH2+]C(C)(C)C1)C1=CC=C(N=N1)C1=CC=C(C=C1O)C1=CNN=C1,NVS-SM2,10.1038/nchembio.1837,,U1 snRNP:SMN2 pre-mRNA Complex,Enhanced binding of components and slowed dissociation,Ligand Max = 10 µM,"38 mM HEPES (pH = 7.6), 60 mM KCl, 0.12 mM EDTA, 3.2 MgCl2, and 0.05 % P20",Binding,Surface Plasmon Resonance,Performed in screening mode due to uncertainty in amount immobilized,Tested binding to two mutants,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0039,R-BIND (SM) 0039,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(C[NH+](C)C)=CC3=C12,IRAB,10.1080/15476286.2015.1025190,,FMDV IRES RNA,IC50 = 0.5 µM,-,Rabbit Reticulocyte Lysates,Activity,Dual Luciferase,Bicistronic RNA harboring picornavirus FMDV IRES between CAT and Luc reporters; Preferential decrease in Luc protein synthesis was observed,Compared Luc and CAT reporters,,BHK-21 Cells,Statistically significant decline in virus yield,"Ligand = 0.5, 1, 2 µM",Antiviral Activity,Plaque Assay,Cells transfected with infectious FMDV RNA synthesized in vitro; Virus yield was determined in the supernatant of transfected monolayers,Used a mock-transfected cell monolayer and untreated cells as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0039,R-BIND (SM) 0039,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(C[NH+](C)C)=CC3=C12,IRAB,10.1080/15476286.2015.1025190,,HCV IRES RNA,IC50 similar to FMDV IRES RNA,-,Rabbit Reticulocyte Lysates,Activity,Dual Luciferase,Bicistronic RNA harboring picornavirus HCV IRES between CAT and Luc reporters; Preferential decrease in Luc protein synthesis was observed,Compared Luc and CAT reporters,,BHK-21 Cells,Dose-dependent reduction in virus titer,"Ligand = 0.5, 1, 2 µM",Antiviral Activity,Western Blot,Viral protein 1; Collected at different at different time points over 24 h,Untreated cell control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0039,R-BIND (SM) 0039,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(C[NH+](C)C)=CC3=C12,IRAB,10.1080/15476286.2015.1025190,,"FMDV IRES RNA, SL3A",EC50 = 18.62 µM,-,10 mM sodium cacodylate buffer (pH = 7.5) and 150 mM NaCl,Binding,Fluorescence-Based Titration (Labeled RNA),2-AP label ,Tested different labeled positions for 2-AP and noticed differences; Looked at structural differences to compare,,,-,-,Cytotoxicity,Cell Staining,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0039,R-BIND (SM) 0039,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(C[NH+](C)C)=CC3=C12,IRAB,10.1080/15476286.2015.1025190,,HCV IRES RNA,Observed changes in SHAPE reactivity,"Ligand = 2, 10, 20 µM","100 mM HEPES (pH = 8.0), 0.5 mM MgCl2, and 100 mM NaCl",Structure Determination,SHAPE,-,Compared to without compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0039,R-BIND (SM) 0039,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(C[NH+](C)C)=CC3=C12,IRAB,10.1080/15476286.2015.1025190,,HCV IRES RNA,Observed changes to form a less compact RNA,Ligand = 20 µM,"40 mM MOPS (pH = 8.0), 80 mM KOAc, and 0.5 mM MgCl2",Structure Determination,Hydroxy Radical Footprinting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0040,R-BIND (SM) 0040,C[NH+](C)CCCOC1=CC=C2[NH+]=C(N)N(CCC[NH+](C)C)C2=C1,Benzimidazole 3,10.1021/jm050815o,,HCV IRES IIA 40-mer,Kd = 17 µM,-,100 mM ammonium acetate with 33% isopropyl alcohol,Binding,ESI-MS,-,Compared to free RNA,,Ntat2ANeo Cells,EC50 = 37 µM,-,RNA Abundance,RT-PCR,HCV RNA levels,Results were normalized to the estimated total RNA content of each sample determined by Ribogreen,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0040,R-BIND (SM) 0040,C[NH+](C)CCCOC1=CC=C2[NH+]=C(N)N(CCC[NH+](C)C)C2=C1,Benzimidazole 3,10.1021/jm050815o,,,,,,,,,,C,Huh-7 Cells,CC50 > 100 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0041,R-BIND (SM) 0041,C[NH+](C)CCCOC1=CC=C2N=C3NCC(C[NH+](C)C)CN3C2=C1,Benzimidazole 10,10.1021/jm050815o,,HCV IRES IIA 40-mer,Kd = 3.5 µM,-,100 mM ammonium acetate with 33% isopropyl alcohol,Binding,ESI-MS,-,Compared to free RNA,,Ntat2ANeo Cells,EC50 = 29 µM,-,RNA Abundance,RT-PCR,HCV RNA levels,Results were normalized to the estimated total RNA content of each sample determined by Ribogreen,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0041,R-BIND (SM) 0041,C[NH+](C)CCCOC1=CC=C2N=C3NCC(C[NH+](C)C)CN3C2=C1,Benzimidazole 10,10.1021/jm050815o,,,,,,,,,,C,Huh-7 Cells,CC50 > 100 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0042,R-BIND (SM) 0042,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(CC[NH+](C)C)CC3=C12,Benzimidazole 11 / Isis-11,10.1021/jm050815o,,HCV IRES IIA 40-mer,Kd = 1.7 µM,-,100 mM ammonium acetate with 33% isopropyl alcohol,Binding,ESI-MS,-,Compared to free RNA,,Ntat2ANeo Cells,EC50 = 1.5 µM,-,RNA Abundance,RT-PCR,HCV RNA levels,Results were normalized to the estimated total RNA content of each sample determined by Ribogreen,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0042,R-BIND (SM) 0042,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(CC[NH+](C)C)CC3=C12,Benzimidazole 11 / Isis-11,10.1073/pnas.0911896107,,HCV IRES IIA 38-mer,Binds to bulge region; Reorganization of loop structure; Helical axis is straight compared to bent in apo form; Ligand binds in extended conformation; Amine nitrogens replace two discrete metal ions in X-ray structure; Bound and unbound states in slow chemical exchange,,,In Silico,Nuclear Magnetic Resonance and Molecular Dynamics,TOCSY; Used NOE and RDC restraints in MD simulations; NOESY and ROESY,"Performed NMR with racemic mixture, performed MD with each enantiomer, and determined each bound similarly",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0042,R-BIND (SM) 0042,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(CC[NH+](C)C)CC3=C12,Benzimidazole 11 / Isis-11,10.1021/jm050815o,,,,,,,,,,C,Huh-7 Cells,CC50 > 100 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0042,R-BIND (SM) 0042,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OC(CC[NH+](C)C)CC3=C12,Benzimidazole 11 / Isis-11,10.1021/jm050815o,,HCV IRES IIA 38-mer,"Kd = 9.0, 2.6 µM",,,Binding,Fluorescence-Based Titration (Labeled RNA),"Separated ligand isomers by chiral HPLC, although absolute conformation not determined",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0043,R-BIND (SM) 0043,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OCC(C[NH+](C)C)CC3=C12,Benzimidazole 12,10.1021/jm050815o,,HCV IRES IIA 40-mer,Kd = 0.87 µM,-,100 mM ammonium acetate with 33% isopropyl alcohol,Binding,ESI-MS,-,Compared to free RNA,,Ntat2ANeo Cells,EC50 = 3.9 µM,-,RNA Abundance,RT-PCR,HCV RNA levels,Results were normalized to the estimated total RNA content of each sample determined by Ribogreen,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0043,R-BIND (SM) 0043,C[NH+](C)CCCN1C(N)=[NH+]C2=CC=C3OCC(C[NH+](C)C)CC3=C12,Benzimidazole 12,10.1021/jm050815o,,,,,,,,,,C,Huh-7 Cells,CC50 > 100 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1021/jm050815o,,-,-,-,-,-,-,-,-,C,Huh 7.5 Cells,CC50 > 100 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1038/nchembio.217,,HCV IRES IIA RNA,EC50 = 600 ± 80 nM,-,2 mM Mg2+,Binding,FRET,-,Tested promiscuous RNA binders which did not elicit FRET quenching; Added 2- to 5-fold excess tRNA and no significant change observed; Investigated five single and one double base mutants with decreased affinity for the compound,,Huh 7.5 Cells,IC50 = 2.0 µM (48 h),-,Antiviral Activity,Reporter,Transfected with HCV replicon (WT) then treated with compound,Tested for effects on HCV RNA-dependent RNA polymerase NS5B,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1021/jm050815o,,HCV IRES IIA 40-mer,Kd = 0.72 µM,-,100 mM ammonium acetate with 33% isopropyl alcohol,Binding,ESI-MS,-,Compared to free RNA,,Ntat2ANeo Cells,EC50 = 5.4 µM,-,RNA Abundance,RT-PCR,HCV RNA levels,Results were normalized to the estimated total RNA content of each sample determined by Ribogreen,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1038/nchembio.217,,HCV IRES IIA 40-mer,Binding Location,NR,NR,Structure Determination,RNase Footprinting,-,-,,Huh 7.5 Cells,IC50 = 4.0 µM (4 h) and 9.5 µM (8 h),-,Antiviral Activity,Reporter,Transfected with BM4-5 FEO RNA and then treated with compound,Compared to a replicon containing a mutation and observed a decrease in Translational Activity,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1016/j.antiviral.2010.11.004,,,,,,,,,,,Huh 7.5 Cells,IC50 = 3.89 ± 0.37 µM (wt),-,Antiviral Activity,Western Blot,Cells transfected with JFH-wt and compounds were added to cells; HCV replication was measured by Western blotting of NS3 protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1016/j.antiviral.2010.11.004,,,,,,,,,,,Huh 7.5 Cells,IC50 = 4.83 ± 0.47 µM (?V3-Rluc),-,Antiviral Activity,Reporter,Cells transfected with  JFH-?V3-Rluc and compounds were added to cells; HCV replication was measured by Renilla luciferase assay,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1016/j.antiviral.2010.11.004,,,,,,,,,,,Huh 7.5 Cells,IC50 = 4.6 µM (?V3-Rluc),-,Antiviral Activity,Western Blot,Cells transfected with JFH-wt and compounds were added to cells; HCV replication was measured by Western blotting of NS3 protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0044,R-BIND (SM) 0044,C[NH+](C)CC1CNC2=[NH+]C3=CC=C4OCC(C[NH+](C)C)CC4=C3N2C1,Benzimidazole 13 / Isis-13,10.1016/j.antiviral.2010.11.004,,,,,,,,,,C,Huh 7.5 Cells,CC50 = 86 ± 20 µM,-,Cytotoxicity,CellTiter 96 Aqueous One Solution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0045,R-BIND (SM) 0045,C[NH+](C)CC1CC2=C3N4CC(C[NH+](C)C)CNC4=[NH+]C3=CC=C2O1,Isis-22,10.1016/j.antiviral.2010.11.004,,HCV IRES RNA,Kd = 2.2 µM,-,NR,Binding,Fluorescence-Based Titration (Labeled RNA),2-aminopurine labeled RNA,-,,Huh 7.5 Cells,IC50 = 1.94 ± 0.33 µM (wt),-,Antiviral Activity,Western Blot,Cells transfected with JFH-wt and compounds were added to cells; HCV replication was measured by Western blotting of NS3 protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0045,R-BIND (SM) 0045,C[NH+](C)CC1CC2=C3N4CC(C[NH+](C)C)CNC4=[NH+]C3=CC=C2O1,Isis-22,10.1016/j.antiviral.2010.11.004,,,,,,,,,,,Huh 7.5 Cells,IC50 = 2.23 ± 0.21 µM (?V3-Rluc),-,Antiviral Activity,Reporter,Cells transfected with  JFH-?V3-Rluc and compounds were added to cells; HCV replication was measured by Renilla luciferase assay,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0045,R-BIND (SM) 0045,C[NH+](C)CC1CC2=C3N4CC(C[NH+](C)C)CNC4=[NH+]C3=CC=C2O1,Isis-22,10.1016/j.antiviral.2010.11.004,,,,,,,,,,,Huh 7.5 Cells,IC50 = 2.9 µM (?V3-Rluc),-,Antiviral Activity,Western Blot,Cells transfected with JFH-wt and compounds were added to cells; HCV replication was measured by Western blotting of NS3 protein,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0045,R-BIND (SM) 0045,C[NH+](C)CC1CC2=C3N4CC(C[NH+](C)C)CNC4=[NH+]C3=CC=C2O1,Isis-22,10.1016/j.antiviral.2010.11.004,,,,,,,,,,C,Huh 7.5 Cells,CC50 = 65 ± 5 µM,-,Cytotoxicity,CellTiter 96 Aqueous One Solution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,,HIV-1 FSS RNA,Stimulated frameshifting by ~2-fold,Ligand = 0.1 - 10 µg/mL; RNA = 87 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Activity,Luciferase,-,-,C,CCRF-CEM Cells,Therapeutic Index > 10,-,Cytotoxicity,Tetrazolium,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HTLV-1 Gag-Pro (GP) FSS RNA,The HTLV-1 GP signal is the most enhanced. (~2.5 fold),Ligand = 0.1 - 10 µg/mL; RNA = 87 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Activity,Luciferase,Constructs equivalent to FS and L17 were generated for four other ?1 frameshift signals from other viruses. This FSS is from human T-cell leukemia virus type 1 (HTLV-1).,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HTLV-1 Pro-Pol (PP) FSS RNA,No stimulation of frameshifting at the HTLV-1 PP signal,Ligand = 0.1 - 10 µg/mL; RNA = 87 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Activity,Luciferase,Constructs equivalent to FS and L17 were generated for four other ?1 frameshift signals from other viruses. This FSS is from human T-cell leukemia virus type 1 (HTLV-1).,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HIV-2 FSS RNA,Slightly less stimulation compared to HIV-1 frameshifting,Ligand = 0.1 - 10 µg/mL; RNA = 87 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Activity,Luciferase,Constructs equivalent to FS and L17 were generated for four other ?1 frameshift signals from other viruses.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,SIV FSS RNA,Slightly less stimulation compared to HIV-1 frameshifting,Ligand = 0.1 - 10 µg/mL; RNA = 87 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Activity,Luciferase,Constructs equivalent to FS and L17 were generated for four other ?1 frameshift signals from other viruses. This FSS is from Simian Immunodeficiency Virus,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,,HIV-1 FSS RNA,Inhibited HIV-1 particle formation,Ligand = 500 µg/mL,Lysates from CH-1 cells,Activity,Western Blot,Gag p24 polyclonal antibody,Untreated cell control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,,HIV-1 FSS RNA,2.2-fold increase in p160,Ligand = 500 µg/mL,Lysates from CH-1 cells,Activity,Western Blot,"HIV-1 RT antibody; Interacts with Gag p55, Gag-Pol p160, and cleavage products p24, p25, and p41; Increase in p160 indicates frameshifting",Anti-HIV-1 immunoglobulin protein ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,,HIV-1 FSS RNA,2.8-fold increase in p160,Ligand = 500 µg/mL,Lysates from 12A2 cells,Activity,Western Blot,"HIV-1 RT antibody; Interacts with Gag p55, Gag-Pol p160, and cleavage products p24, p25, and p41; Increase in p160 indicates frameshifting",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,,HIV-1 FSS RNA,?Tm = + 6.4 ºC,1:1 Ligand:RNA Ratio,NR,Binding,Optical Melting,-,-,,COS Cells,Stimulated frameshifting by ~ 2-fold,-,Frameshifting Activity,Chemiluminescence (SEAP),Functional SEAP is produced only when frameshifting occurs,Compared to plasmid that does not require frameshifting (S17),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1021/cb200082d,,HIV-1 FSS RNA,Binds to RNA,10:1 Ligand:RNA Ratio,"10 mM d11-Tris (pH = 7.3), 10% D2O",Binding,Nuclear Magnetic Resonance ,WaterLOGSY experiment,"Used to eliminate false positives; DSS, a non-binder, was used as a control",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1021/cb200082d,,HIV-1 FSS RNA,Kd = 360 ± 26 µM; Hill coefficient = 1.8 +/- 0.2,-,"10 mM d11-Tris (pH = 7.3), 10% D2O",Binding,Nuclear Magnetic Resonance ,1H-13C correlations; Fit using a modified Hill equation; Noted some nonspecific interactions were likely,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1021/cb200082d,,HIV-1 FSS RNA,?Tm = + 10 ºC,Ligand = 100 µM; RNA = 5 µM,10 mM HEPES (pH = 6.4 to  7.6) and 20 mM KCl,Binding,Optical Melting,-,Stability still observed in presence of 100 mM KCl or 100 µM spermine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HIV-1 RRE,Little effect on Tm,1:1 Ligand:RNA Ratio,NR,Off-Target Effect,Optical Melting,-,-,,CCRF-CEM Cells,IC50 = 2.89 ug/mL,-,Antiviral Activity,ELISA,p24 protein; Acute HIV-1 infection; Cells were infected at a MOI of 0.1 with either HIV-1(IIIB) or HIV-1(RTMDR) (similar IC50 result) and then incubated with the compound,Compared to infected cells left without compound,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HIV-1 FSS RNA L17 Mutant,Minimal effect observed,Ligand = 0.1 - 10 µg/mL,Rabbit Reticulocyte Lysate Cocktail (Promega),Off-Target Effect,Luciferase,Mutant that does not require frameshifting to translate protein,-,,Peripheral Blood Mononuclear,IC50 = 11 µg/mL,-,Antiviral Activity,ELISA,p24 protein; Acute HIV-1 infection; Cells were infected at a MOI of 0.1 with either HIV-1(IIIB) or HIV-1(RTMDR) (similar IC50 result) and then incubated with the compound,Compared to infected cells left without compound,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HIV-1 Protease,No activity,-,NR,Off-Target Effect,-,-,-,,CH-1 Cells,Significantly reduced the level of viral particles in cell medium,-,Antiviral Activity,ELISA,"p24 protein; Chronic HIV-1 infection; Cells were incubated with compound for 48 h, medium was removed, cell were washed, fresh medium and compound were added to the cells and incubated for 24 h","Compared to Zidovudine (AZT), a reverse transcriptase inhibitor",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,PMC110024,C,HIV-1 Reverse Transcriptase (RT),No activity,-,NR,Off-Target Effect,-,-,-,C,Peripheral Blood Mononuclear,Therapeutic Index > 10,-,Cytotoxicity,Tetrazolium,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046A,R-BIND (SM) 0046A,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1021/cb200082d,,HIV-1 FSS RNA,Determined structure,Ligand = 750 µM; RNA = 750 µM,"10 mM d11-Tris (pH = 7.3), 10% D2O",Structure Determination,Nuclear Magnetic Resonance ,2D NOESY NMR; Structure determined using HADDOCK 2.0 and refined in implicit solvent using AMBER 9; Generated 10 lowest energy structures. Also did TROSY-HSQC to map binding site,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,r(CAG)7,Kd = 1.53 ± 0.25 µM,Ligand = 800 µM; RNA = 40 µM.,NR,Binding,Isothermal Titration Calorimetry,MicroCal iTC200 at 25 ºC.,-,,SK-N-MC Neuroblastoma,Suppression of cell death induced by EGFPCAG78 by DB213,"Ligand = 50, 100, and 200 nM",Cytotoxicity,Lactate Dehydrogenase,Cells with expanded repeats (expressed via EGFPCAG78) showed a relatively higher level of cell death compared to the unexpanded control. Enzyme activity was measured 72 hours post-transfection and drugs treatment using the Cytotox 96 non-radioactive cytotoxicity assay (Promega),"Compared to cells transfected with unexpanded control - EGFPCAG27, which did not display high levels of cell death. DMSO control, and a ligand known to bind CUG repeats (C4G2) used to try outcompeting DB213, unsuccessfully. ",,Drosophila (Red-CAG100),Suppressed the DSRed-CAG100 RNA-mediated toxicity in a dose-dependent manner.,"Oral; Ligand = 5, 10, 20, 30, 60, 120, 240 and 460 nM.",Rough Eye Phenotype,Light Microscopy,DsRed-CAG100 model. Expanded CAG repeats located in 3' untranslated region of the DsRed open reading frame. The expression of the DSCAG100 itself induces neurodegeneration as revealed by pseudopupil assay on 12 day-old adult flies. Images were captured by SPOT Insight CCD camera.,Compared to DMSO,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Plasma from C57 mice,The unbound fraction of DB213 in mice plasma was close to 80% (70 ± 5% to 88 ± 5%) at concentrations from 0.3 to 300 ?g/mL with no significant concentration dependency.,"Ligand = 0.3, 3, 30 and 300 µg/mL",100 mM sodium phosphate (pH = 7.4 at 37 ºC) and 150 mM sodium chloride,Pharmacokinetics,Equilibrium Dialysis,DB213 was extracted from these samples by protein precipitation via addition of 1.5 volume (v/v) of acetonitrile.,-,,Calu-3 Cells,Apparent permeability = 1.40 ± 0.21 x 10^-6 cm/s at 10 µM; 1.87 ± 0.29 x 10^-6 cm/s at 100 µM; 1.98 ± 0.48 x 10^-6 cm/s at 300 µM,"Ligand = 10, 100, 300 µM",Cell Permeability,LC-ESI-MS/MS,"After equilibrium for 15 min with blank HBSS in incubation chamber, 1.5 mL of HBSS containing studied compounds was loaded onto apical side, followed by addition of 2.6 mL of blank HBSS into basolateral side. 0.2 mL of samples was taken from basolateral side at 30, 60, 90, 120 and 150 min followed by same volume of blank HBSS adding to the receiver chamber. The
prepared samples were injected to LC/MS/MS system",Compared to transcellular and paracellular marker propranolol (100 ?M) and atenolol (200 ?M),,SD rats,"Pharmacokinetic parameters of intravenously delivered DB213 in different brain regions were comparable with peak concentration in the range of 33.1 ± 4.3 to 52.8 ± 17.0 ng/g, time to reach Cmax,brain regions (Tmax, brain regions) to be 60 min and elimination half-life (t1/2) between 75.2 ± 21.4 min to 100.4 ± 23.1 min. After intranasal administration, the pharmacokinetic profiles of unbound DB213 in different brain regions were found to be different from each other.",Intravenous or intranasal; 50 mg/kg,Pharmacokinetics,LC-ESI-MS/MS,"At 15, 30, 60, 90, 120, 240, 360, and 480 min post-dosing, rats were anesthetized by inhalation of 95% CO2 followed by collection of blood samples via cardiac puncture then were put to euthanasia. Measured via LC-MS/MS.",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain from C57 mice,"The unbound fraction of DB213 in mice brain homogenate was only close to 10% (10 ± 1% to 13 ± 5%), suggesting its higher binding affinity towards brain tissue than plasma.","Ligand = 50, 500, and 5000 ng/g",350 µL artificial extracellular fluid (pH = 7.4 at 37 ºC),Pharmacokinetics,Equilibrium Dialysis,-,-,,Calu-3 Cells,3.55 ± 1.14 % at 10 µM; 3.10 ± 1.43 % at 100 µM; 4.35 ± 1.74 % at 300 µM,"Ligand = 10, 100, 300 µM",Cell Uptake,LC-ESI-MS/MS,-,Compared to transcellular and paracellular marker propranolol (100 ?M) and atenolol (200 ?M),,C57 mice,"Cmax, plasma = 2027.5 ± 398.1 ng/mL at 30 min post-dosing. Cmax, brain = 1126.29 ± 212.4 ng/g at 30 minute post dosing, t1/2 in brain = 70 ± 10 min.",Intranasal; 25 mg/kg,Pharmacokinetics,LC-ESI-MS/MS,"The animals were sacrificed at 30, 60, 120, 240, 360, 480, 600, 1200 and 1440 min (n = 3–6 per group per time point) post-dosing",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from SD rats,50.45 ± 16.15% metabolized after 1 h at 200 µM.  26.64 µL/min/mig intrinsic clearance.,"Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,MDCK II Cells,"For 10 µM concentration, significant differences of DB213 cell uptake were found between MDCK II WT cell line and MDCK MRP2, MDCK MRP3 cell lines, respectively. Furthermore, the fact that DB213 cell uptake differed significantly in MDCK MRP2/MRP3 cell lines in presence and absence of MRPs inhibitor indicated DB213 as substrates of efflux transporters MRP2 and MRP3. No statistically significant difference in DB213 cell uptake was found between MDCK II cell line and MDCK MDR1, as well as in MDCK MDR1 cell line with or without inhibitors. For 100 µM concentration,  DB213 cell uptake is not changing significantly either between wild type cell lines and transporter transfected cell lines, or between groups with or without inhibitors on transfected cell lines.",Ligand = 10 and 100 µM,Cell Uptake,LC-ESI-MS/MS,Cells were washed twice with HBSS and pre-incubated at 37 °C for 30 min in HBSS with or without transporter inhibitors. Then the cells were washed three times with HBSS followed by addition of HBSS containing DB213 or inhibitor substrates for incubation of 10 min.,"Used MDCK II WT, MDR1, MRP2 and MRP3 lines.  Non-wt cell lines contain channels that may be transporters for cell uptake. Compared to empty vector. Used inhibitor controls: verapamil at 50 ?M served as MDR1 inhibitor; MK571 at 50 ?M served as MRP2/MPR3 inhibitor. Also used positive controls: HLS-3 at 30 µM served as MDR1 and MRPs substrate.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from SD Rats,13.87 ± 1.23% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.,"Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,HEK-293 Cells,"No statistically significant changes were found in DB213 cell uptake between HEK 293 MOCK and HEK293 OAT3, and in HEK293 OAT3 cell line in presence or absence of inhibitors and at both concentrations.",Ligand = 10 and 100 µM,Cell Uptake,LC-ESI-MS/MS,"Cells were transfected with human organic anion transporter 3 (OAT3). to induce the expression of OAT3, medium in plates was replaced with fresh culture medium containing 5 mM sodium butyrate 24 h before the uptake study.",Compared to empty vector. Used probenecid at 100 µM as OAT3 inhibitor control and oseltamivir at 100 µM as positive substrate control.,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from C57 mice,58.51 ± 0.76% metabolized after 1 h at 200 µM. 26.98 µL/min/mg intrinsic clearance.,"Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,SD mice brain slices,Significant decreased transport in presence of 2?amino?2?norbornanecarboxylic acid. No statistically significantly change of DB213 uptake in presence of MK571 or quinine,Ligand = 50 and 200 nM,Cell Uptake,LC-ESI-MS/MS,-,"To confirm the viability of brain slices, an LDH cytotoxicity assay was applied. Experiments conducted in presence or absence of transporter inhibitors including Quinine at 200 nM as OCTs inhibitor; MK571 at 200 nM as MRPs inhibitor and 2?amino?2?norbornanecarboxylic acid at 200 nM as amino acid transporter inhibitor.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from C57 mice,15.79 ± 2.75% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.,"Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,C57 mice brain slices,Significant decreased transport in presence of 2?amino?2?norbornanecarboxylic acid. No statistically significantly change of DB213 uptake in presence of MK571 or quinine,Ligand = 50 and 200 nM,Cell Uptake,LC-ESI-MS/MS,-,"To confirm the viability of brain slices, an LDH cytotoxicity assay was applied. Experiments conducted in presence or absence of transporter inhibitors including Quinine at 200 nM as OCTs inhibitor; MK571 at 200 nM as MRPs inhibitor and 2?amino?2?norbornanecarboxylic acid at 200 nM as amino acid transporter inhibitor.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from R6/2 mice,61.02 ± 4.35% metabolized after 1 h at 200 µM. 21.41 µL/min/mg intrinsic clearance.,"Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,R6/2 Huntington's mice brain slices,Significant decreased transport in presence of 2?amino?2?norbornanecarboxylic acid. No statistically significantly change of DB213 uptake in presence of MK571 or quinine,Ligand = 50 and 200 nM,Cell Uptake,LC-ESI-MS/MS,-,"To confirm the viability of brain slices, an LDH cytotoxicity assay was applied. Experiments conducted in presence or absence of transporter inhibitors including Quinine at 200 nM as OCTs inhibitor; MK571 at 200 nM as MRPs inhibitor and 2?amino?2?norbornanecarboxylic acid at 200 nM as amino acid transporter inhibitor.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Plasma from R6/2 mice,The unbound fraction of DB213 in mice plasma was close to 80% (70 ± 5% to 88 ± 5%) at concentrations from 0.3 to 300 ?g/mL with no significant concentration dependency.,"Ligand = 0.3, 3, 30 and 300 µg/mL",100 mM sodium phosphate (pH = 7.4 at 37 ºC) and 150 mM sodium chloride,Pharmacokinetics,Equilibrium Dialysis,DB213 was extracted from these samples by protein precipitation via addition of 1.5 volume (v/v) of acetonitrile.,-,,MDCK II Cells,>80 % viability in presence of up to 300 µM compound,"Ligand = 10, 100, 300 µM",Cytotoxicity,MTT,-,Atenolol and propranolol used as control. Blank HBSS used too,,R6/2 Huntington's mice,"Cmax, plasma = 2950.9 ng/mL at 30 min post-dosing. Cmax, brain = 950.86 ± 364.12 ng/g at 30 minute post dosing, t1/2 in brain = 80 ± 15 min.",Intranasal; 25 mg/kg,Pharmacokinetics,LC-ESI-MS/MS,"The animals were sacrificed at 30, 60, 90, 120 min",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain from R6/2 mice,"The unbound fraction of DB213 in mice brain homogenate was only close to 10% (10 ± 1% to 13 ± 5%), suggesting its higher binding affinity towards brain tissue than plasma.","Ligand = 50, 500, and 5000 ng/g",350 µL artificial extracellular fluid (pH = 7.4 at 37 ºC),Pharmacokinetics,Equilibrium Dialysis,-,-,,HEK-293 Cells,>80 % viability in presence of up to 300 µM compound,"Ligand = 10, 100, 300 µM",Cytotoxicity,MTT,-,Atenolol and propranolol used as control. Blank HBSS used too,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from R6/2 mice,"59.13 ± 6.43% metabolized after 1 h at 200 µM. 15.82 µL/min/mig intrinsic clearance, much higher than in other two systems.","Ligand = 6.25, 12.5, 25, 50, 100, 200, and 400 µM. Protein = 1 mg/mL","Tris (pH = 7.4), 8 mM of MgCl2, 3.3 mM glucose?6?phosphate and 0.4 U/mL of glucose?6?phosphate dehydrogenase",Pharmacokinetics,CYP450 Metabolism Kinetics,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 1.3 mM NADP,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from SD rats,50.45 ± 16.15% metabolized after 1 h at 200 µM.  26.64 µL/min/mig intrinsic clearance. 3.92 ± 3.77% metabolized through glucuronidation,"Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from SD Rats,13.87 ± 1.23% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.  < 1% metabolized through glucuronidation,"Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from C57 mice,58.51 ± 0.76% metabolized after 1 h at 200 µM. 26.98 µL/min/mg intrinsic clearance. 4.98 ± 1.02% metabolized through glucuronidation,"Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from C57 mice,15.79 ± 2.75% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.  <1% metabolized through glucuronidation,"Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from R6/2 mice,61.02 ± 4.35% metabolized after 1 h at 200 µM. 21.41 µL/min/mg intrinsic clearance. 5.26 ± 1.81% metabolized through glucuronidation,"Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from R6/2 mice,"15.79 ± 2.75% metabolized after 1 h at 200 µM. 15.82 µL/min/mig intrinsic clearance, much higher than in other two systems.  < 1% metabolized through glucuronidation","Ligand = 200 µM, Protein = 2 mg/mL","50 mM Tris (pH = 7.4), 8 mM of MgCl2, 25 ?g/mL of alamethicin",Pharmacokinetics,Glucuronidation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 2 mM UDPGA.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from SD rats,50.45 ± 16.15% metabolized after 1 h at 200 µM.  26.64 µL/min/mig intrinsic clearance. 3.99 ± 2.31% metabolized through sulfation.,Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from SD Rats,13.87 ± 1.23% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.,Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from C57 mice,58.51 ± 0.76% metabolized after 1 h at 200 µM. 26.98 µL/min/mg intrinsic clearance. 10.21 ± 1.02% metabolized through sulfation.,Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from C57 mice,15.79 ± 2.75% metabolized after 1 h at 200 µM. Not very high intrinsic clearance.,Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Liver microsomes from R6/2 mice,61.02 ± 4.35% metabolized after 1 h at 200 µM. 21.41 µL/min/mg intrinsic clearance. 13.78 ± 1.18% metabolized through sulfation.,Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,10.1016/j.ejps.2018.10.025,,Brain microsomes from R6/2 mice,"15.79 ± 2.75% metabolized after 1 h at 200 µM. 15.82 µL/min/mig intrinsic clearance, much higher than in other two systems.",Ligand = 200 µM; Protein = 2 mg/mL,"50 mM Tris (pH = 7.4), 5 mM of MgCl2, 8 mM dithiothreitol, and 0.0625% (v/v) BSA",Pharmacokinetics,Sulfation Potential,The protein content of S9 and microsomes were measured using the BCA protein assay kit. The reaction was initiated by addition of 200 µM Paps.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,SK-N-MC Neuroblastoma,IC50 = 6.9 ± 1.8 nM,"Ligand = 1, 5, 10, 20, 50, 100, and 200 nM",Cytotoxicity,Lactate Dehydrogenase,Cells with expanded repeats  (expressed via EGFPCAG78) showed a relatively higher level of cell death compared to the unexpanded control. Enzyme activity was measured 72 hours post-transfection and drugs treatment using the Cytotox 96 non-radioactive cytotoxicity assay (Promega),Compared to untransfected cells and DMSO,C,Drosophila (Red-CAG0),No dominant toxic effect.,"Oral; Ligand = 5, 10, 20, 30, 60, 120, 240 and 460 nM.",Rough Eye Phenotype,Light Microscopy,As revealed by pseudopupil assay on 12 day-old adult flies. Images were captured by SPOT Insight CCD camera.,Compared to DMSO,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,trMJD Cells (CAG78),Partial inhibition of the abnormal cell death,"Ligand = 50, 100, and 200 nM",Cytotoxicity,Lactate Dehydrogenase,Cells posses both trMJDCAG78 RNA and trMJDQ78 protein toxicities.,Compared to DMSO control,C,Drosophila (alpha-synuclein),No suppression of neurodegeneration.,"Oral; Ligand = 5, 10, 20, 30, 60, 120, 240 and 460 nM.",Rough Eye Phenotype,Light Microscopy,Parkinson's disease model. As revealed by pseudopupil assay on 12 day-old adult flies. Models show degenerative phenotypes. Images were captured by SPOT Insight CCD camera.,Compared to DMSO,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,C,trMJD Cells (CAA/G78),No effect on cell death,"Ligand = 50, 100, and 200 nM",Cytotoxicity,Lactate Dehydrogenase,Cells only possess trMJDQ78 protein toxicities.,Compared to DMSO control,C,Drosophila (CTG480),No suppression of neurodegeneration.,"Oral; Ligand = 5, 10, 20, 30, 60, 120, 240 and 460 nM.",Rough Eye Phenotype,Light Microscopy,Myotonic dystrophy 1 model. As revealed by pseudopupil assay on 12 day-old adult flies. Models show degenerative phenotypes. Images were captured by SPOT Insight CCD camera.,Compared to DMSO,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,C,Primary Rat Cortical Neurons,No dominant toxic effect,"Ligand = 50, 100, 200, 400, 800, 1600, 3200, 6400, 12800 nM",Cytotoxicity,Lactate Dehydrogenase,-,Compared to DMSO control,C,Drosophila (CGG90),No suppression of neurodegeneration.,"Oral; Ligand = 5, 10, 20, 30, 60, 120, 240 and 460 nM.",Rough Eye Phenotype,Light Microscopy,Fragile X syndrome. As revealed by pseudopupil assay on 12 day-old adult flies. Models show degenerative phenotypes. Images were captured by SPOT Insight CCD camera.,Compared to DMSO,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,SK-N-MC Neuroblastoma,Ligand could restore the pre-45s rRNA transcription level which was reduced by the expanded repeat RNA,"Ligand = 1, 10 and 100 nM",RNA Abundance,RT-PCR,Cells with expanded repeats (expressed via EGFPCAG78) showed a relatively higher level of cell death compared to the unexpanded control.,"Compared to cells transfected with unexpanded control - EGFPCAG27, where the compound did not alter pre-45s rRNA transcription level. Fold-change measured relative to Actin.",,R6/2 Huntington's mice,A significant difference was found on day 3: 300 mg/kg intranasal treatment group had significantly higher mean score on day 3 compared to vehicle group. No differences in intravenous treatment groups.,Intranasal (daily administration) or intravenous (twice weekly); varying concentrations; both starting at 6 weeks of age for 7 days,Motor Behavior,Neurological Index Score,"Scored on days 1 (baseline) and days 3, 5, and 7.",Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,,,,,,,,,R6/2 Huntington's mice,On day 7 the body temperature was increased in both 100 and 300 mg/kg  intranasal treatment groups compared to vehicle. No significant differences in temperature between the intravenous treatment groups.,Intranasal and intravenous; varying concentrations,Body Temperature,-,"Measured from rectum on day 1 (baseline), and on days 3, 5, and 7.",Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,,,,,,,,,R6/2 Huntington's mice,No differences in body weight intranasally or intravenously.,Intranasal and intravenous; varying concentrations,Body Weight,-,Body weights were measured daily.,Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0046B,R-BIND (SM) 0046B,C[NH+](C)CCCNC(=[NH2+])C1=CC=C(C=C1)C(=[NH2+])NCCC[NH+](C)C,DB213,US Patent 2017/0181986 A1,,,,,,,,,,,,,,,,,,,R6/2 Huntington's mice,"No differences in open field distance, rearings, distance in center, rearings in center or velocity between the intranasal treatment groups on day 7., intranasally or intravenously.",Intranasal and intravenous; varying concentrations,Motor Behavior,Open Field Test,Performed at day 0 (baseline) and day 7,Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,,HIV-1 RRE IIB,Kd = 12.4 ± 1.2 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 4.3 µM (infection),-,Antiviral Activity,Reporter,Infectious supernatants were obtained from plasmid pNL4.3-Ren on 293T cells and used to infect MT-2 cells in the presence of compound; Quantification occurred 48 h post infection,Compared to antiretrovirals zidovudine and nelfinavir,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,C,"HIV-1 RRE IIB, 100-fold Excess tRNA",Kd = 6.00 ± 1.1 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 4.3 µM (post-integration),-,Antiviral Activity,Reporter,"Full-length proviral DNA plasmid with a luciferase reporter gene under the control of the HIV-1 LTR promoter (NL4.3-luc); After transfection, cells were treated and harvested after 48 h",,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,C,"HIV-1 RRE IIB, 100-fold Excess dsDNA",Kd = 16.1 ± 1.5 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 3.3 µM (HIV-1 LTR),-,Antiviral Activity,Reporter,"Cells were collected with a full-length DNA plasmid containing a luciferase reporter gene under control of HIV-1 LTR; After transfection, cells were treated and harvested after 48 h","LTRd DNA duplex was used as a control, contains binding sites of transcription factors NF-kB and Sp-1",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,,HIV-1 RRE IIB:Rev34-50,IC50 = 3.7 ± 1.3 µM,-,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,RRE IIB-Rev34-50 values were obtained  using 60 nM IIBh and 10 nM frevp,Aminoglycoside antibiotics (Neomycin B and Neamine) and homochlorcyclizine were used as controls,,MT-2 Cells,EC50 = 5.9 µM (NF-?B),-,Antiviral Activity,Reporter,"Cells were collected with a full-length DNA plasmid containing a luciferase reporter gene under control of NF-?B; After transfection, cells were treated and harvested after 48 h","LTRd DNA duplex was used as a control, contains binding sites of transcription factors NF-kB and Sp-1",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,,HIV-1 RRE:REV,IC50 = 5 ± 1 µM,-,"10 mM HEPES pH 7.5, 300 mM KCl, 1 mM MgCl2, and 0.5 mM EDTA",Protein Displacement,Electrophoretic Mobility Shift Assay,Full length RRE-Rev IC50s were measured with 78 nM RRE and 1.32  µM Rev.,As comparison ciprofloxacin showed no activity,C,MT-2 Cells,CC50 = 17.4 µM,-,Cytotoxicity,CellTiter Glo,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,,,,,,,,,,,MT-2 Cells,EC50 = 5.1 - 8.7 µM,pCMV-REV = 10 - 200 ng,On-Target Effect,Reporter,EMSA pCMV-Rev and pDM628 plasmids encoding Rev and a luciferase gene controlled by RRE,"Ciprofloxacin showed no activity as a comparison, in agreement with the other experiments",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0047,R-BIND (SM) 0047,CC[NH+](CC)CCOC1=CC=C(C=C1)C(=C(\Cl)C1=CC=CC=C1)\C1=CC=CC=C1,Clomiphene,10.1016/j.bcp.2016.02.007,,,,,,,,,,,MT-2 Cells,~50% reduction of HIV-1 RNA transcripts,Ligand = 5 µM,RNA Abundance,RT-qPCR,Transfected with pNL4.3 plasmid and treated with compound,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,,HIV-1 RRE IIB,Kd = 1.8 ± 0.7 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 17.5 µM (infection),-,Antiviral Activity,Reporter,Infectious supernatants were obtained from plasmid pNL4.3-Ren on 293T cells and used to infect MT-2 cells in the presence of compound; Quantification occurred 48 h post infection,Compared to antiretrovirals zidovudine and nelfinavir,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,C,"HIV-1 RRE IIB, 100-fold Excess tRNA",Kd = 11.2 ± 4.7 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 25.6 µM (post-integration),-,Antiviral Activity,Reporter,"Full-length proviral DNA plasmid with a luciferase reporter gene under the control of the HIV-1 LTR promoter (NL4.3-luc); After transfection, cells were treated and harvested after 48 h",,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,C,"HIV-1 RRE IIB, 100-fold Excess dsDNA",Kd = 9.2 ± 5.1 µM,-,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),Studied using IIBh-19ap (2-aminopurine labeled structure),-,,MT-2 Cells,EC50 = 20.7 µM (HIV-1 LTR),-,Antiviral Activity,Reporter,"Cells were collected with a full-length DNA plasmid containing a luciferase reporter gene under control of HIV-1 LTR; After transfection, cells were treated and harvested after 48 h","LTRd DNA duplex was used as a control, contains binding sites of transcription factors NF-kB and Sp-1.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,,HIV-1 RRE IIB:Rev34-50,IC50 = 4.2 ± 2.2 µM,-,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,RRE IIB-Rev34-50 values were obtained using 60 nM IIBh and 10 nM frevp,Aminoglycoside antibiotics (Neomycin B and Neamine) and homochlorcyclizine were used as controls,,MT-2 Cells,EC50 = 22.5 µM (NF-?B),-,Antiviral Activity,Reporter,"Cells were collected with a full-length DNA plasmid containing a luciferase reporter gene under control of NF-?B; After transfection, cells were treated and harvested after 48 h","LTRd DNA duplex was used as a control, contains binding sites of transcription factors NF-kB and Sp-1.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,,HIV-1 RRE:REV,IC50  = 3 ± 1 µM,-,"10 mM HEPES pH 7.5, 300 mM KCl, 1 mM MgCl2, and 0.5 mM EDTA",Protein Displacement,Electrophoretic Mobility Shift Assay,Full length RRE-Rev IC50s were measured with 78 nM RRE and 1.32 µM Rev,As comparison ciprofloxacin showed no activity,C,MT-2 Cells,CC50 = 17.4 µM,-,Cytotoxicity,CellTiter Glo,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,,,,,,,,,,,MT-2 Cells,EC50 = 23.9 - 34.0 µM,pCMV-REV = 10 - 200 ng,On-Target Effect,Reporter,EMSA pCMV-Rev and pDM628 plasmids encoding Rev and a luciferase gene controlled by RRE,"Ciprofloxacin showed no activity as a comparison, in agreement with the other experiments",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0048,R-BIND (SM) 0048,C[NH+]1CCC(CC1)=C1C2=C(C=CC=C2)C=CC2=C1C=CC=C2,Cyproheptadine,10.1016/j.bcp.2016.02.007,,,,,,,,,,,MT-2 Cells,Reduced levels of HIV-1 transcripts,Ligand = 50 µM,RNA Abundance,RT-qPCR,Transfected with pNL4.3 plasmid and treated with compound,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0049,R-BIND (SM) 0049,CCC1=C(C)C=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,4478-7480,10.1021/ja502754f,,HIV-1 TAR,Bound to RNA,-,1 X PBST (pH = 7.4) and 0.01% Tween-20,Binding,Microarray,Cy5-labeled 29-nt TAR RNA hairpin,Negative control buffer incubated used; miR-21 RNA (Cy5 labeled) to rule out promiscuous binder; Verified to not interact with three separate DNA sequences screened against the small molecule microarray,,CEM-SS,EC50 = 123 µM,-,Antiviral Activity,XTT,HIV-1RF challenged CEM-SS cell viability,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0049,R-BIND (SM) 0049,CCC1=C(C)C=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,4478-7480,10.1021/ja502754f,,HIV-1 TAR,Dose-dependent decrease in the differential fluorescence with a concomitant increase in the melting temperature,Ligand = 1 - 30 µM; RNA = 0.5 µM,1 X PBS (pH = 7.4),Binding,Differential Scanning Fluorimetry,SYBR Green II dye,Compared to acepromazine (known binder) and 2 other ligands,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0050,R-BIND (SM) 0050,CC(C)(C)N1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 7a,10.1021/jm9903390,,HIV-1 TAR,Derivative of compound WM5 which binds to HIV-1 TAR RNA in vitro,-,-,-,-,-,-,,C8166 Human Lymphoblast T,EC50 = 2.0 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Confirmed activity by measuring antigen gp120 production with an ELISA method,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0050,R-BIND (SM) 0050,CC(C)(C)N1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 7a,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,EC50 = 82 µM,-,Antiviral Activity,Plaque Assay,Infected with herpes simplex virus type 1; Measure of selectivity for HIV-1 virus,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0050,R-BIND (SM) 0050,CC(C)(C)N1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 7a,10.1021/jm9903390,,,,,,,,,,C,C8166 Human Lymphoblast T,TC50 = 77.9 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0050,R-BIND (SM) 0050,CC(C)(C)N1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 7a,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,TC50 = 290 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0051,R-BIND (SM) 0051,NC1=C(C=C2N(C=C(C([O-])=O)C(=O)C2=C1)C1CC1)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 8a,10.1021/jm9903390,,HIV-1 TAR,Derivative of compound WM5 which binds to HIV-1 TAR RNA in vitro,-,-,-,-,-,-,,C8166 Human Lymphoblast T,EC50 = 0.7 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Confirmed activity by measuring antigen gp120 production with an ELISA method,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0051,R-BIND (SM) 0051,NC1=C(C=C2N(C=C(C([O-])=O)C(=O)C2=C1)C1CC1)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 8a,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,EC50 = 38 µM,-,Antiviral Activity,Plaque Assay,Infected with herpes simplex virus type 1; Measure of selectivity for HIV-1 virus,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0051,R-BIND (SM) 0051,NC1=C(C=C2N(C=C(C([O-])=O)C(=O)C2=C1)C1CC1)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 8a,10.1021/jm9903390,,,,,,,,,,C,C8166 Human Lymphoblast T,TC50 = 9 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0051,R-BIND (SM) 0051,NC1=C(C=C2N(C=C(C([O-])=O)C(=O)C2=C1)C1CC1)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 8a,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,TC50 = 95 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0052,R-BIND (SM) 0052,CN1C=C(C([O-])=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 22a,10.1021/jm9903390,,HIV-1 TAR,Derivative of compound WM5 which binds to HIV-1 TAR RNA in vitro,-,-,-,-,-,-,,C8166 Human Lymphoblast T,EC50 = 1.3 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Confirmed activity by measuring antigen gp120 production with an ELISA method,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0052,R-BIND (SM) 0052,CN1C=C(C([O-])=O)C(=O)C2=CC(F)=C(C=C12)N1CCN(CC1)C1=NC=CC=C1,Aminoquinolone 22a,10.1021/jm9903390,,,,,,,,,,C,C8166 Human Lymphoblast T,TC50 = 7 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,,HIV-1 TAR,Kd = 19 ± 0.6 nM,-,"10 mM Tris HCl (pH = 7.0), 20 mM NaCl, and 1 mM Mg(ClO4)2",Binding,Fluorescence-Based Titration (Intrinsic),Addition of TAR to WM5,-,,CD4+ T-Cell Line Jurkat,IC50 = 0.60 ± 0.06 µM,-,Antiviral Activity,Reverse Transcriptase Activity,Cells incubated with virus stock at MOI = 0.1 or 0.01 TCID50 per cell,"Compared to a WM5E, an inactive derivative",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,,HIV-1 TAR,Reduced quantum yield; Saturation in µM range,Ligand = 2 µM,"25 mM Tris-HCl (pH = 7.0), 20 mM NaCl, and 1 mM MnCl2",Binding,Fluorescence-Based Titration (Intrinsic),-,"Compared to ciprofloxacin, a fluoroquinolone; Also tested tRNA and calf thymus DNA, where no change in quantum yield was observed",,293T to Infect Jurkat,IC50 = 0.64 ± 0.05 µM,-,Antiviral Activity,Chloramphenicol Acetyl Transferase (CAT) ,env complementation assay for single round of infection; Transfected with pHXBH10?envCAT and pSVIIIenv plasmid expressing HIV-1HXBC2,"Compared to a WM5E, an inactive derivative",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.2174/1874104501913010016,,HIV-1 TAR:Tat Interaction,Ki = 2.22 ± 0.66 µM,NR,"Tris 10 mM (pH = 7.5), Mg(ClO4)2 1 mM, NaCl 20 mM (TNMg), 0.01% Triton X-100",Binding,FRET,Tat-derived peptide labelled with the donor fluorescein at its N terminus and the 29 nt wtTAR labeled at its 3’-end with a dabcyl moiety (quencher).,-,,HIV-1 IIIB-infected MT-4,EC50 = 0.15 ± 0.05 µM,NR,Cytotoxicity,MTT,"EC50 reflects measure of protection from HIV-1 induced cytopathogenicity, as determined by the MTT method.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,C,HIV-1 IN Protein,IC50 = 60 ± 20 (3' processing); IC50 = 75 ± 15 (strand transfer),-,"25 mM Tris-HCl (pH = 7.5), 40 mM NaCl, 10 mM MnCl2, 1 mM dithiothreitol, and 2% glycerol",Off-Target Effect,HIV-1 IN Protein Activity,-,WM5E and RDS 1028 used as controls,,H9 Cells,IC50 = 0.85 ± 0.05 µM,-,Antiviral Activity,Reverse Transcriptase Activity,HIV-1 (IIIB) chronically infected cells activated with PHA and IL-2 were incubated with ligand,Compared to no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,C,RNA-Dependent DNA Polymerase,IC50 = 800 ± 150 µM,-,Supernatant from HIV-1 chronically infected H9 cells,Off-Target Effect,Reverse Transcriptase Activity,-,-,C,CD4+ T-Cell Line Jurkat,CC50 = 56.24 ± 8.84 µM,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,C,HIV-1 Protease,IC50 = 71; Used WM5E and RDS 1028 as controls 21 µM,-,"100 mM MES (pH = 5.5), 400 mM NaCl, and 0.5% DMSO",Off-Target Effect,HIV-1 Protease Activity,-,Saquinavir used as control,C,H9 Cells,Similar to CD4+ T-cell line Jurkat,-,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1128/AAC.47.3.889–896.2003,,,,,,,,,,,293T to Infect Jurkat,IC50 = 0.60 ± 0.04 µM,-,Antiviral Activity,Chloramphenicol Acetyl Transferase (CAT) ,env complementation assay for single round of infection; Transfected with pHXBH10?envCAT and pSVIIIenv plasmid expressing 89.6 envelope glycoproteins,"Compared to a WM5E, an inactive derivative",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1021/jm9903390,,,,,,,,,,,C8166 Human Lymphoblast T,EC50 = 0.1 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Confirmed activity by measuring antigen gp120 production with an ELISA method,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,EC50 = 30 µM,-,Antiviral Activity,Plaque Assay,Infected with herpes simplex virus type 1; Measure of selectivity for HIV-1 virus,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1021/jm9903390,,,,,,,,,,C,C8166 Human Lymphoblast T,TC50 = 7 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.1021/jm9903390,,,,,,,,,,C,Vero Cells,TC50 = 95 µM,-,Cytotoxicity,NR,Infected with herpes simplex virus type 1,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0053,R-BIND (SM) 0053,CN1C=C(C([O-])=O)C(=O)C2=CC(N)=C(C=C12)N1CCN(CC1)C1=CC=CC=N1,WM5,10.2174/1874104501913010016,,,,,,,,,,C,MT-4 Cells,CC50 = 2.21 ± 1.05 µM,NR,Cytotoxicity,MTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0054,R-BIND (SM) 0054,C1C[NH+]=C(N1)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C1=[NH+]CCN1,DB60,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR RNA,?Tm = 24 ºC,Ligand = 5 µM,"6 mM Na2HPO4 (pH = 7.1), 2 mM Na2H2PO4, and 1 mM EDTA",Binding,Optical Melting,-,Control with no drug; Used mutants to verify specificity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0054,R-BIND (SM) 0054,C1C[NH+]=C(N1)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C1=[NH+]CCN1,DB60,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR:Tat Interaction,IC50 = 1 µM,-,"50 mM Tris HCl (pH = 7.4), 20 mM KCl, 5 mM DTT, and 0.1% Triton X-100",Protein Displacement,Electrophoretic Mobility Shift Assay,-,Compared to TAR-Tat with no drug and TAR with no Tat,,SX22-1 derived from HeLa T4,IC50 ? 1 µM,-,Antiviral Activity,Beta-Galactosidase,Fusion-induced gene stimulation assay where tat protein is constitutively expressed in chronically infected Hut/4-3 HIV-1 donor cells and is rapidly transferred into an LTR reporter cell via HIV mediated membrane fusion during cellular coculture,Compared to untreated control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0054,R-BIND (SM) 0054,C1C[NH+]=C(N1)C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C1=[NH+]CCN1,DB60,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR RNA,Evidence for TAR binding at GCUCU site (bulge region),Ligand = 5 - 25 µM,NR,Structure Determination,RNase Footprinting,-,Control with no drug; Used mutants to identify specificity ,C,SX22-1 derived from HeLa T4,Toxicity observed,Ligand > 10 µM,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055A,R-BIND (SM) 0055A,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR RNA,?Tm = 20 ºC,Ligand = 5 µM,"6 mM Na2HPO4 (pH = 7.1), 2 mM Na2H2PO4, and 1 mM EDTA",Binding,Optical Melting,-,Control with no drug; Used mutants to verify specificity,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055A,R-BIND (SM) 0055A,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR:Tat Interaction,IC50 = 5 µM,-,"50 mM Tris HCl (pH = 7.4), 20 mM KCl, 5 mM DTT, and 0.1% Triton X-100",Protein Displacement,Electrophoretic Mobility Shift Assay,-,Compared to TAR-Tat with no drug and TAR with no Tat,,SX22-1 derived from HeLa T4,IC50 ~ 30 µM,-,Antiviral Activity,Beta-Galactosidase,Fusion-induced gene stimulation assay where tat protein is constitutively expressed in chronically infected Hut/4-3 HIV-1 donor cells and is rapidly transferred into an LTR reporter cell via HIV mediated membrane fusion during cellular coculture,Compared to untreated control; Inferred that IC50 is above toxic levels,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055A,R-BIND (SM) 0055A,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1016/S0968-0896(99)00041-3,,HIV-1 TAR RNA,Evidence for TAR binding at GCUCU site (bulge region),Ligand = 5 - 25 µM,NR,Structure Determination,RNase Footprinting,-,Control with no drug; Used mutants to identify specificity ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,"HTT exon1, 47 CAG repeats",Dose-dependent reduction in translation,"Ligand = 10, 50 µM",Promega Luciferase Assay Buffer,Activity,Luciferase,In vitro transcribed firefly luciferase reporter sequence fused to HTT exon1 with 47 CAG repeats in 3' UTR,Fluorescence normalized to luciferase without HTT exon1; Control with no drug,C,HEK293T Cells,"No change in levels of endogenous nonmutant polyglutamine proteins HTT, Ataxin-2, and Ataxin-3",Ligand = 10 - 100 µM,Protein Abundance,Western Blot,-,Tubulin loading control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,"HTT exon1 RNA, 48 repeats",Kd = 160 ± 15.1 ?M,RNA = 400 nM,"50 mM Tris-HCl (pH = 8.0), 100 mM KCl, and 10 mM MgCl2",Binding,Microscale Thermophoresis,RNA was Cy5-labeled,-,C,HEK293T Cells,No toxicity observed at study concentrations,Ligand = 10 - 100 µM,Cytotoxicity,Lactate Dehydrogenase,Cells stably expressed FLAG-HTT exon1 with 51 CAG repeats under inducible Tet promoter,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,"HTT exon1 RNA, 18 repeats",Kd = 59.9 ± 8.61 ?M; ?G ? ?5 kcal/mol,RNA = 400 nM,"50 mM Tris-HCl (pH = 8.0), 100 mM KCl, and 10 mM MgCl2",Binding,Microscale Thermophoresis,RNA was Cy5-labeled,-,,HEK293T Cells,No change in HTT exon1 mRNA levels,Ligand = 10 - 50 µM,RNA Abundance,RT-PCR,Cells stably expressed FLAG-tagged HTT exon1 with 83 CAG repeats under inducible Tet promoter,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,CAG x 10 repeat RNA,"Ligand binds to RNA major groove, forming salt bridges with the A4, G5, and A17 phosphate groups; Two salt bridges between ligand amidine tails and the G5 and G2 phosphate groups also observed; Aromatic rings are solvent exposed; Standard state binding free energy ? ?7 kcal/mol",N/A,pH = 7.4,In Silico,Metadynamics-Based Free Energy Calculations,Calculated free energy surface of ligand binding to a model CAG RNA (PDB 3NJ6) used in previous work,-,,HEK293T Cells,Clear reduction in HTT exon1 polyQ protein levels,Ligand = 10 - 50 µM,Protein Abundance,Filter Retardation,Cells stably expressed FLAG-tagged HTT exon1 with 83 CAG repeats under inducible Tet promoter,Actin detected by Western blot as loading control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,HTT exon1 RNA:MID1 protein,Binding inhibited partially at 50 µM and fully at 100 µM,Ligand = 1 - 100 µM,HEK293T cell protein extracts,Protein Displacement,RNA Pull-Down,"In vitro transcribed RNA containing 72 repeats was biotinylated, incubated with protein extracts from FLAG-MID1-expressing cells, and immobilized; RNA:protein complexes were incubated with ligand and washed; RNA-bound protein was eluted and analyzed by Western blot detecting FLAG-MID1",Control with no drug; Control with no RNA, ,HEK293T Cells,Clear reduction in HTT exon1 polyQ protein levels,Ligand = 10 - 100 µM,Protein Abundance,Western Blot,Cells stably expressed FLAG-HTT exon1 with 51 CAG repeats under inducible Tet promoter,Actin loading control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027, ,HTT exon1 RNA-binding proteins,Reduced binding of additional proteins,Ligand = 100 µM,HEK293T cell protein extracts,Protein Displacement,RNA Pull-Down,"In vitro transcribed RNA containing 49 or 72 repeats was biotinylated, incubated with protein extracts from FLAG-MID1-expressing cells, and immobilized; RNA:protein complexes were incubated with ligand and washed; RNA-bound protein was eluted and analyzed by silver staining using the SilverQuest Silver Staining Kit (Thermo Fisher Scientific)",Control with no drug; Control with no RNA, ,HEK293T Cells,No change in HTT exon1 mRNA levels,Ligand = 10 - 50 µM,RNA Abundance,RT-PCR,Cells stably expressed FLAG-HTT exon1 with 51 CAG repeats under inducible Tet promoter,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,,,,,,,,,,HeLa Cells,Intracellular concentration after 5 h = 74.5 ± 3.1 ?M,Ligand = 50 µM,Cell Uptake,ESI-MS,Cell volume estimated by measuring volume of cell pellet,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,,,,,,,,,C,HeLa Cells,No toxicity observed at study concentrations,Ligand = 10 - 100 µM,Cytotoxicity,Lactate Dehydrogenase,Cells stably expressed FLAG-HTT exon1 with 51 CAG repeats under inducible Tet promoter,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,,,,,,,,,,HEK293T Cells,Significantly reduced expression of construct containing pure CAG repeats,Ligand = 25 µM,Reporter,Dual Luciferase ,Cells transfected with Renilla luciferase reporter construct that contained a pure (CAG)50 repeat in its 3?-UTR; Above experiments used HTT exon1 constructs that contained a repeat flanking sequence that could have interacted with the ligand,Control with luciferase vector alone; Fluorescence normalized to fluc gene expression within the same plasmid, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0055B,R-BIND (SM) 0055B,NC(=[NH2+])C1=CC=C(C=C1)C1=CC=C(O1)C1=CC=C(C=C1)C(N)=[NH2+],DB75,10.1021/acschemneuro.8b00027,,,,,,,,,,,HeLa Cells,Significantly reduced HTT exon1 translation,"Ligand = 12.5, 25 µM",Translational Activity,FRAP,"Cells expressed HTT exon1 with 46 CAG repeats fused to GFP; After cell is bleached, the fluorescence signal of GFP-HTT exon1 is lost, and signal recovery of newly translated GFP-tagged protein can be captured",Control with no drug; Control with GFP translation alone, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0056,R-BIND (SM) 0056,C[NH+]1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1,Prochlorperazine,10.1016/S1074-5521(02)00106-0,,HIV-1 TAR:Tat:CycT1,Inhibited the interaction,Ligand = 0.1 - 1 µM,"30 mM Tris-HCl (pH = 8.o), 70 mM KCl, 0.01% Nonidet P-40, 5.5 mM MgCl2, 1 mM DTT, and 13% glycerol",Protein Displacement,Electrophoretic Mobility Shift Assay,Inhibition of the interaction of Tat with TAR in the presence of CycT1,-,,HeLa Cells,Up to 6-fold inhibition of Tat transactivation,Ligand = 5 - 20 µM,On-Target Effect,Chloramphenicol Acetyl Transferase (CAT) ,Cells were pre-incubated with drug and the cotransfected target and effector plasmids; Measured CAT enzyme activity through measuring 3H-acetyl-chloramphenicol,"Used a heterology tethering system of the Rev genes and the RRE, where no effect was observed",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0056,R-BIND (SM) 0056,C[NH+]1CCN(CCCN2C3=CC=CC=C3SC3=CC=C(Cl)C=C23)CC1,Prochlorperazine,10.1016/S1074-5521(02)00106-0,,HIV-1 TAR,Bound to 5' bulge,Ligand = 2 - 3 mM,20 mM sodium phosphate (pH = 6.5) and 20 mM NaCl,Structure Determination,Nuclear Magnetic Resonance,TOCSY and COSY NMR,-,C,HeLa Cells,Significant cellular toxicity,Ligand > 20 µM,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0057,R-BIND (SM) 0057,NC1=NC2=CC=C(N)C(N)=C2C(N)=[NH+]1,Quinoxaline 3,10.1021/bi981308u,,HIV-1 TAR:Tat,"At high ligand concentration, > 1:1 ligand:RNA stoichiometry and complete displacement of Tat",NR,"10 mM ammonium acetate (pH = 6.9), 10% MeOH, and 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA)",Protein Displacement,ESI-MS,-,Compared to known binders neomycin and quinoxaline derivative; Performed with TAR hexaloop replaced with a polyethylene glycol linker,C,HeLa Cells,No toxicity observed,Ligand Max = 100 µM,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0057,R-BIND (SM) 0057,NC1=NC2=CC=C(N)C(N)=C2C(N)=[NH+]1,Quinoxaline 3,10.1021/bi981308u,,HIV-1 TAR:Tat,IC50 = 10 µM,-,"10 mM Tris-HCl (pH = 7.5), 70 mM NaCl, 0.2 mM EDTA, 0.01% Nonidet P-40, and 5% glycerol",Protein Displacement,Electrophoretic Mobility Shift Assay,32P-labeled free RNA is separated from the RNA protein complex; Calculated in the presence of 10 nM Tat,Compared to known binders neomycin and quinoxaline derivative; Used control samples containing no potential inhibitors,,HeLa Cells,EC50 = 19 µM,-,On-Target Effect,Beta-Galactosidase,Tat-activated reporter gene assay: HeLa cells were transfected with RSV-Tat-Neo that constitutively express HIV-1 Tat proteins; LacZ gene is driven by the HIV-1 LTR promoter,"Compared to system with LacZ gene controlled by CMV promoter, where no effect was observed",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0057,R-BIND (SM) 0057,NC1=NC2=CC=C(N)C(N)=C2C(N)=[NH+]1,Quinoxaline 3,10.1021/bi981308u,,HIV-1 TAR,Binding location,Ligand = 1 - 500 µM,"25 mM Tris-HCl (pH = 7.5), 10 mM MgCl2, 200 mM NaCl, 1 µg of yeast tRNA, and 5% DMSO",Structure Determination,"DEPC, DMS, and V1 Nuclease Footprinting",-,Compared to known binders neomycin and quinoxaline derivative,,OM-10.1 Cells,EC50 = 4 µM,-,Antiviral Activity,ELISA,Measured production of viral protein p24; Integrated copy of HIV-1 genome from acute infection,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0057,R-BIND (SM) 0057,NC1=NC2=CC=C(N)C(N)=C2C(N)=[NH+]1,Quinoxaline 3,10.1021/bi981308u,,,,,,,,,,,U1 Cells,EC50 = 16 µM,-,Antiviral Activity,NR,U1 cells derived from U-937 promonocytic cells;  Integrated copy of HIV-1 genome from chronic infection,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0057,R-BIND (SM) 0057,NC1=NC2=CC=C(N)C(N)=C2C(N)=[NH+]1,Quinoxaline 3,10.1021/bi981308u,,,,,,,,,,C,OM-10.1 Cells,TC50 = 54 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0058,R-BIND (SM) 0058,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 1b,10.1002/chem.201303664,,HIV-1 TAR,Kd = 7.5 µM,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),,MAGIC-5B Cells,IC50 = 0.63 µM,-,Antiviral Activity,Beta-Galactosidase,Cells pre-incubated with ligand and then challenged with the HIV-1 NL4.3 strain at MOI = 1,Azidothymidine (AZT) used as a reference HIV-1 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0058,R-BIND (SM) 0058,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 1b,10.1002/chem.201303664,,"HIV-1 TAR, 100-fold Excess tRNA",K'd = 10.4 µM; K'd/Kd = 1.4,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),C,MAGIC-5B Cells,No toxicity observed,Ligand Max = 100 µM,Cytotoxicity,CellTiter 96 Aqueous One Solution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0058,R-BIND (SM) 0058,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 1b,10.1002/chem.201303664,,"HIV-1 TAR, 100-fold Excess dsDNA",K'd = 11.5 µM; K'd/Kd = 1.5,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0058,R-BIND (SM) 0058,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 1b,10.1002/chem.201303664,,HIV-1 TAR,?G = -28.8 kJ/mol; ?H = -38.1 ± 1.5 kJ/mol; T?S = -9.26 ± 1.5 kJ/mol,-,0.1 M KCl,Binding,Fluorescence-Based Titration (Labeled RNA),Proposed binding mode using thermodynamic calculations,Neomycin control; Electrostatic contributions also calculated by using salt/temperature gradient,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0059,R-BIND (SM) 0059,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CC2=CNC=N2)=CC=C1,S-Amino Acid Conjugate 3b,10.1002/chem.201303664,,HIV-1 TAR,Kd = 17.5 µM,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),,MAGIC-5B Cells,IC50 = 0.41 µM,-,Antiviral Activity,Beta-Galactosidase,Cells pre-incubated with ligand and then challenged with the HIV-1 NL4.3 strain at MOI = 1,Azidothymidine (AZT) used as a reference HIV-1 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0059,R-BIND (SM) 0059,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CC2=CNC=N2)=CC=C1,S-Amino Acid Conjugate 3b,10.1002/chem.201303664,,"HIV-1 TAR, 100-fold Excess tRNA",K'd = 18.10 µM; K'd/Kd = 1.1,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),C,MAGIC-5B Cells,No toxicity observed,Ligand Max = 100 µM,Cytotoxicity,CellTiter 96 Aqueous One Solution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0059,R-BIND (SM) 0059,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CC2=CNC=N2)=CC=C1,S-Amino Acid Conjugate 3b,10.1002/chem.201303664,,"HIV-1 TAR, 100-fold Excess dsDNA",K'd = 20.5 µM; K'd/Kd = 1.2,-,"20 mM HEPES (pH = 7.4), 20 mM NaCl, 140 mM KCl, and 3mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),5'-Alexa 488 fluorescent tag,Neomycin (positive control),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0059,R-BIND (SM) 0059,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)[C@@H]([NH3+])CC2=CNC=N2)=CC=C1,S-Amino Acid Conjugate 3b,10.1002/chem.201303664,,HIV-1 TAR,?G = -25.6 kJ/mol; ?H = -49.0 ± 3.1 kJ/mol; T?S = -23.4 ± 3.2 kJ/mol,-,0.1 M KCl,Binding,Fluorescence-Based Titration (Labeled RNA),Proposed binding mode using thermodynamic calculations,Neomycin control; Electrostatic contributions also calculated by using salt/temperature gradient,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0060,R-BIND (SM) 0060,CC1=CC=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,ST4133609,10.1021/ja502754f,,HIV-1 TAR,Kd = 2.4 ± 1.1 µM,-,1 X PBS (pH = 7.4),Binding,Fluorescence-Based Titration (Labeled RNA),2-aminopurine labeled RNA,-,,CEM-SS Cells,EC50 = 28 µM,-,Antiviral Activity,XTT,HIV-1RF challenged CEM-SS cell viability,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0060,R-BIND (SM) 0060,CC1=CC=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,ST4133609,10.1021/ja502754f,,HIV-1 TAR,Dose-dependent decrease in the differential fluorescence with a concomitant increase in the melting temperature,Ligand = 1 - 30 µM; RNA = 0.5 µM,1 X PBS (pH = 7.4),Binding,Differential Scanning Fluorimetry,SYBR Green II dye,Compared to acepromazine (known binder) and 2 other ligands,C,CEM-SS Cells,CC50 > 1 mM,-,Cytotoxicity,XTT,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0060,R-BIND (SM) 0060,CC1=CC=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,ST4133609,10.1039/C8OB02753F,,HIV-1 TAR,Kd = 46.2 ± 22.3 µM,"Ligand = 2.5, 5, 10, 15, and 20 µM. RNA = 0.5 µM","8 mM Na2HPO4 (pH = 7.4), 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl",Binding,Fluorescence-Based Titration (Labeled RNA),2-aminopurine labeled RNA,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0060,R-BIND (SM) 0060,CC1=CC=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,ST4133609,10.1039/C8OB02753F,C,HIV-1 RRE,Not determined,"Ligand = 2.5, 5, 10, 15, and 20 µM. RNA = 0.5 µM","8 mM Na2HPO4 (pH = 7.4), 2 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl",Binding,Fluorescence-Based Titration (Labeled RNA),2-aminopurine labeled RNA,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0060,R-BIND (SM) 0060,CC1=CC=C2C(N)=C(SC2=N1)C(=O)NC1=CC(=CC=C1)C(F)(F)F,ST4133609,10.1021/ja502754f,,HIV-1 5' UTR,Observed substantial changes only in the TAR region of the HIV 5' UTR; Effects of compound binding were mapped to the hairpin,Ligand = 5.0 µM,"50 mM Tris-HCl (pH = 8.0), 100 mM NaCl, and 5 mM MgCl2",Structure Determination,SHAPE,1M7 probe,Compared to NMR of RNA without compound,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 61.45 µM,-,10 mM potassium phosphate (pH = 6.0) and 150 mM NaCl,Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound,,MDCK-HA Cells,IC50 = 549 µM,-,Antiviral Activity,Reporter,"WSN-Ren luciferase assay; Coding sequence of Renilla luciferase was engineered into A/WSN/33 influenza virus in place of hemagglutinin (HA); After treatment, Renilla luciferase substrate was added and fluorescence was measured",Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 50.5 ± 9 µM,-,"10 mM potassium phosphate (pH = 6.1), 50 mM NaCl, and 0.1 mM EDTA",Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound,C,MDCK-HA Cells,CC50  > 1000 µM,-,Cytotoxicity,ATPlite,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1039/c3cc46973e,,Influenza RNA Promoter,Binding location; RNA helix tilt 6.7 +/- 3.4 º (bound) compared to 46 +/- 10º (free),NR,"10 mM potassium phosphate (pH = 6.1), 50 mM NaCl, and 0.1 mM EDTA",Structure Determination,Nuclear Magnetic Resonance,"Proton, NOESY, TOCSY, HSQC",Compared to NMR of RNA without compound,,MDCK Cells,EC50 = 71.6 ± 28.8 µM,-,Antiviral Activity,Fluoresceine Diacetate Cytopathic Effect Inhibition,"Cells were infected with Influenza A H1N1, TW strain followed by treatment with DPQ","Compared to anti-influenza drugs amantadine, oseltamivir, and ribavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1039/c3cc46973e,,,,,,,,,,,MDCK Cells,EC50 = 275.5 ± 97.6 µM,-,Antiviral Activity,Fluoresceine Diacetate Cytopathic Effect Inhibition,"Cells were infected with Influenza A H3N2, HK strain followed by treatment with DPQ","Compared to anti-influenza drugs amantadine, oseltamivir, and ribavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1039/c3cc46973e,,,,,,,,,,,MDCK Cells,EC50 = 113.7 ± 8.9 µM,-,Antiviral Activity,Fluoresceine Diacetate Cytopathic Effect Inhibition,"Cells were infected with Influenza B, PNM strain followed by treatment with DPQ","Compared to anti-influenza drugs amantadine, oseltamivir, and ribavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1039/c3cc46973e,,,,,,,,,,,MDCK Cells,Plaque formation reduced at ligand concentrations of 56 - 500 µM; Plaque size decreased; Plaque number reduction was much less ,-,Antiviral Activity,Plaque Assay,"Cells were infected with either Influenza A H1N1, TW strain and Influenza A H3N2, HK strain followed by treatment with DPQ","Compared to anti-influenza drugs amantadine, oseltamivir, and ribavirin",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0061,R-BIND (SM) 0061,COC1=CC2=NC(=NC(N)=C2C=C1OC)N1CC[NH2+]CC1,DPQ,10.1039/c3cc46973e,,,,,,,,,,C,MDCK Cells,CC50 > 500 µM,-,Cytotoxicity,Fluoresceine Diacetate Cytopathic Effect Inhibition,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0062,R-BIND (SM) 0062,CCC(=O)N1CCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=[NH+]1,DPQ 6,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 114.2 µM,-,10 mM potassium phosphate (pH = 6.0) and 150 mM NaCl,Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound; Also compared to the 1H NMR binding of the parent compound DPQ,,MDCK-HA Cells,IC50 = 39.67 µM,-,Antiviral Activity,Reporter,"WSN-Ren luciferase assay; Coding sequence of Renilla luciferase was engineered into A/WSN/33 influenza virus in place of hemagglutinin (HA); After treatment,  substrate was added and fluorescence was measured",Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0062,R-BIND (SM) 0062,CCC(=O)N1CCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=[NH+]1,DPQ 6,10.1111/cbdd.12534,,,,,,,,,,C,MDCK-HA Cells,CC50 > 250 µM,-,Cytotoxicity,ATPlite,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0063,R-BIND (SM) 0063,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C(C)C,DPQ 7,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 158.5 µM,-,10 mM potassium phosphate (pH = 6.0) and 150 mM NaCl,Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound; Also compared to the 1H NMR binding of the parent compound DPQ,,MDCK-HA Cells,IC50 = 33.89 µM,-,Antiviral Activity,Reporter,"WSN-Ren luciferase assay; Coding sequence of  was engineered into A/WSN/33 influenza virus in place of hemagglutinin (HA); After treatment, substrate was added and fluorescence was measured",Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0063,R-BIND (SM) 0063,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C(C)C,DPQ 7,10.1111/cbdd.12534,,,,,,,,,,,MDCK-HA Cells,Statistically significant inhibition of viral nucleoprotein (a/PR8/34) mRNA production,Ligand = 50 µM,Antiviral Activity,RT-qPCR,Cells infected with WT influenza virus (A/Puerto Rico/8/1935) at MOI = 0.2,"Compared to parent compound DPQ, DMSO, and oseltamivir (an antiviral medication)",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0063,R-BIND (SM) 0063,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C(C)C,DPQ 7,10.1111/cbdd.12534,,,,,,,,,,C,MDCK-HA Cells,CC50 > 250 µM,-,Cytotoxicity,ATPlite,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0064,R-BIND (SM) 0064,CCCC(=O)N1CCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=[NH+]1,DPQ 8,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 44.35 µM,-,10 mM potassium phosphate (pH = 6.0) and 150 mM NaCl,Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound; Also compared to the 1H NMR binding of the parent compound DPQ,,MDCK-HA Cells,IC50 = 44.18 µM,-,Antiviral Activity,Reporter,"WSN-Ren luciferase assay; Coding sequence of  was engineered into A/WSN/33 influenza virus in place of hemagglutinin (HA); After treatment,  substrate was added and fluorescence was measured",Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0064,R-BIND (SM) 0064,CCCC(=O)N1CCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=[NH+]1,DPQ 8,10.1111/cbdd.12534,,,,,,,,,,,MDCK-HA Cells,Statistically significant inhibition of viral nucleoprotein (a/PR8/34) mRNA production,Ligand = 50 µM,Antiviral Activity,RT-qPCR,Cells infected with WT influenza virus (A/Puerto Rico/8/1935) at MOI = 0.2,"Compared to parent compound DPQ, DMSO, and oseltamivir (an antiviral medication)",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0064,R-BIND (SM) 0064,CCCC(=O)N1CCN(CC1)C1=NC(N)=C2C=C(OC)C(OC)=CC2=[NH+]1,DPQ 8,10.1111/cbdd.12534,,,,,,,,,,C,MDCK-HA Cells,CC50 > 250 µM,-,Cytotoxicity,ATPlite,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0065,R-BIND (SM) 0065,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CC1,DPQ 10,10.1111/cbdd.12534,,Influenza RNA Promoter,Kd = 127.2 µM,-,10 mM potassium phosphate (pH = 6.0) and 150 mM NaCl,Binding,Nuclear Magnetic Resonance,Proton ,Compared to NMR of RNA without compound; Also compared to the 1H NMR binding of the parent compound DPQ,,MDCK-HA Cells,IC50 = 34.18 µM,-,Antiviral Activity,Reporter,"WSN-Ren luciferase assay; Coding sequence of  was engineered into A/WSN/33 influenza virus in place of hemagglutinin (HA); After treatment, substrate was added and fluorescence was measured",Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0065,R-BIND (SM) 0065,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CC1,DPQ 10,10.1111/cbdd.12534,,,,,,,,,,,MDCK-HA Cells,Statistically significant inhibition of viral nucleoprotein (a/PR8/34) mRNA production,Ligand = 50 µM,Antiviral Activity,RT-qPCR,Cells infected with WT influenza virus (A/Puerto Rico/8/1935) at MOI = 0.2,"Compared to parent compound DPQ, DMSO, and oseltamivir (an antiviral medication)",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0065,R-BIND (SM) 0065,COC1=CC2=[NH+]C(=NC(N)=C2C=C1OC)N1CCN(CC1)C(=O)C1CC1,DPQ 10,10.1111/cbdd.12534,,,,,,,,,,C,MDCK-HA Cells,CC50 > 250 µM,-,Cytotoxicity,ATPlite,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,JEV Translational Frameshift Site RNA 3,Kd = 84.2 ± 4.24 µM; ?H = -15.95 ± 0.47 kcal/mol; ?S = -17.2 ± 0.47 kcal/mol*K,-,"50 mM Tris-HCl (pH = 7.3), 150 mM NaCl, and 0.1% DMSO",Binding,Isothermal Titration Calorimetry,Large entropic component suggests conformational change in RNA,Compared to 7-hydroxyflavone and DAI as a control,,BHK21 Cells,Dose-dependent inhibition; EC50 = 12.6 µM; EC70 = 25.7 µM,MOI = 0.1 for 72 h,Antiviral Activity,MTS Reduction,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,JEV Translational Frameshift Site RNA 1,"1:1 to 7:1 and 1:1 to 4:1 ligand:RNA stoichiometries for z = 5 and z = 4 charge states, respectively",Ligand = 50 µM; RNA = 10 µM,150 mM NH4+,Binding,ESI-MS,-,Compared to 7-hydroxyflavone and DAI as a control,,BHK21 Cells,Viral inhibition rate (VIR) = 49.5%,Ligand = 12.5 µM,Antiviral Activity,MTS Reduction,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,JEV Translational Frameshift Site RNA 2,1:1 to 5:1 and 1:1 to 4:1 ligand:RNA stoichiometries for z = 4 charge state,Ligand = 50 µM; RNA = 10 µM,150 mM NH4+,Binding,ESI-MS,-,Compared to 7-hydroxyflavone and DAI as a control,,BHK21 Cells,EC50 = 21.5 µM; EC70 = 45.8 µM,MOI = 0.1 for 2 h,Antiviral Activity,MTS Reduction,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,Viral inhibition rate (VIR) = 21.5%,Ligand = 12.5 µM,Antiviral Activity,MTS Reduction,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,Significant reduction in fluorescence-positive cells,Ligand = 25 µM,Antiviral Activity,Immunofluorescence,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,C,BHK21 Cells,Fluorescence across entire cell; fluorescence more intense in infected cells,Ligand = 50 µM,Cell Uptake,Fluorescence Microscopy,-,"Compared to uninfected, infected cells, and mock-infection groups with and without ligand",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,C,BHK21 Cells,CC50 = 230 µM,-,Cytotoxicity,MTS Reduction,Maximum non-toxic dose is 180 µM,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,"Inhibited E, NS1, and NS1' protein expression by > 44.8%, 36.8%, and 22.1%, respectively with pre-infection",Ligand = 25 µM,Protein Abundance,Western Blot,Pre-infection: cells infected with MOI = 0.1 JEV for 2 h and treated with ligand for 2 h,Compared to uninfected cells and mock-infection groups; Also compared to 7-hydroxyflavone treated infected or uninfected cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,"Inhibited E, NS1, and NS1' protein expression by >12.9%, 7.1%, and 1.2%, respectively with pre-treatment",Ligand = 25 µM,Protein Abundance,Western Blot,Pre-treatment: cell pretreated with ligand for 2 h and infected for 48 h,Compared to uninfected cells and mock-infection groups; Also compared to 7-hydroxyflavone treated infected or uninfected cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,Inhibited JEV mRNA transcription by > 14.2 % with pre-treatment,NR,RNA Abundance,RT-PCR,Pre-treatment: cell pretreated with ligand for 2 h and infected for 48 h; Extracted total RNA from cells,Compared to uninfected cells and mock-infection groups; Also compared to 7-hydroxyflavone treated infected or uninfected cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0066,R-BIND (SM) 0066,OC1=CC=C(C=C1)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Kaempferol,10.1371/journal.pone.0030259,,,,,,,,,,,BHK21 Cells,Inhibited JEV mRNA transcription by 21.6% with pre-infection,NR,RNA Abundance,RT-PCR,Pre-infection: cells infected with MOI = 0.1 JEV for 2 h and treated with ligand for 2 h; Extracted total RNA from cells,Compared to uninfected cells and mock-infection groups; Also compared to 7-hydroxyflavone treated infected or uninfected cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,,SARS-Pseudoknot,80% decrease in -1 RF efficiency,Ligand = 250 µM,NR,Activity,Transcription/Translation Coupled (TNT),Measured by SDS-PAGE,Compared to DMSO control; Monitored non-frameshifting product efficiency as a control,,HEK-293 Cells,IC50 ? 0.45 µM,-,Antiviral Activity,Reporter,Reporter plasmids were transfected and then cells were treated with compound; Cells were then assayed for transient expression of reporter genes,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,,SARS-Pseudoknot,Decreased -1 RF to 1%,Ligand = 250 µM,NR,Activity,Luciferase,"Used a dual reporter construct with the -1 RF system induced by the SARS-pseudoknot between two reporter genes, the Renilla luciferase and fluc genes",Compared to DMSO control; Monitored non-frameshifting product efficiency as a control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,,SARS-Pseudoknot,No effect on synthesis of RNA ,Ligand = 250 µM,NR,Activity,Transcription ,In vitro transcription assay to assess the synthesis of RNA,Compared to DMSO; Compared activities of less-active compounds,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,,SARS-Pseudoknot,Effect similar to coupled transcription/translation assay,Ligand = 250 µM,NR,Activity,Luciferase,In vitro translation assay to verify that the compounds acted at the translation level,Compared to DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja410344b,,SARS-Pseudoknot Construct,Kd = 210 ± 20 µM,-,"50 mM HEPES (pH = 7.5), 100 mM KCl, 10 mM MgCl2, and 4 mM TCEP",Binding,Surface Plasmon Resonance,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja410344b,,SARS-Pseudoknot Construct,Reduced the fraction of force extension curves; Unfolding of the alternate structure at increasing ligand concentrations,"Ligand = 75, 250, 500 µM","50 mM MOPS (pH = 7.0), 130 mM KCl, 4 mM MgCl2, and 0.3% DMSO",Binding,Optical Tweezers,No change observed in the average unfolding force and landscape parameters,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,C,Biotin-Binding Pseudoknot,No interaction,Ligand = 250 µM,NR,Off-Target Effect,Transcription/Translation Coupled (TNT),"Used a dual reporter construct with the -1 RF system induced by the SARS-pseudoknot between two reporter genes, the Renilla luciferase and fluc genes",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,C,PEMV-Pseudoknot,No interaction,Ligand = 250 µM,NR,Off-Target Effect,Transcription/Translation Coupled (TNT),"Used a dual reporter construct with the -1 RF system induced by the SARS-pseudoknot between two reporter genes, the Renilla luciferase and fluc genes",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0067,R-BIND (SM) 0067,CCOC(=O)C1=CC=CC=C1NC(=O)N1CCCN(CC2=CSC(C)=N2)CC1,Compound 43 (MTDB),10.1021/ja1098325,C,SARS-Pseudoknot Mutant,28% decrease in -1 RF efficiency,Ligand = 250 µM,NR,Off-Target Effect,Transcription/Translation Coupled (TNT),"Used a dual reporter construct with the -1 RF system induced by the SARS-pseudoknot between two reporter genes, the Renilla luciferase and fluc gene",Mutant designed from docking studies,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Kd = 1.29 ± 0.0589 µM,-,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Binding,Microscale Thermophoresis,FAM-labeled RNA,-,C,MCF-7 Cells,IC50 = 12.5 µM,-,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Dose-dependent decrease in G4 signals,Ligand = 5 µM,10 mM Tris HCl (pH = 7.4) and 100 mM KCl,Binding,Circular Dichroism,Signal at 260 nm,"G-quad signals in Mutant IRES-A 2, IRES-A DNA, and a G-rich sequence in hVEGF-A promoter changed very little",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,?Tm = 18.7 ºC,Ligand = 5 µM,10 mM Tris HCl (pH = 7.4) and 100 mM KCl,Binding,Circular Dichroism,Signal at 262 nm,Compared to compound 2 and 3 (stabilizing ligands),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Increasing concentration of ligand reduced G4 and increased ssRNA populations,NR,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Binding,Electrophoretic Mobility Shift Assay,-,No change for Mutant IRES-A 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,BG4-RNA complex was reduced,Ligand = 1.25 - 10 µM,10 mM Tris HCl (pH = 7.4) and 100 mM KCl,Binding,Filter Binding,BG4 antibody that stabilizes G4 structures,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,BG4-RNA complex was reduced,"Ligand = 2.5, 10 µM",10 mM Tris HCl (pH = 7.4) and 100 mM KCl,Binding,RNA Pull-Down,BG4 antibody that stabilizes G4 structures,BSA as control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,BG4-RNA complex was reduced,NR,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Binding,Electrophoretic Mobility Shift Assay,BG4 antibody that stabilizes G4 structures,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Increased Kd of BG4:IRES-A from 10.8 nM to 4.64 µM,NR,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Binding,Microscale Thermophoresis,FAM-labeled RNA; Annealed RNA in presence and absence of Compound 1 (2017),No change for Mutant IRES-A 2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Highest binding to IRES-A,Ligand = 1 µM,10 mM Tris HCl (pH = 7.4) and 100 mM NaCl,Binding ,Competition Dialysis,Spectrophotometric quantitation,-,,MDA-MB-231 Cells,Cell migration reduced to ~25%; Cell migration suppressed after 4 h and plateaued at 10 h,Ligand = 3 µM,Cell Migration,Trans-Well, A real-time cell analyzer system was employed to monitor and record cell migration rate over 24 h after cells were seeded into wells,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,,HCV IRES-A,Kd = 0.928 µM,-,"50 mM Tris (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Binding ,Surface Plasmon Resonance,Oligomers immobilized on a GLH chip using biotin-streptavidin,-,,MCF-7 Cells,BG4:IRES-A complex reduced in a dose-dependent manner,"Ligand = 2.5, 5 µM",On-Target Effect,RNA Immunoprecipitation,Transfected plasmid and treated cells; Quantified by dot blotting,Ligand did not influence the expression of BG4 protein,,BALB/c female nude mice,Control tumor size: >700 mm^3; Treated tumor size: < 300 mm^3.,Intraperitoneal; 7.5 mg/kg once a day for 20 days,Tumor Burden,Tumor Size,Mice were xenografted with MCF-7 cells,"Doxorubicin was used as a positive control with a dose of 1mg/kg once a day; Observed no change in body weight during the treatment, indicating fewer side effects; Saline was used as a negative control group.",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,HCV IRES-A DNA,Kd = 14.5 ± 0.695 µM,-,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Off-Target Effect,Microscale Thermophoresis,FAM-labeled RNA,-,,MCF-7 Cells,Relative wound closure decreased to 35%,Ligand = 3 µM,Cell Migration,Scratch Test,Cells were treated with 100  µM CoCl2 to create a hypoxic environment; Western blot also showed a drastic reduction of VEGF-A when treated with 3 µM compound,Used a blank control and DMSO-treated control; siRNA (led to ~30% reduction) and VEGF-A protein were used as a negative controls;  VEGF-A was added to cell to allowed cells to migrate again after treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,HCV IRES-A 1 Mutant,Kd = 20.5 ± 0.995 µM,-,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Off-Target Effect,Microscale Thermophoresis,FAM-labeled RNA,-,C,MCF-7 Cells,65.5% (24 h) and 82.7% (48 h),-,Cell Uptake,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,Hairpin DNA,Kd = 21.2 µM; 22-fold selectivity,-,"50 mM Tris (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Off-Target Effect,Surface Plasmon Resonance,Oligomers immobilized on a GLH chip using biotin-streptavidin,-,,MCF-7 Cells,80% decrease in MetLuc activity,Ligand = 1.5 µM,On-Target Effect,Reporter,Dual-reporter luciferase assay to monitor translation level of hVEGF-A under control of IRES-A; Inserted sequences upstream of Met-luc gene,Tested two mutant IRES-A sequence and no significant change was observed; Compared to compound 2 and 3 (stabilizing ligands),,BALB/c female nude mice,Significantly decreased expression of VEGF-A relative to the negative control,Intraperitoneal; 7.5 mg/kg once a day for 20 days,Activity,Immunohistochemistry,Mice were xenografted with MCF-7 cells,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,HCV IRES-A 1 Mutant,Kd = 3.71 µM; 4-fold selectivity,-,"50 mM Tris (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Off-Target Effect,Surface Plasmon Resonance,Oligomers immobilized on a GLH chip using biotin-streptavidin,Lack of selectivity attributed to ability to form partial G4 structures,,MCF-7 Cells,Statistically significant decrease in BG4:IRES-A Complex,Ligand = 5 µM,On-Target Effect,RNA Immunoprecipitation,Transfected plasmid and treated cells; Quantified by RT-PCR and qRT-PCR,Ligand did not influence the expression of BG4 protein,,BALB/c female nude mice,Tumor weight reduced around 60.1% compared to control weight,Intraperitoneal; 7.5 mg/kg once a day for 20 days,Tumor Burden,Tumor Mass,Mice were xenografted with MCF-7 cells,"Doxorubicin was used as a positive control with a dose of 1mg/kg once a day; Observed no change in body weight during the treatment, indicating fewer side effects; Saline was used as a negative control group.",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,HCV IRES-A 2 Mutant,Did not reach binding platform,Ligand = 100 µM,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Off-Target Effect,Microscale Thermophoresis,FAM-labeled RNA,Does not form G4 structures,,MCF-7 Cells,~75% decrease in VEGF-A protein expression,Ligand = 1.5 µM,Protein Abundance,ELISA,-,RT-PCR and qRT-PCR assays showed no effect on the transcription of IRES-A cDNA and hVEGF-A gene; A PCR stop assay was performed to confirm that the compound did not affect the transcription process at 10 µM ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0068,R-BIND (SM) 0068,CC[NH+](CC)CCOC1=CC=C(NC2=C3C=CC=CC3=NC(=N2)C2=C(NC(=O)CC[NH+]3CCN(C)CC3)C=CC=C2)C=C1,Compound 1 (2017),10.1021/acs.jmedchem.6b01444,C,c-Kit1 G-Quadruplex DNA,Kd = 13.4 ± 0.032 µM,-,"10 mM Tris HCl (pH = 7.4), 100 mM KCl, and 0.1 mM EDTA",Off-Target Effect,Microscale Thermophoresis,FAM-labeled RNA,-,,MCF-7 Cells,Dose-dependent decrease in VEGF-A protein expression,-,Protein Abundance,Western Blot,-,RT-PCR and qRT-PCR assays showed no effect on the transcription of IRES-A cDNA and hVEGF-A gene; A PCR stop assay was performed to confirm that the compound did not affect the transcription process at 10 µM ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,,pre-miR-18a,Low µM range activity and dose-dependent,NR,1 X reaction buffer (Genlantis) supplemented with 1 mM ATP and 2.5 mM MgCl2,Activity,Dicer Protection,Radioactive-labeled RNA,Also inhibits pre-miR-17 and -20a at low µM concentrations but not pre-miR-19a and -19b,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,,GAU/A_C Bulge in miR-18a,Kd = 32 ± 5 µM,-,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Labeled Ligand),Fluorescein tag,-,,DU145 Prostate Cancer,2.5-fold increased in STK4,Ligand = 20 µM,Protein Abundance,Western Blot,miR-18a represses STK4 protein expression,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,,G_U/CUA Bulge in miR-18a,Kd = 30 ± 2 µM,-,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Binding,Fluorescence-Based Titration (Labeled Ligand),Fluorescein tag; Motif also in miR-17 and miR-20a,-,,DU145 Prostate Cancer,IC50 ? 10 µM,-,RNA Abundance,RT-qPCR,"Tested miR-17-92 cluster; miR-17, 18a, and 20a abundance affected and miR-19a, -19b, and -92a not affected",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,C,GGU/A_C Bulge Mutant,Kd = 40 ± 6 µM,-,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Off-Target Effect,Fluorescence-Based Titration (Labeled Ligand),Fluorescein tag; Motif in miR-17 and miR-20a,-,,DU145 Prostate Cancer,Triggered apoptosis,Ligand = 20 µM,Apoptosis,Annexin V/Propidium Iodide,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,C,GAU/CUA Stem Mutant,Kd > 100 µM,-,"8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, and 1 mM EDTA",Off-Target Effect,Fluorescence-Based Titration (Labeled Ligand),Fluorescein tag,-,C,DU145 Prostate Cancer,No statistically significant effect,-,RNA Abundance,RT-qPCR,Assessed miRs with G_U/CUA bulge (n = 27),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0069,R-BIND (SM) 0069,C[NH+]1CCN(CC1)C1=CC=C(C=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targapremir-18a,10.1021/acscentsci.7b00009,,pre-miR-18a,4-fold enrichment of pre-miR-18a and 2-fold enrichment of pre-miR-17 and -20a,Ligand = 10 µM,DU145 prostate cancer cell lysates,On-Target Effect,Chem-CLIP,Analyzed enrichment of pre-miR-17-92 cluster and miRs with G_U/CUA bulge (n =33),Tested probe in vitro for binding to pre-miR-18a and tRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,pre-miR-210,nM range activity and dose-dependent,NR,1 X reaction buffer (Genlantis) supplemented with 1 mM ATP and 2.5 mM MgCl2,Activity,Dicer Protection,Radioactive-labeled RNA,-,,MDA-MB-231 TNBC Cells,3-fold increase in pri-miR-210 and 2.6-fold increase in pre-miR-210,Ligand = 200 nM,RNA Abundance,RT-qPCR,Hypoxic conditions; Increase in transcripts indicates that the compound's mode of action is inhibition of Dicer processing and not transcriptional silencing,Compared to antagomir for mRNA-210,,TNBC mouse model (NOD/SCID),Decreased tumor burden,Intraperitoneal; 200 nM,Tumor Burden,Tumor Mass,1) MDA-MB-231 cells that stably express MDA-MB-231-GFP-Luc were pretreated with the compound and implanted into the mammary fat pads; 2) The cells were implanted and then the mice were treated with an injection,Fluorescence microscopy confirmed localization of ligand to tumor for 21 day period; Compared to antagomir,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,pre-miR-210,Kd = 662 ± 18 nM,-,"8 mM Na2HPO4, 190 mM NaCl, 1 mM EDTA, and 40 µg/mL BSA",Binding,Fluorescence-Based Titration (Intrinsic),-,Did not bind an RNA in which the Dicer site was ablated,,MDA-MB-231 TNBC Cells,IC50 ? 200 nM,-,RNA Abundance,RT-qPCR,Hypoxic conditions; mRNA-210 abundance,-,,TNBC mouse model (NOD/SCID),Decreased tumor burden,Intraperitoneal; 200 nM,Tumor Burden,Luciferase,1) MDA-MB-231 cells that stably express MDA-MB-231-GFP-Luc were pretreated with the compound and implanted into the mammary fat pads; 2) The cells were implanted and then the mice were treated with an injection,Fluorescence microscopy confirmed localization of ligand to tumor for 21 day period; Compared to antagomir,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,C,Topoisomerase,Did not inhibit,Ligand = 200 nM,"50 mM Tris HCl (pH = 8), 150 mM NaCl, 10 mM MgCl2, 0.5 mM dithiothreitol, 30 ?g/mL BSA, and 2 mM ATP",Off-Target Effect,Topoisomerase Inhibition,Bis-benzimidazoles are known topoisomerase inhibitors,-,,MDA-MB-231 TNBC Cells,4-fold increase in GPD1L mRNA levels and 75% reduction in HIF-1? mRNA levels,Ligand = 200 nM,RNA Abundance,RT-qPCR,Hypoxic conditions,Compared to antagomir for mRNA-210; Returns to levels in normoxic state,,TNBC mouse model (NOD/SCID),"Reduced miR-210 and HIF-1? levels by ~90% and ~75%, respectively; GPD1L was doubled",Intraperitoneal; 200 nM,RNA Abundance,RT-qPCR,1) MDA-MB-231 cells that stably express MDA-MB-231-GFP-Luc were pretreated with the compound and implanted into the mammary fat pads; 2) The cells were implanted and then the mice were treated with an injection,Fluorescence microscopy confirmed localization of ligand to tumor for 21 day period; Compared to antagomir,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,,MDA-MB-231 TNBC Cells,Induced apoptosis,Ligand = 200 nM,Apoptosis,Annexin V/Propidium Iodide,Hypoxic conditions,Overexpression of pre-miR-210 allowed cells to escape apoptosis; Not observed in normoxic conditions,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.8b10558,,,,,,,,,,C,MCF-7 Cells,No effect on mir-515-p5 levels,Ligand = 500 nM,Off-Target Effect,RT-qPCR,After 48 hours of treatment,Compared to untreated cells and active compound 2,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,C,MDA-MB-231 TNBC Cells,Bound to four other miRNAs but did not have a statistically significant affect on expression levels,Ligand = 200 nM,On-Target Effect,Chem-CLIP,Also performed in cell lysates where selectivity for miR-210 was observed,Compared to probe without RNA binding module,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,C,MDA-MB-231 TNBC Cells,Selective for miR-210,Ligand = 200 nM,RNA Abundance,RT-qPCR,Panel of 28 hypoxia-associated miRNAs,Compared to antagomir for mRNA-210,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,C,MDA-MB-231 TNBC Cells,Selectivity similar to an antagomir,Ligand = 200 nM,RNA Abundance,RT-qPCR,Panel of ~2500 miRNAs,Queried INFORNA for secondary structural elements present in pre-miRNA-210 and identified miRNAs containing the pre-miR-210 Dicer site motif and other motifs,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0070,R-BIND (SM) 0070,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC=CC(OCCCC(=O)NCCCN=[N+]=[N-])=C1,Targapremir-210,10.1021/jacs.6b11273,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0071,R-BIND (SM) 0071,CC(=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCCC[NH3+])C(=O)N1C[C@@H]([NH3+])C[C@@H]([NH3+])C1,Compound 2ab,10.1002/cbic.201000177,,HCV IRES IIa,EC50 = 6.3 ± 0.6 µM,-,100 µM MgCl2,Binding,Fluorescence-Based Titration (Labeled RNA),2-Aminopurine,-,,Huh-7.5 Cells,Dose Dependent Response,Ligand = 0.010 - 100 µM,Antiviral Activity,Reporter,BM4-5 FEW HCV replicon and under control of IRES,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0071,R-BIND (SM) 0071,CC(=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCCC[NH3+])C(=O)N1C[C@@H]([NH3+])C[C@@H]([NH3+])C1,Compound 2ab,10.1002/cbic.201000177,,HCV IRES IIa,EC50 = 270 ± 100 µM,-,1 mM MgCl2,Binding,Fluorescence-Based Titration (Labeled RNA),2-Aminopurine,-,C,Huh-7.5 Cells,NR,Ligand = 0.010 - 100 µM,Cytotoxicity,Colorimetric Viability,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0071,R-BIND (SM) 0071,CC(=O)C1=CC=C(C=C1)C(=O)N[C@@H](CCCC[NH3+])C(=O)N1C[C@@H]([NH3+])C[C@@H]([NH3+])C1,Compound 2ab,10.1002/cbic.201000177,,HCV IRES IIa,IFRET = 1.3,Ligand = 1 mM,NR,Binding,FRET,IFRET is relative change of FRET intensity,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1021/bi401270d,,SL3 of HIV-1 ? Packaging Domain,Binds,Ligand = 1.25 - 10 µM; RNA = 5 µM,"25 mM NaOAc (pH = 6.5), 50 mM NaCl, and 1 mM MgCl2",Binding,Circular Dichroism,-,Tested a nonspecific binder (ellipticine) as a control against the RNA,,TZM-bl Cells,IC50 = 4.5 µM,-,Antiviral Activity,Beta-Galactosidase,Supernatant from transfected 293T cells utilized,Compared to protease inhibitor drugs saquinavir and lopinavir; Results consistent with mutated target studies,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1021/bi401270d,,SL3 of HIV-1 ? Packaging Domain,Tm > 95 ºC,Ligand = 30 µM,"25 mM NaOAc (pH = 6.5), 50 mM NaCl, and 1 mM MgCl2",Binding,Fluorescence Melting,-,-,,293T Cells,p24(50) = 11.3 µM,-,Antiviral Activity,ELISA,Env-defective proviral DNA and VSV-G plasmids; Measured p24 capsid,Compared to protease inhibitor drugs saquinavir and lopinavir,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1021/bi401270d,,SL3 of HIV-1 ? Packaging Domain,Binding 1:1 ratio,NR,"5 mM PBS (pH = 7.0 or 5.0), 25 mM NaCl, and 10 % D2O",Binding,Nuclear Magnetic Resonance,Proton,-,C,293T Cells,CC50 = N/A,-,Cytotoxicity,CellTiter-Glo,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1186/s12977-018-0407-4,,SL3 RNA dimer,No significant differences in dimerization,Ligand = 10 µM; RNA = 1 µM,"10 mM Tris-HCl, 140 mM KCl, 1 mM NaCl, and 1 mM MgCl2",Binding,Dimerization by PAGE,Ligand added either before RNA snap-cooling and refolding or after snap-cooling but before refolding,DMSO control,,NR,No change in reverse transcription,NR,Off-Target Effect,PCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1186/s12977-018-0407-4,,Gag protein:SL3 RNA,"Genomic RNA reduced to ~35% of wild-type levels, compared to 34% for the ?p1 control; The ratio of virion:cytoplasmic gRNA was 18.5% of wild-type levels, compared to 22.3% for the ?p1  control, suggesting the ligand acts after the cytoplasmic phase of the viral lifecycle",Ligand = 50 µM,293T cell lysates,RNA Abundance,RT-qPCR,"?p1 is a mutant lacking SL3, an RNA proposed to interact with Gag during viral packaging",DMSO control; ?p1 control; Cells transfected without virus as negative control; RNA levels normalized to ?-actin, ,Jurkat Cells,No statistically significant difference in integration events,Ligand = 50 µM,Antiviral Activity,HIV-1 gag RT-qPCR,"Cells pretreated with ligand (100 µM) or raltegravir (1 µM) and then infected with HIV-LAI; Post-treatment, HIV-1 integration assayed by Alu-gag RT-qPCR followed by quantification of integration events by HIV-1 gag qPCR",Control with no drug; Treatment with the integrase inhibitor raltegravir (500 nM) as a positive control led to > 95% reduction in integration events; Samples normalized to actin levels by Alu-gag PCR, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1186/s12977-018-0407-4,,SL3 RNA,"Ligand stabilized the sugar–phosphate backbone structure, reducing RNA conformational flexibility: Free energy change from ?155.3 to ?165.3 kcal/mole; Stabilization occurred at SL3 in particular",Ligand = 10 µM; RNA = 1 µM,"10 mM Tris-HCl, 140 mM KCl, 1 mM NaCl, and 1 mM MgCl2",Structure Determination,SHAPE,"Previously, it was unclear whether the major mechanism of action of the ligand was prevention of Gag binding to SL3 or prevention of SL3 unwinding, although evidence in support of the latter included a rise in SL3 melting temperature in the presence of the ligand; Data analyzed with SHAPEfinder software; Structures modeled using RNAstructure",DMSO control; Control without reactive NMIA reagent, ,293T Cells,No statistically significant change in p24 levels,Ligand = 50 µM,Antiviral Activity,ELISA,"Accounted for both extracellular and intracellular p24 capsid protein; Cells infected with HIV-LAI; ?p1 is a mutant lacking SL3, an RNA proposed to interact with Gag during viral packaging; ELISA measures the major  Capsid protein, p24, in a specific 3D structure",DMSO control; ?p1 control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1186/s12977-018-0407-4,C,?p1 SL3 RNA,Transcript not stabilized,Ligand = 10 µM; RNA = 1 µM,"10 mM Tris-HCl, 140 mM KCl, 1 mM NaCl, and 1 mM MgCl2",Structure Determination,SHAPE,RNA has a 19 nt deletion at SL3,-,,293T Cells,No statistically significant difference in intracellular/extracellular Gag protein levels,Ligand = 50 µM,Protein Abundance,Western Blot,"?p1 is a mutant lacking SL3, an RNA proposed to interact with Gag during viral packaging; Western blot analyzes all Gag products, regardless of 3D conformation ",DMSO control; ?p1 control; Protein levels normalized to GAPDH, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0072,R-BIND (SM) 0072,C[N+]1=CC=C(NC2=CC=C(NC(=O)C3=CC=C(NC4=CC=[N+](C)C5=CC=C(C=C45)[N+]([O-])=O)C=C3)C=C2)C=C1,NSC260594,10.1186/s12977-018-0407-4,,,,,,,,,,,TZMbl Cells,"Infectivity reduced to 26% of wild-type levels, similar to the ?p1 control",Ligand = 50 µM,Antiviral Activity,Luciferase,"TZMbl is a reporter cell line derived from HeLa cells expressing CXCR4, engineered to express CD4 and CCR5, fluc, and ?-galactosidase under the control of the HIV-1 LTR; ?p1 is a mutant lacking SL3, an RNA proposed to interact with Gag during viral packaging",DMSO control; ?p1 control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,,HIV-1 RRE IIB,Kd = 11 and 25 µM (2:1 stoichiometry),-,10 mM Na2HPO4 (pH = 6.0) and 0.1 mM EDTA,Binding,Nuclear Magnetic Resonance,TOCSY,Compared to Neomycin B,,293T Cells,EC50 = 3.4 µM,-,Antiviral Activity,Reporter,pNL4.3-Luc or pNL4.3-Ren plasmid (one replication cycle),HeLa Tet-On Luc cells to control for unspecific inhibition of protein synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,,HIV-1 RRE IIB,Kd = 0.6 ± 0.1 µM,-,10 mM Na2HPO4 (pH = 6.0) and 0.1 mM EDTA,Binding,Isothermal Titration Calorimetry,-,Compared to Neomycin B,,293T Cells,EC50 = 5.9 µM,-,Antiviral Activity,Reporter,pNL4.3-Luc-R-E- with pcDNA3-VSV Plasmid (one replication cycle),"Does not express HIV envelope, ruling out mode of actions related to CD4, CXCR4, or CCR5 receptors; HeLa Tet-On Luc cells to control for unspecific inhibition of protein synthesis",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,C,"HIV-1 RRE IIB, Hairpin Control",Kd (GG) / Kd (IIB) = 3.0,-,10 mM Na2HPO4 (pH = 6.0) and 0.1 mM EDTA,Binding,Isothermal Titration Calorimetry,Specificity Measurement,-,C,293T Cells,CC50 > 100 µM,-,Cytotoxicity,CellTiter Glo,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,,HIV-1 RRE IA,Binding at low ligand:RNA ratios,"Ligand = 60, 120 µM; RNA = 60 µM",10 mM Na2HPO4 pH = 6.0 and 0.1 mM EDTA,Binding,Nuclear Magnetic Resonance,Proton,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,C,DNA Duplex,Binding at low ligand:DNA ratios,"Ligand = 70, 140, 280 µM; DNA = 70 µM",10 mM Na2HPO4 pH = 6.0 and 0.1 mM EDTA,Off-Target Effect,Nuclear Magnetic Resonance,TOCSY and NOESY,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,,HIV-1 RRE IIB:Rev Peptide,IC50 = 6.8 ± 0.5 µM,-,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM Na2HPO4, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton-X-100",Protein Displacement,Fluorescence Polarization,-,Compared to Neomycin B,,MT-2 Cells,IC50 = 10.4 - 21.4 µM,Plasmid = 20 - 500 ng/well,On-Target Effect,Reporter,"pCMV-Rev and pDM628 plasmid (encode REV and luciferase under control of RRE, respectively)",HeLa Tet-On Luc cells to control for unspecific inhibition of protein synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0073,R-BIND (SM) 0073,COC1=CC(CC[NH3+])=C(C(CC[NH3+])=C1)C1=CC(C)=C(C(C)=C1)C1=CC(CC[NH3+])=C(O)C(CC[NH3+])=C1,p-Terphenyl 6b,10.1002/anie.201306665,,HIV-1 RRE IIB,Binding location for 1 of the 2 ligands,"Ligand = 120, 240, 360, 480 µM; RNA = 120 µM",10 mM Na2HPO4 (pH = 6.0) and 0.1 mM EDTA,Structure Determination,Nuclear Magnetic Resonance,"dpf-COSY, TOCSY, ROESY and NOESY",Compared to previous report of Rev peptide binding location,,MT-2 Cells,EC50 = 5.0 µM,-,Antiviral Activity,Reporter,"Full-length, replication-competent HIV-1 clone",HeLa Tet-On Luc cells to control for unspecific inhibition of protein synthesis,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0074,R-BIND (SM) 0074,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCC[NH+]2CCCCC2)C(N)=C1,Phenylquinolone 5,10.1002/cmdc.200800437,,HIV-1 TAR:Tat Peptide,Ki = 0.96 ± 0.02 µM,Ligand = 10 ?M,"50 mM Tris-HCl (pH = 7.5), 80 mM KCl, 0.1 % DMSO, 0.01 % Triton X-100, and 5 mg/mL BSA",Protein Displacement,Fluorescence Quenching,-,20 nM dsTAR competitor in assay,,Jurkat Cells,11.10%,Ligand = 100 ?M,Cell Uptake,Centrifugation/Fluorescence,-,Absence of compound,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0074,R-BIND (SM) 0074,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCC[NH+]2CCCCC2)C(N)=C1,Phenylquinolone 5,10.1002/cmdc.200800437,,,,,,,,,,,Jurkat Lymphoblastoid T,IC50 = 75 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Compared to compound 1 (analog with known bioactivity),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0074,R-BIND (SM) 0074,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCC[NH+]2CCCCC2)C(N)=C1,Phenylquinolone 5,10.1002/cmdc.200800437,,,,,,,,,,C,Jurkat Lymphoblastoid T,CC50 = 90 µM,-,Cytotoxicity,MTT,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0075,R-BIND (SM) 0075,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCCN2CC[NH+](C)CC2)C(N)=C1,Phenylquinolone 6,10.1002/cmdc.200800437,,HIV-1 TAR:Tat Peptide,Ki = 0.99 ± 0.16 µM,Ligand = 10 ?M,"50 mM Tris-HCl (pH = 7.5), 80 mM KCl, 0.1 % DMSO, 0.01 % Triton X-100, and 5 mg/mL BSA",Protein Displacement,Fluorescence Quenching,-,20 nM dsTAR competitor in assay,,Jurkat Cells,10.30%,Ligand = 100 ?M,Cell Uptake,Centrifugation/Fluorescence,-,Absence of compound,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0075,R-BIND (SM) 0075,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCCN2CC[NH+](C)CC2)C(N)=C1,Phenylquinolone 6,10.1002/cmdc.200800437,,,,,,,,,,,Jurkat Lymphoblastoid T,IC50 = 85 µM,-,Antiviral Activity,Reverse Transcriptase Activity,-,Compared to compound 1 (analog with known bioactivity),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0075,R-BIND (SM) 0075,CN1C(=CC(=O)C2=CC=CC=C12)C1=CC=C(OCCCN2CC[NH+](C)CC2)C(N)=C1,Phenylquinolone 6,10.1002/cmdc.200800437,,,,,,,,,,C,Jurkat Lymphoblastoid T,CC50 = > 100 µM,-,Cytotoxicity,MTT,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0076,R-BIND (SM) 0076,O=C1NC(NC2CCCCC2)=NC2=C1N=CN2,Guanine Analog 25f,10.1016/j.ejmech.2017.11.079, ,C. difficile guaA riboswitch,Kd = 6.5 µM,-,"50 mM Tris-HCl (pH = 8.5), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,RNA was 5'-32P-labeled,Control with no drug,,C. difficile Strain ATCC 700057,MIC = 78 µg/mL,-,Antimicrobial Activity,Growth Inhibition,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0076,R-BIND (SM) 0076,O=C1NC(NC2CCCCC2)=NC2=C1N=CN2,Guanine Analog 25f,10.1016/j.ejmech.2017.11.079, ,,,,,,,,,C,E. coli Strain MC 4100 imp,MIC > 5000 µg/mL,-,Antimicrobial Activity,Growth Inhibition,Strain is guanine riboswitch-deficient and possesses increased membrane permeability to maximize cellular penetration,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842, ,lysC riboswitch,Kd = 2.5 ± 0.3 µM,Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,The RNA is a 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P; Curves indicated the best fit of the data to an equation for a two-state binding mode,Compounds with Kd values within 40-fold of the Kd for lysine (360 nM) were considered hits; Control with no drug, ,B. subtilis Bacteria,Complete inhibition of growth; Kd < 13 µM,Ligand = 100 µM,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,Control with no drug; Lysine control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,C,lysC riboswitch mutant 1 (M1),Kd = 14 µM; Increased scission in nucleotides surrounding mutation (P4 region),Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Off-Target Effect,In-Line Probing,The RNA is a mutated 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P,Wild-type bacterial Kd = 13 µM; Wild-type bacterial Kd (lysine) = 1.7 µM, ,B. subtilis Bacteria,MIC = 26 ± 11 µM,-,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,C,lysC riboswitch mutant 2 (M2),Kd = 24 µM; Increased scission in nucleotides surrounding mutation (loop E region),Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Off-Target Effect,In-Line Probing,The RNA is a mutated 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P,Wild-type bacterial Kd = 13 µM; Wild-type bacterial Kd (lysine) = 1.7 µM, ,B. subtilis Lysine Auxotroph Bacteria,Did not support growth,Ligand = 1 mM,Antimicrobial Activity,Proliferation,B. subtilis lysine auxotroph strain 1A40 ,Lysine control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,C,lysC riboswitch mutant 2 (M2),Required an increased concentration of ligand to induce termination,-,"150 mM Tris-HCl (pH = 8.0), 20 mM NaCl, 14 mM MgCl2, 0.1 mM EDTA, and 0.01 mg/ml BSA",Off-Target Effect,Transcription,-,Compared to wild-type lysC riboswitch, ,B. subtilis Bacteria,"Spore formation 7% and 0% viable at 0.2 and 2 mM ligand, respectively","Ligand = 0.2, 2 mM",Colony Formation,Sporulation,Data expressed as the number of viable colony-forming spores formed after heat shock relative to the number formed before,Control with no drug, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,MIC = 1560 ± 625 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 26 ± 11 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,MIC = 3438 ± 1875 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M2 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 26 ± 11 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. cereus Bacteria,MIC = 2 µM,-,Antimicrobial Activity,Growth Inhibition,"In a few species, such as Bacillus cereus and Bacillus anthracis, an additional copy of the lysC riboswitch regulates the gene encoding diaminopimelate decarboxylase (lysA in B. subtilis), for which no alternate pathway exists; Repression of genes that are more critical to survival may therefore be more detrimental",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. cereus Bacteria,Not inhibited,Ligand = 512 mg/mL ,Antimicrobial Activity,Growth Inhibition,"In a few species, such as Bacillus cereus and Bacillus anthracis, an additional copy of the lysC riboswitch regulates the gene encoding diaminopimelate decarboxylase (lysA in B. subtilis), for which no alternate pathway exists; Repression of genes that are more critical to survival may therefore be more detrimental",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. anthracis Bacteria,Not inhibited,Ligand = 512 mg/mL ,Antimicrobial Activity,Growth Inhibition,"In a few species, such as Bacillus cereus and Bacillus anthracis, an additional copy of the lysC riboswitch regulates the gene encoding diaminopimelate decarboxylase (lysA in B. subtilis), for which no alternate pathway exists; Repression of genes that are more critical to survival may therefore be more detrimental",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,C,B. subtilis Mutant 2 (M2) Bacteria,Spore formation 17% viable,Ligand = 2 mM,Colony Formation,Sporulation,The L-4-oxalysine-resistant strain M2 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; Data expressed as the number of viable colony-forming spores formed after heat shock relative to the number formed before,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Bacteria,Expression of ?-galactosidase = 2.3 ± 0.6 Miller units,Ligand = 5 mM,Reporter,?-Galactosidase,B. subtilis 168 strain 1A1; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,Control with no drug = 54 ± 2 Miller units; Lysine control = 2.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Bacteria,The relative concentration required to completely repress expression corresponded well with relative Kd and MIC values,Ligand = 0.3 - 1000 µM,Reporter,?-Galactosidase,B. subtilis 168 strain 1A1; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,Control with no drug; Lysine control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,Expression of ?-galactosidase = 140 ± 20 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M1 bacterial ?-galactosidase expression (5 mM lysine) = 200 ± 24 Miller units; M1 bacterial ?-galactosidase expression (no drug) = 157 ± 9 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 2.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0077,R-BIND (SM) 0077,[NH3+]CCS(=O)(=O)C[C@H]([NH3+])C([O-])=O,Lysine Analog 8,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,Expression of ?-galactosidase = 110 ± 31 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M2 bacterial ?-galactosidase expression (5 mM lysine) = 184 ± 9 Miller units; M2 bacterial ?-galactosidase expression (no drug) = 150 ± 17 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 2.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842, ,lysC riboswitch,Kd = 13 ± 2 µM,Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,The RNA is a 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P; Curves indicated the best fit of the data to an equation for a two-state binding mode,Compounds with Kd values within 40-fold of the Kd for lysine (360 nM) were considered hits; Control with no drug, ,B. subtilis Bacteria,Complete inhibition of growth; Kd < 13 µM,Ligand = 100 µM,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,Control with no drug; Lysine control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,C,lysC riboswitch mutant 1 (M1),Kd = 29 µM; Increased scission in nucleotides surrounding mutation (P4 region),Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Off-Target Effect,In-Line Probing,The RNA is a mutated 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P,Wild-type bacterial Kd = 26 µM; Wild-type bacterial Kd (lysine) = 1.7 µM, ,B. subtilis Bacteria,MIC = 173 ± 69 µM,-,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,C,lysC riboswitch mutant 2 (M2),Kd = 75 µM; Increased scission in nucleotides surrounding mutation (loop E region),Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Off-Target Effect,In-Line Probing,The RNA is a mutated 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P,Wild-type bacterial Kd = 26 µM; Wild-type bacterial Kd (lysine) = 1.7 µM, ,B. subtilis Lysine Auxotroph Bacteria,Did not support growth,Ligand = 1 mM,Antimicrobial Activity,Proliferation,B. subtilis lysine auxotroph strain 1A40 ,Lysine control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,C,lysC riboswitch mutant 2 (M2),Required an increased concentration of ligand to induce termination,-,"150 mM Tris-HCl (pH = 8.0), 20 mM NaCl, 14 mM MgCl2, 0.1 mM EDTA, and 0.01 mg/ml BSA",Off-Target Effect,Transcription,-,Compared to wild-type lysC riboswitch, ,B. subtilis Bacteria,"Spore formation 71% and 6% viable at 0.2 and 2 mM ligand, respectively","Ligand = 0.2, 2 mM",Colony Formation,Sporulation,Data expressed as the number of viable colony-forming spores formed after heat shock relative to the number formed before,Control with no drug, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,MIC = 1560 ± 625 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 173 ± 69 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,MIC = 1560 ± 625 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M2 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 173 ± 69 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. cereus Bacteria,Not inhibited,Ligand = 512 mg/mL ,Antimicrobial Activity,Growth Inhibition,"In a few species, such as Bacillus cereus and Bacillus anthracis, an additional copy of the lysC riboswitch regulates the gene encoding diaminopimelate decarboxylase (lysA in B. subtilis), for which no alternate pathway exists; Repression of genes that are more critical to survival may therefore be more detrimental",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. anthracis Bacteria,Not inhibited,Ligand = 512 mg/mL ,Antimicrobial Activity,Growth Inhibition,"In a few species, such as Bacillus cereus and Bacillus anthracis, an additional copy of the lysC riboswitch regulates the gene encoding diaminopimelate decarboxylase (lysA in B. subtilis), for which no alternate pathway exists; Repression of genes that are more critical to survival may therefore be more detrimental",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,C,B. subtilis Mutant 2 (M2) Bacteria,Spore formation 65% viable,Ligand = 2 mM,Colony Formation,Sporulation,The L-4-oxalysine-resistant strain M2 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; Data expressed as the number of viable colony-forming spores formed after heat shock relative to the number formed before,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,Lysine Analog 9-Resistant B. subtilis Bacteria,The 24 mutant colonies had one of two distinct point mutations in lysC riboswitch,N/A,On-Target Effect,Serial Passage,The L-4-oxalysine-resistant strains (M1 and M2) were cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,MIC values for the ligand were at least nine-fold higher than that of wild-type bacteria, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Bacteria,Expression of ?-galactosidase = 2.3 ± 0.6 Miller units,Ligand = 5 mM,Reporter,?-Galactosidase,B. subtilis 168 strain 1A1; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,Control with no drug = 54 ± 2 Miller units; Lysine control = 2.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Bacteria,The relative concentration required to completely repress expression corresponded well with relative Kd and MIC values,Ligand = 0.3 - 1000 µM,Reporter,?-Galactosidase,B. subtilis 168 strain 1A1; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,Control with no drug; Lysine control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,Expression of ?-galactosidase = 118 ± 9 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M1 bacterial ?-galactosidase expression (5 mM lysine) = 200 ± 24 Miller units; M1 bacterial ?-galactosidase expression (no drug) = 157 ± 9 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 3.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0078,R-BIND (SM) 0078,[NH3+]CCOC[C@H]([NH3+])C([O-])=O,Lysine Analog 9,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,Expression of ?-galactosidase = 100 ± 27 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M2 bacterial ?-galactosidase expression (5 mM lysine) = 184 ± 9 Miller units; M2 bacterial ?-galactosidase expression (no drug) = 150 ± 17 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 3.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842, ,lysC riboswitch,Kd = 0.97 ± 0.04 µM,Ligand = 0.001 - 6000 µM; RNA = 1 nM,"50 mM Tris-HCl (pH = 8.3), 20 mM MgCl2, and 100 mM KCl",Binding,In-Line Probing,The RNA is a 179-nucleotide receptor domain from B. subtilis; RNA was 5' labeled with 32P; Curves indicated the best fit of the data to an equation for a two-state binding mode,Compounds with Kd values within 40-fold of the Kd for lysine (360 nM) were considered hits; Control with no drug, ,B. subtilis Bacteria,Complete inhibition of growth; Kd < 13 µM,Ligand = 100 µM,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,Control with no drug; Lysine control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842, ,,,,,,,,,,B. subtilis Bacteria,MIC = 938 ± 361 µM,-,Antimicrobial Activity,Growth Inhibition,B. subtilis 168 strain 1A1,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Lysine Auxotroph Bacteria,Did not support growth,Ligand = 1 mM,Antimicrobial Activity,Proliferation,B. subtilis lysine auxotroph strain 1A40 ,Lysine control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,MIC > 5000 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 938 ± 361 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,MIC > 5000 µM,-,Antimicrobial Activity,Growth Inhibition,The L-4-oxalysine-resistant strain M2 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9,Wild-type bacterial MIC = 938 ± 361 µM, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Bacteria,Expression of ?-galactosidase = 2.0 ± 0.2 Miller units,Ligand = 5 mM,Reporter,?-Galactosidase,B. subtilis 168 strain 1A1; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,Control with no drug = 54 ± 2 Miller units; Lysine control = 2.3 ± 0.6 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 1 (M1) Bacteria,Expression of ?-galactosidase = 113 ± 9 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M1 bacterial ?-galactosidase expression (5 mM lysine) = 200 ± 24 Miller units; M1 bacterial ?-galactosidase expression (no drug) = 157 ± 9 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 2 ± 1 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0079,R-BIND (SM) 0079,[NH3+]C\C=C\CC([NH3+])C([O-])=O,Lysine Analog 11,10.1038/nchembio842,,,,,,,,,,,B. subtilis Mutant 2 (M2) Bacteria,Expression of ?-galactosidase = 110 ± 19 Miller units,Ligand = 1 mM,Reporter,?-Galactosidase,The L-4-oxalysine-resistant strain M1 was cultivated from B. subtilis 168 strain 1A1 using serial passage in the presence of Lysine Analog 9; ?-galactosidase gene was fused downstream of a second copy of the lysC riboswitch,M2 bacterial ?-galactosidase expression (5 mM lysine) = 184 ± 9 Miller units; M2 bacterial ?-galactosidase expression (no drug) = 150 ± 17 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM lysine) = 2.3 ± 0.6 Miller units; Wild-type bacterial ?-galactosidase expression (no drug) = 51 ± 2 Miller units; Wild-type bacterial ?-galactosidase expression (1 mM ligand) = 2 ± 1 Miller units, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,,Bcl-X-681 pre-mRNA,At 10 µM: 1.82-fold increase in usage of XS splice site; At 40 µM: 2.86-fold increase in usage of XS splice site and 7.69-fold decrease in usage of XL splice site,"Ligand = 1, 10, 40 µM",NR,Activity,In Vitro Splicing,"The RNA comprises the 3' half of Bcl-X pre-mRNA, including both alternative 5 splice sites (SSs), and the 5' part of exon 3; Bcl-XL is the dominant, anti-apoptotic isoform, and Bcl-XS is the pro-apoptotic isoform",Control with no drug,,HeLa Cells,Produced clear shift toward XS,Ligand = 10 µM,RNA Splicing,RT-PCR,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,C,Bcl-X-681:Spliceosome,"Spliceosome formation reduced, consistent with inhibition of the XL splicing pathway",NR,50 mM Tris base and 50 mM glycine,Activity,Spliceosome Assembly,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,,Bcl-X-681 pre-mRNA,Fluorescence intensity of ligand increased 15-fold and underwent shift in emission peak,Ligand = 20 µM; RNA = 1 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,XS and XL RNA also bound; The intron and 3’SS domains produced relatively little change, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,C,Mutated Bcl-X-681 pre-mRNA,Emission peaks attributed to interaction with G-quadruplexes were greatly reduced,Ligand = 20 µM; RNA = 1 µM,NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic),"Mutations made to disrupt base-pairing in Q2, Q5, or Q4 regions; Q4 does not form a G-quadruplex; In separate RNAs, mutations made to preserve base-pairing but disrupt G-quadruplex formation",Compared to wild-type sequences, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,C,Mutated Bcl-X-681 pre-mRNA,XS splicing not stimulated when Q5 region mutated; Disruption of the potential G-quadruplex in a Q2 mutant prevented upregulation of XS splicing; Disruption of the potential G-quadruplex in a Q5 mutant prevented downregulation of XL splicing,NR,NR,Off-Target Effect,In Vitro Splicing,-,Compared to wild-type sequences; Control with no drug, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0080,R-BIND (SM) 0080,C[NH+](C)CCOC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,GQC-05,10.1093/nar/gkx1122,,Bcl-X-681 pre-mRNA,Q2 region stabilized; Q5 region underwent significant restructuring,"Ligand = 1, 5, 10 µM",NR,Structure Determination,RNase Footprinting,Q2 region is near XS splice site; Q5 region is near XL splice site,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0081,R-BIND (SM) 0081,NC(=[NH2+])C1=CC=C(NCCNC2=CC=C(C=C2)C(N)=[NH2+])C=C1,EBAB,10.1007/s00216-018-1107-6, ,CUG x 50 repeat RNA,"Disappearance of RNA peak, suggesting possible interaction",Ligand = 1 mM,50 mM HEPES (pH = 7.4),Binding,Affinity Capillary Electrophoresis,Fused silica capillary coated with polyethylene oxide,Control with no drug,,HeLa Cells,Compared to water control: Significant decrease (23.0%) in percentage of nuclei presenting foci; Significant decrease in percentage of nuclei with > 5 foci (from 36.0 ± 3.0% to 24.0 ± 4.0%),Ligand = 50 µM,Localization,Fluorescence Microscopy,"The toxicity of CUG repeats can be attributed to the sequestration of splicing factors such as MBNL1; Cells transfected with pMBNL1-GFP and pDT960, the latter of which is transcribed into a CUG x 960 interrupted repeat RNA that is detected by fluorescence in situ hybridization; The co-transfected cells present a classic DM1 pattern with characteristic nuclear RNA foci that colocalize with the MBNL1 protein; Nuclei presenting foci were grouped into three subsets (? 2 foci, ? 5 foci, and > 5 foci)",Pentamidine as positive control; Water control; Cells transfected with pMBNL1-GFP alone led to a non-pathological pattern in which MBNL1 localized to the nucleoplasm, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0081,R-BIND (SM) 0081,NC(=[NH2+])C1=CC=C(NCCNC2=CC=C(C=C2)C(N)=[NH2+])C=C1,EBAB,10.1007/s00216-018-1107-6,,CUG x 50 repeat RNA,"Binding constant = 10.17 x 10^3 M^-1 (Nonlinear regression), 12.09 x 10^3 M^-1 (Scatchard analysis)",RNA = 5 µM,50 mM HEPES (pH = 7.4),Binding,Affinity Capillary Electrophoresis,Fused silica capillary coated with polyethylene oxide,Control with no drug,,HeLa Cells,Compared to water control: Significant decrease (31.0%) in percentage of nuclei presenting foci; Significant decrease in percentage of nuclei with ? 5 foci (from 26.0 ± 5.0% to 13.0 ± 5.0%); Significant decrease in percentage of nuclei with > 5 foci (from 36.0 ± 3.0% to 24.0 ± 10.0%),Ligand = 75 µM,Localization,Fluorescence Microscopy,"The toxicity of CUG repeats can be attributed to the sequestration of splicing factors such as MBNL1; Cells transfected with pMBNL1-GFP and pDT960, the latter of which is transcribed into a CUG repeat RNA that is detected by fluorescence in situ hybridization; The co-transfected cells present a classic DM1 pattern with characteristic nuclear RNA foci that colocalize with the MBNL1 protein; Nuclei presenting foci were grouped into three subsets (? 2 foci, ? 5 foci, and > 5 foci)",Pentamidine as positive control; Water control; Cells transfected with pMBNL1-GFP alone led to a non-pathological pattern in which MBNL1 localized to the nucleoplasm, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0081,R-BIND (SM) 0081,NC(=[NH2+])C1=CC=C(NCCNC2=CC=C(C=C2)C(N)=[NH2+])C=C1,EBAB,10.1007/s00216-018-1107-6,,CUG x 50 repeat RNA,Average interaction stoichiometry = 122.99 ± 2.51,Ligand = 700 - 900 µM; RNA = 5 µM,50 mM HEPES (pH = 7.4),Binding,Capillary Zone Electrophoresis,Fused silica capillary coated with polyethylene oxide,-,,HeLa Cells,Compared to water control: Significant decrease (43.0%) in percentage of nuclei presenting foci; Significant decrease in percentage of nuclei with ? 5 foci (from 26.0 ± 5.0% to 11.0 ± 4.0%); Significant decrease in percentage of nuclei with > 5 foci (from 36.0 ± 3.0% to 14.0 ± 6.0%),Ligand = 100 µM,Localization,Fluorescence Microscopy,"The toxicity of CUG repeats can be attributed to the sequestration of splicing factors such as MBNL1; Cells transfected with pMBNL1-GFP and pDT960, the latter of which is transcribed into a CUG repeat RNA that is detected by fluorescence in situ hybridization; The co-transfected cells present a classic DM1 pattern with characteristic nuclear RNA foci that colocalize with the MBNL1 protein; Nuclei presenting foci were grouped into three subsets (? 2 foci, ? 5 foci, and > 5 foci)",Pentamidine as positive control; Water control; Cells transfected with pMBNL1-GFP alone led to a non-pathological pattern in which MBNL1 localized to the nucleoplasm, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0081,R-BIND (SM) 0081,NC(=[NH2+])C1=CC=C(NCCNC2=CC=C(C=C2)C(N)=[NH2+])C=C1,EBAB,10.1007/s00216-018-1107-6,,,,,,,,,,C,HeLa Cells,Lower toxicity than pentamidine,Ligand = 100 µM,Cytotoxicity,NR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0082,R-BIND (SM) 0082,CC(=O)NC1=CC=CC(NC(=O)C2=CSC(NC(=O)C3=CC=C(Cl)C=C3)=N2)=C1,Pentamidine-Like Compound 2-5,10.1371/journal.pone.0178931,,CUG x 12 repeat RNA,Kd = 4.87(7),Ligand = 0.1 mM; RNA = 0.25 µM; TO = 0.5 µM (Fig. 7),50 mM sodium cacodylate (pH = 7.4),Binding,Fluorescence Displacement,Displacement of thiazole orange,Control with no drug,,DM1 hTERT Myoblasts,Amount of MBNL1 increased in cytoplasm and nuclei,Ligand = 40 µM,Localization,Confocal Imaging,MBNL1 sequestration in CUG-RNA ribonuclear foci are histopathological hallmarks in DM1; Immortalized fibroblasts expressed 1300 CTG repeats and conditionally expressed MyoD for transdifferentiation into myoblasts; Cells were plated in muscle differentiation medium to increase MBNL levels; r(CUG)exp RNA foci detected with Cy3-(CAG)7-Cy3-labelled probe; Analyzed a minimum of 1000 cell nuclei,DMSO control (1%); Normal myoblast DMSO control (1%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0082,R-BIND (SM) 0082,CC(=O)NC1=CC=CC(NC(=O)C2=CSC(NC(=O)C3=CC=C(Cl)C=C3)=N2)=C1,Pentamidine-Like Compound 2-5,10.1371/journal.pone.0178931,,CUG x 23 repeat RNA,"At 37.5 µM, similar polarization values to pentamidine",RNA = 6 nM,"50 mM Tris-HCl (pH = 7.0), 250 mM NaCl, 50?M ZnCl2, 10% glycerol, and 1 mM DTT",Binding,Fluorescence Polarization,RNA was 6-FAM labeled,Fluorescence polarization normalized to pentamidine (100 µM), ,DM1 hTERT skin fibroblasts,At 40 µM: Significantly increased number of foci,Ligand = 0.04 - 40 µM,On-Target Effect,Fluorescence In Situ Hybridization,MBNL1 sequestration in CUG-RNA ribonuclear foci are histopathological hallmarks in DM1; Immortalized fibroblasts expressed 1300 CTG repeats and conditionally expressed MyoD for transdifferentiation into myoblasts; Cells were plated in muscle differentiation medium to increase MBNL levels; r(CUG)exp RNA foci detected with Cy3-(CAG)7-Cy3-labelled probe; Analyzed a minimum of 1000 cell nuclei,"Chromomycin A3 (4 µM), a drug that reduces foci number in DM1 fibroblasts, as positive control; Normalized to DMSO control (1%)", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0082,R-BIND (SM) 0082,CC(=O)NC1=CC=CC(NC(=O)C2=CSC(NC(=O)C3=CC=C(Cl)C=C3)=N2)=C1,Pentamidine-Like Compound 2-5,10.1371/journal.pone.0178931,,CUG x 3 repeat RNA,Improved score over Hoechst 33258 and pentamidine references,N/A,-,In Silico,Docking,"Constructed a dynamic ensemble of the 20 lowest-frequency RNA modes, with two deformations per mode, giving 40 total conformations",-,C,hTERT Skin Fibroblasts,IC10 = 46.56 µM,-,Cytotoxicity,NR,-,-,,Drosophila,Robust rescue of strongly impaired climbing speed of DM1 flies (~5 mm/s) compared to wild-type control (17 ± 0.7 mm/s): Treated fly speed more than doubled,40 µM,Motor Behavior,Climbing Assay,"Flies expressed non-coding 480 CTG repeat RNA under the myosin heavy chain (Mhc)-Gal4 driver expression pattern, which shows general expression in Drosophila musculature; Flies reproduce DM1-like phenotypes, chiefly muscle atrophy and locomotion defects; Treatment for 5 days; Flies were transferred into 1.5 cm diameter, 25 cm long disposable pipettes, and the height reached by each fly during a period of 10 s was recorded",DMSO control (1%); Compared to wild-type flies,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850, ,(G4C2)4 G-quadruplex RNA,At 2 µM: ?Tm > 13 ºC,"Ligand = 1, 2 µM; RNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neurons,At 1 µM: Reduced RNA foci burden,Ligand = 0.1 - 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Dose-dependent stabilization,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 2,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Appearance of characteristic additional induced CD signal in separate region of spectrum; ?Tm = 9.72 ºC,Ligand = 2 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,Circular Dichroism,RNA alone formed the expected parallel G-quadruplex structure; Temperature = 15 - 95 ºC; Tm was calculated by fitting the curve to the Van’t Hoff equation,Ligand alone gave no signal; Control with no ligand or RNA, ,Patient iPSC-Derived Motor Neuron Cell Line 3,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,G4C2 repeat G-quadruplex RNA,Kd = 410 ± 79 nM,Ligand = 50 nM,10 mM Tris-HCl (pH = 7.4) and 50 mM KCl,Binding,Fluorescence Anisotropy,Used 1:1 binding model,-,,Patient iPSC-Derived Motor Neurons,No reduction in poly(GP) protein levels,"Ligand = 1, 4 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 4 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,At 2 µM: ?Tm(RNA) – ?Tm(DNA) ? 5 ºC,"Ligand = 1, 2 µM; DNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 1,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,Dose-dependent stabilization; Preferential stabilization of RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 3,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex RNA,Reduced stabilization compared to sense RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 1,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex DNA,Similar stabilization to sense DNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 2,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.1 - 40 µM,Cytotoxicity,XTT,Treatment for 7 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,,,,,,,,,C,Human Fibroblasts,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.04 - 40 µM,Cytotoxicity,XTT,Cells were WI-38 non-transformed lung fibroblasts; Treatment for 4 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,Significantly reduced poly(GP) protein levels,"Ligand = 8, 12, 16 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 7 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,Three C9orf72 transcript variants not significantly affected,Ligand = 16 µM,RNA Abundance,RT-qPCR,Expression of RNA transcript variants measured using previously described isoform-specific primers; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0083,R-BIND (SM) 0083,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(O1)C1=CC=C(O1)C1=NC=C(C=C1)C(N)=[NH2+],DB1246,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,"MCM2 transcript not significantly affected, indicating ligand specificity for RNA",Ligand = 16 µM,RNA Abundance,RT-qPCR,MCM2 is a transcript with a DNA G-quadruplex in its core promoter; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850, ,(G4C2)4 G-quadruplex RNA,At 2 µM: ?Tm > 13 ºC,"Ligand = 1, 2 µM; RNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neurons,At 1 µM: Reduced RNA foci burden,Ligand = 0.1 - 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Dose-dependent stabilization,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 2,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Appearance of characteristic additional induced CD signal in separate region of spectrum; ?Tm = 3.67 ºC,Ligand = 2 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,Circular Dichroism,RNA alone formed the expected parallel G-quadruplex structure; Temperature = 15 - 95 ºC; Tm was calculated by fitting the curve to the Van’t Hoff equation,Ligand alone gave no signal; Control with no ligand or RNA, ,Patient iPSC-Derived Motor Neuron Cell Line 3,No significant reduction in RNA foci burden,Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,G4C2 repeat G-quadruplex RNA,Kd = 258 ± 60 nM,Ligand = 50 nM,10 mM Tris-HCl (pH = 7.4) and 50 mM KCl,Binding,Fluorescence Anisotropy,Used 1:1 binding model,-,,Patient iPSC-Derived Motor Neurons,No reduction in poly(GP) protein levels,"Ligand = 1, 4 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 4 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,At 2 µM: ?Tm(RNA) – ?Tm(DNA) ? 5 ºC,"Ligand = 1, 2 µM; DNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 1,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,Dose-dependent stabilization; Preferential stabilization of RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 3,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex RNA,Reduced stabilization compared to sense RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 1,No significant reduction in RNA foci burden,Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex DNA,Similar stabilization to sense DNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 2,No significant reduction in RNA foci burden,Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.1 - 40 µM,Cytotoxicity,XTT,Treatment for 7 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,,,,,,,,,C,Human Fibroblasts,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.04 - 40 µM,Cytotoxicity,XTT,Cells were WI-38 non-transformed lung fibroblasts; Treatment for 4 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,No reduction in poly(GP) protein levels,"Ligand = 8, 12, 16 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 7 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,Three C9orf72 transcript variants not significantly affected,Ligand = 16 µM,RNA Abundance,RT-qPCR,Expression of RNA transcript variants measured using previously described isoform-specific primers; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0084,R-BIND (SM) 0084,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C(S1)C1=CC=C(S1)C1=NC=C(C=C1)C(N)=[NH2+],DB1247,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,"MCM2 transcript not significantly affected, indicating ligand specificity for RNA",Ligand = 16 µM,RNA Abundance,RT-qPCR,MCM2 is a transcript with a DNA G-quadruplex in its core promoter; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850, ,(G4C2)4 G-quadruplex RNA,At 2 µM: ?Tm > 13 ºC,"Ligand = 1, 2 µM; RNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neurons,At 1 µM: Reduced RNA foci burden,Ligand = 0.1 - 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,,daGS>36R adult Drosophila,Significant and dose-dependent decrease in poly(GP) protein levels,"200, 500 µM",Protein Abundance,Western Blot,"Flies ubiquitously expressed 36 G4C2 repeats under UAS promoter; Expression driven with the inducible daughterless-GeneSwitch (da-GS) driver RU486 (100 µM); Ligand treatment for 7 days through liquid food, which did not support the flies long enough to determine whether the ligand improved survival",Food intake was not altered in treated flies; Control with no induction of G4C2 repeats; DMSO control; Protein levels normalized to ?-tubulin; Chamber without flies was included to determine evaporative losses during feeding,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Dose-dependent stabilization,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 2,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,,daGAL4>36R Drosophila first instar larvae,Significant (33%) decrease in poly(GP) protein levels,1 mM,Protein Abundance,Meso Scale Discovery (MSD) Immunoassay,Assay specifically detects (GR)7 peptide; Larvae ubiquitously expressed 36 G4C2 repeats under UAS promoter; Expression driven with the constitutive daughterless-GAL4  (daGAL4) driver; Ligand delivered to larvae in solid food,DMSO control; An individual wild-type value was chosen at random and subtracted from all samples to correct for background,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,(G4C2)4 G-quadruplex RNA,Appearance of characteristic additional induced CD signal in separate region of spectrum; ?Tm = 7.17 ºC,Ligand = 2 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Binding,Circular Dichroism,RNA alone formed the expected parallel G-quadruplex structure; Temperature = 15 - 95 ºC; Tm was calculated by fitting the curve to the Van’t Hoff equation,Ligand alone gave no signal; Control with no ligand or RNA, ,Patient iPSC-Derived Motor Neuron Cell Line 3,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex DNA,Similar stabilization to sense DNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 2,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,,daGAL4>36R Drosophila first instar larvae,"Broad distribution throughout the gut, including epithelium; Infrequent puncta in other tissues, including the central nervous system",1 mM,Distribution,Confocal Imaging,Used inherent fluorescence of ligand; Larvae ubiquitously expressed 36 G4C2 repeats under UAS promoter; Expression driven with the constitutive daughterless-GAL4  (daGAL4) driver; Ligand delivered to larvae in solid food for 5 - 6 days,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,At 2 µM: ?Tm(RNA) – ?Tm(DNA) ? 5 ºC,"Ligand = 1, 2 µM; DNA = 1 µM",10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 1,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,,daGAL4>36R Drosophila first instar larvae,Significant increase in survival,1 mM,Lifespan,-,Larvae ubiquitously expressed 36 G4C2 repeats under UAS promoter; Expression driven with the constitutive daughterless-GAL4  (daGAL4) driver; Ligand delivered to larvae in solid food for 7 days,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,C,Antisense (G2C4)4 G-quadruplex RNA,Reduced stabilization compared to sense RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Motor Neuron Cell Line 1,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,C,daGAL4/+ Drosophila first instar larvae,No significant differences in survival to pupa or adult,"0.5, 1 mM",Lifespan,-,Control larvae with no repeats; Expression driven with the constitutive daughterless-GAL4  (daGAL4) driver; Ligand delivered to larvae in solid food for 10 days,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,C,(G4C2)4 G-quadruplex DNA,Dose-dependent stabilization; Preferential stabilization of RNA,Ligand = 0.5 - 3 µM; RNA = 1 µM,10 mM sodium cacodylate (pH = 7.35),Off-Target Effect,FRET-Thermal Melting,5'-FAM- and 3'-TAMRA-labeled oligonucleotide,DMSO control,,Patient iPSC-Derived Cortical Neuron Cell Line 3,Significantly reduced RNA foci burden (~50%),Ligand = 1 µM,On-Target Effect,Fluorescence In Situ Hybridization,"Primary fibroblast lines generated from skin biopsies, reprogrammed, and differentiated as previously described",Normalized to DMSO control,,daGAL4>36R Drosophila first instar larvae,"No significant change in expression of transgene, indicating a specific effect on RAN translation",1 mM,RNA Abundance,RT-qPCR,Larvae ubiquitously expressed 36 G4C2 repeats under UAS promoter; Expression driven with the constitutive daughterless-GAL4  (daGAL4) driver; Ligand delivered to larvae in solid food for 5 days,DMSO control; RNA levels normalized to ?-tubulin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.1 - 40 µM,Cytotoxicity,XTT,Treatment for 7 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,C,Human Fibroblasts,No toxicity observed at MSD ELISA study concentrations,Ligand = 0.04 - 40 µM,Cytotoxicity,XTT,Cells were WI-38 non-transformed lung fibroblasts; Treatment for 4 days,Cisplatin as positive control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,No reduction in poly(GP) protein levels,"Ligand = 1, 4 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 4 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,Significantly reduced poly(GP) protein levels at all concentrations; At 16 µM: > 50% reduction,"Ligand = 8, 12, 16 µM",Protein Abundance,Meso Scale Discovery (MSD) ELISA,Treatment for 7 days,Normalized to DMSO control; Blank with no peptide, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,,Patient iPSC-Derived Motor Neurons,Three C9orf72 transcript variants not significantly affected,Ligand = 16 µM,RNA Abundance,RT-qPCR,Expression of RNA transcript variants measured using previously described isoform-specific primers; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0085,R-BIND (SM) 0085,NC(=[NH2+])C1=CC=C(N=C1)C1=CC=C([Se]1)C1=CC=C([Se]1)C1=NC=C(C=C1)C(N)=[NH2+],DB1273,10.15252/emmm.201707850,,,,,,,,,,C,Patient iPSC-Derived Motor Neurons,"MCM2 transcript not significantly affected, indicating ligand specificity for RNA",Ligand = 16 µM,RNA Abundance,RT-qPCR,MCM2 is a transcript with a DNA G-quadruplex in its core promoter; Treatment for 7 days,DMSO control; RNA levels normalized to GAPDH and TATA-binding protein mRNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 3 repeat RNA,"Kd1 = 0.0058 µM, Kd2 = 0.4047 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,Cos-7 Cells,Alleviated proteotoxicity of expanded polyQ proteins,NR,Cytotoxicity,MTT,"Cells transfected with EGFP-HDQ74 or ataxin-3 (Q84), expanded polyQ proteins",Compared to cells transfected with empty vector; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 , ,5?CAG/3?GAC internal loop,Kd = 4 nM,RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,No RNA,C,Cos-7 Cells,Reduction in protein aggregates,Ligand = 25 - 100 µM,On-Target Effect,Fluorescence Microscopy,"Cells transfected with EGFP-HDQ23, a wild-type polyQ protein",DMSO control,,HD rat model,Treatment with 3-NP induced significant inhibition of mitochondrial complex activity and mitochondrial chain respiratory enzymes; Elevated mitochondrial oxidative stress; Significantly decreased levels of mitochondrial swelling,Oral; 50 mg/kg once a day for 17 days,Enzymatic Activity,High Resolution Clear Native (hrCN-)PAGE,"A large body of evidence suggests that the 3-nitropropionic acid (3-NP)-induced Huntington's disease model might offer a suitable platform for therapeutic testing; Administered 3-nitropropionic acid (3-NP) at a sub-chronic dose twice a day intraperitoneally for 17 days; Observed significantly inhibited activity of mitochondrial complex I (18.56%), complex II (19.07%), complex III + IV (37.5%), complex IV (13.47%), and complex V (9.67%); Significantly inhibited activity of NADH dehydrogenase (62.75%), succinate dehydrogenase (55.38%), cytochrome oxidase (68.63%), and F1F0-ATP synthase (45.21%); Decreased levels of mitochondrial lipid peroxides (35.01%), protein ROS levels (40.96%), nitrite levels (72.27%), and mitochondrial swelling (66.87%); Increased enzymatic activity of Mn-superoxide dismutase (43.77%); No significant change in catalase activity, GSH, GSSG, or the redox ratio",Control with no drug; Control with no 3-NP; Control with 3-NP but no drug,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 2 repeat RNA,"Kd1 =  0.0637 µM, Kd2 = 2.1613 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,Cos-7 Cells,Reduction in protein aggregates,Ligand = 25 - 100 µM,On-Target Effect,Fluorescence Microscopy,"Cells transfected with EGFP-HDQ74 or ataxin-3 (Q84), expanded polyQ proteins",DMSO control; GFP and ?-actin antibodies to further confirm intracellular plasmid expression, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 4 repeat RNA,"Kd1 = 0.0411 µM, Kd2 = 2.8572 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 5 repeat RNA,"Kd1 = 0.0570 µM, Kd2 = 0.6505 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5'CAG/3'GUC x 6 repeat RNA,"Kd1 = 0.0730 µM, Kd2 = 0.4699 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 33 repeat RNA,"Kd1 = 0.0017 µM, Kd2 = 13.96 µM",RNA = 4 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,Average lifetime increased by ~6 fold,Ligand:RNA Ratio = 2:1,NR,Binding,Time-Correlated Single-Photon Counting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,Kd = 0.25 µM,Ligand = 50 µM; RNA = 7 µM,"10 mM sodium phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Isothermal Titration Calorimetry,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,Decrease in intensity of initial double-stranded A-form band,RNA = 20 µM,"10 mM sodium phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,RNA unfolded with a single transition of ~1?4 °C with increasing number of repeats,Ligand:RNA Ratio = 2:1,NR,Binding,UV Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,Retarded mobility,Ligand =  9.375 - 300 µM; RNA = 5 µM,NR,Binding,Electrophoretic Mobility Shift Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC x 6 repeat RNA,Retarded mobility,Ligand =  9.375 - 300 µM; RNA = 5 µM,NR,Binding,Electrophoretic Mobility Shift Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,"Binding between C4 and A5 as well as above the C1 base step; Supports intercalative binding mode; Ligand stacks in between C4 and A5, and benzopyran ring involved in ??? stacking with C4 and G6; Also supports CD and melting analyses that ligand binding caused no change in global RNA structure; Ligand also bound at terminal bases",N/A,NR,In Silico,Restrained Molecular Dynamics,100 converged structures with no NOE violations larger than 0.5 A?; Ensemble of 10 conformations with the lowest potential energy superimposed,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,Duplex DNA,Kd = 22.907 µM,DNA = 4 µM,NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic),-,-,,Cos-7 Cells,Reduction in protein aggregates,Ligand = 25 - 100 µM,On-Target Effect,Fluorescence Microscopy,"Cells transfected with EGFP-HDQ74, an expanded polyQ protein",DMSO control,,HD rat model,3-NP treatment reduced counts from 235.6 to 154.8; Ligand treatment restored counts to 226.8,Oral; 50 mg/kg once a day for 17 days,Motor Behavior,Locomotor Activity,Monitored spontaneous locomotor activity by counting number of beam breaks; Administered 3-nitropropionic acid (3-NP) at a sub-chronic dose twice a day intraperitoneally for 17 days,Cleaned chamber with 5% (w/v) alcohol solution to eliminate residual odor; Control with no drug; Control with no 3-NP; Control with 3-NP and no drug,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC x 6 repeat RNA,Kd = 2.4757 µM,RNA = 4 µM,NR,Off-Target Effect,Fluorescence-Based Titration (Intrinsic),Canonically paired,-,C,Cos-7 Cells,Reduction in protein aggregates,Ligand = 25 - 100 µM,On-Target Effect,Fluorescence Microscopy,"Cells transfected with EGFP-HDQ23 or ataxin-3 (Q28), wild-type polyQ proteins",DMSO control; GFP and ?-actin antibodies to further confirm intracellular plasmid expression,,HD rat model,3-NP treatment increased time from 20.4 s to 71.4 s; Ligand treatment restored time to 22.4 s,Oral; 50 mg/kg once a day for 17 days,Motor Behavior,Narrow Beam Test,Hind-limb impairment assessed by recording time taken by rats to walk across narrow beam with progressively decreasing width,Control with no drug; Control with no 3-NP; Control with 3-NP and no drug,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC x 6 repeat RNA,Average lifetime increased by ~2.5 fold,Ligand:RNA Ratio = 2:1,NR,Off-Target Effect,Time-Correlated Single-Photon Counting,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC internal loop,Kd = 202 µM,Ligand = 50 µM; RNA = 7 µM,"10 mM sodium phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Off-Target Effect,Isothermal Titration Calorimetry,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC internal loop,No change from initial double-stranded A-form,RNA = 20 µM,"10 mM sodium phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Off-Target Effect,Circular Dichroism,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC internal loop,No changes observed,Ligand:RNA Ratio = 2:1,NR,Off-Target Effect,UV Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC x 6 repeat RNA,No change in mobility,Ligand =  9.375 - 300 µM; RNA = 5 µM,NR,Off-Target Effect,Electrophoretic Mobility Shift Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5?CAG/3?GAC DNA internal loop,Decreased intensity of PCR bands,Ligand =  4.6875 - 300 µM,"1 X PCR buffer, 0.33 mM dNTPs, 4.25 mM MgCl2, 2 ?M oligonucleotide, and 2.5 units Taq DNA polymerase",Off-Target Effect,PCR Stop Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GAC x 6 repeat DNA,Decreased intensity of PCR bands,Ligand =  4.6875 - 300 µM,"1 X PCR buffer, 0.33 mM dNTPs, 4.25 mM MgCl2, 2 ?M oligonucleotide, and 2.5 units Taq DNA polymerase",Off-Target Effect,PCR Stop Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,C,5'CAG/3'GUC x 6 DNA,No change in intensity of PCR bands,Ligand =  4.6875 - 300 µM,"1 X PCR buffer, 0.33 mM dNTPs, 4.25 mM MgCl2, 2 ?M oligonucleotide, and 2.5 units Taq DNA polymerase",Off-Target Effect,PCR Stop Assay,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,"Changes in chemical shifts and shape of proton resonances near internal loop; Ligand also bound at a second, terminal site",Ligand:RNA Ratio = 0.2:1 - 2:1,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA in 10% D2O",Structure Determination,Nuclear Magnetic Resonance,Proton,TSP sodium salt reference, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0086,R-BIND (SM) 0086,OC1=CC(=CC(O)=C1O)C1OC2=CC([O-])=CC(=O)C2=C(O)C1=O,Myricetin,10.1021/acschembio.7b00699 ,,5?CAG/3?GAC internal loop,Changes in chemical shift of proton resonances near internal loop; Supports intercalative binding mode,"Ligand:RNA Ratio = 0.6:1, 1:1, 2:1","10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA in 10% D2O",Structure Determination,Nuclear Magnetic Resonance,NOESY NMR,Control with no drug; TSP sodium salt reference, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-z,?Tm = 11 °C; 16 ºC; or 28 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,-,The Tm of the utr-1 G-quadruplex in the presence of the ligand did not change upon addition of a 5- or 10-fold excess of 21-mer RNA duplex,C,Panc-1 Cells,Taken up 20-fold more efficiently than the guanidine precursor,Ligand = 3 µM,Cell Uptake,Fluorescence-Activated Cell Sorting,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-1,?Tm = 16 °C; 23 ºC; or 32 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,-,-,,Panc-1 Cells,Preferential accumulation to cytoplasm over nucleus,Ligand = 3 µM,Localization,Confocal Imaging,-,"Cells were also treated with Syto-14, a fluorescent dye that binds nucleic acids and has higher affinity for RNA than DNA", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-c,?Tm = 11 °C; 14 ºC; or 30 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,-,-,,Panc-1 Cells,Dramatically lower luciferase; Clear correlation between luciferase inhibition and uptake,Ligand = 0.3 - 1.6 µM,Reporter,Dual Luciferase,"Used a dual reporter construct with the Renilla luciferase gene driven by the KRAS promoter, as well as the firefly luciferase gene driven by a mutated HRAS promoter, which does not bear G-quadruplex motifs",Compared to guanidine precursor, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622, ,KRAS RNA G-quadruplex utr-1,Kd = 75 ± 6 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,Dose-response inhibitory effect observed; Clear correlation between luciferase inhibition and uptake,Ligand = 0.07 - 0.33 µM,Reporter,Dual Luciferase,"Used a dual reporter construct with the Renilla luciferase gene driven by the KRAS promoter, as well as the firefly luciferase gene driven by a mutated HRAS promoter, which does not bear G-quadruplex motifs",Compared to untreated cells, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-z,Kd = 251 ± 151 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,Dose-dependent repression of Rluc,Ligand = 0.6 - 1.6 µM,Reporter,Luciferase,"Renilla luciferase gene, driven by the CMV promoter and the KRAS 5' UTR","Compared to reference vector containing fluc driven by a mutated HRAS promoter, which does not bear G-quadruplex motifs, in treated and untreated cells", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-4,Kd = 96 ± 45 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"utr-4 is a G-quadruplex motif present in the KRAS 5? UTR that overlaps other G-quadruplex motifs; RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,No luciferase reduction,Ligand = 0.15 - 0.6 µM,Reporter,Luciferase,"Renilla luciferase gene, driven by the CMV promoter and the KRAS 5' UTR","Compared to reference vector containing fluc driven by a mutated HRAS promoter, which does not bear G-quadruplex motifs, in treated and untreated cells", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,C,1:1 mixture of DNA strands with/without G-quadruplex motif,At 4ºC: ~2000-fold enrichment of G-quadruplex-containing DNA; At 25 ºC: ~4000-fold enrichment of G-quadruplex-containing DNA,Ligand = 20 µM; DNA = 0.2 µM,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Off-Target Effect,DNA Pull-Down,"G-quadruplex was from telomeric hTel; Ligand was biotinylated, incubated with DNA mixture, and pulled down with streptavidin-coated beads","100-fold enrichment of non-G-quadruplex-containing DNA in the absence of ligand, as the G-quadruplex stalled DNA polymerase", ,Panc-1 Cells,Strong activation of caspases 3/7,"Ligand = 0.6, 1.6 µM",Apoptosis,Apo-ONE Homogeneous Caspase-3/7 Assay,These proteins are activated during apoptosis,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,C,KRAS promoter DNA G-quadruplex,Kd = 626 ± 71 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Off-Target Effect,FRET,-,-,C,Panc-1 Cells,Reduced level of KRAS protein to <10% of control,Ligand = 1.6 µM,Protein Abundance,Western Blot,-,Compared to ?-actin, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,C,RNA Hairpin,Kd = 514 ± 103 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Off-Target Effect,FRET, 7-C:G stem and 4-nt loop (AGUG),-,,Panc-1 Cells,Reduced level of KRAS mRNA to 50% of control,Ligand = 1.6 µM,RNA Abundance,RT-qPCR,-,Compared to ?2-microglobulin and HPRT, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,KRAS mRNA,KRAS mRNA/HPRT mRNA = ~2; ~2.3; ~1.6,"Ligand = 400, 600, 800 nM","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, and Panc-1 total cellular RNA",On-Target Effect,RNA Pull-Down,Biotinylated ligand was incubated with total cellular RNA from Panc-1 cells; HPRT mRNA does not contain a G-quadruplex,Compared to untreated cellular RNA, ,Panc-1 Cells,Increased percentage of apoptotic cells from ~1.2% to ~32.5%,Ligand = 1.6 µM,Apoptosis,Annexin V/Propidium Iodide Stain,Annexin V detects translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane during early apoptosis; Propidium iodide permeates the cell membrane during late apoptosis,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,,,,,,,,,,Panc-1 Cells,Strong inhibition (?80%) of colony formation,"Ligand = 0.25, 0.5 µM",Colony Formation,Methylene Blue,Methylene blue is reduced in viable cells,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,,,,,,,,,,BxPC-3 Cells,Strong inhibition (?80%) of colony formation,"Ligand = 0.25, 0.5 µM",Colony Formation,Methylene Blue,Pancreatic cancer cell line; Methylene blue is reduced in viable cells,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0087,R-BIND (SM) 0087,[NH3+]CCNC1=C2OC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrafurandione 2a,10.1021/acs.jmedchem.7b00622,,,,,,,,,,,Panc-1 Cells,IC50 = 0.26 ?M,Ligand = 0.07 - 0.33 µM,Metabolic Activity,Resazurin,Resazurin becomes highly fluorescent in metabolically-active cells,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-4,Kd = 83 ± 27 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"utr-4 is a G-quadruplex motif present in the KRAS 5? UTR that overlaps other G-quadruplex motifs; RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,Activation of caspases 3/7,"Ligand = 0.6, 1.6 µM",Apoptosis,Apo-ONE Homogeneous Caspase-3/7 Assay,These proteins are activated during apoptosis,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-z,?Tm = 4 °C; 6 ºC; or 15 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,The lower ?Tm relative to anthrafurandione 2a is probably due to the polarizability of sulfur that may reduce the stacking of the chromophore upon the G-tetrads,-,C,Panc-1 Cells,Taken up 4-fold more efficiently than the guanidine precursor,Ligand = 3 µM,Cell Uptake,Fluorescence-Activated Cell Sorting,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-1,?Tm = 9 °C; 12 ºC; or 16 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,The lower ?Tm relative to anthrafurandione 2a is probably due to the polarizability of sulfur that may reduce the stacking of the chromophore upon the G-tetrads,-,,Panc-1 Cells,Preferential accumulation to cytoplasm over nucleus,Ligand = 3 µM,Localization,Confocal Imaging,-,"Cells were also treated with Syto-14, a fluorescent dye that binds nucleic acids and has higher affinity for RNA than DNA", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-z,Kd = 294 ± 138 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,Reduced level of KRAS protein to <10% of control,Ligand = 1.6 µM,Protein Abundance,Western Blot,-,Compared to ?-actin, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,KRAS RNA G-quadruplex utr-c,?Tm = 10 °C; 13 ºC; or 20 ºC,"Ligand = 5, 10, 20 µM; RNA = 5 µM",50 mM Tris-HCl (pH = 7.4) and 150 mM KCl (Fig. 5C) ,Binding,UV Melting,The lower ?Tm relative to anthrafurandione 2a is probably due to the polarizability of sulfur that may reduce the stacking of the chromophore upon the G-tetrads,-,,Panc-1 Cells,Dramatically lower luciferase; Clear correlation between luciferase inhibition and uptake,Ligand = 0.3 - 1.6 µM,Reporter,Dual Luciferase,"Used a dual reporter construct with the Renilla luciferase gene driven by the KRAS promoter, as well as the firefly luciferase gene driven by a mutated HRAS promoter, which does not bear G-quadruplex motifs",Compared to guanidine precursor, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622, ,KRAS RNA G-quadruplex utr-1,Kd = 91 ± 15 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Binding,FRET,"RNA labeled at 5' and 3' ends with fluorescein and rhodamine, respectively; Upon binding to the RNA, the ligand quenched the emission of the fluorophores",-,,Panc-1 Cells,Did not reduce level of KRAS mRNA,Ligand = 1.6 µM,RNA Abundance,RT-qPCR,-,Compared to ?2-microglobulin and HPRT, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,C,RNA Hairpin,Kd = 482 ± 109 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Off-Target Effect,FRET, 7-C:G stem and 4-nt loop (AGUG),-,,Panc-1 Cells,Increased percentage of apoptotic cells from ~1.2% to ~20.6%,Ligand = 1.6 µM,Apoptosis,Annexin V/Propidium Iodide Stain,Annexin V detects translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane during early apoptosis; Propidium iodide permeates the cell membrane during late apoptosis,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,C,KRAS promoter DNA G-quadruplex,Kd = 278 ± 21 nM,-,50 mM Tris-HCl (pH = 7.4) and 150 mM KCl,Off-Target Effect,FRET,-,-,,Panc-1 Cells,IC50 = 0.9 ?M,Ligand = 0.30 - 1.60 µM,Metabolic Activity,Resazurin,Resazurin becomes highly fluorescent in metabolically-active cells,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,,,,,,,,,,Panc-1 Cells,Strong inhibition of colony formation,"Ligand = 1, 1.5 µM",Colony Formation,Methylene Blue,Methylene blue is reduced in viable cells,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0088,R-BIND (SM) 0088,[NH3+]CCNC1=C2SC=CC2=C(NCC[NH3+])C2=C1C(=O)C1=CC=CC=C1C2=O,Anthrathiophenedione 2b,10.1021/acs.jmedchem.7b00622,,,,,,,,,,,BxPC-3 Cells,Strong inhibition of colony formation,"Ligand = 1, 1.5 µM",Colony Formation,Methylene Blue,Pancreatic cancer cell line; Methylene blue is reduced in viable cells,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,C,HEK-293T Cells,> 90% cell viability,-,Cytotoxicity,MTT,-,DMSO control (0.5%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,"Increased expression of PPP2R2A, E2F2, and STK40 proteins",NR,Protein Abundance,Western Blot,-,"Levels of PPP2R2A, E2F2, and STK40 proteins normalized to ?-actin, GAPDH, and ?-tubulin, respectively (Fig. 5); DMSO control", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,"Treatment-induced increases in expression of PPP2R2A, E2F2, and STK40 proteins was suppressed by co-treatment with miR-31 mimics",NR,Protein Abundance,Western Blot,-,"Levels of PPP2R2A, E2F2, and STK40 proteins normalized to ?-tubulin, GAPDH, and ?-tubulin, respectively (Fig. 7); DMSO control", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331, ,,,,,,,,,,HEK-293T Cells,"Inhibited expression of miR-31; No effect on miR-21-5p, miR-92a-1- 3p, miR-155, or miR-223-3p",Ligand = 5 µM,Reporter,Chemiluminescence (SEAP),Cells transfected with RNA-GFP construct and SEAP construct containing complementary sequence to RNA target in 3' UTR; Functional SEAP produced only through RNA inhibition,"Flow cytometry based on GFP expression was used to measure transfection efficiency; To minimize false negatives/positives, SEAP activity was normalized with respect to cell viability; Repeated experiments performed for primary hits", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,HEK-293T Cells,Dose-dependent inhibition of miR-31 expression; Dose-dependent increase in reporter activity,Ligand = 0.63 - 10 µM,Reporter,Chemiluminescence (SEAP),Cells transfected with RNA-GFP construct and SEAP construct containing complementary sequence to RNA target in 3' UTR; Functional SEAP produced only through RNA inhibition,DMSO control; SEAP activity did not increase in the absence of miR-31 expression, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,HEK-293T Cells,"Treatment did not block the function of mature miR-31 mimics, resulting in decrease in SEAP reporter activity",NR,Reporter,Chemiluminescence (SEAP),Cells transfected with mature miR-31 mimics and SEAP reporter construct containing the miR-31 binding region in the 3' UTR,DMSO control; Cells transfected with scrambled miRNA mimics, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Expression of endogenous RNA significantly reduced; No effect on other oncogenic miRNAs,Ligand = 5 µM,RNA Abundance,RT-qPCR,-,miRNA expression levels normalized to RNU6B; Gene expression levels normalized to GAPDH; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Upregulation of E2F2 and STK40 mRNA; No effect on PPP2R2A expression,NR,RNA Abundance,RT-qPCR,"In colon cancer, esophageal neoplasia, and lung cancer, miR-31 inhibits the expression of E2F2, STK40, and PPP2R2A, respectively; E2F2 is a tumor suppressor that inhibits the cell cycle; STK40 acts as a negative regulator of NF-kB-mediated transcription; PPP2R2A has been demonstrated as a tumor suppressor that induces apoptosis ",mRNA levels normalized to GAPDH; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Increase in pre-miR-31 expression,NR,RNA Abundance,RT-qPCR,-,DMSO control; Ct value normalized to RNU6B, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0089,R-BIND (SM) 0089,CC1=NOC(=C1C)C1=CC=C(C)C(=C1)S(=O)(=O)N1CCC2=CC=CC=C12,Aminosulfonylarylisooxazole 2,10.1371/journal.pone.0182331,,,,,,,,,,C,A549 Cells,No change in expression of the non-target miRNA pre-miR-16,NR,RNA Abundance,RT-qPCR,-,DMSO control; Ct value normalized to RNU6B, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,C,HEK-293T Cells,> 90% cell viability,-,Cytotoxicity,MTT,-,DMSO control (0.5%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,"Increased expression of PPP2R2A, E2F2, and STK40 proteins",NR,Protein Abundance,Western Blot,-,"Levels of PPP2R2A, E2F2, and STK40 proteins normalized to ?-actin, GAPDH, and ?-tubulin, respectively (Fig. 5); DMSO control", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,"Treatment-induced increases in expression of PPP2R2A, E2F2, and STK40 proteins was suppressed by co-treatment with miR-31 mimics",NR,Protein Abundance,Western Blot,-,"Levels of PPP2R2A, E2F2, and STK40 proteins normalized to ?-tubulin, GAPDH, and ?-tubulin, respectively (Fig. 7); DMSO control", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331, ,,,,,,,,,,HEK-293T Cells,"Inhibited expression of miR-31; No effect on miR-21-5p, miR-92a-1- 3p, miR-155, or miR-223-3p",Ligand = 5 µM,Reporter,Chemiluminescence (SEAP),Cells transfected with RNA-GFP construct and SEAP construct containing complementary sequence to RNA target in 3' UTR; Functional SEAP produced only through RNA inhibition,"Flow cytometry based on GFP expression was used to measure transfection efficiency; To minimize false negatives/positives, SEAP activity was normalized with respect to cell viability; Repeated experiments performed for primary hits", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,HEK-293T Cells,Dose-dependent inhibition of miR-31 expression; Dose-dependent increase in reporter activity,Ligand = 0.63 - 10 µM,Reporter,Chemiluminescence (SEAP),Cells transfected with RNA-GFP construct and SEAP construct containing complementary sequence to RNA target in 3' UTR; Functional SEAP produced only through RNA inhibition,DMSO control; SEAP activity did not increase in the absence of miR-31 expression, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,HEK-293T Cells,"Treatment did not block the function of mature miR-31 mimics, resulting in decrease in SEAP reporter activity",NR,Reporter,Chemiluminescence (SEAP),Cells transfected with mature miR-31 mimics and SEAP reporter construct containing the miR-31 binding region in the 3' UTR,DMSO control; Cells transfected with scrambled miRNA mimics, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Expression of endogenous RNA significantly reduced; No effect on other miRNAs,Ligand = 5 µM,RNA Abundance,RT-qPCR,-,miRNA expression levels normalized to RNU6B; Gene expression levels normalized to GAPDH; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Upregulation of E2F2 and STK40 mRNA; No affect on PPP2R2A expression,NR,RNA Abundance,RT-qPCR,"In colon cancer, esophageal neoplasia, and lung cancer, miR-31 inhibits the expression of E2F2, STK40, and PPP2R2A, respectively; E2F2 is a tumor suppressor that inhibits the cell cycle; STK40 acts as a negative regulator of NF-kB-mediated transcription; PPP2R2A has been demonstrated as a tumor suppressor that induces apoptosis ",mRNA levels normalized to GAPDH; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,,A549 Cells,Increase in pre-miR-31 expression,NR,RNA Abundance,RT-qPCR,-,DMSO control; Ct value normalized to RNU6B, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0090,R-BIND (SM) 0090,COC1=CC=C(C=C1S(=O)(=O)N1CCC2=CC=CC=C2C1)C1=C(C)C(C)=NO1,Aminosulfonylarylisooxazole 4,10.1371/journal.pone.0182331,,,,,,,,,,C,A549 Cells,No change in expression of the non-target miRNA pre-miR-16,NR,RNA Abundance,RT-qPCR,-,DMSO control; Ct value normalized to RNU6B, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,Synthetic TSL2 RNA,Significantly increased RNA base stacking,Ligand = 100 µM; RNA = 1 µM,"8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Binding,Fluorescence-Based Titration (Labeled RNA),"2-Aminopurine, labeled in stem",DMSO control (1%),C,GM03814B Fibroblasts,10.1% cytotoxicity at concentration of maximum splicing,Ligand = 40 µM,Cytotoxicity,Lactate Dehydrogenase,-,DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,Synthetic TSL2 RNA,Residues U2 and U19 showed significant chemical shift perturbations,Ligand = 0.8 - 1 mM; RNA = 40 - 50 µM ,"10 mM sodium phosphate (pH = 6.4), 50 mM NaCl, and 0.1 mM EDTA",Binding,Nuclear Magnetic Resonance,TOCSY NMR,DMSO control (10%),,GM03813C Fibroblasts,SMN protein expression increased 1.5-fold,Ligand = 40 µM,Protein Abundance,Western Blot,GM03813C cells were derived from a type-I SMA patient,"Compare to phenotypically unaffected GM03814B cells, which showed 2.3-fold higher SMN expression than GM03813C fibroblasts; Compared to ?-tubulin protein expression; DMSO control (0.04%)", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1, ,Synthetic TSL2 RNA,> 20% displacement of TO-PRO-1,Ligand = 100 µM; RNA = 0.5 µM; TO-PRO-1 = 1 µM,"8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Binding,Fluorescence Displacement,TO-PRO-1 is a nucleic acid intercalator that fluoresces when bound to RNA; Molecules that decreased TO-PRO-1 fluorescence intensity by >20% were considered positives,DMSO control (1%),,HeLa Cells,40 µM: Increased E7 inclusion from 19% to 72% (3.8 ± 0.3 fold); ; EC50 = 25 µM,"Ligand = 10, 20, 40 µM",RNA Abundance,RT-PCR,Cells transfected with SMN2(E6–to–8) minigene,DMSO control (0.04%),,Drosophila,E7 inclusion increased from 72% to 84%,Oral; 25 - 200 µM,RNA Abundance,RT-PCR,D24-Gal4 activated UAS-SMN2(E6?to?8) in motor neurons; E7 inclusion more prevalent (72%) in Drosophila system than in human cells; Flies fed as larvae; rp49 loading control,DMSO control (0.5%),,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,Synthetic TSL2 RNA,EC50 = 16.1 µM,-,"8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Binding,Fluorescence Displacement,TO-PRO-1 is a nucleic acid intercalator that fluoresces when bound to RNA,-,,GM03813C Fibroblasts,40 µM: Increased E7 inclusion from 48.8% to 94.6% (Fig. 3),Ligand = 10 - 50 µM,RNA Abundance,RT-PCR,GM03813C cells were derived from a type-I SMA patient; SMN2 isoforms including and excluding E7 were detected simultaneously,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,Synthetic TSL2 RNA,Dose-dependent response,"Ligand = 33, 67, 100 µM","8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Binding,Fluorescence Displacement,Molecules that decreased TO-PRO-1 fluorescence intensity by >20% were considered positives,-,,GM03814B Fibroblasts,40 µM: Increased E7 inclusion from 50.7% to 90.1% (Fig. 3),Ligand = 10 - 50 µM,RNA Abundance,RT-PCR,GM03814B cells are phenotypically unaffected fibroblasts carrying a mutated copy of SMN1 in heterozygosis; ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,TSL2,"Binding mediated by hydrogen bond interactions with residues U2 and U19, as well as ?–? stacking between G18 and the indole moiety of PK4C9, and additional hydrophobic contacts; Significant decrease in mobility of loop residues U11 and U12 ; Conformational shift from pentaloop to triloop RNA",N/A,pH = 6.4,In Silico,Molecular Docking and Molecular Dynamics,-,-,,GM03813C Fibroblasts,Significant increase in number of SMN-positive gems and coilin-p80-positive gems per cell; Increase in percentage of cells with gems,Ligand = 40 µM,Localization,Confocal Imaging,"Stained for SMN and coilin-p80; In the nucleus, functional SMN oligomerizes and forms punctate aggregates known as gems, which co-localize with coilin-p80; Stained for SMN and coilin-p80",DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,TSL2,No binding pose that recapitulated the pose of PK4C9 could be identified for two analogues that displayed the lowest binding to TSL2 by fluorescence displacement and the lowest SMN2 splicing modifier activity,N/A,pH = 6.4,In Silico,Molecular Docking and Molecular Dynamics,-,-,,GM03814B Fibroblasts,Significant increase in number of SMN-positive gems and coilin-p80-positive gems per cell; Increase in percentage of cells with gems,Ligand = 40 µM,Localization,Confocal Imaging,"Stained for SMN and coilin-p80; In the nucleus, functional SMN oligomerizes and forms punctate aggregates known as gems, which co-localize with coilin-p80; Stained for SMN and coilin-p80",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,C,Unrelated RNA structure,Significantly less fluorescence displacement,Ligand = 2.5 - 15 µM,"8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Off-Target Effect,Fluorescence Displacement,TO-PRO-1 is a nucleic acid intercalator that fluoresces when bound to RNA,DMSO control,,GM03813C and GM03814B Fibroblasts,GM03813C cells: 5.2-fold decrease in expression of E7-excluding SMN2 isoforms; Up to 3-fold increase in E7-including isoforms,Ligand = 10 - 50 µM,RNA Abundance,RT-qPCR,GM03813C cells were derived from a type-I SMA patient; GM03814B cells are phenotypically unaffected fibroblasts carrying a mutated copy of SMN1 in heterozygosis; SMN2 isoforms including and excluding E7 were amplified in two separate reactions,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,C,Denatured TSL2 RNA,Dramatic decrease in binding,Ligand = 2.5 - 15 µM,"8 mM Na2HPO4 (pH = 7), 185 mM NaCl, 0.1 mM EDTA, and 40 ?g/mL BSA",Off-Target Effect,Fluorescence Displacement,TO-PRO-1 is a nucleic acid intercalator that fluoresces when bound to RNA,DMSO control,C,HeLa Cells,Structural analogs of PK4C9 that showed reduced binding to TSL2 RNA by fluorescence displacement also had reduced SMN2 E7 splicing modifier activity (R^2 = 0.90),Ligand = 40 µM,RNA Abundance,RT-PCR,One analog excluded from curve fitting,DMSO control (0.04%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,C,Mutated TSL2,"Mutation 2A, which increased E7 splicing and enhanced ligand activity in HeLa cells, showed the largest A1–U19 base pair opening, as well as the lowest mobility of loop residues A8–U11; Conversely, mutations 2C and 3G17C, both of which hindered E7 inclusion and reduced PK4C9 activity in HeLa cells, displayed reduced A1-to-U19 distances and a proportional increase in loop residue mobility",N/A,pH = 6.4,Off-Target Effect,Molecular Docking and Molecular Dynamics,"Mutations:  2A, 2C and 3G17C, which modified SMN2 E7 splicing and ligand activity in transfected HeLa cells",-,,GM03813C Fibroblasts,290 transcripts showed modified splicing; No significantly overrepresented biological pathways,Ligand = 40 µM,RNA Abundance,RNAseq,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,,GM03813C and GM03814B Fibroblasts,"Four genes (RPS6KB1, LPIN1, PHF14 and INSR) showed dose-sensitive responses","Ligand = 20, 30 µM",RNA Abundance,RT-qPCR,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,C,ND36091A Wild-Type Fibroblasts,No dose-sensitive response of the four genes tested above,"Ligand = 20, 30 µM",RNA Abundance,RT-qPCR,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,C,SMA Fibroblasts,"Structural analogs of PK4C9 that showed reduced binding to TSL2 RNA by fluorescence displacement also had reduced SMN2 E7, LPIN1 E7 and RPS6KB1 E2 splicing modifier activity",Ligand = 40 µM,RNA Abundance,RT-PCR,LPIN1 E7 and RPS6KB1 E2 are splicing events that depend on SMN levels,DMSO control (0.04%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,C,HeLa Cells,"Strengthening local base pairing in the 5? ss portion of TSL2 significantly reduced splicing effects; Conversely, weakening base pairing in this region increased splicing effects",Ligand = 40 µM,RNA Abundance,RT-PCR,Cells transfected with SMN2 minigenes carrying structural mutations in the TSL2 region,DMSO control (0.04%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,,HeLa Cells,Mutation 2A increased E7 splicing and enhanced ligand activity; Mutations 2C and 3G17C hindered E7 inclusion and reduced ligand activity,Ligand = 40 µM,RNA Abundance,RT-PCR,Cells transfected with SMN2(E6–to–8) minigene,Compared to WT cells, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0091,R-BIND (SM) 0091,OC1=CC=C2C(NC=C2C(=O)C2=NC(=CN2)C(=O)C2=CNC3=CC=CC=C23)=C1,PK4C9,10.1038/s41467-018-04110-1,,,,,,,,,,C,HeLa Cells,Cells transfected with triloop-stabilizing SMN mutations yielded E7 inclusion of nearly 100%,-,RNA Abundance,RT-PCR,Cells transfected with SMN2(E6–to–8) minigene carrying an A8U12 to 8G12C double mutation that stabilizes TSL2 as a triloop,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,C,hERG,IC20 > 5 µM,NR,NR,Off-Target Effect,NR,Data not shown,Compared to other compounds in series,,HEK293H Cells,EC1.5x (SMN2) = 4 nM,NR,RNA Splicing,RT-qPCR,EC1.5x is defined as the concentration of compound that increases amount of full length SMN2 mRNA by 1.5 fold relative to DMSO control; Cells transfected with full length SMN2 minigene containing exon 7,mRNA levels normalized to GAPDH; DMSO control,,Rat,Clearance = 8.9 mL min-1 kg-1,"Intravenous, 1.9 mg/kg",Pharmacokinetics,Clearance,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,3T3 Fibroblasts,"The compound did not show any effect up to the highest solubility-limited concentration of 9 ?M (?3600 ng/mL), i.e., well above any expected therapeutic free concentration.",Ligand = 0 - 9 µM,Cytotoxicity,Neutral Red Assay,Neutral red is a eurhodin dye that stains lysosomes in viable cells.,NR,,C/C-allele SMA mouse model,Area Under the Curve = 9.0 µg*h/mL,Oral; 10 mg/kg,Pharmacokinetics,Plasma Drug Concentration Over Time,Assessed after 24h. Adult mice with mild SMA phenotype.,Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,LLC PK1 Cells,"Average passive permeability in parental cells of 350 nm/s. Similar permeability in other cells in the presence of inhibitor. Not a substrate of human MDR1 with an ER of 2.2, but a weak substrate of rodent Mdr1a",Ligand = 1 µM,Permeability,Scintillation Counting or HPLC-MS,Prepared L-MDR1 cells by transfecting with human MDR1 as well as L-Mdr1a by transfecting with rodent Mdr1a,"Used inhibitor zosuquidar, 1 ?M for L?MDR1 and L?Mdr1a",,FVB mouse model,Similar total drug levels in plasma and brain.,Intraperitoneal; 3 mg/kg for 10 day-old mice. Oral; 10 mg/kg for adult mice. Both dosed for 1 day,Distribution,HESI-MS/MS,Sampled plasma and brain tissues. ,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,MDCK-II Cells,"Similar permeability to parental LLC-PK1. Weak human BCRP substrate with an ER of 3.7, and a strong Bcrp substrate in rodents with an ER of 44.",Ligand = 1 µM,Permeability,Scintillation Counting or HPLC-MS,"Prepared M-BCRP by transfecting cells with human Breast Cancer Resistance Protein, BCRP as well as M-Bcrp1 by transfecting with rodent Bcrp1","Used inhibitor Ko143, 1 ?M for M?BCRP and M?Bcrp",,C/C-allele SMA mouse model,Similar total drug levels in plasma and brain.,"Oral; 1, 3, and 10 mg/kg for 10 days",Distribution,HESI-MS/MS,Sampled plasma and brain tissues. ,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,HEK293H Cells,EC1.5x (SMN2) = 29 nM,NR,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),GM03813 cells were derived from a type-I SMA patient; EC1.5x is defined as the concentration of compound that increases amount of SMN2 protein by 1.5 fold relative to DMSO control,DMSO control; Fluorescence normalized to average blank controls,,Monkey (cynomolgus),Clearance = 5.7 mL min-1 kg-1,"Intravenous, 0.1 mg/kg",Pharmacokinetics,Clearance,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,SMA Type I Fibroblasts,Increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,DMSO control (0.5%),,Rat,t1/2 = 6.4 h,"Oral, 5.5 mg/kg",Pharmacokinetics,Half-life,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,SMA Type I Islet-1+ Motoneurons,Increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,DMSO control (0.5%),,Monkey (cynomolgus),t1/2 = 5.4 h,"Oral, 0.5 mg/kg",Pharmacokinetics,Half-life,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,"US Patent 9,969,754 B2",,,,,,,,,,,GM03813 Fibroblasts,EC1.5x = 37 nM; SMN protein levels increased 1.72 fold,-,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),GM03813 cells were derived from a type-I SMA patient; EC1.5x is defined as the concentration of compound that increases amount of SMN2 protein by 1.5 fold relative to DMSO control,DMSO control; Fluorescence normalized to average blank controls, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,C,SMA Type I Fibroblasts,EC50 (FOXM1)= 67 nM,NR,RNA Splicing,RT-qPCR,"The transcriptionally inactive FOXM1a variant contains exon A2 (full length), and the transcriptionally active FOXM1b/c variants lack exon A2 (?A2).",DMSO control (0.5%),,Rat,Distribution = 3.1 L/kg,"Intravenous, 1.9 mg/kg",Pharmacokinetics,Distribution,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,SMA Type I Fibroblasts,Promotion of exon 7 inclusion,Ligand = 0.003 - 1 µM,RNA Splicing,RT-qPCR,-,DMSO control (0.5%),,Monkey (cynomolgus),Distribution = 2.0 L/kg,"Intravenous, 0.1 mg/kg",Pharmacokinetics,Distribution,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,Human Induced Pluripotent Stem Cells (iPSCs),IC50 ?A2 (FOXM1) = 113 nM,NR,RNA Splicing,RT-qPCR,-,-,,Rat,F = ~100 %,"Oral, 5.5 mg/kg",Pharmacokinetics,Fraction in Systemic Circulation,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,Cynomolgus Monkey Induced Pluripotent Stem Cells (iPSCs),IC50 ?A2 (FOXM1) = 155 nM,NR,RNA Splicing,RT-qPCR,-,-,,Monkey (cynomolgus),F = 43 %,"Oral, 0.5 mg/kg",Pharmacokinetics,Fraction in Systemic Circulation,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,SMA Fibroblasts,"Most prominent effect on primary target SMN2. Most prominent secondary splice targets in these experiments were STRN3, FOX M1, MADD, APLP2, and SLC25A17 mRNAs.",Ligand = 121  and 605 nM,RNA Splicing,RNAseq,Active concentration of ligand chosen for experiments.,NR,,C/C-allele SMA mouse model,0% increase at 1 mg/kg; 17% SMN increase in brain and 0% increase in quadriceps at 3 mg/kg; 100 % SMN increase in brain and 49 % increase in quadriceps at 10 mg/kg,"Oral; 1, 3, and 10 mg/kg",Protein Abundance,NR,Adult mice with mild phenotype. Treated for 10 days.,Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,"US Patent 9,969,754 B2",,,,,,,,,,,HEK293H Cells,EC1.5x = 4.3 nM,-,RNA Splicing,RT-qPCR,EC1.5x is defined as the concentration of compound that increases amount of full length SMN2 mRNA by 1.5 fold relative to DMSO control; Cells transfected with full length SMN2 minigene containing exon 7,mRNA levels normalized to GAPDH; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Increase in body weight gain.,"Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg. or Oral; 1, 3, and 10 mg/kg",Body Weight,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Weight gain followed a similar trend to that of lifespan,"Intraperitoneal; 0.1, 0.3, and 1 mg/kg once daily from day 3 to day 23, then Oral; 0.3, 1, 3, and 10 mg kg-1 day-1",Body Weight,-,Severe SMA model. Once daily treatment.,Compared to vehicle and heterozygous mice,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,"Similar total drug levels in plasma, brain, and muscle.","Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg. or Oral; 1, 3, and 10 mg/kg",Distribution,HESI-MS/MS,"Sampled plasma, brain, and muscle for IP and plasma/blood and brain for PO administration. ",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,Wistar Rat,Similar total drug levels in plasma and brain.,"Oral; 1, 3, and 9 mg/kg for 28 days or 1, 3, and 7.5 mg/kg for 1 or 90 days",Distribution,HESI-MS/MS,Sampled plasma and brain tissues.,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,Wistar and Partially Pigmented Rat,"Similar total drug levels in plasma, brain, muscle, and CSF.",Oral; 3 mg/kg for 4 days,Distribution,HESI-MS/MS,"Sampled plasma, brain, muscle, and CSF tissues.",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,Monkey (cynomolgus),"Drug levels were below the limit of quantification in plasma, CSF, and brain after 22 weeks’ treatment?free recovery period (muscle not sampled). In nonhuman primates, the ratios of total risdiplam concentration in plasma to brain and muscle concentrations were close to 1 for all tissues measured. ","Oral; 3 mg/kg for 7 days or 1.5, 3, and 5 mg/kg for 275 days",Distribution,HESI-MS/MS,"Sampled plasma, brain, muscle, CSF, bone marrow, heart, liver, kidney, and spleen tissues.",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,Wistar Rat,"Majority of tissues measured attaining peak concentrations at 2 hours (the first sampling point). Concentrations of radioactivity declined over the duration of the study in plasma and tissues. Tissue/plasma ratios of radioactivity were high in the bone marrow (5.5), kidney cortex (9.1), kidney medulla (4.1), liver (7.2), lung (7.1), heart (2.4), pancreas (4.7), spleen (8.0), trachea (2.7), mucosa of small intestine (3.4), large intestine (1.5), and rectum (4.1) 2 hours after oral administration. Tissue/plasma ratios 10 minutes after IV administration were similar to the oral 2?hour ratios in all tissues including intestinal mucosa.",Intravenous; 2 mg/kg. Oral; 5 mg/kg for 1 day,Distribution,Autoradiography,Administered 14C-risdiplam.,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Prolonged survival,"Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg. or Oral; 1, 3, and 10 mg/kg",Lifespan,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,"Prolonged animal survival at all doses, with a minor but significant effect already at the lowest dose tested (MST of 26 days)","Intraperitoneal; 0.1, 0.3, and 1 mg/kg once daily from day 3 to day 23, then Oral; 0.3, 1, 3, and 10 mg kg-1 day-1",Lifespan,-,Severe SMA model. Once daily treatment.,Compared to vehicle and heterozygous mice,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Improved phenotype and motor function,"Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg. or Oral; 1, 3, and 10 mg/kg",Motor Behavior,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,"Significant and dose-dependent increase of number of vGlut1 inputs, the number of motor neurons, the percentage of fully innervated NMJs and increased muscle size in the extensor digitorum longus (EDL) muscles","Intraperitoneal; 0.1, 0.3, and 1 mg/kg",Muscle Morphology,Immunohistochemistry,"Severe SMA model. Relative to heterozygous littermates, SMA?7 mice showed a significant loss of vesicular glutamate transporter 1 (vGlut1)-positive proprioceptive inputs onto motor neuron, loss of motor neurons, neuromuscular junction (NMJ) denervation in the longissimus muscle, and muscle atrophy.  Once daily treatment from day 3 to day 14. Spinal cord and muscle tissues were processed for histological assessment. ",Compared to vehicle and heterozygous mice,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Area Under the Curve = 2.2 µg*h/mL,Intraperitoneal; 3 mg/kg,Pharmacokinetics,Plasma Drug Concentration Over Time,Assessed after 24h,Compared to vehicle,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1002/prp2.447,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,"Dose?dependent increase in SMN protein levels in brain and muscle (0.1 mg/kg/day: brain 28%, muscle 32%; 1 mg/kg/day, brain 206%, muscle 210%) . ","Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg. or Oral; 1, 3, and 10 mg/kg",Protein Abundance,Homogenous Time Resolved Fluorescence,Total protein content was quantified in each tissue homogenate using the BCA assay.,SMN protein level increases were measured relative to SMN levels in heterozygous control animals.,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0092,R-BIND (SM) 0092,CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CC[NH2+]C2(CC2)C1,Risdiplam,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,,,,,,,,,SMN ?7 mouse model,Dose-dependent SMN increase in brain (28-202 %) and quadriceps (32-241 %),"Intraperitoneal; 0.1, 0.3, 1, and 3 mg/kg",Protein Abundance,NR,Severe SMA model. Once daily treatment.,Compared to vehicle and heterozygous mice,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"Oligo-4, an AGGAAG-containing RNA 15-mer",Kd = 16 ± 2 µM,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Binding,Fluorescence Polarization,"AGGAAG is the putative SMN-C2 binding sequence; Ligand contains a coumarin fluorophore; Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,293T Cells,"Identification of SMN-C2-BD binding motif, GAGGAAGA, resembling SMN2 exon 7; E value = 1.3 × 10^?151",Ligand = 2 µM,On-Target Effect,Chem-CLIP,"SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; Sequencing results analyzed by motif discovery function (MEME) in MEME suite",Cells competitively treated with 50 µM SMN-C3, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"Oligo-7, an AAGGAG-containing RNA 15-mer",Kd = 46 ± 3 ?M,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Binding,Fluorescence Polarization,"AAGGAG is similar to the putative SMN-C2 binding sequence; Ligand contains a coumarin fluorophore; Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,293T Cells,"TSL2 region remained unchanged, but TSL1 underwent some base pair rearrangement, potentially due to RNA-binding proteins; Base pairing retained between AGGAAG and the polypyrimidine tract; Decrease of SHAPE reactivity near the AGGAAG binding site indicated a more constrained conformation; Overall, ligand did not disrupt the secondary structure of TSL1, but tuned the conformation of the nucleotides in the bulge and loop of TSL1",Ligand = 10 µM,Structure Determination,SHAPE-Mutational Profiling (SHAPE-MaP),"Cells transfected with SMN2 minigene; Cells also treated with NAI, which forms 2’-O-adducts on single stranded regions of RNA; Replacing Mg2+ with Mn2+ in the buffer system results in an error-prone reverse transcription at the NAI-addition position, creating mutations; Secondary structure predicted with SuperFold software package",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"Oligo-1, a pyrimidine-rich RNA 15-mer",Kd > 160 µM,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,"Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,C,293T Cells,SMN-C2-Ac showed similar results to DMSO control,Ligand = 10 µM,Structure Determination,SHAPE-Mutational Profiling (SHAPE-MaP),SMN-C2-Ac is a less active SMN-C2 analog ,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"Oligo-2, an RNA 15-mer",Kd > 160 µM,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,"Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"Oligo-3, a purine-rich RNA 15-mer","Kd > 160 µM; Therefore, high purine content alone is probably not sufficient for binding",Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,"Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"Oligo-5, an RNA 15-mer",Kd > 160 µM,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,"Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"Oligo-6, an RNA 15-mer",Kd > 160 µM,Ligand = 200 nM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,"Oligomers 1–7 cover exon 7 and the adjacent intron 6 and 7 regions, with consecutive oligomers 2–7 having 5-nt overlaps",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,FUBP1 protein,No binding,Ligand = 200 nM; Protein = 20 µM,,Off-Target Effect,Fluorescence Polarization,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"hnRNP A1 protein:Oligo-4, an AGGAAG-containing RNA 15-mer",No significant polarization,Ligand = 200 nM; RNA = 20 µM; Protein = 20 µM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,C,"hnRNP A1 protein:SMN2 intron 6, exon 7, and intron 7",Polarization induced; Likely that the longer RNA contains both SMN-C2 and multiple hnRNP A1 binding sites,Ligand = 200 nM; RNA = 20 µM; Protein = 20 µM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",Off-Target Effect,Fluorescence Polarization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,hnRNP A1 protein,Binding by SMN-C2-BD; Likely due to high nuclear abundance of protein,SMN-C2-BD = 2 µM; SMN-C3 = 100 ?M,293T cell lysates,Off-Target Effect,Photocrosslinking,"hnRNP A1 is known to play a role in pre-mRNA splicing; SMN-C2-BD is a photocrosslinking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing; Cell lysates treated with SMN-C2-BD, followed by immunoblotting for biotinylated proteins; Lysates resolved 2D SDS-PAGE; Blotted for biotin; Proteins identified by a parallel silver staining followed by in-gel digestion and peptide identification with mass spectrometry",Performed with or without unlabeled SMN-C3 competitor, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,hnRNP A1 protein,Not significantly enriched in presence of probe,"SMN-C2-BD = 2 µM; SMN-C3 = 20, 80 ?M",293T cell lysates,Off-Target Effect,Protein Pull-Down,"hnRNP A was crosslinked by SMN-C2-BD above; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,FUBP1 protein,Binding by SMN-C2-BD,SMN-C2-BD = 2 µM; SMN-C3 = 100 ?M,293T cell lysates,On-Target Effect,Photocrosslinking,"FUBP1 is known to play a role in pre-mRNA splicing; SMN-C2-BD is a photocrosslinking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing; Cell lysates treated with SMN-C2-BD, followed by immunoblotting for biotinylated proteins; Lysates resolved 2D SDS-PAGE; Blotted for biotin; Proteins identified by a parallel silver staining followed by in-gel digestion and peptide identification with mass spectrometry",Performed with or without unlabeled SMN-C3 competitor, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,FUBP1 protein,Competed from SMN-C2-BD with SMN-C3,"SMN-C2-BD = 2 µM; SMN-C3 = 20, 80 ?M",293T cell lysates,On-Target Effect,Protein Pull-Down,"FUBP1 is known to play a role in pre-mRNA splicing; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,FUBP1 protein,"RNase caused reduced FUBP1 signal, suggesting the ligand:protein interaction is dependent on RNA",Ligand = 2 µM,293T cell lysates,On-Target Effect,Protein Pull-Down,"FUBP1 is known to play a role in pre-mRNA splicing; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,KHSRP protein,SMN-C2-BD can specifically bind to KHSRP; Dose-dependent competition by SMN-C3,SMN-C2-BD = 2 µM; SMN-C3 = 100 ?M,293T cell lysates,On-Target Effect,Photocrosslinking,"KHSRP has 61% homology to FUBP1 and is another multi-KH domain RNA-binding protein that has been shown to regulate pre-mRNA splicing through cooperation with other splicing regulatory proteins; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing; Binding detected by Western blot with anti-KHSRP antibody",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,,,,,,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"FUBP1 protein:Oligo-4, an AGGAAG-containing RNA 15-mer","Polarization induced, suggesting ternary complex formation by FUBP1, SMN-C2, and exon 7",Ligand = 200 nM; RNA = 20 µM; Protein = 20 µM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",RNA:Protein Stabilization,Fluorescence Polarization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"FUBP1 protein:SMN2 intron 6, exon 7, and intron 7","Polarization induced, suggesting ternary complex formation by FUBP1, SMN-C2, and exon 7",Ligand = 200 nM; RNA = 1 µM; Protein = 20 µM,"50 mM HEPES, 150 mM NaCl, and 4 mM MgCl2",RNA:Protein Stabilization,Fluorescence Polarization,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"SMN2 intron 6, exon 7, and intron 7",SMN-C2–Phen–Cu exclusively cleaved exon 7 three nucleotides away from putative binding site,"Ligand = 40, 400 nM; RNA = 10 nM","60 mM HEPES (pH = 8.0), 20 mM MgCl2, 0.2 ?g/mL yeast tRNA, 0.5 M KCl, 0.1% H2O2, and 1 mM sodium ascorbate",Structure Determination,RNase Footprinting,"Copper chelates in the presence of H2O2 have previously been used as  artificial chemical ribonucleases to probe the nucleic acid binding sites of molecules; SMN-C2–Phen–Cu is a conjugate of SMN-C2 and 1,10-phenanthroline with a two-carbon linker; RNA was 5?-32P–labeled",Control with no ligand, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"SMN2 intron 6, exon 7, and intron 7",SMN-C2–GGH–Cu exclusively cleaved exon 7 three nucleotides away from putative binding site,"Ligand = 40, 400 nM","60 mM HEPES (pH = 8.0), 20 mM MgCl2, 0.2 ?g/mL yeast tRNA, 0.5 M KCl, 0.1% H2O2, and 1 mM sodium ascorbate",Structure Determination,RNase Footprinting,"Copper chelates in the presence of H2O2 have previously been used as  artificial chemical ribonucleases to probe the nucleic acid binding sites of molecules; SMN-C2–GGH–Cu is a conjugate of SMN-C2 and Gly-Gly-His, another copper ligand; RNA was 5?-32P–labeled",Control with no ligand, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1073/pnas.1800260115,,"SMN2 intron 6, exon 7, and intron 7",No change in overall 2º structure of exon 7; Ligand binding did not displace strand complementary to the putative ligand binding domain; Increased band intensity in binding region suggested adoption of more flexible conformation,Ligand = 50 µM,-,Structure Determination,SHAPE,RNA was imbedded within a stabilizing cassette,DMSO control allowed for determination/confirmation of RNA 2º structure, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127,,,,,,,,,,,PNN 1-51 Fibroblasts,Dose-dependent increase in SMN levels,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),SMA Type II; SMN1 copy # 0; SMN2 copy # 3,DMSO control (0.5%),,?7 SMA mouse model,Marked body weight gain,Intraperitoneal; 1 mg/kg once a day from postnatal day 3 (P3) through P23; Then oral; 6 mg/kg once a day,Body Weight,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127,,,,,,,,,,,PNN 2-15 Fibroblasts,Dose-dependent increase in SMN levels,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),SMA Type III; SMN1 copy # 0; SMN2 copy # 4,DMSO control (0.5%),,?7 SMA mouse model,Survival beyond 150 days after birth,Intraperitoneal; 1 mg/kg once a day from postnatal day 3 (P3) through P23; Then oral; 6 mg/kg once a day,Lifespan,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127,,,,,,,,,,,SMA Type I Fibroblasts,Dose-dependent increase in SMN levels,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),SMA Type I; SMN1 copy # 0; SMN2 copy # 2,DMSO control (0.5%),,C/C-allele SMA mouse model,"Marked elevation of SMN protein levels in brain, spinal cord and quadriceps muscle",Oral; 20 mg/kg once a day for 10 days,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127,,,,,,,,,,C,GM03814 Fibroblasts,Dose-dependent increase in SMN levels,Ligand = 0.003 - 1 µM,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),SMA Type: Carrier; SMN1 copy # 1; SMN2 copy # 5,DMSO control (0.5%),,?7 SMA mouse model,Dose-dependent increase in SMN protein levels in brain and spinal cord,"Intraperitoneal; 0.01, 0.03, 0.1, or 0.3 mg/kg once a day from postnatal day 3 (P3) through P9",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),These animals have a severe form of SMA,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127,,,,,,,,,,,GM03813 Fibroblasts,Increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Western Blot,SMA Type I; SMN1 copy # 0; SMN2 copy # 2,GAPDH control; DMSO control (0.05%),,C/C-allele SMA mouse model,SMN2 alternative splicing shifted toward full-length mRNA in brain and quadriceps muscle,Oral; 20 mg/kg once a day for 10 days,RNA Abundance,RT-qPCR,-,Compared to GAPDH mRNA; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0093,R-BIND (SM) 0093,CC[NH+]1CCN(C[C@@H]1C)C1=CC=C2C=C(C3=CN4C=C(C)N=C(C)C4=N3)C(=O)OC2=C1,SMN-C2,10.1126/science.1250127, ,,,,,,,,,,GM03813 Fibroblasts,Increase in level of full-length mRNA; Reduction in level of ?7 mRNA,Ligand = 0.003 - 1 µM,RNA Abundance,RT-PCR,SMA Type I; SMN1 copy # 0; SMN2 copy # 3,"DMSO control (0.5%); Parent compound(s) identified by luciferase reporter assay in which HEK293H cells were stably transfected with SMN2 minigene containing a fluc gene that was in frame for the full-length but not the ?7 mRNA product; Parent compound(s) promoted inclusion of SMN2 exon 7, with > 250% fluorescence over DMSO control (0.5%); Parent compound(s) validated by RT-qPCR assays in various SMA fibroblast lines; By end-point RT-PCR in GM03813 fibroblasts, parent compound induced concentration-dependent (0.3 - 30 µM) increase in full-length mRNA relative to Trichostatin A (TSA) and 0.5% DMSO controls; mRNA abundances were normalized to GAPDH levels",,C/C-allele SMA mouse model,Excellent brain penetration,Oral; 10 mg/kg,Distribution,LC-ESI-MS/MS,"These animals have a mild form of SMA and live a normal life span but show muscle weakness, peripheral necrosis, and reduced body weight gain",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,SMN2 pre-mRNA,No change in exon 7 inclusion,Ligand = 0.1 - 20 µM,"1.56 mM MgCl2, 32 mM HEPES, 0.5 mM ATP, 20 mM creatine phosphate, 1.3% PVA, 40% HeLa nuclear extract, and 1x buffer D [20 mM HEPES-KOH (pH = 8), 25% glycerol, 1.5 mM MgCl2, 0.2 mM PMSF, 0.5 mM DTT, and 0.6 M KCl]",Activity,In Vitro Splicing,"Splicing tested on ten fmol of 32P-labeled, m7G-capped T7 transcripts isolated from HeLa cell nuclear extracts; RNA analyzed by denaturing PAGE and autoradiography",Splicing of SMN1 minigene transcript, ,SMA Type I Patient Fibroblasts,"Isoginkgetin significantly reduced ligand-induced exon 7 inclusion, indicating that the ligand acts on the pre-mRNA splicing process",NR,RNA Abundance,RT-qPCR,"Concurrent treatment with isogingketin (50 µM), an inhibitor of spliceosome assembly",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1073/pnas.1800260115,C,hnRNP A1 protein,Not significantly enriched in presence of probe,"SMN-C2-BD = 2 µM; SMN-C3 = 20, 80 ?M",293T cell lysates,Off-Target Effect,Protein Pull-Down,"hnRNP A was crosslinked by SMN-C2-BD above; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,293T Cells,No significant effect on SMN2 splicing or SMN-C3 treatment,Ligand = 4 - 1000 nM,RNA Abundance,End-Point RT-PCR,siRNA knockdown of KHSRP; Cells transfected with SMN2 minigene,Random siRNA control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1073/pnas.1800260115,,FUBP1 protein,Competed from SMN-C2-BD with SMN-C3,"SMN-C2-BD = 2 µM; SMN-C3 = 20, 80 ?M",293T cell lysates,On-Target Effect,Protein Pull-Down,"FUBP1 is known to play a role in pre-mRNA splicing; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,293T Cells,No significant effect on SMN2 splicing or SMN-C3 treatment,Ligand = 4 - 1000 nM,RNA Abundance,End-Point RT-PCR,siRNA knockdown of FUBP1; Cells transfected with SMN2 minigene,Random siRNA control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1073/pnas.1800260115,,KHSRP protein,SMN-C2-BD can specifically bind to KHSRP; Dose-dependent competition by SMN-C3,SMN-C2-BD = 2 µM; SMN-C3 = 100 ?M,293T cell lysates,On-Target Effect,Photocrosslinking,"KHSRP has 61% homology to FUBP1 and is another multi-KH domain RNA-binding protein that has been shown to regulate pre-mRNA splicing through cooperation with other splicing regulatory proteins; SMN-C2-BD is a photo–cross-linking probe in which a biotin-diazirine bifunctional handle replaces the ethyl group of SMN-C2; SMN-C2-BD is ?20-fold less active than its parent compound, as demonstrated by Western blot analyses of SMN protein in SMN?7 mouse astrocytes; SMN-C3 is a ligand analog that was previously identified to correct exon 7 splicing; Binding detected by Western blot with anti-KHSRP antibody",Control with no ligand; Performed with or without unlabeled SMN-C3 competitor, ,293T Cells,Decreased basal level of full-length SMN mRNA; Shifted ligand dose–response curve,Ligand = 4 - 1000 nM,RNA Abundance,End-Point RT-PCR,Dual siRNA knockdown of FUBP1 and KHSRP; Cells transfected with SMN2 minigene,Random siRNA control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1073/pnas.1800260115,,FUBP1 protein:500-nt SMN2 exon 7 RNA,Dose-dependent increase in RNA:protein complex formation; No complex formation in absence of ligand,Ligand = 0.39 - 12.5 µM; Protein = 120 nM,NR,RNA:Protein Stabilization,Electrophoretic Mobility Shift Assay,RNA was 3'-biotin-labeled; Visualization by Northern blot with streptavidin–HRP conjugate,Control with no ligand, ,THP-1 Cells,25 µM: Amount of FUBP1 in supernatant increased 58%; Dose-dependent increase,Ligand = 0.034 - 25 µM,On-Target Effect,Cellular Thermal Shift Assay (CETSA),"In CETSA, small molecules bind and protect their specific cellular protein targets from unfolding and aggregation when the cell suspension is heated; Protein concentration determined by Western blot with anti-FUBP1 antibody",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,SMA Type I Islet-1– Cells,Dose-dependent increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Confocal Imaging,Mainly glia and neuronal stem cells; Derived from SMA type I patient iPSCs,DMSO control,,C/C-allele SMA mouse model,mRNA levels correlated with ligand plasma levels,Oral; 10 mg/kg,Plasma Levels,LC-ESI-MS/MS,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,SMA Type II Islet-1+ Motoneurons,Dose-dependent increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Confocal Imaging,Derived from SMA type II patient iPSCs,DMSO control,,C/C-allele SMA mouse model,mRNA levels correlated with ligand plasma levels,Oral; 10 mg/kg once a day for 10 days,Plasma Levels,LC-ESI-MS/MS,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,SMA Type II Islet-1– Cells,Dose-dependent increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Confocal Imaging,Mainly glia and neuronal stem cells; Derived from SMA type II patient iPSCs,DMSO control,,C/C-allele SMA mouse model,SMN protein levels were increased by ~50 to 70% over baseline in brain and quadriceps muscle after a single oral dose (peaking at 24 hours) and by more than 200% above baseline in brain and quadriceps muscle,Oral; 10 mg/kg,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,GM03813 Fibroblasts,Increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Western Blot,SMA Type I; SMN1 copy # 0; SMN2 copy # 3,GAPDH control; DMSO control,,C/C-allele SMA mouse model,"After 4 h, SMN2 full-length mRNA increased from ~40% to 90% of total mRNA; Levels of full-length and ?7 mRNA returned to baseline within 32 hours",Oral; 10 mg/kg,RNA Abundance,RT-qPCR,-,Normalized to GAPDH mRNA; Untreated control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,SMA Type I Islet-1+ Motoneurons,Dose-dependent increase in SMN protein level,Ligand = 0.003 - 1 µM,Protein Abundance,Confocal Imaging,Derived from SMA type I patient iPSCs,DMSO control,,C/C-allele SMA mouse model,"After 4 h, SMN2 full-length mRNA increased from ~40% to 90% of total mRNA; Levels of full-length and ?7 mRNA returned to baseline within 32 hours",Oral; 10 mg/kg once a day for 10 days,RNA Abundance,RT-qPCR,-,Normalized to GAPDH mRNA; Untreated control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,C,SMA Type I Patient Fibroblasts,"Point mutations in SMN2 cis-acting splicing regulatory elements affected ligand-induced alternative splicing, but not critically",Ligand = 0.01 - 10 µM,RNA Abundance,End-Point RT-PCR,"Introduced point mutations in several cis-acting splicing regulatory elements—Exinct//ESE1, ESE2, and ESE3/TSL2 in exon 7 and ISS–N1 in intron 7—in the SMN2 minigene",DMSO control,,?7 SMA mouse model,"Dose-dependent body weight gain, up to ~80% of heterozygous controls; At P16, DMSO-treated ?7 mice much smaller than heterozygous littermate controls and appeared moribund; ?7 mice treated with high dose of ligand resembled heterozygous controls","Intraperitoneal; 0.1, 0.3, or 1 mg/kg once a day from postnatal day 3 (P3) through P9",Body Weight,-,-,Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127, ,,,,,,,,,,GM03813 Fibroblasts,Increase in level of full-length mRNA; Reduction in level of ?7 mRNA,Ligand = 0.003 - 1 µM,RNA Abundance,RT-PCR,SMA Type I; SMN1 copy # 0; SMN2 copy # 3,DMSO control,,C/C-allele SMA mouse model,Excellent brain penetration,Oral; 10 mg/kg,Brain Penetration,LC-ESI-MS/MS,"These animals have a mild form of SMA and live a normal life span but show muscle weakness, peripheral necrosis, and reduced body weight gain",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,PNN 1-46 Fibroblasts,"Did not induce widespread changes in gene expression: 12 of 11,714 genes either up- or down-regulated by a factor > 2; No deregulated expression of gene families involved in DNA or RNA metabolism or cell survival; To date, none of these genes has been directly linked to SMN expression and/or function or to SMA pathogenesis",Ligand = 500 nM,RNA Abundance,RNAseq,SMA Type I; SMN1 copy # 0; SMN2 copy # 2,DMSO control (0.5%),,C/C-allele SMA mouse model,SMN protein levels increased by more than 200% above baseline in brain and quadriceps muscle,Oral; 10 mg/kg once a day for 10 days,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,C,PNN 1-46 Fibroblasts,Confirmed five genes identified by RNA-Seq (Fig. S4),Ligand = 500 nM,RNA Abundance,RT-qPCR,SMA Type I; SMN1 copy # 0; SMN2 copy # 2,DMSO control,,C/C-allele SMA mouse model,"SMN protein levels elevated in brain, spinal cord, quadriceps, and longissimus muscle",Oral; 10 mg/kg once a day for 10 days,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1073/pnas.1800260115,,,,,,,,,,C,293T Cells,Diminished or absent dose-dependent alternative splicing after cells transfected with mutated SMN2 minigene variants,Ligand = 0.01 - 1 µM,RNA Abundance,End-Point RT-PCR,Cells transfected with mutated SMN2 minigene,Control with no ligand; Control with no mutation,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,"Pladienolide B significantly reduced ligand-induced exon 7 inclusion, indicating that the ligand acts on the pre-mRNA splicing process",NR,RNA Abundance,RT-qPCR,"Concurrent treatment with pladienolide B (100 nM), an inhibitor of spliceosome assembly",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,Cordycepin did not affect ligand activity,NR,RNA Abundance,RT-qPCR,"Concurrent treatment with cordycepin (40 µM), a polyadenylation blocker",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,Puromycin did not accept ligand activity,NR,RNA Abundance,RT-qPCR,"Concurrent treatment with puromycin (10 µg/mL), an inhibitor of protein translation",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,"EC50 = 17 nM; Actinomycin D reduced ligand-induced exon 7 inclusion and decreased baseline amounts of SMN2 pre-mRNA, which is known to generally occur concurrently with RNA polymerase II transcription",NR,RNA Abundance,RT-qPCR,"Concurrent treatment with actinomycin D (1 µg/mL), an inhibitor of RNA polymerase II",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,?-Amanitin reduced ligand-induced exon 7 inclusion and decreased baseline amounts of SMN2 pre-mRNA,NR,RNA Abundance,RT-qPCR,"Concurrent treatment with ?-amanitin (50 µg/mL), an inhibitor of RNA polymerase II",mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,EC50 = 11 nM,Ligand = 0.01 - 1 µM,RNA Abundance,RT-qPCR,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1038/s41467-017-01559-4,,,,,,,,,,,SMA Type I Patient Fibroblasts,"Observed 42 transcriptome-wide splicing event changes, with NVS-SM1 affecting 36 transcripts and SMN-C3 only 13; Expression changes in 313 genes overall, with 229 expression changes for NVS-SM1 as opposed to 13 for SMN-C3",Ligand = 500 nM,RNA Abundance,RT-qPCR,"Ligand concentration ~50x EC50; A database of alternative splicing events was generated based on the human RefSeq database of transcripts; Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7","Treatment with NVS-SM1 (24 nM, ~5x EC50)",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,PNN 1-46 Fibroblasts,"~300,000 splice junctions analyzed, 114 with p > 100 and 20 with p > 300; SMN2 exon 7 junctions affected",Ligand = 500 nM,RNA Splicing,RNAseq,SMA Type I; SMN1 copy # 0; SMN2 copy # 2; p = Absolute difference in counts (?) * Relative changes (Log2FC); Paired-end RNASeq reads were mapped to RefSeq human transcripts using the alignment software GSNAP,DMSO control (0.5%),,?7 SMA mouse model,"Dose-dependent increase in SMN protein levels in brain and quadriceps by up to 150% and 90%, respectively","Intraperitoneal; 0.1, 0.3, or 1 mg/kg once a day from postnatal day 3 (P3) through P9",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),These mice have a severe form of SMA and die within 3 weeks after birth,Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,DMSO-treated mice died within 3 weeks after birth with median survival of 18 days; Ligand treatment increased survival in dose-dependent manner to median survival time of 28 days in the low-dose group; ~90% of remaining treated animals survived beyond P65,"Intraperitoneal; 0.1, 0.3, or 1 mg/kg once a day from postnatal day 3 (P3) through P9",Lifespan,-,-,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,Normalized ability of mice to right themselves; Increased level of locomotor activity,"Intraperitoneal; 0.1, 0.3, or 1 mg/kg once a day from postnatal day 3 (P3) through P9",Motor Behavior,-,"Tested at P9 and P16; Mouse was given a maximum of 30 seconds to right itself when placed on its back; If mouse did not right itself after 30 seconds, a time of 30 seconds was used for subsequent calculations; Each mouse was tested 3 times, with 2 minutes intervals between each trial",Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,Dose-dependent prevention of spinal cord motoneuron loss,Intraperitoneal; 0.3 or 3 mg/kg once a day,Motor Neuron Pathology,Confocal Imaging,"To assess motoneuron pathology, lumbar spinal cords were sectioned at 25 µm, and motoneurons were stained with anti-choline acetyltransferase antibody",Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,"Dose-dependent prevention of extensor digitorum longus muscle atrophy, with complete prevention at highest dose",Intraperitoneal; 0.3 or 3 mg/kg once a day,Muscle Morphology,Toluidine Blue Stain,"To examine muscle morphology, one-micron cross-sections of the extensor digitorum longus (EDL) muscles were prepared; Toluidine blue stains acidic tissues",Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,"At P65, weight of the tibialis anterior muscle and the innervation of splenius capitis muscle neuromuscular junctions were near normal",Intraperitoneal; 3 mg/kg once a day from postnatal day 3 (P3) through P23; Then oral; 10 mg/kg once a day,Muscle Morphology,Confocal Imaging,Tibialis anterior muscle weight and splenius capitis neuromuscular junction morphology and innervation were quantitatively assessed in surviving mice at P65,Heterozygous littermate control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,Prevention of tail and eye necrosis,"Intraperitoneal; 0.3, 1, or 3 mg/kg once a day from postnatal day 3 (P3) through P23; Then oral; 1, 3, or 10 mg/kg once a day",Necrosis,-,"These phenotypes are associated with SMN deficiency; Tail length was measured at P16, P30 and P60; Eye necrosis was evaluated at P60 using a semi-quantitative eye necrosis score in which mice were visually inspected for necrosis around the eyes, and a score was given to each eye ranging from 0 (no necrosis) to 3 (severe necrosis); The average score across the group for each eye was calculated",Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0094,R-BIND (SM) 0094,CC[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C(C)=C1)C1=NN2C=C(C)N=C(C)C2=C1,SMN-C3,10.1126/science.1250127,,,,,,,,,,,,,,,,,,,?7 SMA mouse model,Dose-dependent prevention of splenius capitis NMJ denervation,Intraperitoneal; 0.3 or 3 mg/kg once a day,Neuromuscular Junction Morphology,Confocal Imaging,"To examine neuromuscular junction innervation patterns, splenius capitis motor nerve terminals were labeled with anti-synaptophysin and antineurofilament antibodies, and acetylcholine receptors (AChRs) with ?-bungarotoxin in muscles; The percentage of endplates (identified by AChR clusters) that were fully, partially, or not occupied by nerve terminals in the splenius capitis muscle was quantified in whole-mount preparations",Heterozygous littermate control; DMSO control, ,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 pre-mRNA,Concentration-dependent correction of SMN2 splicing to increase exon 7 inclusion,Ligand = 0.1 - 20 µM,"1.56 mM MgCl2, 32 mM HEPES, 0.5 mM ATP, 20 mM creatine phosphate, 1.3% PVA, 40% HeLa nuclear extract, and 1x buffer D [20 mM HEPES-KOH (pH = 8), 25% glycerol, 1.5 mM MgCl2, 0.2 mM PMSF, 0.5 mM DTT, and 0.6 M KCl]",Activity,In Vitro Splicing,"Splicing tested on ten fmol of 32P-labeled, m7G-capped T7 transcripts isolated from HeLa cell nuclear extracts; RNA analyzed by denaturing PAGE and autoradiography",Splicing of SMN1 minigene transcript, ,SMA Type I Patient Fibroblasts,EC50 = 15 nM,NR,RNA Abundance,RT-qPCR,-,mRNA levels normalized to GAPDH; DMSO control (0.5%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,SMN2 E7 Splicing Complex,E complex accumulates while the H complex disappears; EC50 = 43 ± 18 nM,Ligand = 10 nM - 10 µM; RNA probe ~ 0.6 mg/mL,"HeLa nuclear extract, yeast transfer RNA (0.025??g?ml?1), polyvinyl-alcohol (1.3%), RNAsin (Promega; diluted 40 times) in 20 mM Hepes (pH = 8), 100 mM KCl, 1.5 mM MgCl2, 10 % glycerol, and 0.5 mM DTT",Activity,Electrophoretic Mobility Shift Assay,The RNA probe (SMN2 E7 pre-mRNA fragment) was radiolabeled directly using ?-32P ATP. Reactions were ran for 30 ºC for 30 minutes. The most retarded complex corresponds to the spliceosomal E complex in which U1 snRNP is bound to the 5? SS together with splicing regulators. ,Compared to ESE ASO at 2 µM,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,SMN2 E7 pre-mRNA fragment:U1 snRNP,"SMN-C5 promotes the binding of U1 snRNP on SMN2 E7 pre-mRNA in a dose-dependent manner with a much higher EC50 of 1.6?±?0.4??M, which is in a similar range to the affinity constant of SMN-C5 for the U1 snRNP:5??SS complex using NMR spectroscopy",Ligand = 10 nM - 10 µM; RNA probe ~ 0.6 mg/mL,"Yeast transfer RNA (0.025??g?ml?1), polyvinyl-alcohol (1.3%), RNAsin (Promega; diluted 40 times) in 20 mM Hepes (pH = 8), 100 mM KCl, 1.5 mM MgCl2, 10 % glycerol, and 0.5 mM DTT",Activity,Electrophoretic Mobility Shift Assay,The RNA probe (SMN2 E7 pre-mRNA fragment) was radiolabeled directly using ?-32P ATP. Reactions were ran for 30 ºC for 30 minutes. U1snRNP was in vitro reconstituted without nuclear extracts. ,First determined the U1 snRNP concentration required to upshift half of the RNA (500?nM),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,C,SMN2 E7 Splicing Complex with RNA fragment A-1C mutant,Addition of SMN-C5 does not promote E complex accumulation as observed with the wild-type RNA,Ligand = 10 nM - 10 µM; RNA probe ~ 0.6 mg/mL,"HeLa nuclear extract, yeast transfer RNA (0.025??g?ml?1), polyvinyl-alcohol (1.3%), RNAsin (Promega; diluted 40 times) in 20 mM Hepes (pH = 8), 100 mM KCl, 1.5 mM MgCl2, 10 % glycerol, and 0.5 mM DTT",Activity,Electrophoretic Mobility Shift Assay,The RNA probe (SMN2 E7 pre-mRNA fragment) was radiolabeled directly using ?-32P ATP. Reactions were ran for 30 ºC for 30 minutes. Both the E and H complexes at a ratio of 60:40 in the absence of ligand,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 (containing ESE2),Strong binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Binding,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",Control with no drug; No detectable binding to NVS-SM1, ,HEK 293 Cells,Very little but detectable promotion of exon 7 inclusion,Ligand = 0.01 - 10 µM,RNA Abundance,RT-qPCR,Cells transfected with SMN2 minigene construct with 5?ss mutation (G1C),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNA:E7 5' SS duplex,Kd = 28 ± 9 µM. Compound interacted with the intermolecular RNA helix at the same binding site located at the exon–intron junction.,Ligand = 2.5 mM; RNA = 0 - 300 µM,"5 mM MES d-4?(pH = 5.5), 50 mM NaCl complemented with 6% d8-glycerol ",Binding,Nuclear Magnetic Resonance,Plotted 19F chemical shift perturbation as a function of increasing RNA concentration.,"Compared to another high-affinity binder (SMN-CX), an in vitro binder (SMN-CY) and a non-binder (SMN-Core)",,HEK-293T Cells,EC50 (wild-type SMN2 mini-gene) = 31 ± 10 nM. EC50 (A1-U mutant mini-gene) = 598 ± 112 nM. No change in splicing of A-1G and A-1C mutant minigenes.,"Ligand = 0, 1, 2, 5, 10, 30, 100, 300, 1,000, 2,000, 5,000 or 10,000?nM",RNA Splicing,RT-PCR,One microgram of pCI-SMN2 (wild-type or mutant) was transfected in HEK293T cells. SMN2 mini-genes that differ at the position ?1. Splicing products analyzed on agarose gels.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE2,Strong binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Binding,Surface Plasmon Resonance,"SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM); Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",Bound to SMN-C7; No binding to NVS-SM1; Control with no ligand, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,STRN3 exon 8,Ligand bound more strongly than it did to SMN2 ESE2,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Binding,Surface Plasmon Resonance,"Sequence homology was identified between SMN2 exon 7 and an identical weak 5?ss and purine-rich region similar to the SMN2 ESE2 motif in the STRN3 exon 8; SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM); Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized","Bound to SMN-C7, although less potently; No detectable binding to NVS-SM1", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE2,Induced largest chemical shift perturbations and formation of broad imino signals,Ligand = 0.2 - 2 mM; RNA = 400 µM,"10 mM MES (pH = 5.5), 50 mM NaCl, and 10% D20",Binding,Nuclear Magnetic Resonance,"Proton; SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM); Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7",SMN-C7 induced chemical shift perturbations and no imino signals; NVS-SM1 induced weakest chemical shift perturbations and imino signals, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNP : 5' SS,"Following addition of the U1 snRNP:E7 5?SS complex, the SMN-C5 19F signal was perturbed and almost disappeared as a consequence of binding to a large-molecular-weight complex. The binding affinity of SMN-C5 for the ribonucleoparticle could be estimated to 15.0 ± 1.0?M, meaning that the splicing modifier binds the RNA duplex more strongly in the context of U1 snRNP. Addition of ribonucleases restored the initial SMN-C5 19F signal, indicating that the interaction is RNA dependent. Replacement of the weak E7 5?SS by a strong and canonical 5?SS impairs the interaction",Ligand = 0-50 µM; RNA = 250 µM; RNase A = 1 mg/ml; RNase T1 = 1 U/µL; Benzonase = 1 U/µL,"10 mM Hepes (pH = 7.4), 50 mM NaCl, 1 mM DTT",Binding,Nuclear Magnetic Resonance,In vitro reconstituted U1 snRNP bound to the canonical 5?SS (strong) or the SMN2 E7 5?SS (weak) and monitored the direct binding of the small molecule using 19F NMR spectroscopy.,"Compared to non-canonical splice site, RNases added.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNA:E7 5' SS duplex,Increased stability by almost 1 ºC,Ligand = NR; RNA = 5 µM,NR,Binding,UV Melting,NR,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNA:E7 5' SS duplex:U1-C zinc finger protein,A threefold affinity increase of U1-C when SMN-C5 is present,"3:1 ligand:RNA ratio, added to 0.2 mM U1-C zinc finger protein","10 mM Hepes (pH = 7.0), 100 mM NaCl, 1 mM MgCl2, and 2.5 mM ?-mercapto-ethanol complemented with 10% D2O",Binding,Nuclear Magnetic Resonance,15N-labeled U1-C zinc finger. 1D 1H and 2D 1H–15N HSQC were recorded after each SMN-C5 addition,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,C,A-1G mutant U1 snRNA:E7 5' SS duplex,Not determined,Ligand = 2.5 mM; RNA = 0 - 300 µM,"5 mM MES d-4?(pH = 5.5), 50 mM NaCl complemented with 6% d8-glycerol ",Binding,Nuclear Magnetic Resonance,Plotted 19F chemical shift perturbation as a function of increasing RNA concentration.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,C,A-1C mutant U1 snRNA:E7 5' SS duplex,Kd > 120 µM,Ligand = 2.5 mM; RNA = 0 - 300 µM,"5 mM MES d-4?(pH = 5.5), 50 mM NaCl complemented with 6% d8-glycerol ",Binding,Nuclear Magnetic Resonance,Plotted 19F chemical shift perturbation as a function of increasing RNA concentration.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,C,A-1U mutant U1 snRNA:E7 5' SS duplex,Kd = 113 ± 35 µM,Ligand = 2.5 mM; RNA = 0 - 300 µM,"5 mM MES d-4?(pH = 5.5), 50 mM NaCl complemented with 6% d8-glycerol ",Binding,Nuclear Magnetic Resonance,Plotted 19F chemical shift perturbation as a function of increasing RNA concentration.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNA:E7 5' SS duplex:U1-C zinc finger protein,"Modeling of the U1-C zinc finger recognition with RNA structures reveals that the position of A?1 induced a major steric clash with the protein in the absence of the drug. However, the addition of SMN-C5 makes the minor groove accessible for optimal interactions with U1-C.",-,-,In Silico,Molecular Modeling,Conducted using PyMol,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE1,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,HEK 293 Cells,No promotion of exon 7 inclusion,Ligand = 0.01 - 10 µM,RNA Abundance,RT-qPCR,Cells transfected with SMN2 minigene construct with ESE2 deletion and 5?ss mutation (G1C),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE3,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE3 TSL2,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM); Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,C,SMN2 antisense TSL2,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 intron 7 ISS-N2,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 intron 7 TSTL4/6,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 intron 7 c,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 intron 7 TSL7,Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,"SMN2 ""GA"" motif",Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,"SMN2 ""GU"" motif",Little to no binding,Ligand = 10 µM; RNA = 100 µM,"10 mM HEPES (pH = 7.4), 150 mM NaCl, 0.05% P20 (w/v), 35 mM EDTA, and 0.1% (v/v) DMSO",Off-Target Effect,Surface Plasmon Resonance,"Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",No detectable binding to NVS-SM1, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN-C6 protein targets,"SMN-C6 bound 430 proteins; Strong enrichment of proteins involved in RNA splicing, including all five major spliceosomal snRNPs",Ligand = 1 µmol in 1 mL bead solution,SMA type I patient fibroblast lysates,On-Target Effect,Protein Pull-Down,"SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM); Elution fractions from affinity chromatography were combined, separated by 1D gel electrophoresis, in gel digested and peptides extracted followed by LC-MS/MS analysis and quantification","Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,RNase-sensitive SMN-C6 protein targets,Protein binding to SMN-C6 was RNase-sensitive,Ligand = 1 µmol in 1 mL bead solution,SMA type I patient fibroblast lysates,On-Target Effect,Protein Pull-Down,SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM),No RNase, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 mRNA,Binding by SMN-C6,Ligand = 1 µmol in 1 mL bead solution,SMA type I patient fibroblast whole protein extracts,On-Target Effect,RNA Pull-Down,SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM),"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,STRN3 mRNA,Binding by SMN-C6,Ligand = 1 µmol in 1 mL bead solution,SMA type I patient fibroblast whole protein extracts,On-Target Effect,RNA Pull-Down,Sequence homology was identified between SMN2 exon 7 and an identical weak 5?ss and purine-rich region similar to the SMN2 ESE2 motif in the STRN3 exon 8; SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM),"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,ESE2-dependent SMN-C6 protein targets,"SMN-C6 induced binding of 10 proteins to SMN2 ESE2 RNA; These include seven RNA-binding proteins, two of which (U1-A and U1-70K) are protein components of the U1 snRNP, and one of which is RBMX/hnRNP G, a known positive regulator of exon 7 inclusion",Ligand = 0.5 - 10 µM; RNA = 100 pmol,SMA type I patient fibroblast nuclear extracts,On-Target Effect,RNA Pull-Down,SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM); RNA was 5' biotinylated and immobilized; Samples analyzed by LC-MS,"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE2:hnRNP G RRM peptide,Partial competition for binding,Ligand = 3.13 - 50 µM; RNA = 100 µM; Peptide = 1.5 ?M,20 mM NaH2PO4 (pH = 5.5) and 150 mM NaCl,Protein Displacement,Surface Plasmon Resonance,"Splicing proteins SRSF9 and hnRNP G interact with Tra2-?1; hnRNP G and Tra2-?1 in combination are thought to strongly enhance exon 7 inclusion; SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM); Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7; RNA was 5' biotinylated and immobilized",Titration experiments (RNA = 0.094 - 1.5 ?M) confirmed RNA:protein interaction; Control with no drug; SMN-C7 did not compete for binding; NVS-SM1 did not compete for binding; SPR signals normalized according to immobilized levels of ESE2, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE2:hnRNP G RRM peptide,Chemical shift perturbations toward free-form protein,5:1:1 Ligand:RNA:Protein Ratio,"20 mM NaHPO4 (pH = 5.5), 50 mM L-Glu, 50 mM L-Arg, and 0.05% ?-mercaptoethanol",Protein Displacement,Nuclear Magnetic Resonance,Proton; Splicing proteins SRSF9 and hnRNP G interact with Tra2-?1; hnRNP G and Tra2-?1 in combination are thought to strongly enhance exon 7 inclusion; SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM),Control with free protein; Control with no drug; SMN-C7 did not induce chemical shift perturbations, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 exon 7 ESE2:Tra2-?1 RRM,No chemical shift perturbations,5:1:1 Ligand:RNA:Protein Ratio,"20 mM NaHPO4 (pH = 5.5), 50 mM L-Glu, 50 mM L-Arg, and 0.05% ?-mercaptoethanol",Protein Displacement,Nuclear Magnetic Resonance,Proton; Splicing proteins SRSF9 and hnRNP G interact with Tra2-?1; hnRNP G and Tra2-?1 in combination are thought to strongly enhance exon 7 inclusion,Control with no drug, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 ESE2:hnRNP G RRM peptide,SMN-C6 competitively displaced the hnRNP G RRM peptide from binding to SMN2 ESE2 RNA,Ligand = 0.5 - 10 µM; RNA = 100 pmol,SMA type I patient fibroblast nuclear extracts,Protein Displacement,RNA Pull-Down,SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM); RNA was 5' biotinylated and immobilized; Samples analyzed by LC-MS,"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 ESE2:Tra2-?1 protein,SMN-C6 did not inhibit binding of Tra2-?1 protein to SMN2 ESE2 RNA,Ligand = 0.5 - 10 µM; RNA = 100 pmol,SMA type I patient fibroblast nuclear extracts,Protein Displacement,RNA Pull-Down,Splicing proteins SRSF9 and hnRNP G interact with Tra2-?1; hnRNP G and Tra2-?1 in combination are thought to strongly enhance exon 7 inclusion; SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM); RNA was 5' biotinylated and immobilized; Samples analyzed by LC-MS,"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 ESE2:SRSF9 protein,SMN-C6 did not inhibit binding of SRSF9 protein to SMN2 ESE2 RNA,Ligand = 0.5 - 10 µM; RNA = 100 pmol,SMA type I patient fibroblast nuclear extracts,Protein Displacement,RNA Pull-Down,SRSF9 is a splicing protein whose overexpression promotes exon 7 inclusion; SMN-C6 is an immobilizable derivative of SMN-C5 with comparable activity (43 nM vs. 15 nM); RNA was 5' biotinylated and immobilized; Samples analyzed by LC-MS,"Treatment with SMN-C7, an inactive derivative of SMN-C5 (EC50 > 1 µM)", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 pre-mRNA:U1 snRNA,"Ligand induced changes in the resonance of the [5? U1 snRNA:5?ss SMN2 pre-mRNA] RNA duplex: Preferential binding upstream in the last adenine of exon 7, a previously reported site known for lowering the splicing efficiency of exon 7",Ligand = 0.2 - 2 mM; RNA = 400 µM,"10 mM MES (pH = 5.5), 50 mM NaCl, and 10% D20",Structure Determination,Nuclear Magnetic Resonance,"Proton; The 5?ss in the SMN2 gene has been reported to be inherently weak at interacting with the U1 snRNA component of U1 snRNP23; SMN-C7 is an inactive derivative of SMN-C5 (EC50 > 1 µM);  Recently published data suggested that NVS-SM1, a different class of compound from SMN-C, increases the binding affinity of U1 snRNP for the 5?ss of exon 7",SMN-C7 and NVS-SM1 preferentially bound downstream of the consecutive pseudouridine:adenine pairs in the RNA duplex,C,HEK 293 Cells,Promotion of exon 7 inclusion,Ligand = 0.01 - 10 µM,RNA Abundance,RT-qPCR,Cells transfected with wild-type SMN2 minigene,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41467-017-01559-4,,SMN2 pre-mRNA:U1 snRNA:U1-C zinc finger domain,Very similar chemical shift changes to those observed in the absence of U1-C; Binding interfaces of SMN-C5 and U1-C are located on opposite sites of the 5?ss,Ligand = 0.2 - 2 mM; RNA = 400 µM,"10 mM MES (pH = 5.5), 50 mM NaCl, and 10% D20",Structure Determination,Nuclear Magnetic Resonance,"Proton; The U1 snRNA:5?ss duplex is stabilized by the zinc finger domain of U1-C, a subunit of U1 snRNP",-,,HEK 293 Cells,Less efficient exon 7 inclusion at higher concentration,Ligand = 0.01 - 10 µM,RNA Abundance,RT-qPCR,Cells transfected with SMN2 minigene construct with ESE2 deletion,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0095,R-BIND (SM) 0095,C[NH+]1CCN(CC1)C1=CN2C(=O)C=C(N=C2C=C1)C1=CN2C=C(C)N=C2C(F)=C1,SMN-C5,10.1038/s41589-019-0384-5,,U1 snRNA:E7 5' SS duplex,"SMN-C5 contacts the exon–intron junction and positions itself across the entire major groove.  SMN-C5 anchors to the U1 snRNA phosphate group of C9 via its piperazine group that is positively charged at neutral pH. At the other extremity of the molecule, the second aromatic cycle interacts exclusively with the 5? SS. The structure also revealed the crucial role of the central aromatic ring that forms a direct hydrogen bond with the amino group of the unpaired A?1 and inserts between C8 and C9 of U1 snRNA. ",Ligand = 400 µM; 1:2 RNA:ligand ratio,"5 mM MES d-4?(pH = 5.5), 50 mM NaCl complemented with 6% d8-glycerol ",Structure Determination,Nuclear Magnetic Resonance,2D homonuclear experiments (2D 1H–1H TOCSY and 2D 1H–1H NOESY),-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015, ,TERRA G-quadruplex (TERRA22),?Tm = 12 ºC,Ligand = 1 µM; RNA = 0.2 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Binding,FRET-Thermal Melting,5?-FAM and 3?-TAMRA dual labeled RNA,-, ,U2OS Cells,Significant increase in number of BG4 cytoplasmic foci,NR,On-Target Effect,Immunofluorescence,BG4 is a G-quadruplex antibody,"DMSO control; By UV and fluorescence spectrometry, ligand not fluorescent", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,"TERRA G-quadruplex, 25-fold excess telomeric DNA (HTG22)",Tm only slightly affected,Ligand = 2 µM; RNA = 0.4 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Binding,FRET-Thermal Melting,-,-, ,U2OS Cells,IC50 = 4.03 µM,-,Proliferation,MTT,Osteosarcoma cell line overexpressing TERRA,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,"TERRA G-quadruplex, 50-fold excess telomeric DNA (HTG22) ",Tm only slightly affected,Ligand = 2 µM; RNA = 0.4 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Binding,FRET-Thermal Melting,-,-,,A549 Cells,IC50 = 7.77 µM,-,Proliferation,MTT,Telomerase-active lung adenocarcinoma cell line,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,,TERRA G-quadruplex (TERRA22),Kd = 2.56 ± 0.48 ?M,-,"50 mM Tris-HCl (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA was biotinylated and conjugated to streptavidin-coated chIntraperitoneal; Immobilization may have affected the RNA conformation and led to weakened ligand binding,-, ,HeLa Cells,IC50 = 23.10 µM,-,Proliferation,MTT,Telomerase-active cervical cancer cell line,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,,TERRA G-quadruplex (TERRA22),Kd = 0.22 ± 0.01 ?M ,-,NR,Binding,Microscale Thermophoresis,"TERRA G-quadruplexes are repetitive parallel RNA G-quadruplexes, and therefore the ligand could act as a multifunctional inhibitor in cells",-, ,U2OS Cells,IC50 = 4.39 ± 0.58 µM,-,Proliferation,xCelligence Real-Time Cellular Analysis,Osteosarcoma cell line overexpressing TERRA,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,,TERRA G-quadruplex (TERRA22),Exhibited a strong positive peak at 265 nm and a negative peak at 240 nm (G-quadruplex),-,10 mM Tris-HCl (pH = 7.4) ,Binding,Circular Dichroism,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,,TERRA G-quadruplex (TERRA22),?Tm = 14 °C; Dose-dependent,-,60 mM K+,Binding,Circular Dichroism,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,IRES RNA G-quadruplex,Kd = 1.38 ± 0.06 ?M ,-,NR,Off-Target Effect,Microscale Thermophoresis,Target is another parallel promoter RNA G-quadruplex,-, ,U2OS Cells,Increase in cells in the early apoptosis phase (A4) from 2.68% to 23.22% and increase in cells in the late apoptosis phase (A2) from 0.46% to 10.18%; Ligand treatment also caused dissipation of normal cells (A3) in comparison to untreated controls (from 95.07% to 60.40%),-,Apoptosis,Annexin V/Propidium Iodide Stain,Osteosarcoma cell line overexpressing TERRA; Cells were stained with Annexin V and propidium iodide,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,TRF2 protein,No interaction,-,NR,Off-Target Effect,Microscale Thermophoresis,TRF2 is a known TERRA-binding protein,-, ,U2OS Cells,Dose-dependent increase in cells in G2/M phase from 23.7% to 28.7% and dose-dependent decrease in cells in G0/G1 phase from 48.3% to 36.7%,Ligand = 0.5 - 2 µM,Cell Cycle Progression,Cell Cycle Staining,Osteosarcoma cell line overexpressing TERRA,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Telomeric DNA G-quadruplex (HTG22),Kd = 234 ± 6 ?M,-,NR,Off-Target Effect,Microscale Thermophoresis,Target is an antiparallel G-quadruplex,-,,U2OS Cells,Colony formation inhibited with 2 µM compound,Ligand = 0.25 - 2 µM,Colony Formation,-,Osteosarcoma cell line overexpressing TERRA,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Telomeric DNA G-quadruplex (HTG22),?Tm = 1 ºC,Ligand = 1 µM; DNA = 0.2 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Off-Target Effect,FRET-Thermal Melting,5?-FAM and 3?-TAMRA dual labeled DNA,-, ,U2OS Cells,Dose-dependent dissociation of TRF2 from telomeric duplex DNA,Ligand = 1 - 4 µM,On-Target Effect,Chromatin Immunoprecipitation,"In vitro results suggested that the TERRA G-quadruplex, stabilized with CK1-14, could serve as an allosteric modulator of TRF2, producing a weakened binding interaction between TRF2 and telomeric duplex DNA",-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Telomeric DNA G-quadruplex (HTG22),Kd = 16.6 ± 2.2 ?M,-,"50 mM Tris-HCl (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Off-Target Effect,Surface Plasmon Resonance,DNA was biotinylated and conjugated to streptavidin-coated chip,-, ,SiHa Cells,IC50 = 9.07 µM,-,Proliferation,MTT,Telomerase-active cervical cancer cell line,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Hairpin DNA,Kd = 341 ± 4 mM,-,"50 mM Tris-HCl (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Off-Target Effect,Surface Plasmon Resonance,DNA was biotinylated and conjugated to streptavidin-coated chip,-, ,MCF7 Cells,IC50 = 16.30 µM,-,Proliferation,MTT,Epithelial cancer cell line,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Mutant TERRA,No interaction,-,"50 mM Tris-HCl (pH = 7.4), 150 mM KCl, and 0.005% Tween-20",Off-Target Effect,Surface Plasmon Resonance,RNA was biotinylated and conjugated to streptavidin-coated chip,-,C,Mouse Mesangial Cells,IC50 = 30.45 µM,-,Proliferation,MTT,Primary cultured mouse cell line,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Telomeric DNA–RNA hybrid G-quadruplex (HQ),?Tm = 2 ºC,Ligand = 1 µM; DNA/RNA = 0.2 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Off-Target Effect,FRET-Thermal Melting,5?-FAM and 3?-TAMRA dual labeled DNA/RNA,-, ,U2OS Cells,"Dose-dependent increase in phospho-ATM, phospho-p53, and ?H2AX",Ligand = 0.25 - 2 µM,Protein Abundance,Western Blot,Upregulation of p-ATM and p-p53 indicate occurrence of DNA damage and repair,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,BCL2 RNA G-quadruplex,Kd = 2.95 ± 0.16 ?M ,-,NR,Off-Target Effect,Microscale Thermophoresis,Target is another parallel promoter RNA G-quadruplex,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,NRAS RNA G-quadruplex,Kd = 0.44 ± 0.03 ?M ,-,NR,Off-Target Effect,Microscale Thermophoresis,Target is another parallel promoter RNA G-quadruplex,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Pu22 DNA G-quadruplex,Kd = 7.10 ± 0.14 ?M ,-,NR,Off-Target Effect,Microscale Thermophoresis,Target is a parallel promoter DNA G-quadruplex,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,Telomeric DNA G-quadruplex (HTG22),No significant change,-,10 mM Tris-HCl (pH = 7.4) ,Off-Target Effect,Circular Dichroism,-,-, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,C,TRF2:Telomeric duplex DNA (hTELO-dup),Kd = 58.65 ± 2.76 nM,Ligand = 1 µM; DNA = 0.1 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,Off-Target Effect,ELISA,It has been reported that TRF2 simultaneously binds to TERRA and telomeric duplex or G-quadruplex DNA,Kd (DMSO) = 38.92 ± 1.75 nM, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0096,R-BIND (SM) 0096,C(CN1C=C(CNC2=C3C=CC=CC3=[NH+]C3=C2OC2=C3C=CC=C2)N=N1)C[NH+]1CCCCC1,Quindoline CK1-14,10.1016/j.bbagen.2017.09.015,,TRF2:TERRA G-quadruplex (TERRA22):Telomeric duplex DNA (hTELO-dup),Kd = 533.6 ± 33.4 nM,Ligand = 1 µM; RNA = 0.1 µM; DNA = 0.1 µM,10 mM Tris-HCl (pH = 7.4) and 100 mM KCl,RNA:Protein Stabilization,ELISA,RNA was 5'-biotin labeled; It has been reported that TRF2 simultaneously binds to TERRA and telomeric duplex or G-quadruplex DNA,Kd (DMSO) = 112.5 ± 15.3 nM, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,U4 5?SL RNA,Binding in time-dependent manner; Kd = 91 ± 7 µM,Ligand = 50 µM,"20 mM Bis-Tris (pH = 6.5), 200 mM NaCl, 2 mM TCEP, 0.01% Triton X-100, 10% glycerol, and 5% DMSO",Binding,Surface Plasmon Resonance,RNA was conjugated to biotin and immobilized on neutravidin-coated gold chips; Kd determined by globally fitting the data to a 1:1 equilibrium affinity model,Control with no drug; Control with no RNA, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,U4 5?SL RNA,Shifted peaks,Ligand = 100 - 1000 µM; RNA = 100 µM,,Binding,Nuclear Magnetic Resonance,WaterLOGSY experiment,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,C,NHP2L1 protein,Markedly less binding compared to U4 5'SL RNA,Ligand = 50 µM,"20 mM Bis-Tris (pH = 6.5), 200 mM NaCl, 2 mM TCEP, 0.01% Triton X-100, 10% glycerol, and 5% DMSO",Off-Target Effect,Surface Plasmon Resonance,Protein was conjugated to biotin and immobilized on neutravidin-coated gold chips,Control with no drug; Control with no protein, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,C,NHP2L1 protein,Few changes upon addition of ligand,Ligand = 1 mM; Protein = 100 µM,"100 mM Na3PO4 (pH = 5.0), 100 mM NaCl, 10% D2O, and 2% DMSO-d6",Off-Target Effect,Nuclear Magnetic Resonance,TROSY NMR,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,C,NHP2L1 protein,No change in spectrum,Ligand = 100 - 2000 µM; Protein = 100 µM,"100 mM Na3PO4 (pH = 5.0), 100 mM NaCl, 10% D2O, and 2% DMSO-d6",Off-Target Effect,Nuclear Magnetic Resonance,3D NMR,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,Cy5-U4 5?SL RNA:His-NHP2L1 protein,Inhibition of 81.6%,Ligand = 15 µM; RNA = 2 nM; Protein = 2 nM,"20 mM Tris-HCl (pH = 7.6), 150 mM NaCl, 0.1% Triton X-100, 0.5 mg/mL tRNA, 0.01% BSA, and 2 mM DTT",Protein Displacement,TR-FRET,"Monitored RNA:protein interaction using a terbium anti-His-tag antibody, which recognizes His-NHP2L1:Cy5-U4 5?SL",Control with no His-tagged NHP2L1; DMSO control, ,HEK293 Cells,Significantly decreased splicing efficiency without significantly decreased ?-galactosidase expression,Ligand = 250 nM,RNA Splicing,Luciferase,"Cells transfected with plasmid in which ?-galactosidase is constitutively expressed, but luciferase is only expressed when splicing occurs",Control with no transfection; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,Cy5-U4 5?SL RNA:His-NHP2L1 protein,IC50 = 2.1 ± 0.3 µM,RNA = 2 nM; Protein = 2 nM,"20 mM Tris-HCl (pH = 7.6), 150 mM NaCl, 0.1% Triton X-100, 0.5 mg/mL tRNA, 0.01% BSA, and 2 mM DTT",Protein Displacement,TR-FRET,"Monitored RNA:protein interaction using a terbium anti-His-tag antibody, which recognizes His-NHP2L1:Cy5-U4 5?SL",Control with no His-tagged NHP2L1; DMSO control, ,HEK293 Cells,Overexpression of NHP2L1 protein significantly reduced ligand effect on splicing,Ligand = 250 nM,RNA Splicing,Luciferase,"Cells transfected with plasmid carrying NHP2L1-GFP; Cells transfected with plasmid in which ?-galactosidase is constitutively expressed, but luciferase is only expressed when splicing occurs",Control with GFP expression rather than NHP2L1-GFP expression; Control with no transfection of reporter plasmid; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,U4 5?SL RNA:His-NHP2L1 protein,Greater inhibition with increasing concentrations of ligand,Ligand = 0.2 - 200 µM,"20 mM Tris-HCl (pH = 7.6),150 mM NaCl, 0.1% Triton X-100, 2 mM DTT, and 0.5 g/L tRNA",Protein Displacement,Electrophoretic Mobility Shift Assay,RNA was biotin-labeled,Control with no protein; DMSO control, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,U4 5?SL RNA:NHP2L1 protein,Restoration of free NHP2L1 signals,Ligand = 2 mM; RNA = 100 µM; Protein = 100 µM,"100 mM Na3PO4 (pH = 5.0), 100 mM NaCl, 10% D2O, and 2% DMSO-d6",Protein Displacement,Nuclear Magnetic Resonance,TROSY NMR; Titrated RNA into a solution of 15N-labeled protein and observed shifted NMR signals for several residues,Control with no RNA or drug; Control with no drug, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0097,R-BIND (SM) 0097,CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC(O)=C(C[NH+](C)C)C1=C3)C2=O,Topotecan,10.1177/2472555217735035,,U4 5?SL RNA:NHP2L1 protein,Possible ternary complex formation: Appearance of additional ligand resonances,Ligand = 2 mM; RNA = 100 µM; Protein = 100 µM,"100 mM Na3PO4 (pH = 5.0), 100 mM NaCl, 10% D2O, and 2% DMSO-d6",Protein Displacement,Nuclear Magnetic Resonance,WaterLOGSY experiment,"Controls with ligand alone, ligand + RNA, and ligand + protein", ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0098,R-BIND (MV) 0001,[NH3+]CCCC[C@H]([NH3+])C(=O)NC1=CC2=C(C=C1)C1C3=CC=C(NC(=O)[C@@H]([NH3+])CCCC[NH3+])C=C3C2C2=C1C=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=C2,Triptycene 1,10.1002/anie.201601626,,"?32 mRNA, 5' end",Ligand-induced stabilization observed,Ligand = 2.5 µM; RNA = 0.25 µM,10 mM sodium phosphate (pH = 7.2),Binding,Optical Melting,-,Compared to absence of ligand,,E. coli DH5? ,Moderately inhibitory at high concentrations,Ligand = 25 µM,Antimicrobial Activity,Growth Inhibition,E. coli DH5? cells transformed with the ?32-EmGFP plasmid were grown overnight at 30°C in Luria broth (LB) supplemented with 50 µg/mL ampicillin. Overnight cultures were diluted  S4 1:100 in LB.  Samples were allowed to grow at 30 °C for 3 hours. Cultures were kept at 30 °C or heat shocked at 42 °C for 18 hours.,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0098,R-BIND (MV) 0001,[NH3+]CCCC[C@H]([NH3+])C(=O)NC1=CC2=C(C=C1)C1C3=CC=C(NC(=O)[C@@H]([NH3+])CCCC[NH3+])C=C3C2C2=C1C=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=C2,Triptycene 1,10.1002/anie.201601626,,RpoH ?32mRNA factor,Kd = 2.5 µM,Ligand = NR; RNA = 120 nM,50 mM sodium phosphate (pH = 7.2),Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with FAM (5') and IowaBlk (3'). Errors not reported.,Decreased fluorescence consistent with reforming the folded 3WJ state. ,C,E. coli DH5? ,mRNA levels were not significantly affected,"Ligand = 12.5, 25 µM",Transcriptional Inhibition,qRT-PCR,Samples were allowed to grow at 30 °C for 3 hours. Cultures were then kept at 30 °C for 18 hours. Total RNA from E. coli was extracted and purified. Reverse transcription was conducted,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0098,R-BIND (MV) 0001,[NH3+]CCCC[C@H]([NH3+])C(=O)NC1=CC2=C(C=C1)C1C3=CC=C(NC(=O)[C@@H]([NH3+])CCCC[NH3+])C=C3C2C2=C1C=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=C2,Triptycene 1,10.1002/anie.201601626,,RpoH ?32mRNA factor,?Tm = 11.3 °C,Ligand = 2 µM; RNA = 1 µM,10 mM sodium phosphate (pH = 7.2),Binding,Optical Melting,Errors not reported.,Compared to absence of ligand,,E. coli DH5? ,~20-50% decrease in fluorescence,"Ligand = 5, 25 µM",Translational Activity,Reporter,rpoHgene was inserted into a plasmid encoding GFP; Cells were subject to heat shock at 42 ºC and fluorescence measured.,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0098,R-BIND (MV) 0001,[NH3+]CCCC[C@H]([NH3+])C(=O)NC1=CC2=C(C=C1)C1C3=CC=C(NC(=O)[C@@H]([NH3+])CCCC[NH3+])C=C3C2C2=C1C=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=C2,Triptycene 1,10.1002/anie.201601626,,RpoH ?32mRNA factor,Ligand-induced stabilization observed,Ligand = 10 µM; RNA = 5 µM,10 mM sodium phosphate (pH = 7.2),Binding,Circular Dichroism,Spectra were measured every 1 nm between 350 nm and 200 nm,Compared to absence of ligand,C,E. coli DH5? ,Low relative GFP fluorescence prior to heat shock; slight increase in presence or absence of ligand upon heat shock,"Ligand = 5, 25 µM",Translational Activity,Reporter,Control GFP plasmid with no rpoH gene; Cells were subject to heat shock at 42 ºC and fluorescence measured.,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0098,R-BIND (MV) 0001,[NH3+]CCCC[C@H]([NH3+])C(=O)NC1=CC2=C(C=C1)C1C3=CC=C(NC(=O)[C@@H]([NH3+])CCCC[NH3+])C=C3C2C2=C1C=CC(NC(=O)[C@@H]([NH3+])CCCC[NH3+])=C2,Triptycene 1,10.1002/anie.201601626,,"?32 mRNA, 5' end",Thermal stabilization,Ligand = 5 µM; RNA = 0.5 µM,10 mM sodium phosphate (pH = 7.2),Binding,Circular Dichroism,Spectra were measured every 1 nm between 350 nm and 200 nm,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0099,R-BIND (MV) 0005,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 6,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,IC50 = 73.4 ± 6.0 µM; Ki = 8.7 ± 1.9 µM,Ligand = 0.05 - 200 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,"MBNL1-r(CCUG)8 complexes were pre-incubated prior to ligand additions. To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers.",Compared to water-treated and untreated RNA. Values were normalized to the control.,,HeLa Cells (DM2),No cell death or changes in cell morphology,Ligand = 100 µM,Cytotoxicity,Sulforhodamine B,Incubated for 48 hr,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0099,R-BIND (MV) 0005,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 6,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,Qualitative displacement observed,Ligand = 100 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,"MBNL1-r(CCUG)8 complexes were pre-incubated prior to ligand additions. To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers.",Compared to water-treated and untreated RNA. Values were normalized to the control.,,HeLa Cells (DM2),15-30% cell death observed,Ligand = 0.005 - 100 µM,Cytotoxicity,Sulforhodamine B,"In the 96-well plate, the HeLa cells were incubated at 37 °C for 72 hours with the treatment of the ligand.",Compared to absence of ligand and to healthy cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0099,R-BIND (MV) 0005,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 6,10.1002/cmdc.201402095,,,,,,,,,,,HeLa Cells (DM2),50-70% foci dispersion,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"HeLa cells were co-transfected with GFP-MBNL1 and (CCTG)1200 plasmids to generate a DM2 cell model. The location of MBNL1 and the r(CCUG)1200 transcripts were readily tracked by confocal microscopy, monitoring the fluorescent signal of GFP and a Cy3-(CAGG)8 FISH probe, respectively.",Confirmed colocalization of RNA and protein prior to ligand addition; utilized inactive ligand as negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0100,R-BIND (MV) 0006,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 8,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,IC50 = 12.9 ± 1.0 µM; Ki = 1.5 ± 0.3 µM,Ligand = 0.05 - 200 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated with different ligand concentrations,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),No cell death or changes in cell morphology,Ligand = 100 µM,Cytotoxicity,Sulforhodamine B,Incubated for 48 hr,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0100,R-BIND (MV) 0006,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 8,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,Qualitative displacement observed,Ligand = 100 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated prior to ligand additions,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),15-30% cell death observed,Ligand = 0.005 - 100 µM,Cytotoxicity,Sulforhodamine B,"In the 96-well plate, the HeLa cells were incubated at 37 °C for 72 hours with the treatment of the ligand.",Compared to absence of ligand and to healthy cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0100,R-BIND (MV) 0006,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 8,10.1002/cmdc.201402095,,,,,,,,,,,HeLa Cells (DM2),50-70% foci dispersion,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"HeLa cells were co-transfected with GFP-MBNL1 and (CCTG)1200 plasmids to generate a DM2 cell model. The location of MBNL1 and the r(CCUG)1200 transcripts were readily tracked by confocal microscopy, monitoring the fluorescent signal of GFP and a Cy3-(CAGG)8 FISH probe, respectively.",Confirmed colocalization of RNA and protein prior to ligand addition; utilized inactive ligand as negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0101,R-BIND (MV) 0007,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC(=CC=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 10,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,IC50 = 14.7 ± 1.2 µM; Ki = 1.7 ± 0.4 µM,Ligand = 0.05 - 200 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated with different ligand concentrations,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),No cell death or changes in cell morphology,Ligand = 100 µM,Cytotoxicity,Confocal Microscopy,Incubated for 48 hr,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0101,R-BIND (MV) 0007,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC(=CC=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 10,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,Qualitative displacement observed,Ligand = 100 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated prior to ligand additions,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),No cell death measured,Ligand = 0.005 - 100 µM,Cytotoxicity,Sulforhodamine B,"In the 96-well plate, the HeLa cells were incubated at 37 °C for 72 hours with the treatment of the ligand.",Compared to absence of ligand and to healthy cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0101,R-BIND (MV) 0007,NC1=NC(N)=C(CCCNC(=[NH2+])C2=CC(=CC=C2)C(=[NH2+])NCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 10,10.1002/cmdc.201402095,,,,,,,,,,,HeLa Cells (DM2),50-70% foci dispersion,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"HeLa cells were co-transfected with GFP-MBNL1 and (CCTG)1200 plasmids to generate a DM2 cell model. The location of MBNL1 and the r(CCUG)1200 transcripts were readily tracked by confocal microscopy, monitoring the fluorescent signal of GFP and a Cy3-(CAGG)8 FISH probe, respectively.",Confirmed colocalization of RNA and protein prior to ligand addition; utilized inactive ligand as negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0102,R-BIND (MV) 0008,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=CC(=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 11,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,IC50 = 24.9 ± 2.0 µM; Ki = 2.9 ± 0.6 µM,Ligand = 0.05 - 200 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated with different ligand concentrations,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),No cell death or changes in cell morphology,Ligand = 100 µM,Cytotoxicity,Confocal Microscopy,Incubated for 48 hr,Compared to absence of ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0102,R-BIND (MV) 0008,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=CC(=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 11,10.1002/cmdc.201402095,,r(CCUG)8-MBNL1 complex,Qualitative displacement observed,Ligand = 100 µM,NR,Protein Displacement,Electrophoretic Mobility Shift Assay,MBNL1-r(CCUG)8 complexes were pre-incubated prior to ligand additions,"To avoid slipped repeats and to restrict the structure, complementary GC rich regions were added at the 3'/5' end of the RNA oligomers. Compared to water-treated and untreated RNA. Values were normalized to the control.",,HeLa Cells (DM2),No cell death measured,Ligand = 0.005 - 100 µM,Cytotoxicity,Sulforhodamine B,"In the 96-well plate, the HeLa cells were incubated at 37 °C for 72 hours with the treatment of the ligand.",Compared to absence of ligand and to healthy cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0102,R-BIND (MV) 0008,NC1=NC(N)=C(CCCCNC(=[NH2+])C2=CC=CC(=C2)C(=[NH2+])NCCCCC2=C(N)N=C(N)[NH+]=C2N)C(N)=N1,Bisamidinium 11,10.1002/cmdc.201402095,,,,,,,,,,,HeLa Cells (DM2),50-70% foci dispersion,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"HeLa cells were co-transfected with GFP-MBNL1 and (CCTG)1200 plasmids to generate a DM2 cell model. The location of MBNL1 and the r(CCUG)1200 transcripts were readily tracked by confocal microscopy, monitoring the fluorescent signal of GFP and a Cy3-(CAGG)8 FISH probe, respectively.",Confirmed colocalization of RNA and protein prior to ligand addition; utilized inactive ligand as negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0103,R-BIND (MV) 0022,CC(=O)NCCC[NH2+]CCC[NH2+]CCCNC(=O)C1=C2[NH+]=C3C=CC=CC3=C(NCCCCNC3=NC(N)=NC(N)=[NH+]3)C2=CC=C1,Acridine 1,10.1021/cb400046u,,r(CUG)12,?Tm = 2.5 ºC (1 equiv); 5.5 ºC (3 equiv),"Ligand = 3.3, 9.9 µM; RNA = 3.3 µM",PBS buffer (pH = 7.4) and 0.05% Tween-20,Binding,Optical Melting,-,-,,HeLa Cells (DM1),~86% disappearance of (CUG)960 foci ,Ligand = 75 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"Cotransfected with two plasmids: (1) truncated DMPK-CUG960, (2) GFP-MBNL1. Used FISH and TO-PRO-3 to monitor localization by confocal microscopy.",Cells also transfected with DMPK-CUG0 and GFP-MBNL1 and repeated experiments with 50 uM spermine - both had no effect on foci,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0103,R-BIND (MV) 0022,CC(=O)NCCC[NH2+]CCC[NH2+]CCCNC(=O)C1=C2[NH+]=C3C=CC=CC3=C(NCCCCNC3=NC(N)=NC(N)=[NH+]3)C2=CC=C1,Acridine 1,10.1021/cb400046u,,r(CUG)12-MBNL1 complex; excess tRNA,IC50 = 15 ± 2 µM,NR,PBS buffer (pH = 7.4) and 0.05% Tween-20,Protein Displacement,Surface Plasmon Resonance,-,-,,HeLa Cells (DM1),Less than 10% cell death at highest concentration tested,Ligand =  1 - 100 µM,Cytotoxicity,Sulforhodamine B,Tested after 24 h,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0103,R-BIND (MV) 0022,CC(=O)NCCC[NH2+]CCC[NH2+]CCCNC(=O)C1=C2[NH+]=C3C=CC=CC3=C(NCCCCNC3=NC(N)=NC(N)=[NH+]3)C2=CC=C1,Acridine 1,10.1021/cb400046u,,r(CUG)12-MBNL1 complex,IC50 = 15 ± 2 µM,NR,PBS buffer (pH = 7.4) and 0.05% Tween-20,Protein Displacement,Surface Plasmon Resonance,-,-,,HeLa Cells (DM1),40% rescue for the IR splicing defect,"Ligand = 50, 75, 150 µM",RNA Splicing,RT-PCR,-,Cells also transfected with DMPK-CUG0 and GFP-MBNL1 and repeated experiments with 50 uM spermine - both had no effect ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0103,R-BIND (MV) 0022,CC(=O)NCCC[NH2+]CCC[NH2+]CCCNC(=O)C1=C2[NH+]=C3C=CC=CC3=C(NCCCCNC3=NC(N)=NC(N)=[NH+]3)C2=CC=C1,Acridine 1,10.1021/cb400046u,,,,,,,,,,,HeLa Cells (DM1),Most foci dispersed over a 2-4 h period.,Ligand = 75 µM,Nuclear Foci Dispersion,Confocal Microscopy,"Utilized inherent fluorescence of the acridine unit, and observed GFP-MBNL1 foci",Negative control done without compound incubation but imaging at same timepoints,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0104,R-BIND (MV) 0023,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CC[NH3+])=N1,Acridine 5,10.1021/jacs.5b09266,,d(CTG/CAG)74,Dose-dependent inhibition of transcription up to 100%,"Ligand = 1, 10, 50, 100 µM; DNA = 15 ng","80 mM Tris (pH = 8.3), 10 mM MgCl2, 2 mM spermine, 0.1% Triton-X, and 10 mM NaCl",Activity,Denaturing Gel,"T7 RNA polymerase at 37 ºC, for 2 h",Compared to untreated reaction; Conducted experiments with two separate control plasmids each lacking repeats,,HeLa Cells (DM1),Significant decrease in the level of toxic r(CUG) RNA,Ligand = 50 µM,Transcriptional Inhibition,RT-PCR,"Transfected with GFP-DT0 or GFP-DT960 containing 0 or 960 CTG repeats, respectively, in exon 15 of a truncated DMPKgene. Cells were treated with ligands for 3 d, and total mRNA was isolated and subject to RT-PCR. mRNA levels of exon 15 upstream of CUPexp were measured relative to PABP mRNA.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0104,R-BIND (MV) 0023,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CC[NH3+])=N1,Acridine 5,10.1021/jacs.5b09266,,r(CUG)16,Decreased % r(CUG)16 to 84 %,Ligand = 100 µM; RNA = 100 nM,"Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Activity,PAGE,RNA was stained with EtBr,HIV FS RNA was used as an internal standard. Repeated with (CUG)16 competitor and inhibitor was reduced.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0104,R-BIND (MV) 0023,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CC[NH3+])=N1,Acridine 5,10.1021/jacs.5b09266,,r(CUG)4,Kd = 86 nM,Ligand = NR; RNA = 0 - 6 µM,NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,HeLa Cells (DM1),Inhibited nuclear foci formation; lead to dispersion of MBNL1 protein throughout nucleus,Ligand = 50 µM,Nuclear Foci Dispersion,Confocal Microscopy,"Transfected with GFP-DT0 or GFP-DT960 containing 0 or 960 CTG repeats, respectively, in exon 15 of a truncated DMPKgene. ",GFP-DT0 control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0104,,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CC[NH3+])=N1,,,C,r(CCUG)8,No effect on cleavage,Ligand = 100 µM; RNA = 100 nM,"Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Off-Target Effect,PAGE,RNA was stained with EtBr,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0104,,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CC[NH3+])=N1,,,C,HIV-1 FSS RNA,No effect on cleavage,Ligand = 100 µM; RNA = 100 nM,"Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Off-Target Effect,PAGE,RNA was stained with EtBr,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0105,R-BIND (MV) 0024,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CCNC(=O)CC2=CNC=N2)=N1,Acridine 6,10.1021/jacs.5b09266,,(CTG*CAG)74,Dose-dependent inhibition of transcription up to 80 %,"Ligand = 1, 10, 50, 100 µM; DNA = 15 ng","80 mM Tris (pH = 8.3), 10 mM MgCl2, 2 mM spermine, 0.1% Triton-X, and 10 mM NaCl",Activity,Denaturing Gel,"T7 RNA polymerase at 37 ºC, for 2 h",Compared to untreated reaction; Conducted experiments with two separate control plasmids each lacking repeats,,HeLa Cells (DM1),Inhibited nuclear foci formation; lead to dispersion of MBNL1 protein throughout nucleus,Ligand = 50 µM,Nuclear Foci Dispersion,Confocal Microscopy,"Transfected with GFP-DT0 or GFP-DT960 containing 0 or 960 CTG repeats, respectively, in exon 15 of a truncated DMPKgene. ",GFP-DT0 control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0105,R-BIND (MV) 0024,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CCNC(=O)CC2=CNC=N2)=N1,Acridine 6,10.1021/jacs.5b09266,,r(CUG)16,Decreased % r(CUG)16 to 71 %,Ligand = 100 µM; RNA = 100 nM,"Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Activity,PAGE,RNA was stained with EtBr,HIV FS RNA was used as an internal standard. Repeated with (CUG)16 competitor and inhibitor was reduced.,,HeLa Cells (DM1),60-70 % decrease in the level of toxic r(CUG) RNA,Ligand = 50 µM,Transcriptional Inhibition,RT-PCR,"Transfected with GFP-DT0 or GFP-DT960 containing 0 or 960 CTG repeats, respectively, in exon 15 of a truncated DMPKgene. Cells were treated with ligands for 3 d, and total mRNA was isolated and subject to RT-PCR. mRNA levels of exon 15 upstream of CUPexp were measured relative to PABP mRNA.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0105,R-BIND (MV) 0024,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CCNC(=O)CC2=CNC=N2)=N1,Acridine 6,10.1021/jacs.5b09266,C,cTNT32,No effect on cleavage,"Ligand = 0.1, 10, 25, 50, 100 µM","Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Off-Target Effect,PAGE,RNA was stained with EtBr,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0105,R-BIND (MV) 0024,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CCNC(=O)CC2=CNC=N2)=N1,Acridine 6,10.1021/jacs.5b09266,C,r(CCUG)8,Has effect on cleavage at higher concentrations,"Ligand = 25, 50, 100 µM; RNA = 100 nM","Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Off-Target Effect,PAGE,RNA was stained with EtBr,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0105,R-BIND (MV) 0024,NC1=NC(N)=[NH+]C(NCCCCNC2=C3C=CC=CC3=[NH+]C3=C(C=CC=C23)C(=O)NCCN(CC[NH3+])CCNC(=O)CC2=CNC=N2)=N1,Acridine 6,10.1021/jacs.5b09266,C,HIV-1 FSS RNA,No effect on cleavage,"Ligand = 25, 50, 100 µM; RNA = 100 nM","Tris (pH = 7.4), 150 mM NaCl, 2 mM MgCl2",Off-Target Effect,PAGE,RNA was stained with EtBr,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,,(CTG/CAG)74,No inhibition of transcription,"Ligand = 1, 10, 50 and 100 µM; DNA = 15 ng","80 mM Tris (pH = 8.3), 10 mM MgCl2, 2 mM spermine, 0.1% Triton-X, and 10 mM NaCl",Activity,Denaturing Gel Electrophoresis,"T7 RNA polymerase at 37 ºC, for 2 h",Compared to untreated reaction; Conducted experiments with two separate control plasmids each lacking repeats,,,,,,,,,,Drosophila [UAS-(CTG)480],14 - 83% improvement in larval crawling activity,"Oral; 200, 400, or 800 µM",Motor Behavior,Locomotor Activity,-,"Compared to untreated larvae and larvae without repeats (""healthy"")",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,,r(CUG)16,Decreased % r(CUG)16 to 97 %,Ligand = 100 µM; RNA = 100 nM,"Tris (pH = 7.4), 150 mM NaCl, and 2 mM MgCl2",Activity,PAGE,RNA was stained with EtBr,HIV FS RNA was used as an internal standard. Repeated with (CUG)16 competitor and inhibitor was reduced.,,,,,,,,,,Drosophila [UAS-(CTG)480],No effect on the SV40 mRNA levels,"Oral; 200, 400, or 800 µM",RNA Abundance,RT-PCR,The SV40 mRNA was expressed approximately equally in larvae bearing either i(CUG)60 or i(CUG)480,Compared to untreated flies; normalized to beta actin,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,,r(CUG)12,Kd = 8 ± 2 µM,Ligand = 500 µM; RNA = 10 µM,20 mM MOPS (pH = 7.0) and 300 mM NaCl,Binding,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,HeLa Cells (DM1),74 % exon 5 inclusion in cTNT mre-mRNA after 72 h at 100 µM,"Ligand = 25, 50, 75, 100 µM",RNA Splicing,RT-PCR,-,"As a positive control, HeLa cells transfected with a plasmid containing DMPK exons 11?15 but no CTG repeats (DT0) was used. Ligand 5 was used as a negative control.",C,Drosophila (EGFP-CGG90),No suppression of the rough eye phenotype,"Oral; 200, 400, or 800 µM",Rough Eye Phenotype,Scanning Electron Microscopy,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,,r(CUG)4,Kd = 86 nM,"Ligand = NR, RNA = 0 - 6 µM",NR,Binding,Fluorescence-Based Titration (Intrinsic),-,-,,,,,,,,,,Drosophila [UAS-(CTG)480],Glossy eye phenotype suppressed at 200 uM,"Oral; 200, 400, or 800 µM",Rough Eye Phenotype,Light Microscopy and SEM,"Tissue-specific expression of the interrupted 480 CTG repeats, i(CTG)480, in flies using the gmrGAL4 driver induces glossy and rough eye phenotypes with reduced eye size, which reflects severe morphological disturbance of the adult eye architecture.","SEM images taken to compare rough eye phenotype compared to untreated flies. Also treated flies with interrupted r(CUG)60, which did not exhibit a severe morphological phenotype. No effects were observed.",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,,[r(CUG)6]2,Indicated stable major groove binding with formation of two base triplets; Greater flexibility allowed the two triaminotriazine units to interact with the U-U pairs forming a total of 5-6 hydrogen bonds,-,-,In Silico,Molecular Modeling and Molecular Dynamics,Ligand 3 in the paper,-,,HeLa Cells (DM1),Significant reduction in the amount of foci at 48 h,Ligand = 100 µM,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization,"MBNL1 with IF, FISH with Cy3-labeled (CAG)10 probe. Cells infected with plasmid containing DMPK exons 11-15 with 960 CTG repeats in exon 15. Done at 24, 48 and 72 h",Compared to untreated cells and other ligands,,Drosophila [UAS-(CTG)480],Glossy eye phenotype suppressed at 200 uM; Significant improvement in glossy eye phenotype at 400 uM,"Oral; 200, 400, or 800 µM",Rough Eye Phenotype,Scanning Electron Microscopy,"Tissue-specific expression of the interrupted 480 CTG repeats, i(CTG)480, in flies using the gmrGAL4 driver induces glossy and rough eye phenotypes with reduced eye size, which reflects severe morphological disturbance of the adult eye architecture.","SEM images taken to compare rough eye phenotype compared to untreated flies. Also treated flies with interrupted r(CUG)60, which did not exhibit a severe morphological phenotype. No effects were observed.",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,C,HIV-1 FSS RNA,Kd > 200 µM,Ligand = 500 µM; RNA = 20 µM,22 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,HeLa Cells (DM1),No observable cell death,Ligand = 1 - 100 µM,Cytotoxicity,Sulforhodamine B,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,C,cTNT,Kd > 200 µM,Ligand = 500 µM; RNA = 10 µM,23 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,Human Fibroblasts,No observable cell death,Ligand = 1 - 100 µM,Cytotoxicity,Sulforhodamine B,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,C,GST-MBNL1,Kd > 200 µM,Ligand = 500 µM; Protein = 10 µM,24 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,3T3 Mouse Fibroblasts,No observable cell death,Ligand = 1 - 100 µM,Cytotoxicity,Sulforhodamine B,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,C,tRNA,Kd > 200 µM,Ligand = 500 µM; RNA = 10 µM,21 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,HeLa Cells (DM1),43 % exon 11 inclusion in IR pre-mRNA after 72 h; statistically significant correction of missplicing observed at 50 and 75 µM,"Ligand = 20, 50, 75, 100 µM",RNA Splicing,RT-PCR,-,"As a positive control, HeLa cells transfected with a plasmid containing DMPK exons 11?15 but no CTG repeats (DT0) was used. Ligand 5 was used as a negative control.",,C57/BL6 mice,MTD = 50 - 100 mg/kg,"Intraperitoneal; 5, 10, 20, 50, or 100 mg/kg ",Toxicity,Mortality,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,C,r(CCUG)8,Kd > 200 µM,Ligand = 500 µM; RNA = 20 µM,25 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,HeLa Cells (DM1),No significant decrease in the level of toxic r(CUG) RNA,Ligand = 100 µM,Transcriptional Inhibition,RT-PCR,"Transfected with GFP-DT0 or GFP-DT960 containing 0 or 960 CTG repeats, respectively, in exon 15 of a truncated DMPKgene. Cells were treated with ligands for 3 d, and total mRNA was isolated and subject to RT-PCR. mRNA levels of exon 15 upstream of CUPexp were measured relative to PABP mRNA.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,C,d(CAG)12,No binding,Ligand = 500 µM; RNA = 10 µM,20 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,C,d(CTG/CAG)12,No binding,Ligand = 500 µM; RNA = 10 µM,20 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/jacs.5b09266,C,d(CTG)12,No binding,Ligand = 500 µM; RNA = 10 µM,20 mM MOPS (pH = 7.0) and 300 mM NaCl,Off-Target Effect,Isothermal Titration Calorimetry,Each injection was 24 s and the delay between injections was 400 s,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0106,R-BIND (MV) 0026,NC1=NC(N)=[NH+]C(NCCCCNC(=[NH2+])C2=CC=C(C=C2)C(=[NH2+])NCCCCNC2=[NH+]C(N)=NC(N)=N2)=N1,Bisamidinium 2,10.1021/ja5012146,,r(CUG)12-MBNL1,IC50 = 115 ± 14 µM; Ki = 8 ± 2 µM (0.05% Triton X-100); Ki = 14 ± 2 µM (0.1 % Triton X-100),Ligand = < 2.4 mM; RNA = 0.22 nM; Protein = 0.1 µM,"20 mM Tris-HCl (pH = 8.0), 175 mM NaCl, 5 mM MgCl2, 1.25 mM 2-mercapto-ethanol (BME), 12.5% glycerol, 2mg/mL bovine serum albumin (BSA), 0.1 mg/mL heparin, and 0.05% or 0.1% Triton X",Protein Displacement,Electrophoretic Mobility Shift Assay,-,"Compared to pentamidine, H1 and ligand 1",,HeLa Cells (DM1),Increasing ligand concertation led to a steady reduction in the area of ribonuclear foci occupied by the cells,"Ligand = 5, 10 20, 35, 50, 75, 100 µM",Nuclear Foci Dispersion,Confocal Microscopy,Quantification conducted by measuring ratio of ribonuclear foci area (µm^2) to the total number of cells analyzed,Compared to untreated cells and ligand 5 as negative control,C,Drosophila (Red-CAG100),No suppression of the rough eye phenotype,"Oral; 200, 400, or 800 µM",Rough Eye Phenotype,Scanning Electron Microscopy,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,HIV-1 TAR RNA,Docking indicated linker space was optimal for binding,-,-,In Silico,Docking,-,-,,CEM-SS Cells (HIV-1),IC50 = 4.6 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,,,,,,,,,,MT4 Cells (HIV-1),IC50  > 100 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,,,,,,,,,,PBMC Cells (HIV-1),IC50 = 8.7 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,,,,,,,,,,CEM-SS Cells (HIV-1),CC50  > 100 µM,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,,,,,,,,,,MT4 Cells (HIV-1),CC50  > 100,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0107,R-BIND (MV) 0034,C[N+]1=C(C2=CC=CC(=C2)C(=O)NCCCCCC(=O)NCCC(=O)NC(CCCNC(N)=[NH2+])C([O-])=O)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 17,10.1021/jm980728e,,,,,,,,,,,PBMC Cells (HIV-1),IC50 = CC50 > 100 µM,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,HIV-1 TAR RNA,?Tm = 11.5 °C,Ligand = NR; RNA = 20 µM,"6 mM Na2HPO4 (pH = 7.1), 2 mM Na2H2PO4, and 1 mM EDTA",Binding,Optical Melting,-,Compared to Ethidium,,CEM-SS Cells (HIV-1),CC50 > 100 µM,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,HIV-1 TAR RNA,Docking indicated linker space was optimal for binding,-,-,In Silico,Docking,-,-,,CEM-SS Cells (HIV-1),IC50 = 2.4 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,HIV-1 TAR RNA,Binding site results were in agreement with modeling studies,"Ligand = 1, 2 µM",-,Structure Determination,RNase Footprinting,"Samples of labeled RNA fragments were incubated with the drug, then digestion was initiated using RNase A, RNase T1 and RNase V1. RNA was subject to electrophoresis and analyzed by band assignment using sequencing standards.",Compared to untreated controls,,MT4 Cells (HIV-1),IC50 = 11 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,,,,,,,,,,PBMC Cells (HIV-1),IC50 =  2.5 µM,NR,Antiviral Activity,Reverse Transcriptase Activity,The rate of virus production was measured by quantification of the reverse transcriptase activity associated with the virus particles released in the culture supernatant,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,,,,,,,,,,MT4 Cells (HIV-1),CC50  > 100 µM,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0108,R-BIND (MV) 0035,COC(=O)C(CCCNC(N)=[NH2+])NC(=O)CCNC(=O)CCCCCNC(=O)C1=CC(=CC=C1)C1=[N+](C)C2=CC(N)=CC=C2C2=CC=C(N)C=C12,Ethidium-Arg Conjugate 20,10.1021/jm980728e,,,,,,,,,,,PBMC Cells (HIV-1),IC50 = CC50 > 100 µM,NR,Cytotoxicity,MTT,Measured after a 5d incubation,Used Ethidium and arginine as controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0109,R-BIND (MV) 0036,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCC[NH3+])NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 13b,10.1002/chem.201303664,,HIV-1 TAR RNA,Kd = 0.24 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Intrinsic),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,MAGIC-5B Cells,IC50 = 1.78 µM,Ligand = 20 µM,Antiviral Activity,?-Galactosidase,Cells were pre-incubated with the compounds then challenged with the HIV-1 NL4.3 strain at MOI = 1. Cells were washed/lysed and cell culture infection was monitored by ?-galactosidase activity using a Galacto-Star chemiluminescent assay kit. Luminescence was recorded and IC50s were estimated from plots of luciferase per ug of protein vs. drug concentration,Azidothymidine (AZT) used as a reference HIV-1 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0109,R-BIND (MV) 0036,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCC[NH3+])NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 13b,10.1002/chem.201303664,C,HIV-1 TAR RNA; 100-fold excess tRNA,Kd = 0.69 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Intrinsic),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,MAGIC-5B Cells,No effect on cell viability,"Ligand = 0.1, 1, 10, 100 µM",Cytotoxicity,CellTiter 96 Aqueous One Solution,48 h incubation,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0109,R-BIND (MV) 0036,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCC[NH3+])NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 13b,10.1002/chem.201303664,C,HIV-1 TAR RNA; 100-fold excess dsDNA,Kd = 0.72 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0109,R-BIND (MV) 0036,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCC[NH3+])NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 13b,10.1002/chem.201303664,,HIV-1 TAR RNA,?Gº = -37.1 kJ mol-1; ?H = -46.7 ± 2.4 kJ mol-1; T?S = -9.84 ± 2.9 kJ mol-1; T?Sº/?Hº = 0.21,NR,NR,Binding,Optical Melting,No Tm reported,Neomycin used as positive control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0109,R-BIND (MV) 0036,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCC[NH3+])NC(=O)[C@@H]([NH3+])CCCC[NH3+])=CC=C1,S-Amino Acid Conjugate 13b,10.1002/chem.201303664,,HIV-1 TAR RNA,Ligand affects the signal at 210?nm,NR,NR,Binding,Circular Dichroism,-,Neomycin used as positive control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0110,R-BIND (MV) 0037,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])=CC=C1,S-Amino Acid Conjugate 14b,10.1002/chem.201303664,,HIV-1 TAR RNA,Kd = 0.11 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,MAGIC-5B Cells,IC50 = 1.79 µM,Ligand = 20 µM,Antiviral Activity,?-Galactosidase,Cells were pre-incubated with the compounds then challenged with the HIV-1 NL4.3 strain at MOI = 1. Cells were washed/lysed and cell culture infection was monitored by ?-galactosidase activity using a Galacto-Star chemiluminescent assay kit. Luminescence was recorded and IC50s were estimated from plots of luciferase per ug of protein vs. drug concentration,Azidothymidine (AZT) used as a reference HIV-1 inhibitor,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0110,R-BIND (MV) 0037,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])=CC=C1,S-Amino Acid Conjugate 14b,10.1002/chem.201303664,C,HIV-1 TAR RNA; 100-fold excess tRNA,Kd = 0.35 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,MAGIC-5B Cells,No effect on cell viability,"Ligand = 0.1, 1, 10, 100 µM",Cytotoxicity,CellTiter 96 Aqueous One Solution,48 h incubation,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0110,R-BIND (MV) 0037,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])=CC=C1,S-Amino Acid Conjugate 14b,10.1002/chem.201303664,C,HIV-1 TAR RNA; 100-fold excess dsDNA,Kd = 0.40 µM,Ligand = 61 nM - 1 mM; RNA = 10 nM,"HEPES (pH?= 7.2), 20?mM NaCl, 140?mM KCl, and 3?mM MgCl2",Binding,Fluorescence-Based Titration (Labeled RNA),TAR RNA (5'-Alexa488 fluorescent tag) was diluted in buffer and refolded. Ligand was added (serial dilution). Fluorescence changes were measured.,Neomycin used as positive control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0110,R-BIND (MV) 0037,CC(=O)NC1=NC(=CS1)C1=CC(NC(=O)C(CNC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CCCNC(N)=[NH2+])=CC=C1,S-Amino Acid Conjugate 14b,10.1002/chem.201303664,,HIV-1 TAR RNA,?Gº = -39.1 kJ mol-1; ?H = -38.7 ± 1.9 kJ mol-1; T?S = -0.317 ± 0.1 kJ mol-1; T?Sº/?Hº = 0.0082,NR,NR,Binding,Optical Melting,No Tm reported,Neomycin used as positive control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0111,R-BIND (MV) 0042,CC1CC2=C(NC1=O)N=C(NCC1=CC=C(CNC3=NC(N)=C4CC(C)C(=O)NC4=[NH+]3)C=C1)N=C2N,"Pyrido[2,3-d]pyrimidine 1-3",10.1371/journal.pone.0178931,,CUG x 12 repeat RNA,Kd = 6.73(1),Ligand = 0.1 mM; RNA = 0.25 µM; TO = 0.5 µM (Fig. 7),50 mM sodium cacodylate (pH = 7.4),Binding,Fluorescence Displacement,Displacement of thiazole orange,Control with no drug,,DM1 hTERT Myoblasts,Amount of MBNL1 increased in cytoplasm and nuclei,Ligand = 100 µM,Localization,Confocal Microscopy,MBNL1 sequestration in CUG-RNA ribonuclear foci are histopathological hallmarks in DM1; Immortalized fibroblasts expressed 1300 CTG repeats and conditionally expressed MyoD for transdifferentiation into myoblasts; Cells were plated in muscle differentiation medium to increase MBNL levels; r(CUG)exp RNA foci detected with Cy3-(CAG)7-Cy3-labelled probe; Analyzed a minimum of 1000 cell nuclei,DMSO control (1%); Normal myoblast DMSO control (1%), ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0111,R-BIND (MV) 0042,CC1CC2=C(NC1=O)N=C(NCC1=CC=C(CNC3=NC(N)=C4CC(C)C(=O)NC4=[NH+]3)C=C1)N=C2N,"Pyrido[2,3-d]pyrimidine 1-3",10.1371/journal.pone.0178931,,CUG x 23 repeat RNA,"At 125 µM, similar polarization values to pentamidine",RNA = 6 nM,"50 mM Tris-HCl (pH = 7.0), 250 mM NaCl, 50?M ZnCl2, 10% glycerol, and 1 mM DTT",Binding,Fluorescence Polarization,RNA was 6-FAM labeled,Fluorescence polarization normalized to pentamidine (100 µM), ,DM1 hTERT Skin Fibroblasts,No effect on number of foci,Ligand = 0.1 - 100 µM,On-Target Effect,Fluorescence In Situ Hybridization,MBNL1 sequestration in CUG-RNA ribonuclear foci are histopathological hallmarks in DM1; Immortalized fibroblasts expressed 1300 CTG repeats and conditionally expressed MyoD for transdifferentiation into myoblasts; Cells were plated in muscle differentiation medium to increase MBNL levels; r(CUG)exp RNA foci detected with Cy3-(CAG)7-Cy3-labelled probe; Analyzed a minimum of 1000 cell nuclei,"Chromomycin A3 (4 µM), a drug that reduces foci number in DM1 fibroblasts, as positive control; Normalized to DMSO control (1%)", ,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0111,R-BIND (MV) 0042,CC1CC2=C(NC1=O)N=C(NCC1=CC=C(CNC3=NC(N)=C4CC(C)C(=O)NC4=[NH+]3)C=C1)N=C2N,"Pyrido[2,3-d]pyrimidine 1-3",10.1371/journal.pone.0178931,,CUG x 3 repeat RNA,Improved score over Hoechst 33258 and pentamidine references; Binding through RNA minor groove,N/A,-,In Silico,Docking,"Constructed a dynamic ensemble of the 20 lowest-frequency RNA modes, with two deformations per mode, giving 40 total conformations",-,C,hTERT Skin Fibroblasts,IC10 = 116 µM,-,Cytotoxicity,NR,-,-,,Drosophila,Robust rescue of strongly impaired climbing speed of DM1 flies (~5 mm/s) compared to wild-type control (17 ± 0.7 mm/s): Treated fly speed more than doubled,100 µM,Motor Behavior,Climbing Assay,"Flies expressed non-coding 480 CTG repeat RNA under the myosin heavy chain (Mhc)-Gal4 driver expression pattern, which shows general expression in Drosophila musculature; Flies reproduce DM1-like phenotypes, chiefly muscle atrophy and locomotion defects; Treatment for 5 days; Flies were transferred into 1.5 cm diameter, 25 cm long disposable pipettes, and the height reached by each fly during a period of 10 s was recorded",DMSO control (1%); Compared to wild-type flies,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,r(CUG)12,Observed a decrease in maximal fluorescence and a shift of the melting towards higher temperatures with growing concentrations of daunorubicin,Ligand = 0.1 - 2 ?M; RNA = 600 nM; RiboGreen = 300 nM,Sodium cacodylate at pH 6.1,Binding,Differential Scanning Fluorimetry ,,DMSO control,C,Primary Cultures of DM1 Myoblasts,Daunorubicin did not modify DMPK mRNA expression levels,"Ligand = 0.3, 1, 3 and 10 µM",RNA Abundance,RT-qPCR,Cells originated from a muscle biopsy of an individual with DM1; Compound treatment performed in DMSO for 24 hours.,Normalization to RPL0 levels; DMSO control,C,Drosophilla,Daunorubicin treatment did not alter the pattern of Serca exon 13 ,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Splicing,RT-qPCR,Flies expressed GFP in cardiomyocytes as control,Levels were compared to endogenous tubulin; DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,r(CUG)26-MBNL1 complex,Inhibit binding of MBNL1 to CUG-repeat RNA,Ligand = 10 µM; RNA = 50 nM; Protein = 400 nM,-,Protein Displacement,Fluorescence Anisotropy,RNA was labelled with a tetramethylrhodamine; Protein: purified recombinant GST-MBNL1-HIS produced from Escherichia coli.,-,,Primary Cultures of DM1 Myoblasts,Reduced the colocalization of MBNL1 with CUG RNA foci by 20-30%,Ligand =  3-10 ?M ,Nuclear Foci Dispersion,Immunofluorescence Coupled with Fluorescence In Situ Hybridization,Cells originated from a muscle biopsy of an individual with DM1; Compound treatment performed in DMSO for 24 hours.,DMSO control,,Drosophilla,"Daunorubicin corrects Serca exon 13 splicing event
","Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Splicing,RT-qPCR,Flies expressed CUG repeats,Levels were compared to endogenous tubulin; DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,r(CUG)10-MBNL1 complex,IC50 = 100 nM,Ligand = 1 - 300 nM; RNA = 10 pM; Protein = 10 nM,"0.75 mM MgCl2, 50 mM Tris-HCl (pH = 7.0), 75 mM NaCl, 37.5 mM KCl, 5.25 mM DTT, 0.1 mg/ml BSA, 0.1 mg/ml Bulk tRNA",Protein Displacement,Electrophoretic Mobility Shift Assay,RNA was internally labeled; Protein: recombinant GST-MBNL1,-,C,Primary Cultures of DM1 Myoblasts,Daunorubicin did not modify MBNL1 expression levels,"Ligand = 0.3, 1, 3 and 10 µM",Protein Abundance,Immunoblotting,Cells originated from a muscle biopsy of an individual with DM1; Compound treatment performed in DMSO for 24 hours.,Actin loading control,,Drosophilla,Daunorubicin corrects formin (Fhos) exon 16? splicing event,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Splicing,semiquantitative RT-PCR,Flies expressed CUG repeats,Levels were compared to endogenous Rp49; DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,Immortalized (hTERT) Human DM1 (1300 CTG repeats) Skin Fibroblasts,Significant reduction of foci number at concentrations higher than 1 ?M,,Nuclear Foci Dispersion,Immunofluorescence Coupled with Fluorescence In Situ Hybridization,Skin fibroblasts conditionally expressed MyoD,DMSO control,C,Drosophilla,Daunorubicin treatment did not alter the pattern Fhos exon 16' splicing events,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Splicing,semiquantitative RT-PCR,Flies expressed GFP in cardiomyocytes as control,Levels were compared to endogenous Rp49; DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,,Drosophilla,Significant improvement in HP length; significant 2-fold decrease in both the DI and SI; 3-fold decrease in AI; Rescue of heart contractility,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",Cardiac Function,-,Flies expressed CUG repeats,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,C,Drosophilla,The DNA region including the CTG repeats had the same length (1178 bp) in DM1 flies fed with either DMSO or daunorubicin,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",DNA Abundance,PCR amplification ,Flies expressed CUG repeats,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,,Drosophilla,Rescue of median survival,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",Lifespan,-,Flies expressed CUG repeats,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,C,Drosophilla,No effect on survival,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",Lifespan,-,Flies expressed GFP in cardiomyocytes as control,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,,Drosophilla,Ribonuclear foci were not observed; Mbl was found homogeneously distributed in the nuclei,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",Nuclear Foci Dispersion,Immunofluorescence coupled with Fluorescence In Situ Hybridization,Flies expressed CUG repeats,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,C,Drosophilla,Mbl expression was not modified in DM1 flies treated with daunorubicin compared to DM1 flies fed or not with DMSO,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Abundance,RT-qPCR,Flies expressed CUG repeats,Levels were compared to endogenous tubulin; DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0112,,COC1=C2C(=O)C3=C(C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H]([NH3+])[C@H](O)[C@H](C)O5)C4=C3O)C(C)=O)C(=O)C2=CC=C1,Daunorubicin Hydrochloride,10.1242/dmm.032557,,,,,,,,,,,,,,,,,,C,Drosophilla,No changes of CTG transgene expression in DM1 flies fed with DMSO compared to daunorubicin treatment,"Daunorubicin hydrochloride (Sigma) was added to the standard fly food to a final concentration of 1 ?M in 0.1% DMSO. The control group was fed with
0.1% DMSO in standard food.",RNA Abundance,RT-qPCR,Flies expressed CUG repeats,DMSO control,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Increased FRET efficiency across the entire landscape of ionic conditions,Ligand = 10 µM,"20 mM HEPES-KOH (pH = 6.9), 0.1?1 mM MgCl2, and 2.6?202.6 mM monovalent salt including 2.6 mM K+ from the HEPES buffer.",Binding,FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,Similar results were observed with a second MALAT1 triplex FRET construct; DMSO control,,Mouse Primary Mammary Tumor Organoids,"38% decrease in organoid branching, cells remained as spherical acini",Ligand = 1 ?M,Organoid Branching Morphogenesis,-,Organoids were derived from the MMTV-PyMT mouse model,Malat1 antisense oligonucleotide (200 nM); DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Malat1 minimal triple helix motif,Hit molecules had a Z-score > 3,Ligand was immobilized,"RNA folding buffer: 25 mM sodium cacodylate, 50 mM KCl, and 1 mM MgCl2 (pH = 6.9)",Binding,Small Molecule Microarray,"The RNA was fluorescently labeled at the 5' end. The mouse Malat1 ENE triplex, which shares ?90% of its identity with the human MALAT1 ENE triplex.",Visual inspection of array fluorescence signals and elimination of false positive signals,,Mouse Primary Mammary Tumor Organoids,54% reduction in Malat1 RNA levels,Ligand = 1 ?M,RNA Abundance,RT-qPCR,Organoids were derived from the MMTV-PyMT mouse model,"Malat1 antisense oligonucleotide (200 nM); DMSO control; Reference genes: Mouse Gapdh, Actb (?-actin), and 18s rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Kd = 2.3 ± 1.7 ?M,Ligand = 0?100 ?M; RNA = 100 nM,"20 mM HEPES-KOH (pH = 6.9), 0.1 mM MgCl2, 2.56 mM KCl",Binding,FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,Similar Kd values were determined from titrations using a second MALAT1 triplex FRET construct,,Mouse Primary Mammary Tumor Organoids,Reduction in Krt16 and increase in Csn2 RNA levels were consistent with the effect observed following Malat1 ASO treatment,"Ligand = 0.5 ?M, 1 ?M",RNA Abundance,RT-qPCR,Organoids were derived from the MMTV-PyMT mouse model; krt16 and csn2 are downstream targets of Malat1.,"Malat1 antisense oligonucleotide (200 nM); DMSO control; Reference genes: Mouse Gapdh, Actb (?-actin), and 18s rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Kd = 2.9 ± 1.3 ?M,Ligand = 0?100 ?M; RNA = 100 nM,"20 mM HEPES-KOH (pH = 6.9), 1 mM MgCl2, 2.56 mM KCl",Binding,DS-FRET,"The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail. Cy3 signal is used for Kd determination instead of FRET due to Cy5 quenching at high
compound concentrations",Similar Kd values were determined from titrations using a second MALAT1 triplex FRET construct,C,Mouse Primary Mammary Tumor Organoids,No effect on Neat1 levels,Ligand = 1 ?M,RNA Abundance,RT-qPCR,Organoids were derived from the MMTV-PyMT mouse model; NEAT1 lncRNA possesses a triple helix homologous to the MALAT1 ENE triplex.,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Kd = 7.7 ± 5.2 ?M,Ligand = 0?100 ?M; RNA = 100 nM,"20 mM HEPES-KOH (pH = 6.9), 0.1 mM MgCl2, 2.56 mM KCl",Binding,DS-FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,Similar Kd values were determined from titrations using a second MALAT1 triplex FRET construct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Unimolecular MALAT1 triple helix,Kd = 2.9 ± 1.6 ?M,RNA = 75 ?M in ITC cell; The syringe contained 500 ?M compound 5.,"1 mM MgCl2, 100 mM NaCl, 100 mM KCl, and 1% DMSO in 20 mM HEPES-KOH (pH = 6.9)",Binding,Isothermal Titration Calorimetry,Full-length 94 nt MALAT1 triple helix,No binding to tRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,Unimolecular MALAT1 triple helix construct,Several positive peaks indicating interaction were observed. No peaks were observed with NEAT1 and KSHV PAN ENE triplexes,Ligand: 150 ?M; RNA = 5 ?M,"10 mM potassium phosphate (pH = 6.5), 50 mM KCl, 1 mM MgCl2, 20 ?M DSS, and 0.02% NaN3 with 10% D2O. DMSO-d6 from compound addition was at 4% final concentration. ",Binding,Saturation Transfer Difference NMR,,Comparison to NEAT1 and KSHV PAN ENE triplexes.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0113,,COC1=CC=C(C=C1)C1=C[NH+]=C(NCC2=CC=CC(OC)=C2)N1C,Compound 5,10.1021/acschembio.8b00807,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0114,,CC1=CC=C2NC(=NC2=C1)C1=C(N)N(CC1=O)C1CCCC1,Compound 16,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Decreased FRET efficiency in 50 ?M compound 16 indicates compound-induced triplex disruption,Ligand = 50 ?M,"20 mM HEPES-KOH (pH = 6.9), 0.1?1 mM MgCl2, and 2.6?202.6 mM monovalent salt including 2.6 mM K+ from the HEPES buffer.",Binding,FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,Similar results were observed with a second MALAT1 triplex FRET construct; DMSO control,,Mouse Primary Mammary Tumor Organoids," 27% decrease in organoid branching, cells remained as spherical acini",Ligand = 1 ?M,Organoid Branching Morphogenesis,-,Organoids were derived from the MMTV-PyMT mouse model,Malat1 antisense oligonucleotide (200 nM); DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0114,,CC1=CC=C2NC(=NC2=C1)C1=C(N)N(CC1=O)C1CCCC1,Compound 16,10.1021/acschembio.8b00807,,Malat1 minimal triple helix motif,Hit molecules had a Z-score > 3,-,"RNA folding buffer: 25 mM sodium cacodylate, 50 mM KCl, and 1 mM MgCl2 (pH = 6.9)",Binding,Small Molecule Microarray,"The RNA was fluorescently labeled at the 5' end. The mouse Malat1 ENE triplex, which shares ?90% of its identity
with the human MALAT1 ENE triplex.",Visual inspection of array fluorescence signals and elimination of false positive signals,,Mouse Primary Mammary Tumor Organoids,41% reduction in Malat1 RNA levels,Ligand = 1 ?M,RNA Abundance,RT-qPCR,Organoids were derived from the MMTV-PyMT mouse model,"Malat1 antisense oligonucleotide (200 nM); DMSO control; Reference genes: Mouse Gapdh, Actb (?-actin), and 18s rRNA",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0114,,CC1=CC=C2NC(=NC2=C1)C1=C(N)N(CC1=O)C1CCCC1,Compound 16,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Kd = 6.1 ± 1.8 ?M,Ligand = 0?100 ?M; RNA = 100 nM,"20 mM HEPES-KOH (pH = 6.9), 0.1 mM MgCl2, 52.56 mM equimolar KCl and NaC",Binding,FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,-,C,Mouse Primary Mammary Tumor Organoids,No effect on Neat1 levels,Ligand = 1 ?M,RNA Abundance,RT-qPCR,Organoids were derived from the MMTV-PyMT mouse model; NEAT1 lncRNA possesses a triple helix homologous to the MALAT1 ENE triplex.,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0114,,CC1=CC=C2NC(=NC2=C1)C1=C(N)N(CC1=O)C1CCCC1,Compound 16,10.1021/acschembio.8b00807,,Bimolecular triplex construct (ENE-tail MALAT1 triplex),Kd = 2.5 ± 0.8 ?M,Ligand = 0?100 ?M; RNA = 100 nM,"20 mM HEPES-KOH (pH = 6.9), 1 mM MgCl2, 102.56 mM equimolar KCl and NaCl",Binding,FRET,The ENE motif contains a site-specific Cy3 donor dye. The Cy5 acceptor dye is attached to the A-rich tail.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0114,,CC1=CC=C2NC(=NC2=C1)C1=C(N)N(CC1=O)C1CCCC1,Compound 16,10.1021/acschembio.8b00807,,Unimolecular MALAT1 triple helix,Kd = 6.1 ± 2.1 ?M,RNA = 75 ?M in ITC cell; The syringe contained 500 ?M compound 16.,"1 mM MgCl2, 25 mM NaCl, 25 mM KCl, and 1% DMSO in 20 mM HEPES-KOH (pH = 6.9)",Binding,Isothermal Titration Calorimetry,Full-length 94 nt MALAT1 triple helix,Minor ITC binding signal between compound 16 and tRNA,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,"Broadening of signals of internal loop residues C9, A19, C20 and U23 comprising the Rev binding site; Perturbation of the signals of residues located in the double-helical stems flanking the loop.",RNA = 40–60 ?M,-,Binding,Nuclear Magnetic Resonance,"Samples was monitored as described before, using one and two-dimensional (TOCSY) experiments at increasing ligand: RNA molar ratios.",-,,MT-2 cells,Increase in the levels of multiple-spliced species and a decrease in the amount of unspliced or single-spliced HIV-1 transcripts,"Ligand = 5, 10 ?M",RNA Nuclear Export,RT-qPCR,"MT-2 cells were transfected with a full-length proviral vector (pNL4.3). Rev indirectly disfavors splicing by transferring unspliced or partially spliced viral
transcripts from the nucleus to the cytoplasm.",RNA levels are relative to a control obtained from untreated cells; Endogenous control: GAPDH.,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess tRNA,Kd = 2.4 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 6.4 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was transfected in isolation or co-transfected with vectors
pcDNA3-Tat or pcDNA3.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess dsDNA,Kd = 2.8 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 5.6 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was co-transfected with pcDNA3-Tat vector. 
",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,Kd = 1.4 ?M,RNA = 100 nM,10 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 4.1 µM,Ligand = 1-100 ?M,Transcriptional Inhibition,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the full length
proviral HIV-1 (NL4.3-luc).",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,More than 90% inhibition of the complex formation,Ligand = 100 ?M; RNA = 2 nM; fRevp = 10 nM,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with unlabeled Rev.,,MT-2 cells,EC50 = 0.83 µM,Ligand = 0.1-100 ?M,Antiviral Activity,Luciferase,"Infectious supernatants were obtained from transfection of plasmid pNL4.3-Ren on 293T cells,
MT-2 cells were infected with these supernatants in the presence of the
compounds, and anti-HIV activity quantification was performed 48 h
post-infection by determining luciferase activity in cell lysates.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0115,,C[NH+](C)CCOC1=C2C=CC=CC2=C2C3=CC=CC=C3C(=O)C2=C1,1a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,IC50 = 6.7 ?M,"Ligand = 1, 10, 50 and 100 ?M; RNA = 60 nM; frevp = 10 nM","31 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with neomycin B.,,MT-2 cells,CC50 = 28.1 µM,Ligand = 0.1-100 ?M,Cytotoxicity,Luminescence,"Cellular viability was evaluated in mock infected cells similarly treated with the same concentrations of compounds [as in the infection assay] using the CellTiterGlo (Promega, Madison USA) assay.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess dsDNA,Kd = 2.1 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,No clear changes in the patterns of unspliced versus spliced viral transcripts. ,"Ligand = 5, 10 ?M",RNA Nuclear Export,RT-qPCR,"MT-2 cells were transfected with a full-length proviral vector (pNL4.3). Rev indirectly disfavors splicing by transferring unspliced or partially spliced viral
transcripts from the nucleus to the cytoplasm.",RNA levels are relative to a control obtained from untreated cells; Endogenous control: GAPDH.,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,Kd = 3.2 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 8.3 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was transfected in isolation or co-transfected with vectors
pcDNA3-Tat or pcDNA3.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess tRNA,Kd = 2.5 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 4.0 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was co-transfected with pcDNA3-Tat vector. 
",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,"Broadening of signals of internal loop residues C9, A19, C20 and U23 comprising the Rev binding site; Perturbation of the signals of residues located in the double-helical stems flanking the loop.",RNA = 40–60 ?M,-,Binding,Nuclear Magnetic Resonance,"Samples was monitored as described before, using one and two-dimensional (TOCSY) experiments at increasing ligand: RNA molar ratios.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,More than 90% inhibition of the complex formation,Ligand = 100 ?M; RNA = 2 nM; fRevp = 10 nM,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with unlabeled Rev.,,MT-2 cells,EC50 = 3.2 µM,Ligand = 0.1-100 ?M,Antiviral Activity,Luciferase,"Infectious supernatants were obtained from transfection of plasmid pNL4.3-Ren on 293T cells,
MT-2 cells were infected with these supernatants in the presence of the
compounds, and anti-HIV activity quantification was performed 48 h
post-infection by determining luciferase activity in cell lysates.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,IC50 =  6.4 ?M,"Ligand = 1, 10, 50 and 100 ?M; RNA = 60 nM; frevp = 10 nM","31 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with neomycin B.,,MT-2 cells,CC50 = 10.8 µM,Ligand = 0.1-100 ?M,Cytotoxicity,Luminescence,"Cellular viability was evaluated in mock infected cells similarly treated with the same concentrations of compounds [as in the infection assay] using the CellTiterGlo (Promega, Madison USA) assay.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0116,,OC(C[NH2+]CC1CCCO1)CN1C2=C(C=C(Br)C=C2)C2=C1C=CC(Br)=C2,1b,10.1016/j.bcp.2018.07.040,,HIV-1 RRE:Rev complex,IC50 =  3.3 ?M,"Ligand = 0, 0.5, 1, 2, 5, 10, 20, 50 ?M; RNA = 78 nM; Rev = 1.32 ?M","10 mM HEPES (pH = 7.5), 300 mM KCl, 1 mM MgCl2 and 0.5 mM EDTA",Protein Displacement,Electrophoretic Mobility Shift Assay,Full-length RRE and full-length Rev were employed,-,,MT-2 cells,EC50 = 1.7 µM,Ligand = 1-100 ?M,Transcriptional Inhibition,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the full length
proviral HIV-1 (NL4.3-luc).",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,Induced broadening of internal loop residue U23 only at a high drug:RNA molar ratio.,RNA = 40–60 ?M,-,Binding,Nuclear Magnetic Resonance,"Samples was monitored as described before, using one and two-dimensional (TOCSY) experiments at increasing ligand: RNA molar ratios.",-,,MT-2 cells,No clear changes in the patterns of unspliced versus spliced viral transcripts. ,"Ligand = 5, 10 ?M",RNA Nuclear Export,RT-qPCR,"MT-2 cells were transfected with a full-length proviral vector (pNL4.3). Rev indirectly disfavors splicing by transferring unspliced or partially spliced viral
transcripts from the nucleus to the cytoplasm.",RNA levels are relative to a control obtained from untreated cells; Endogenous control: GAPDH.,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess tRNA,Kd = 9.0 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 6.9 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was transfected in isolation or co-transfected with vectors
pcDNA3-Tat or pcDNA3.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,C,HIV-1 RRE IIB + 100-fold excess dsDNA,Kd = 9.2 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 4.1 µM,-,Transcriptional Activity,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the HIV-1 LTR promoter (pLTR-Luc).
pLTR-luc was co-transfected with pcDNA3-Tat vector. 
",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB ,Kd = 10.8 ?M,RNA = 100 nM,11 mM sodium phosphate (pH = 6.6) and 0.1 mM EDTA,Binding,Fluorescence-Based Titration (Labeled RNA),RNA was labeled with 2-aminopurine at nucleotide 19,-,,MT-2 cells,EC50 = 0.9 µM,Ligand = 1-100 ?M,Transcriptional Inhibition,Luciferase,"MT-2 cells were transfected with plasmids containing a luciferase
reporter gene whose expression was under the control of the full length
proviral HIV-1 (NL4.3-luc).",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,More than 90% inhibition of the complex formation,Ligand = 100 ?M; RNA = 2 nM; fRevp = 10 nM,"30 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with unlabeled Rev.,,MT-2 cells,EC50 = 2.0 µM,Ligand = 0.1-100 ?M,Antiviral Activity,Luciferase,"Infectious supernatants were obtained from transfection of plasmid pNL4.3-Ren on 293T cells,
MT-2 cells were infected with these supernatants in the presence of the
compounds, and anti-HIV activity quantification was performed 48 h
post-infection by determining luciferase activity in cell lysates.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0117,,FC1=C(F)C(SC2=CC=C(Cl)C=C2)=C(F)C(=N1)N1CC[NH2+]CC1,2a,10.1016/j.bcp.2018.07.040,,HIV-1 RRE IIB:Rev34-50 complex,IC50 = 4.8  ?M,"Ligand = 1, 10, 50 and 100 ?M; RNA = 60 nM; frevp = 10 nM","31 mM HEPES (pH = 6.8), 100 mM KCl, 10 mM sodium phosphate, 10 mM ammonium acetate, 10 mM guanidinium chloride, 2 mM MgCl2, 20 mM NaCl, 0.5 mM EDTA, and 0.001% (v/v) Triton X-100",Protein Displacement,Fluorescence Anisotropy,Rev34-50 was labeled with FITC,No-ligand control; Competition with neomycin B.,,MT-2 cells,CC50 = 43.9 µM,Ligand = 0.1-100 ?M,Cytotoxicity,Luminescence,"Cellular viability was evaluated in mock infected cells similarly treated with the same concentrations of compounds [as in the infection assay] using the CellTiterGlo (Promega, Madison USA) assay.",Vehicle control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0118,,CC[NH+](CC)CC[N+]1=CC2=C(C)C3=C(NC4=C3C=C(O)C=C4)C(C)=C2C=C1,Compound 2,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,>50% displacement of indicator from r(G4C2)8,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,,HEK293T cells,IC50 > 25 µM,-,Translational Activity,Reporter,"(G4C2)exp was inserted into the 5' UTR of GFP lacking a canonical ATG start codon. cells were co-transfected with
(G4C2)66-No ATG-GFP and a plasmid encoding mCherry (ATG-mCherry).Thus, two fluorescent signals could be produced, where GFP fluorescence
indicates RAN translation and mCherry fluorescence is a metric of canonical translation",The background-corrected ratio of GFP to mCherry was used to determine the effect of compound on RAN translation,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0118,,CC[NH+](CC)CC[N+]1=CC2=C(C)C3=C(NC4=C3C=C(O)C=C4)C(C)=C2C=C1,Compound 2,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,IC50 = 1.4 ± 0.4 ?M,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,C,HEK293T cells,No significant effect on the GFP signal relative to the mCherry signal,Ligand = 0.025-25 ?M,Translational Activity,Reporter,Counterscreen with ATG-GFP (canonical GFP translation) and ATG-mCherry (also canonical translation).,Comparison to untreated cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0119,,CC1=C2C=C[N+](C)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Compound 3,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,>50% displacement of indicator from r(G4C2)8,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,,HEK293T cells,IC50 = 12 ± 2.0 µM,-,Translational Activity,Reporter,"(G4C2)exp was inserted into the 5' UTR of GFP lacking a canonical ATG start codon. cells were co-transfected with
(G4C2)66-No ATG-GFP and a plasmid encoding mCherry (ATG-mCherry).Thus, two fluorescent signals could be produced, where GFP fluorescence
indicates RAN translation and mCherry fluorescence is a metric of canonical translation",The background-corrected ratio of GFP to mCherry was used to determine the effect of compound on RAN translation,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0119,,CC1=C2C=C[N+](C)=CC2=C(C)C2=C1NC1=C2C=C(O)C=C1,Compound 3,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,IC50 = 0.9 ± 0.2?M,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,C,HEK293T cells,No significant effect on the GFP signal relative to the mCherry signal,Ligand = 0.025-25 ?M,Translational Activity,Reporter,Counterscreen with ATG-GFP (canonical GFP translation) and ATG-mCherry (also canonical translation).,Comparison to untreated cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,r(G2C4)8 (antisense),Kd = 80 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The RNA was biotinylated at the 5' end. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,,HEK293T cells,Strong fluorescent spots in the cytoplasm,Ligand (4-TO-PRO) = 0.5 mM,Localization ,Fluorescence Microscopy,Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid; Imaging agent is compound 4 conjugated to TO-PRO-1 (4-TO-PRO). ,Cells treated with TO-PRO-1 alone did not show the observed fluorescent spots. ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,TERRA G-quadruplex r(UAG3(U2AG3)3),Kd = 8.6 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The RNA was biotinylated at the 5' end. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,C,HEK293T cells,Significant reduction in fluorescent spots. Results suggest that 4 localized to these spots enriched with RNA.,Ligand (4) = 5 ?M; 4-TO-PRO = 0.5 ?M,Localization ,Fluorescence Microscopy,Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid; Imaging agent is compound 4 conjugated to TO-PRO-1 (4-TO-PRO); Cells were pre-treated with compound 4. ,Cells treated with TO-PRO-1 alone did not show the observed fluorescent spots. ,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,r(UG3C2)8,Kd = 220 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The RNA was biotinylated at the 5' end. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,,HEK293T cells,Compound 4 treatment reduced the number of foci-positive cells and decreased the number of foci in focipositive cells by 2-fold,Ligand = 5 ?M,Nuclear Foci Dispersion,Fluorescence In Situ Hybridization coupled with Immunofluorescence ,Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid,Comparison to untreated cells; A cell was considered foci-positive if green (RNA) and red (hnRNP H) fluorescence signal overlapped in punctate spots.,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,Fully base paired RNA [r(G2C2)8],Kd = 140 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The RNA was biotinylated at the 5' end. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,,HEK293T cells,"The BG4 signal did not co-localize with 4-TO-PRO, providing evidence that 4 binds the hairpin form of cellular r(G4C2)exp, and that the hairpin fold of r(G4C2)exp occurs in cells",Ligand (4-TO-PRO) = 0.5 mM,On-Target Effect,Fluorescence Microscopy,"Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid; Imaging agent is compound 4 conjugated to TO-PRO-1 (4-TO-PRO) and anti-rabbit IgG DyLight 650; BG4 was added to the
cells first followed by addition of 4-TO-PRO to avoid disrupting BG4 binding.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,d(G4C2)8 DNA,Kd = 0.31 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The DNA was biotinylated. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,,HEK293T cells,"Treatment of HEK293T cells expressing (G4C2)66-No ATG-GFP with 4 reduced the amount of transcript loaded into high-molecular weight
polysomes by 28% (p < 0.001), low-molecular-weight polysomes by 18% (p < 0.01), and monosome-containing fractions by 12%",Ligand = 5 ?M,Ribosome Loading,Polysome Profiling by RT-qPCR,Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid; Cellular lysates were separated using a 10-50% sucrose gradient in 500 mL fractions; The levels of (G4C2)66–No ATG–GFP mRNA in each fraction were measured by qPCR with primers specific to GFP. ,"Comparison to beta-actin, comparison to untreated cells. Data were then normalized to the fraction with the lowest abundance of GFP.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,Kd = 0.26 ?M,Ligand = 0.5 - 25 ?M,"80 mM KH2PO4 (pH = 7.0), 185 mM KCl, 1 mM EDTA",Binding,Biolayer Interferometry,The RNA was biotinylated at the 5' end. ,Subtracting the response of the sensors recorded upon incubation with solutions containing compound and no RNA.,C,HEK293T cells,No effect on (G4C2)66-No ATG-GFP RNA transcript levels.,Ligand = 1-5 ?M,RNA Abundance,RT-qPCR,Cells were transfected with 3.5 mg (G4C2)66–No ATG–GFP plasmid,The levels of (G4C2)66–No ATG–GFP were measured with primers specific for GFP and normalized to 18S or beta-actin values,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,>50% displacement of indicator from r(G4C2)8,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,,HEK293T cells,IC50 = 1.6 ± 0.20µM,-,Translational Activity,Reporter,"(G4C2)exp was inserted into the 5' UTR of GFP lacking a canonical ATG start codon. cells were co-transfected with
(G4C2)66-No ATG-GFP and a plasmid encoding mCherry (ATG-mCherry).Thus, two fluorescent signals could be produced, where GFP fluorescence
indicates RAN translation and mCherry fluorescence is a metric of canonical translation",The background-corrected ratio of GFP to mCherry was used to determine the effect of compound on RAN translation,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,IC50 = 8.5 ± 2.0 ?M,RNA = 600 nM; Indicator = 1.2 µM,"8 mM K2HPO4 (pH = 7.0), 185 mM KCl, and 1 mM EDTA",Binding,Indicator Displacement Assay ,The indicator (1a-TOQ) is a conjugate of the lead compound 1a targeting r(G4C2) and the TOPRO-1 dye. Assays were conducted in the presence of 40 ug/mL BSA. ,Emission of 1a-TOQ in absence of RNA was subtracted.,C,HEK293T cells,No significant effect on the GFP signal relative to the mCherry signal,Ligand = 0.025-25 ?M,Translational Activity,Reporter,Counterscreen with ATG-GFP (canonical GFP translation) and ATG-mCherry (also canonical translation).,Comparison to untreated cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)4,"Assay showed a new peak appearing at 10.5 ppm in the absence of K+ ions, resulting from 4 stabilizing the interactions between the 1 x 1 nucleotide GG internal loop; Binding stoichiometry: 4:1 compound:RNA.",RNA = 0.1 mM,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,1D imino proton NMR; WATERGATE pulse sequence for water suppression.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)8,"Assay showed a new peak appearing at 10.5 ppm in the absence of K+ ions, resulting from 4 stabilizing the interactions between the 1 x 1 nucleotide GG internal loop; Binding stoichiometry: 6:1 compound:RNA.",RNA = 0.1 mM,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,1D imino proton NMR; WATERGATE pulse sequence for water suppression.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,r(G4C2)2,The same imino proton signal corresponding to the GG loops in r(G4C2)4 and r(G4C2)8 was observed.,Ligand = 10 mM; RNA = 0.1 mM,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,1D imino proton NMR; WATERGATE pulse sequence for water suppression; RNA construct cannot form a G-quadruplex,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)4,Compound 4 prevents conversion of the hairpin to the G-quadruplex,Ligand = 10 mM; RNA = 0.1 mM,"RNA samples were prepared in 10 mM sodium phosphate buffer with 50 mM LiCl as the hairpin folded state, followed by addition of 150 mM KCl",Binding,Nuclear Magnetic Resonance,"Four equivalents of 4 were added before the addition of K+. After 12 h of incubation with K+ incubation, the imino proton signal due to GG pairs 10.5 ppm) did not shift or change.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)4,Nuclear Overhauser effects (NOEs) between 4 and the 1 x 1 nucleotide GG internal loops and adjacent GC pairs.,RNA = 0.4 mM; Ligand = 4 equivalents,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,NOESY; Mixing time = 400 ms,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)4,"Compound 4 stabilizes the hairpin structure, as demonstrated by the increase in TM from 71°C to 78°C after the addition of 4; These studies
also revealed that 4 has two binding modes; Binding of 4 is cooperative.",RNA = 10 - 20 ?M,10 mM Na2HPO4 buffer with 50mM LiCl.,Binding,Circular Dichroism Spectroscopy,-,The observed signals were baseline subtracted.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,Duplex stem [r(GUCGCCGGGGCCGGGCGAC)2],Compound 4 stabilizes hydrogen bonding between the 1 x 1 nucleotide GG internal loop,RNA = 0.4 mM; Ligand = 2 equivalents,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,1D imino proton NMR; WATERGATE pulse sequence for water suppression.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,C,Duplex stem [r(GUCGCCGGGGCCGGGCGAC)2],Several NOEs between 4 and the imino protons of the guanine in the 1 x 1 nucleotide GG internal loop were observed.,RNA = 0.4 mM; Ligand = 3 equivalents,10 mM sodium phosphate buffer (pH = 7.0) with 100 mM LiCl,Binding,Nuclear Magnetic Resonance,NOESY; Mixing time = 400 ms,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0120,,COC1=CC2=C(NC3=C2C(C)=C2C=NC=CC2=C3C)C=C1,Compound 4,10.1016/j.chembiol.2018.10.018,,r(G4C2)8:hnRNP H complex,IC50 = 19 ?M,RNA = 80 nM; hnRNP H = 80 nM,"20 mM HEPES (pH = 7.5), 110 mM KCl, 10 mM NaCl, 0.1% (w/v) BSA, 2 mM MgCl2, 2 mM CaCl2, 0.05% Tween-20, 5 mM DTT",Protein Displacement,TR-FRET,Biotinylated r(G4C2)8 forms a complex with hnRNP H-His6. A FRET signal is produced when streptavidin-XL665 binds the biotinylated RNA and Tb-Anti-His6 binds to hnRNP H.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0121,,CC(=O)C1=CC=C(C=C1)C1=CC=C2OC(=CC2=C1)C(=O)C1=CC(O)=C([O-])C(O)=C1,Compound 18 (intronistat A),10.1038/s41589-018-0142-0,,ai5? group II intron ribozyme,>25% inhibition,Ligand = 10 ?M; Ribozyme = 20 nM; Substrate oligonucleotide = 20 nM,"50 mM MOPS (pH = 7.0), 100 mM MgCl2, 0.5 M KCl",Activity ,Fluorescence assay for monitoring ribozyme activity,"The self-splicing ai5? group II intron was transformed into a multiple-turnover ribozyme by removing the flanking exons and consolidating catalytic domains
to create the D135 ribozyme, which efficiently and specifically catalyzes cleavage of RNA ‘substrate’ oligonucleotides that contain sequences of the original 5? splice site. Substrate oligonucleotides contained two
labels: black hole quencher 2 and AlexaFluor555 at the opposite sites of the cleavage site",Positive control: Substrate only; Negative Control: No compound; Z' factor = 0.83±0.03,,S. cerevisiae,MIC in glycerol/ethanol media: 32 ?g/ml; MIC in glucose media: > 128 ?g/ml.,Ligand = 0.25–128 ?g/ml,Metabolic Activity,Yeast Respiration Assay ,Plates were incubated at 30 °C and visually analyzed for turbidity after 24 and 48 h of incubation. The lowest compound concentration at which no growth was apparent is reported as the MIC.,Amphotericin B; DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0121,,CC(=O)C1=CC=C(C=C1)C1=CC=C2OC(=CC2=C1)C(=O)C1=CC(O)=C([O-])C(O)=C1,Compound 18 (intronistat A),10.1038/s41589-018-0142-0,,ai5? group II intron ribozyme,IC50 = 1.5 ± 0.1 ?M,Ligand = 5 nM - 1 mM; Ribozyme = 20 nM; Substrate oligonucleotide = 20 nM,"50 mM MOPS (pH = 7.0), 100 mM MgCl2, 0.5 M KCl",Activity ,Fluorescence assay for monitoring ribozyme activity,"The self-splicing ai5? group II intron was transformed into a multiple-turnover ribozyme by removing the flanking exons and consolidating catalytic domains
to create the D135 ribozyme, which efficiently and specifically catalyzes cleavage of RNA ‘substrate’ oligonucleotides that contain sequences of the original 5? splice site. Substrate oligonucleotides contained two
labels: black hole quencher 2 and AlexaFluor555 at the opposite sites of the cleavage site",-,,S. cerevisiae (wild-type: NP40-36a and mtDNA intronless: XPM46),"Clear difference in growth in between the intronless strain and the wild-type strain in the presence of compound 18 , revealing that the intronless strain is much more resistant to compound 18 in YPGE medium. Growth of the intronless strain is somewhat slower in the presence of inhibitor, suggesting that 18 may cause certain off-target effects.",Ligand: 64 ?g/ml in glucose media; 128 ?g/ml in glycerol/ethanol media. ,Proliferation ,Growth Inhibition,"The intronless strain contains an intact COX1 subunit gene from which the intron has been removed, thereby obviating the requirement for splicing",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0121,,CC(=O)C1=CC=C(C=C1)C1=CC=C2OC(=CC2=C1)C(=O)C1=CC(O)=C([O-])C(O)=C1,Compound 18 (intronistat A),10.1038/s41589-018-0142-0,,Full length ai5? group II intron ribozyme,Ki = 2.1 ± 0.2 ?M,"Ligand = 5 nM - 1 mM, Ribozyme = 2 nM","50 mM MOPS (pH = 7.5), 8 mM MgCl2, 100 mM KCl",Activity ,In vitro self-splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. ,No-ligand control,,S. cerevisiae,Substantial accumulation of precursor RNA molecules containing the 5'-exon–intron junction. Compound 18 specifically targets the ai5? intron in vivo.,Ligand = 32 ?g/ml,RNA Splicing,qRT-PCR,"Relative levels of total and unspliced levels of COX1 are indicated by qRT-PCR quantification of amplicons covering the
eighth exon (total) or the intron–exon junction from the group IIA introns aI1 and aI2, the group I introns aI5? and aI5? , or the group IIB intron aI5? . Levels
of total and unspliced nuclear-encoded YRA1 and MTR2 indicated by quantification of amplicons covering an exon (total) or intron–exon junction of the
splicesomal targeted intron.","Treatment controls: DMSO, inactive compound, amphotericin B, Gel electrophoresis confirmed specific amplification of the intended amplicon.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0121,,CC(=O)C1=CC=C(C=C1)C1=CC=C2OC(=CC2=C1)C(=O)C1=CC(O)=C([O-])C(O)=C1,Compound 18 (intronistat A),10.1038/s41589-018-0142-0,,,,,,,,,,,HEK-293T cells,IC50 = >128 ?g/ml ,Ligand = 0.125–128 ?g/ml,Cytotoxicity,Luminescence,Cell viability was determined using the luminescent Cell Titer Glo cell viability assay.,Cytotoxic control: Terfenadine,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0121,,CC(=O)C1=CC=C(C=C1)C1=CC=C2OC(=CC2=C1)C(=O)C1=CC(O)=C([O-])C(O)=C1,Compound 18 (intronistat A),10.1038/s41589-018-0142-0,,,,,,,,,,,C. parapsilosis,MIC = 2-4 ?g/ml (comparable to that of amphotericin B),Ligand = 0.25–128 ?g/ml,Proliferation,Growth Inhibition ,"The yeast pathogen C. parapsilosis contains a single group IIB intron in its COX1 gene38. The active site of this intron (D5) is almost identical
to that of the ai5? intron. The lowest compound concentration at which no growth was apparent is reported as the MIC.
",Control antifungal drugs (amphotericin B and itraconazole),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess D1,No effect on inhibitory activity of the compound,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 5 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is ai5? intron domain D1. ,No-ligand control,,HEK-293T cells,IC50 = >64 ?g/ml ,Ligand = 0.125–128 ?g/ml,Cytotoxicity,Luminescence,Cell viability was determined using the luminescent Cell Titer Glo cell viability assay.,Cytotoxic control: Terfenadine,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,,ai5? group II intron ribozyme,>25% inhibition,Ligand = 10 ?M; Ribozyme = 20 nM; Substrate oligonucleotide = 20 nM,"50 mM MOPS (pH = 7.0), 100 mM MgCl2, 0.5 M KCl",Activity ,Fluorescence assay for monitoring ribozyme activity,"The self-splicing ai5? group II intron was transformed into a multiple-turnover ribozyme by removing the flanking exons and consolidating catalytic domains
to create the D135 ribozyme, which efficiently and specifically catalyzes cleavage of RNA ‘substrate’ oligonucleotides that contain sequences of the original 5? splice site. Substrate oligonucleotides contained two
labels: black hole quencher 2 and AlexaFluor555 at the opposite sites of the cleavage site",Positive control: Substrate only; Negative Control: No compound; Z' factor = 0.83±0.03,,S. cerevisiae,MIC in glycerol/ethanol media: 64 ?g/ml; MIC in glucose media: > 128 ?g/ml.,Ligand = 0.25–128 ? g/ml,Metabolic Activity,Yeast Respiration Assay ,Plates were incubated at 30 °C and visually analyzed for turbidity after 24 and 48 h of incubation. The lowest compound concentration at which no growth was apparent is reported as the MIC.,Amphotericin B; DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,,Full length ai5? group II intron ribozyme,Ki = 0.36 ± 0.02 ?M,"Ligand = 5 nM - 1 mM, Ribozyme = 2 nM","50 mM MOPS (pH = 7.5), 8 mM MgCl2, 100 mM KCl",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. ,No-ligand control,,C. parapsilosis,MIC = 2-4 ?g/ml (comparable to that of amphotericin B),Ligand = 0.25–128 ?g/ml,Proliferation,Growth Inhibition ,"The yeast pathogen C. parapsilosis contains a single group IIB intron in its COX1 gene38. The active site of this intron (D5) is almost identical
to that of the ai5? intron. The lowest compound concentration at which no growth was apparent is reported as the MIC.
",Control antifungal drugs (amphotericin B and itraconazole),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,,ai5? group II intron ribozyme,IC50 = 3.8 ± 0.5 ?M,Ligand = 5 nM - 1 mM; Ribozyme = 20 nM; Substrate oligonucleotide = 20 nM,"50 mM MOPS (pH = 7.0), 100 mM MgCl2, 0.5 M KCl",Activity ,Fluorescence assay for monitoring ribozyme activity,"The self-splicing ai5? group II intron was transformed into a multiple-turnover ribozyme by removing the flanking exons and consolidating catalytic domains
to create the D135 ribozyme, which efficiently and specifically catalyzes cleavage of RNA ‘substrate’ oligonucleotides that contain sequences of the original 5? splice site. Substrate oligonucleotides contained two
labels: black hole quencher 2 and AlexaFluor555 at the opposite sites of the cleavage site",-,,S. cerevisiae,Substantial accumulation of precursor RNA molecules containing the 5'-exon–intron junction. Compound 18 specifically targets the ai5? intron in vivo.,Ligand = 64 ?g/ml,RNA Splicing,qRT-PCR,-,"Treatment controls: DMSO, inactive compound, amphotericin B, Gel electrophoresis confirmed specific amplification of the intended amplicon.",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess D3,No effect on inhibitory activity of the compound,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 5 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is ai5? intron domain D3.,No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess D56,No effect on inhibitory activity of the compound,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 5 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is ai5? intron domain D56.,No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess yeast tRNA Phe,No effect on inhibitory activity of the compound,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 10 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is yeast tRNA Phe,No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess U2-U6 RNA oligo,No effect on inhibitory activity of the compound,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 5 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is U2–U6 snRNA stem-loop (analogous to group II intron D5),No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Full length ai5? group II intron ribozyme + 1000-fold excess unlabeled ai5? intron with short exons,Inhibition was ablated,"Ligand = 300 nM, Ribozyme = 2 nM, Competitor RNA = 2 ?M","50 mM MOPS (pH = 7.5), 100 mM KCl and 5 mM MgCl2",Activity ,In Vitro Self-Splicing,Ribozyme construct: Internally 32P-labeled ai5? intron with short exons. Competitor RNA is unlabeled ai5? intron with short exons.,No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,C,Azoarcus pre-tRNA (Ile) group I intron37,Splicing was unaffected,"Ligand = 1, 5, 10, 20, 50 and 100 ?M; Azo-PretRNA = 20 nM","25 mM HEPES (pH = 7.5), 10 mM MgCl2",Activity ,In Vitro Splicing,Internally labeled Azo-PretRNA intron,No-ligand control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0122,,OC1=CC(=CC(O)=C1[O-])C(=O)C1=CC2=CC(=CC=C2O1)C(=O)NCC[NH+]1CCCC1,Compound 19 (intronistat B),10.1038/s41589-018-0142-0,,Full length ai5? group II intron ribozyme,"Splicing efficiency was observed to significantly increase upon dilution of the inhibitor, indicating that compound binding is reversible","Ligand = 2 ?M, then 0.2 ?M. ","50 mM MOPS (pH = 7.5), 8 mM MgCl2, 100 mM KCl",Binding,Pulse-Chase Dilution,"Ribozyme construct: Internally 32P-labeled ai5? intron with short exons.; The splicing reaction was initiated at high concentration (2 ?M) of the indicated inhibitor, allowed to react for an hour under near-physiological conditions, and then diluted by ten-fold with reaction buffer. ",-,,C. parapsilosis,"Moderate splicing defect caused by Intronistat B, as indicated by increased levels of unspliced C. parapsilosis COX1 relative to total.",,RNA Splicing,qRT-PCR,"Relative levels of total and unspliced levels of C.p.COX1 indicated by qRT-PCR
quantification of amplicons covering the exon (total) or the intron-exon junction from the group
IIB intron.","Treatment controls: DMSO vehicle, inactive compound 4",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)1,"Kd1 = 2.23 ± 0.077 uM, Kd2 = 2.23 ± 0.16 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,cell viability enhanced,Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,Cells transfected with CGGx20 plasmid,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,"Kd1 = 2.84 ± 0.39 uM, Kd2 = 2.84 ± 0.17 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,cell viability enhanced,Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,Cells transfected with CGGx99 and EGFP plasmids,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CAG)6,"Kd1 = 1.16 ±0.095 uM, Kd2 = 8.74 ± 0.73 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,no effect,Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,Cells transfected with EGFP plasmids,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CCG)6,"Kd1 = 0.86 ± 0.070 uM, Kd2 = 1.86 ± 0.75 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,"no cytotoxic effect, IC50 = 36.51 ± 3.7 uM",Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,-,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CUG)6,"Kd = 1.41 ± 0.075 uM, Kd2 = 6.78 ± 0.55 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,GM00357 (normal fibroblast) cells,"no cytotoxic effect, IC50 = 40.85 ± 3.4 uM",Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,-,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,yeast tRNA,"Kd1 = 3.21 ± 0.27 uM, Kd2 = 9.88 ± 0.81 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,ligand free control,,GM04026 (FXTAS patient-derived fibroblast) cells,"no cytotoxic effect, IC50 = 30.98 ± 2.5 uM",Ligand = 0.2 - 200 uM,Cytotoxicity,MTT,-,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)40,"Kd1 = 0.012 ± 0.0031 uM, Kd2 = 0.74 ± 0.038 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,protein aggregates reduced in a dose dependent manner,"Ligand = 0, 25, 50, 100 uM",Protein Abundance,Fluorescence Microscopy,Cells transfected with CGGx99 and EGFP plasmids,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)60,"Kd1 = 0.009 ± 0.0012 uM, Kd2 = 0.33 ± 0.045 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",C,HEK293 cells,no significant inhibition,"Ligand = 0, 25, 50, 100 uM",Protein Abundance,Fluorescence Microscopy,Cells transfected with EGFP plasmids,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)1,"Kd1 = 0.102 ± 0.0082 uM, Kd2 = 0.41 ± 0.10 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,"20 uM piperine improves splicing defects, 60 uM completely restores alternative pre-mRNA splicing defects","Ligand = 20, 40, 60 uM",RNA Splicing,RT-PCR,FXTAS cellular model; cells transfected with CGGx99 repeat and targeted mini-gene SMN2; cells incubated with ligand for 24 hours,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)2,"Kd1 = 0.093 ± 0.0056 uM, Kd2 = 0.45 ± 0.094 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",C,HEK293 cells,no effect on alternative splicing,"Ligand = 20, 40, 60 uM",RNA Splicing,RT-PCR,"FXTAS cellular model; cells lacking CGG repeat, transfected with targeted mini-gene SMN2; cells incubated with ligand for 24 hours",Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)3,"Kd1 = 0.10 ± 0.0031 uM, Kd2 = 0.47 ± 0.14 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,HEK293 cells,piperine improves pre-mRNA splicing defect in a dose dependent manner,"Ligand = 25, 50, 100 uM",RNA Splicing,RT-PCR,FXTAS cellular model; cells transfected with CGGx99 repeat and targeted mini-gene Bcl-X; cells incubated with ligand for 24 hours,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)4,"Kd1 = 0.081 ± 0.0071 uM, Kd2 = 2.68 ± 0.096 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",C,HEK293 cells,no effect on alternative splicing,"Ligand = 20, 40, 60 uM",RNA Splicing,RT-PCR,"FXTAS cellular model; cells lacking CGG repeat, transfected with targeted mini-gene Bcl-X; cells incubated with ligand for 24 hours",Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,"Kd1 = 0.029 ± 0.0027 uM, Kd2 = 0.82 ± 0.028 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",C,HEK293 cells,no effect on alternative splicing,"Ligand = 25, 50 uM",RNA Splicing,RT-PCR,Cells transfected with CGG repeat plasmid and mini-gene cTNT (not affected by CGG repeats),Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)20,"Kd1 = 0.020 ± 0.0045 uM, Kd2 = 0.51 ± 0.028 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",C,HEK293 cells,no effect on alternative splicing,"Ligand = 25, 50 uM",RNA Splicing,RT-PCR,Cells transfected with CGG repeat plasmid and mini-gene IR (not affected by CGG repeats),Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,cymc DNA,"Kd1 = 2.58 ± 0.39 uM, Kd2 = 158.96 ± 6.0 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,Bcl-2 DNA,"Kd1 = 7.34 ± 0.87 uM, Kd2 = 6.67 ± 0.11 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,CT DNA,"Kd1 = 22.54 ± 1.06 uM, Kd2 = 23.04 ± 1.5 uM",NR,NR,Binding,Fluorescence Based Titration (Intrinsic),-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,"?H = -2.37e4 ± 0.14 cal/mol, Ka = 8.41e6 ± 1.8 M-1, ?S = -47.7 ± 5.7 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,"RNA free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)20,"?H = -3.08e5 ± 1.3 cal/mol, Ka = 3.21e7 ± 1.1 M-1, ?S = -998 ± 471 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,"RNA free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)40,"?H = -2.02e6 ± 1.7e6 cal/mol, Ka = 8.654e7 ± 1.02 M-1, ?S = -3.5e3 ± 3.5 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,"RNA free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)60,"?H = -4.47e6 ± 1.48 cal/mol, Ka = 1.92e8 ± 0.56 M-1, ?S = 1.46e3 ± 1.8 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,"RNA free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,"?H = -1.04e7 ± 1.97e6 cal/mol, Ka = 4.44e5 ± 2.1 M-1, ?S = -3.52e4 ± 1.3 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,RNA free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CAG)6,"?H = -2.58e6 ± 1.1 cal/mol, Ka = 3.39e4 ± 2.5 M-1, ?S = -8.65e3 ± 4.0e3 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,RNA free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CCG)6,"?H = -3.16e6 ± 4.3e5 cal/mol, Ka = 2.75e4 ± 1.5 M-1, ?S = 1.06e4 ± 1.1e4 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,RNA free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CUG)6,"?H = -2.01e7 ± 1.9e7 cal/mol, Ka = 5.17e3 ± 2.2e3 M-1, ?S = -6.74e4 ± 6.5e4 cal/mol/deg","RNA = 20 uM, Ligand = 200 uM","50 mM KCl, 10 mM potassium phosphate, 50 mM EDTA (K+) (pH = 7.0)",Binding,Isothermal Titration Calorimetry,1.86 uL injections with 120 sec pause to homogenize heat,RNA free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)1,changes in CD spectra indicative of binding,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","50 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,changes in CD spectra indicative of binding,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","51 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)20,changes in CD spectra indicative of binding,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","52 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)40,changes in CD spectra indicative of binding,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","53 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)60,changes in CD spectra indicative of binding,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","54 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)1,insignificant changes in CD spectra,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","55 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,insignificant changes in CD spectra,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","56 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CAG)6,insignificant changes in CD spectra,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","57 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CCG)6,insignificant changes in CD spectra,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","58 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CUG)6,insignificant changes in CD spectra,"RNA = 10.0 uM, Ligand = 0 - 40.0 uM","59 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Titration with increasing ligand concentrations,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)1,?Tm = 1.71 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","60 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,?Tm = 2.80 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","61 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)20,?Tm = 3.68 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","62 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)40,?Tm = 4.64 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","63 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)60,?Tm = 5.36 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","64 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,?Tm = 0.36 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","65 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CAG)6,?Tm = 1.05 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","66 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CCG)6,?Tm = 0.70 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","67 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(CUG)6,?Tm = 0.70 ºC,"RNA = 10 uM, Ligand = 0 - 20 uM","68 mM KCl, 10 mM potassium phosphate (K+) (pH = 7.0)",Binding,Circular Dichroism,Melting curve monitored from 25C to 95C with titration of ligand til DN = 2.0,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)60,prominent retardation in migration,"RNA = 10 uM, Ligand = 0, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.50, 5.00 mM",50 mM KCl,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with ligand for 30 min at RT,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)40,prominent retardation in migration,"RNA = 10 uM, Ligand = 0, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.50, 5.00 mM",50 mM KCl,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with ligand for 30 min at RT,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)20,prominent retardation in migration,"RNA = 10 uM, Ligand = 0, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.50, 5.00 mM",50 mM KCl,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with ligand for 30 min at RT,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,no significant retardation in migration,"RNA = 10 uM, Ligand = 0, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.50, 5.00 mM",50 mM KCl,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with ligand for 30 min at RT,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)1,intensity of bands decreased with addition of ligand,"Ligand = 0, 0.0468, 0.0937, 0.187, 0.375, 0.750 mM",-,Binding,PCR Stop Assay,-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,intensity of bands decreased with addition of ligand,"Ligand = 0, 0.0468, 0.0937, 0.187, 0.375, 0.750 mM",-,Binding,PCR Stop Assay,-,"ligand free control, TMPyP4 and TMPyP2 (known nucleic acid binders) as controls",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)1,no significant changes in band intensity,"Ligand = 0, 0.0468, 0.0937, 0.187, 0.375, 0.750 mM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,C,r(AU)6,no significant changes in band intensity,"Ligand = 0, 0.0468, 0.0937, 0.187, 0.375, 0.750 mM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)1,piperine protons found to interact with CGG RNA in a pi-pi interaction,NR,"10 mM phosphate (pH = 7.2), 0.1 M KCl, and 50 mM EDTA in 10% D2O",Structure Determination,Nuclear Magnetic Resonance,"successive addition of RNA, 1D proton NMR",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0123,,O=C(\C=C\C=C\C1=CC=C2OCOC2=C1)N1CCCCC1,Piperine ,10.1021/acschemneuro.9b00282,,r(CGG)6,piperine protons found to interact with CGG RNA in a pi-pi interaction,NR,"10 mM phosphate (pH = 7.2), 0.1 M KCl, and 50 mM EDTA in 10% D2O",Structure Determination,Nuclear Magnetic Resonance,"successive addition of RNA, 1D proton NMR",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,spectra indicated ligand bound to RNA,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,Cos-7 Cells,treatment with ligand showed cytoprotective effects against misfolded expanded polyglutamine proteins,NR,Cytotoxicity,MTT,"Expanded polyglutamine expressing cells,  Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x1 RNA,"Kd1 = 0.0343 uM, Kd2 = 1.1674 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Huntington's Disease patient fibroblasts,"IC50 = 49.26 uM, toxicity in the micromolar range",300.0 - 0.0 uM,Cytotoxicity ,MTT,"Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x1 RNA,"Kd1 = 1.6851 uM, Kd2 = 1.6851 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,C,Healthy Fibroblasts,"IC50 = 94.60 uM, toxicity in the micromolar range",300.0 - 0.0 uM,Cytotoxicity ,MTT,"Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,"Kd1 = 0.093 uM, Kd2 = 0.093 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Huntington's Disease patient fibroblasts,"Compounds were distributed in the cytoplasm only, not the nucleus. Ligands selective to RNA not DNA",100 uM,Localization,Confocal Imaging,Hoechst dye used to stain cells,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,"Kd 1 = 1.181 uM, Kd2 = 1.181 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Cos-7 Cells,Dose dependent reduction of aggregates,NR,On-Target Effect,Fluorescence Microscopy,EGFPHDQ23 and EGFP-HDQ74 expressing COS-7 cells; concentrations of ligands not reported but increasing. ,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,ctDNA,"Kd1 = 70.90 uM, Kd2 = 68.90 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Cos-7 Cells,Reduction of protein aggregates upon treatment with compounds,NR,Protein Abundance,Western Blot,EGFPHDQ23 and EGFP-HDQ74 expressing COS-7 cells; Anti-GFP and anti-GAPDH antibodies used,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,spectra indicated ligand bound to RNA,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,Cos-7 Cells,reduction of diseased plasmid expression upon treatment by compound,NR,Protein Abundance,Western Blot,"Expanded polyglutamine expressing cells, Anti-GFP and anti-GAPDH antibodies used",GFP and GAPDH as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,no binding,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,?Tm = 7.2 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,?Tm = 6.2 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,?Tm = 1.3 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,Kd = 35.08 nM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,Kd = 671 nM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CCG/3'GCC)x6 RNA,Kd = 1.84 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CUG/3'GUC)x6 RNA,Kd = 1.02 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x20 RNA,Kd = 350.87 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,Kd = 58.13 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0124,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=CC=C23)C(=C1N)C1=CC=CC=C1,Compound 3,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GAC)x6 DNA,Kd = 326.8 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,spectra indicated ligand bound to RNA,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,Cos-7 Cells,treatment with ligand showed cytoprotective effects against misfolded expanded polyglutamine proteins,NR,Cytotoxicity,MTT,"Expanded polyglutamine expressing cells,  Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x1 RNA,"Kd1 = 0.0352uM, Kd2 = 0.7426 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Huntington's Disease patient fibroblasts,"IC50 = 24.78 uM, toxicity in the micromolar range",300.0 - 0.0 uM,Cytotoxicity ,MTT,"Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x1 RNA,"Kd1 = 2.2365 uM, Kd2 = 2.2365 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,C,Healthy Fibroblasts,"IC50 = 94.35 uM, toxicity in the micromolar range",300.0 - 0.0 uM,Cytotoxicity ,MTT,"Cells were treated with compound at 70% confluency for 24 hours, then MTT was added. Cells were incubated for 4 hours with MTT",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,"Kd1 = 0.004 uM, Kd2 = 0.159 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Huntington's Disease patient fibroblasts,"Compounds were distributed in the cytoplasm only, not the nucleus. Ligands selective to RNA not DNA",100 uM,Localization,Confocal Imaging,Hoechst dye used to stain cells,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,"Kd1 = 0.662, Kd2 = 11.278 uM","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Cos-7 Cells,Dose dependent reduction of aggregates,NR,On-Target Effect,Fluorescence Microscopy,"EGFPHDQ23 and EGFP-HDQ74 expressing COS-7 cells, concentrations of ligands not reported but increasing. ",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,ctDNA,"Kd2 = 263.9 uM, Kd2 = 263.9","Ligand = 1.0 nM, RNA = 5.0 uM",NR,Binding,Fluorescence Based Titration (Intrinsic),RNA was serially diluted and enhancement in emission was observed in the presence of the compounds. Tested at 25°C,-,,Cos-7 Cells,Reduction of protein aggregates upon treatment with compounds,NR,Protein Abundance,Western Blot,"EGFPHDQ23 and EGFP-HDQ74 expressing COS-7 cells, Anti-GFP and anti-GAPDH antibodies used",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,spectra indicated ligand bound to RNA,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,Cos-7 Cells,reduction of diseased plasmid expression upon treatment by compound,NR,Protein Abundance,Western Blot,"Expanded polyglutamine expressing cells, Anti-GFP and anti-GAPDH antibodies used",GFP and GAPDH as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,no binding,RNA = 20 uM with ligand concentration increasing ,"10 mM phosphate (pH = 7.2), 0.1 M NaCl, and 50 mM EDTA",Binding,Circular Dichroism,"Tested at 25°C, ligand concentration ranged from Drug/Nucleic Acid ratio 0.5-4",Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,?Tm = 9.5 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,?Tm = 4.9 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,?Tm = 0.9 ºC,"Ligand = 2.0 uM, RNA = 1.0 uM",NR,Binding,CD Melting,-,Control with no drug,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x20 RNA,Kd = 43.47 nM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,,(5'CAG/3'GAC)x6 RNA,Kd = 256.41 nM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CCG/3'GCC)x6 RNA,Kd = 3.59 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CUG/3'GUC)x6 RNA,Kd = 3.31 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x20 RNA,Kd = 389.10 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GUC)x6 RNA,Kd = 4.52 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0125,,COC1=CC=C(C=C1)C(=O)C1=NC2=C(C(=O)OC3=CC=C(Br)C=C23)C(=C1N)C1=CC=CC=C1,Compound 15,10.1016/j.biochi.2019.05.001,C,(5'CAG/3'GAC)x6 DNA,Kd = 22.22 uM,"Ligand = 60 uM, RNA = 2.3 uM","10 nM sodium phosphate buffer (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry,21 injections (1.85 uL each) of compound added to the ITC cell with an 120 s pause between injections,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0126,,C[N+]1=CC=C(C=NNC(=O)C2=CC=CC(=N2)C(=O)NN=CC2=C3C=CC=CC3=[N+](C)C=C2)C2=CC=CC=C12,PyDH2,10.1016/j.ejmech.2019.05.042,C,G4-DNA F-25TAG-T,"strongly stabilized G4-DNA, ?Tm ~ 30 °C","ligand = 1.0 µM, DNA = 0.2 ?M","K100 buffer: 10 mM LiAsO2Me2, 100 mM KCl (pH = 7.2)",Binding,Fluorescence Melting Assay,Not significantly affected by 3 or 10 µM of ds26 DNA competitor,-,C,Mutu-1 Cells,GI50 > 100 MM,0.5 - 100 µM,Cytotoxicity,MTT,Ligand is less toxic than prototype drug PhenDC3,DMSO vehicle,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0126,,C[N+]1=CC=C(C=NNC(=O)C2=CC=CC(=N2)C(=O)NN=CC2=C3C=CC=CC3=[N+](C)C=C2)C2=CC=CC=C12,PyDH2,10.1016/j.ejmech.2019.05.042,C,G4 DNA F-myc22-T,"strongly stabilized G4-DNA, ?Tm ~ 24 °C","ligand = 1.0 µM, DNA = 0.2 ?M","K1 buffer: 10 mM LiAsO2Me2, 1 mM KCl, 99 mM LiCl (pH = 7.2)",Binding,Fluorescence Melting Assay,Not significantly affected by 3 or 10 µM of ds26 DNA competitor,-,,H1299 Cells Transfected with EBNA1,"Significantly reduced both the number (0.27 ± 0.11 per cell) and the intensity of PLA signals, hence confirming the ability to disrupt the EBNA1 mRNA-NCL interaction",5 µM,On-Target Effect,Proximity Ligation Assay,-,DMSO control demonstrated high level of PLA signals (1.83 ± 0.54 per cell),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0126,,C[N+]1=CC=C(C=NNC(=O)C2=CC=CC(=N2)C(=O)NN=CC2=C3C=CC=CC3=[N+](C)C=C2)C2=CC=CC=C12,PyDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,?Tm ~ 15 °C; Not significantly affected by dsDNA competitor,ligand = 1.0 µM,"10mM LiAsO2Me2, 10mM KCl, 90mM LiCl (pH = 7.3)",Binding,Fluorescence Melting Assay,"oligoribonucleotide F-g4-EBNA1-T, bearing a fluorophore (50, 6-FAM) and a quencher (30, TAMRA); Each well contained 0.2 mM of double-labelled g4-EBNA1, 1 mM of tested compound, and/or 0, 3 or 10 µM of ds26 DNA competitor","Ligand free control; 0, 3, or 10 µM of ds26 DNA competitor",,H1299 Cells Transfected with EBNA1,Increased EBNA1 expression,10 µM,Protein Abundance,Western Blot,Cells incubated with 10 mM of drug for 40 h after transfection,PhenDC3 was used as a positive control and DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0126,,C[N+]1=CC=C(C=NNC(=O)C2=CC=CC(=N2)C(=O)NN=CC2=C3C=CC=CC3=[N+](C)C=C2)C2=CC=CC=C12,PyDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,DC50 = 0.26 ± 0.05 µm,NR,"10mM KAsO2Me2, 100 mM KCl, 1 mM EDTA, 1% v/v DMSO",Binding,Fluorescence Displacement,non-labelled oligoribonucleotide g4-EBNA1; Thiazole Orange Fluorescent Probe; Ligand was not able to induce displacement of TO from the doublestranded DNA substrate ds26 (DC50 > 2.5 µM),-,C,H1299 Cells Transfected with EBNA1?GAr,No effect on EBNA1 expression,10 µM,Protein Abundance,Western Blot,Cells incubated with 10 mM of drug for 40 h after transfection,PhenDC3 was used as a positive control and DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0126,,C[N+]1=CC=C(C=NNC(=O)C2=CC=CC(=N2)C(=O)NN=CC2=C3C=CC=CC3=[N+](C)C=C2)C2=CC=CC=C12,PyDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,Reduced the amount of RNA-bound NCL almost 10-fold,ligand = 10 µM,"10mM Tris-HCl (pH = 7.5), 100mM KCl, 0.1mM EDTA",On-Target Effect,RNA Pull-down,Using biotin-tagged RNA oligonucleotide G4-EBNA1 and recombinant NCL.,DMSO control. Negligible binding of NCL was detected with a non-G4-forming RNA oligonucleotide GM (obtained from g4-EBNA1 by replacement of guanines critical for G4 formation with A or U residues),,H1299 Cells,"Significantly increased the presentation of antigenic peptides from GAr-OVA (more than a two-fold increase), while having no effect on cells expressing OVA, Increased antigen presentation levels in a GAr-dependent manner, demonstrating ability to significantly interfere with the immune evasion of EBNA1",10 µM,Antigen Presentation,ELISA,Cells were transfected with murine MHC class I Kb and 235GAr-OVA or OVA plasmid constructs and co-cultured with naive OVA257e264 (SL8 peptide) specific CD8+ T-cells from OT-1 mice. Levels of antigen presentation were determined by measuring release of IL-2 in the supernatant because IL-2 is a growth factor stimulating T-cell proliferation,DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,C,G4-DNA F-25TAG-T,"strongly stabilized G4-DNA, ?Tm ~ 30 °C","ligand = 1.0 µM, DNA = 0.2 ?M","K100 buffer: 10 mM LiAsO2Me2, 100 mM KCl (pH = 7.2)",Binding,Fluorescence Melting Assay,Not significantly affected by 3 or 10 µM of ds26 DNA competitor,-,C,Mutu-1 Cells,50 < GI50 < 100 µM,0.5 - 100 µM,Cytotoxicity,MTT,Ligand is less toxic than prototype drug PhenDC3,DMSO vehicle,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,C,G4 DNA F-myc22-T,"strongly stabilized G4-DNA, ?Tm ~ 24 °C","ligand = 1.0 µM, DNA = 0.2 ?M","K1 buffer: 10 mM LiAsO2Me2, 1 mM KCl, 99 mM LiCl (pH = 7.2)",Binding,Fluorescence Melting Assay,Not significantly affected by 3 or 10 µM of ds26 DNA competitor,-,,H1299 cells transfected with EBNA1,"Significantly reduced both the number (0.40 ± 0.21 per cell) and the intensity of PLA signals, hence confirming the ability to disrupt the EBNA1 mRNA-NCL interaction",5 µM,On-Target Effect,Proximity Ligation Assay,-,DMSO control demonstrated high level of PLA signals (1.83 ± 0.54 per cell),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,?Tm ~ 20 °C; Not significantly affected by dsDNA competitor,ligand = 1.0 µM,"10mM LiAsO2Me2, 10mM KCl, 90mM LiCl (pH = 7.3)",Binding,Fluorescence Melting Assay,"oligoribonucleotide F-g4-EBNA1-T, bearing a fluorophore (50, 6-FAM) and a quencher (30, TAMRA); Each well contained 0.2 mM of double-labelled g4-EBNA1, 1 mM of tested compound, and/or 0, 3 or 10 µM of ds26 DNA competitor","Ligand free control; 0, 3, or 10 µM of ds26 DNA competitor",,H1299 cells transfected with EBNA1,Increased EBNA1 expression,10 µM,Protein Abundance,Western Blot,Cells incubated with 10 mM of drug for 40 h after transfection,PhenDC3 was used as a positive control and DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,DC50 = 0.30 ± 0.03 µm,NR,"10mM KAsO2Me2, 100 mM KCl, 1 mM EDTA, 1% v/v DMSO",Binding,Fluorescence Displacement,non-labelled oligoribonucleotide g4-EBNA1; Thiazole Orange Fluorescent Probe,-,C,H1299 cells transfected with EBNA1?GAr,No effect on EBNA1 expression,10 µM,Protein Abundance,Western Blot,Cells incubated with 10 mM of drug for 40 h after transfection,PhenDC3 was used as a positive control and DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,,G4 EBNA1 mRNA,Reduced the amount of RNA-bound NCL almost 10-fold,ligand = 10 µM,"10mM Tris-HCl (pH = 7.5), 100mM KCl, 0.1mM EDTA",On-Target Effect,RNA Pull-down,Using biotin-tagged RNA oligonucleotide G4-EBNA1 and recombinant NCL.,DMSO control. Negligible binding of NCL was detected with a non-G4-forming RNA oligonucleotide GM (obtained from g4-EBNA1 by replacement of guanines critical for G4 formation with A or U residues),,H1299 Cells,"Significantly increased the presentation of antigenic peptides from GAr-OVA (more than a two-fold increase), while having no effect on cells expressing OVA, Increased antigen presentation levels in a GAr-dependent manner, demonstrating ability to significantly interfere with the immune evasion of EBNA1",5 or 10 µM,Antigen Presentation,ELISA,Cells were transfected with murine MHC class I Kb and 235GAr-OVA or OVA plasmid constructs and co-cultured with naive OVA257e264 (SL8 peptide) specific CD8+ T-cells from OT-1 mice. Levels of antigen presentation were determined by measuring release of IL-2 in the supernatant because IL-2 is a growth factor stimulating T-cell proliferation,DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0127,,C[N+]1=CC=C(C=NNC(=O)C2=NC3=C(C=CC4=C3N=C(C=C4)C(=O)NN=CC3=C4C=CC=CC4=[N+](C)C=C3)C=C2)C2=CC=CC=C12,PhenDH2,10.1016/j.ejmech.2019.05.042,,,,,,,,,,,Mutu-1 Cells,Decreased the average number of PLA signals per cell from 1.68 ± 0.44 to 0.59 ± 0.20,5 µM,On-Target Effect,Proximity Ligation Assay,,DMSO as a negative control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0128,,COC1=CC2=CC3=[N+](CCC4=CC(OC)=C(OC)C=C34)C=C2C=C1OC,Pseudopalmatine,10.1016/j.ijbiomac.2018.10.017,,miR-1587 RNA,?Tm = 8 ºC,"RNA = 2.5 uM, Ligand = 5 uM","30 mM Tris-HCl, 0-150 mM KCl",Binding,Circular Dichroism,Temperature range was 20 - 95ºC,ligand free control,,HeLa Cells,ligand had no impact on reporter expression alone but miR-1587 binding to mRNA was inhibited due to binding and stabilization of G-quadruplex by the small molecule,NR,Transcriptional Activity,Dual Luciferase Reporter Assay,3' UTR region or fragments of candidate miRNA target gene was inserted into the vector,"Firefly luciferase as a reporter, Renilla luciferase as a reference",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,Kd = 0.7 ± 0.1 umol/L,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",C,NCM460 Cells,IC50 = 8.8 ± 1.6 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,C,NRAS RNA mutant,N/A,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",,A375 Cells,IC50 = 1.9 ± 0.4 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,C,Hairpin DNA,N/A,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",,A549 Cells,IC50 = 1.1 ± 0.6 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,?Tm = 17.5 ºC,RNA = 5 uM,10 mM Tris-HCl  (pH = 7.4) in the absence or presence of 100 mM KCl,Binding,Circular Dichroism,Experiment was run in absence and presence of potassium,-,,HeLa Cells,IC50 = 1.0 ± 0.5 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,Kd = 1.47 ± 0.1 umol/L,Ligand = 5 uM,"10 mM Tris-HCl  (pH = 7.4), 100 mM KCl",Binding,UV-Vis Titration,"RNA titrated into solution, strong pi-pi interactions between ligand and RNA",-,,Huh7 Cells,IC50 = 1.7 ± 0.5 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,"Kd = 2.50 ± 0.95 umol/L, 2:1 ligand:RNA complex",-,-,Binding,Fluorescence Based Titration (Intrinsic),"RNA titrated into solution, Fluorescence intensity increased with increasing RNA concentration",-,,HCT116 Cells,IC50 = 1.6 ± 0.5 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Ligand arrests cells in the G0/G1 phase in a dose dependent manner,NR,Cell Cycle Progression,Flow Cytometry ,"Cells treated with different concentrations of ligand, highest concentration = 0.5 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,65% of ligand taken into cells after 6 hrs,Ligand = 1.0 uM,Cell Uptake,Confocal Imaging,cells dyed with DAPI,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,MCF-7 Cells,IC50 = 1.5 ±0.3 uM,NR,Proliferation,MTT,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Ligand inhibited proliferation at low concentrations,"Ligand = 0.25 uM, 0.5 uM, 1.0 uM",Proliferation,Real-Time Cellular Analysis,72 hr treatment,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,C,Primary Cultured Mouse Mesangial Cells,no change in proliferation,"Ligand = 0.25 uM, 0.5 uM, 1.0 uM",Proliferation,Real-Time Cellular Analysis,initial inhibition on proliferation but then an increase on proliferation after 36 h of treatment 72 hr treatment,Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Ligand represses NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,MCF-7 Cells,Ligand represses NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,HeLa Cells,Ligand represses NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A549 Cells,Ligand represses NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Ligand inhibits NRAS expression at 0.02 umol/L but has no effect on NRAS transcription from 0.02 to 0.5 umol/L,"Ligand = 0.5, 1.0, 2.0 uM",Translational Activity,qRT-PCR,,"Ligand free control, B-actin used as housekeeping gene",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,MCF-7 Cells,"Dose dependent decrease in relative luciferase % for WT plasmid, not mutants, indicates that ligand might repress NRAS translation by binding to RNA G-quadruplex in 5'-UTR of NRAS",Ligand ranged from 0.125 to 0.5 ?M,Translational Activity,Dual-Luciferase Assay,plasmid carrying NRAS 5'-UTR WT or mutant clones transfected into cells,Plasmid with firefly luciferase as a control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0129,,CSC1=CC=C(\C=C\C2=CC3=C(NCC[NH+]4CCCC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-10,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Stabilization of NRAS RNA G-quadruplex by ligand could interfere with DXH36 protein binding to NRAS mRNA,Ligand = 2 uM,Translational Activity,RNA Pull-Down,"Obtained RNA samples used for RT-PCR detection, determining whether binding of DHX36 protein to NRAS mRNA would be interfered by ligand","DMEM control, IgG negative control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,Kd.= 0.5 ± 0.2 umol/L,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",C,NCM460 Cells,IC50 = 10.0 ± 1.7 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,C,NRAS RNA mutant,N/A,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",,A375 Cells,IC50 = 2.0 ± 1.1 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,C,Hairpin DNA,N/A,"Ligand = 0.3125, 0.625, 1.25, 2.5, 5, 10, and 20 ?M","50 mM Tris-HCl (pH = 7.4), 150 mM KCl, 0.005% Tween-20",Binding,Surface Plasmon Resonance,RNA and DNA immobilized in flow cells,"previous derivative, compound 16 used as control, blank flow cell used as control",,A549 Cells,IC50 = 2.0 ± 0.6 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,?Tm = 7.9 ºC,RNA = 5 uM,10 mM Tris-HCl  (pH = 7.4) in the absence or presence of 100 mM KCl,Binding,Circular Dichroism,Experiment was run in absence and presence of potassium,-,,HeLa Cells,IC50 = 1.7 ± 0.5 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,Kd = 1.98 ± 0.4 umol/L,Ligand = 5 uM,"10 mM Tris-HCl  (pH = 7.4), 100 mM KCl",Binding,UV-Vis Titration,"RNA titrated into solution, strong pi-pi interactions between ligand and RNA",-,,Huh7 Cells,IC50 = 3.2 ± 0.1 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,NRAS RNA G-quadruplex,Kd = 0.75 ± 0.16 umol/L 1:1 stoichiometry,,,,,,,,HCT116 Cells,IC50 = 4.4 ± 1.8 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,MCF-7 Cells,IC50 = 2.3 ± 0.1 uM,NR,Proliferation,MTT,"Ligand concentrations not reported, highest was 50 uM",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A375 Cells,Ligand increases NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,MCF-7 Cells,No effect on NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,HeLa Cells,No effect on NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0130,,CSC1=CC=C(\C=C\C2=CC3=C(NCCN4CC[NH+](C)CC4)C4=C([NH+]=C3C=C2)C2=C(O4)C=CC=C2)C=C1,4a-16,10.1021/acs.jmedchem.8b00257,,,,,,,,,,,A549 Cells,No effect on NRAS translation,NR,Translational Activity,Western Blot,Cells treated with different concentrations of ligand,GAPDH was an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,HSA,negligible fluorescence,"Ligand = 1 uM, HSA = 0.1 mg/L",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"5 uM significantly inhibited protein translation of HCV, protein levels decreased in a dose dependent manner","Ligand = 1, 3, 5 uM",Antiviral Activity,Western Blot,"cells treated with varied concentrations of ThT-NE for 48 hrs and expression levels of essential viral HCV proteins (core, NS3) were measured ","?-actin as internal control, IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,thrombin,negligible fluorescence,"Ligand = 1 uM, thrombin = 2 U/mL",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,no expression of HCV proteins,"Ligand = 1, 3, 5 uM",Antiviral Activity,Western Blot,"cells treated with varied concentrations of ThT-NE for 48 hrs and expression levels of essential viral HCV proteins (core, NS3) were measured ","?-actin as internal control, IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Vitamin C,negligible fluorescence,"Ligand = 1 uM, Vitamin C = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"concentrations greater than 3 uM significantly decreased viral RNA levels, RNA expression decreased in a dose dependent manner","Ligand = 1, 3, 5 uM",Antiviral Activity,RT-qPCR,cells treated with varied concentrations of ThT-NE for 48 hrs copy numbers of HCV core gene and HCV NS3 gene in total RNA were measured,"IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,,HCV CG2a G4 sequence,"Kd = 1.77 ± 0.19 uM, 1:1 binding model","Ligand = 1 uM, RNA = 0-10 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Based Titration (Intrinsic),-,-,C,Huh7 Cells,no expression of viral RNA,"Ligand = 1, 3, 5 uM",Antiviral Activity,RT-qPCR,cells treated with varied concentrations of ThT-NE for 48 hrs copy numbers of HCV core gene and HCV NS3 gene in total RNA were measured,"IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ss20 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 0-10 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Based Titration (Intrinsic),-,-,,GG2 Cells,time dependent inhibition of viral protein expression,Ligand = 3 uM,Antiviral Activity,Western Blot,"cells treated with ThT-NE for 12h, 24h, or 48h,  expression levels of essential viral HCV proteins (core, NS3) were measured ","?-actin as internal control, IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ds26 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 0-10 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Based Titration (Intrinsic),-,-,C,Huh7 Cells,no expression of HCV proteins,Ligand = 3 uM,Antiviral Activity,Western Blot,"cells treated with ThT-NE for 12h, 24h, or 48h,  expression levels of essential viral HCV proteins (core, NS3) were measured ","?-actin as internal control, IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,HP20 hairpin RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 0-10 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Based Titration (Intrinsic),-,-,,GG2 Cells,time dependent inhibition of HCV gene replication,Ligand = 3 uM,Antiviral Activity,RT-qPCR,"cells treated with ThT-NE for 12h, 24h, or 48h,  copy numbers of HCV core gene and HCV NS3 gene in total RNA were measured","IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,miR122 microRNA mimic,negligible fluorescence,"Ligand = 1 uM, RNA = 0-10 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Based Titration (Intrinsic),-,-,C,Huh7 Cells,no expression of viral RNA,Ligand = 3 uM,Antiviral Activity,RT-qPCR,"cells treated with ThT-NE for 12h, 24h, or 48h,  copy numbers of HCV core gene and HCV NS3 gene in total RNA were measured","IFN-? as positive control, ligand free control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,,HCV CG2a G4 sequence,ThT-nE fluorescence increases over 1693-fold,"Ligand = 1 uM, RNA = 10 uM",NR,Binding,Fluorescence Spectroscopy,-,RNA free control,,Huh7 Cells,negligible effect on cell viability,Ligand = 1 uM,Cytotoxicity,MTT,incubation time ranged from 10 min to 24 hrs at 37C,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,HCV CG2a G4 sequence,fluorescence of complex eliminated,"Ligand = 1 uM, RNA = 1 uM",NR,Binding,Fluorescence Spectroscopy,G4-unfolding conditions (10% formamide or 10% urea),-,,GG2 Cells,negligible effect on cell viability,Ligand = 1 uM,Cytotoxicity,MTT,incubation time ranged from 10 min to 24 hrs at 37C,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ss16 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"70% of fluorescence signal retained after 30 min irradiation, demonstrating good photostability",Ligand = 1 uM,Ligand Stability ,Photobleaching ,"incubation time = 10 min, irradiation time = 60 min",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,"mutated HCV CG2a G4 sequence ""CG2a-M""",negligible fluorescence,"Ligand = 1 uM, RNA = 5 uM",NR,Binding,Fluorescence Spectroscopy,-,-,,Huh7 Cells,cell exhibited staining by ThT-NE with ThT-NE foci overlapping with Cy5 signals. ,NR,Localization,Confocal Imaging,CG2a RNA was tagged with Cy5 dye and transfected into Huh7 cells using liposome-based transfection,Cy5 as an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,"mutated HCV CG2a G4 sequence ""CG2a-M2""",negligible fluorescence,"Ligand = 1 uM, RNA = 5 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,no fluorescence based on ThT-NE and no endogenous constituents from cells showed interference with ThT-NE signal,NR,Localization,Confocal Imaging, CG2a-M (mutated) RNA was tagged with Cy5 dye and transfected into Huh7 cells using liposome-based transfection,Cy5 as an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,,HCV CG2a G4 sequence,selectively stained with ThT-NE,"Ligand = 2 uM, RNA = 100 uM","90 mM Tris, 90 mM boric acid (pH = 8.0)",Binding,Native Gel Electrophoresis,Native gel run to analyze RNA folding then stained with ligand,SYBR green II stain,C,Huh7 Cells,"no fluorescence based on ThT-NE, indicating that proper G4-folding is necessary for fluorescence",NR,Localization,Confocal Imaging,AS-CG2a/CG2a (antisense strand introduced to block G4 formation) RNA was tagged with Cy5 dye and transfected into Huh7 cells using liposome-based transfection,Cy5 as an internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,"mutated HCV CG2a G4 sequence ""CG2a-M""",not stained ,"Ligand = 2 uM, RNA = 100 uM","90 mM Tris, 90 mM boric acid (pH = 8.0)",Binding,Native Gel Electrophoresis,Native gel run to analyze RNA folding then stained with ligand,SYBR green II stain,,GG2 Cells,fluorescence due to ThT-NE staining,Ligand = 1 uM,Localization,Confocal Imaging,incubation time = 10 min,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,"mutated HCV CG2a G4 sequence ""CG2a-M2""",not stained ,"Ligand = 2 uM, RNA = 100 uM","90 mM Tris, 90 mM boric acid (pH = 8.0)",Binding,Native Gel Electrophoresis,Native gel run to analyze RNA folding then stained with ligand,SYBR green II stain,C,Huh7 Cells,no fluorescence based on ThT-NE,Ligand = 1 uM,Localization,Confocal Imaging,incubation time = 10 min,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Lys,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"most ThT-NE foci colocalized with the ER tracker, ThT-NE stained HCV vRNA puncta located inside the ER",Ligand = 1 uM,Localization,Confocal Imaging,"cells stained with different organelle trackers including endoplasmic reticulum, lysosome, mitochondria, and golgi apparatus",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Met,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,"Huh7.5 Cells, HCV infected",fluorescence intensity per cell increased over period of infection and the increase was consistent with the increase in NS5A ,Ligand = 1 uM,Localization,Confocal Imaging,"cells were inoculated at a moi = 0.1 and live cell images were taken 12, 24, and 48 hours post infection","NS5A protein as internal control, measured by immunofluorescence",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Phe,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7.5 Cells,"no fluorescence of ThT-NE, no colocalization ",Ligand = 1 uM,Localization,Confocal Imaging,"live cell images were taken 12, 24, and 48 hours post ""infection"" (cells were not infected)","NS5A protein as internal control, measured by immunofluorescence",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Pro,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,"HLCZ01 cells, HCV infected","fluorescence from ThT-NE after 14 days post infection, fluorescent signal showed good agreement with RT-qPCR ""control""",Ligand = 1 uM,Localization,Confocal Imaging,"cells were infected with sera from HCV-infected donors, live cell imaging occurred between 1-18 days post infection",RT-qPCR measuring copy numbers of the HCV core gene at different days post infection mirrored fluorescence changes of ThT-NE over the course of the experiment,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Ser,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,HLCZ01 cells,no fluorescence,Ligand = 1 uM,Localization,Confocal Imaging,live cell imaging occurred between 1-18 days post infection,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ss23 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"ThT-NE staining not affected, indicating that ThT-NE signal derives from RNA ",Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"prior to imaging, cells underwent nuclease digestion with DNase I",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ds18 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,no fluorescence based on ThT-NE,Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"transfected with MB-C (an HCV vRNA specific molecular beacon probe), lacking viral RNA, HCV virus core (ligand target), G4 (motif recognized by ligand)",MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ds26 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,FCA1 Cells,no fluorescence based on ThT-NE,Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"transfected with MB-C (an HCV vRNA specific molecular beacon probe), containing viral RNA, lacking HCV virus core (ligand target), G4 (motif recognized by ligand)",MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,HP20 hairpin RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,GG22 Cells,no fluorescence based on ThT-NE,Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"transfected with MB-C (an HCV vRNA specific molecular beacon probe) and CG2a-M (mutation of target), containing viral RNA, HCV virus core (ligand target), lacking G4 (recognized motif)",MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,miR122 microRNA mimic,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,GG2 Cells,no fluorescence based on ThT-NE,Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"transfected with MB-C (an HCV vRNA specific molecular beacon probe) and AS-CG2a (antisense strand introduced to block G4 formation), containing viral RNA, HCV virus core (ligand target), lacking G4 (recognized motif)",MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,tRNA Val tRNA fragments,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,not stained by ligand,Ligand = 2 uM,Off-Target Effect,Flow Cytometry ,-,MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,total RNA extracted from Huh7 cells,negligible fluorescence,Ligand = 1 uM,NR,Binding,Fluorescence Spectroscopy,-,-,C,FCA1 Cells,not stained by ligand,Ligand = 2 uM,Off-Target Effect,Flow Cytometry ,-,MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,calf thymus DNA,negligible fluorescence,"Ligand = 1 uM, DNA = 50 ug/mL",NR,Binding,Fluorescence Spectroscopy,-,-,C,GG22 Cells,not stained by ligand,Ligand = 2 uM,Off-Target Effect,Flow Cytometry ,transfected with CG2a-M (mutation of target),MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Cys,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,GG2 Cells,"no fluorescence of ThT-NE, no colocalization ",Ligand = 1 uM,Off-Target Effect,Immunofluorescence,"transfected with  AS-CG2a (antisense strand introduced to block G4 formation), BG4 antibody used",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Gln,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,GG2 Cells,"no fluorescence of ThT-NE, no colocalization ",Ligand = 1 uM,Off-Target Effect,Immunofluorescence,"transfected with CG2a-M (mutation of target), BG4 antibody used",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Gly,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,FCA1 Cells,"no fluorescence of ThT-NE, no colocalization ",Ligand = 1 uM,Off-Target Effect,Immunofluorescence,BG4 antibody used,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,His,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,"no fluorescence of ThT-NE, no colocalization ",Ligand = 1 uM,Off-Target Effect,Immunofluorescence,BG4 antibody used,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,adenosine,negligible fluorescence,"Ligand = 1 uM, adenosine = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,"ThT-NE not detectably fluorescent in the concentration range lower than 4 uM, providing an
ultralow-background window in which the intracellular
concentration of the penetrated probe is insufficient to light
up endogenous G4 ","Ligand = 0, 1, 2, 4, 6 uM",Off-Target Effect,Confocal Imaging,cells incubated with different concentrations of ligand for 48 hrs,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,cyt c ,negligible fluorescence,"Ligand = 1 uM, cyt c = 1 ug/uL",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,"ThT-NE not detectably fluorescent in the before one hour of incubation, providing an
ultralow-background window in which the intracellular
concentration of the penetrated probe is insufficient to light
up endogenous G4 ",Ligand = 3 uM,Off-Target Effect,Confocal Imaging,"cells incubated with ligand for 0, 10, 30 min, 1, 2, 4 hrs",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,HRP,negligible fluorescence,"Ligand = 1 uM, HRP = 0.1 mg/L",NR,Binding,Fluorescence Spectroscopy,-,-,C,Huh7 Cells,no fluorescence ,Ligand = 1 uM,Off-Target Effect,Confocal Imaging,"cells incubated with 0, 100, 500, or 1000 ng/mL IFN-? (antiviral for HCV infection) for 48 hours, then stained with ThT-NE for 10 min and live cells were imaged",drug free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ss22 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"ThT-NE staining eliminated, indicating that ThT-NE signal derives from RNA ",Ligand = 1 uM,On-Target Effect,Confocal Imaging,"prior to imaging, cells underwent nuclease digestion with RNase A",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ds17 RNA,negligible fluorescence,"Ligand = 1 uM, RNA = 15 uM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,fluorescence due to ThT-NE staining overlapping with Cy5 signals of MB-C probe,Ligand = 1 uM,On-Target Effect,Confocal Imaging,"transfected with MB-C (an HCV vRNA specific molecular beacon probe), containing viral RNA, HCV virus core (ligand target), G4 (motif recognized by ligand)",MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,sperm DNA,negligible fluorescence,"Ligand = 1 uM, DNA = 50 ug/mL",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,selectively stained by ligand,Ligand = 2 uM,On-Target Effect,Flow Cytometry ,-,MB-C probe (HCV vRNAspecific molecular beacon probe with Cy5/BHQ3 (fluorophore/quencher) pair) as internal control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,cell lysate,negligible fluorescence,Ligand = 1 uM,NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"ThT-NE based fluorescence was eliminated, indicating that ThT-NE competed with the G4 specific ligands",Ligand = 1 uM,On-Target Effect,Confocal Imaging,"cells were incubated with CarboxyPDS and TMPyP4, two G4 specific ligands",Untreated cell control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Arg,negligible fluorescence,"Ligand = 1 uM, amino acid = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,ThT-NE foci colocalized with BG4 staining,Ligand = 1 uM,On-Target Effect,Immunofluorescence,BG4 antibody used,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,BSA,negligible fluorescence,"Ligand = 1 uM, BSA = 0.1 mg/L",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,ThT-NE begins exhibiting fluorescence at 1 uM,"Ligand = 0, 1, 2, 4, 6 uM",On-Target Effect,Confocal Imaging,cells incubated with different concentrations of ligand for 48 hrs,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,GSH,negligible fluorescence,"Ligand = 1 uM, GSH = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,ThT-NE begins exhibiting fluorescence at 10 min,Ligand = 3 uM,On-Target Effect,Confocal Imaging,"cells incubated with ligand for 0, 10, 30 min, 1, 2, 4 hrs",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,Heparin,negligible fluorescence,"Ligand = 1 uM, Heparin = 1 mM",NR,Binding,Fluorescence Spectroscopy,-,-,,GG2 Cells,"increasing concentrations of antiviral drug significantly decreased ThT-NE signals in cells, consistent with trend observed in RT-qPCR analysis of HCV vRNA",Ligand = 1 uM,On-Target Effect,Confocal Imaging,"cells incubated with 0, 100, 500, or 1000 ng/mL IFN-? (antiviral for HCV infection) for 48 hours, then stained with ThT-NE for 10 min and live cells were imaged","drug free control, RT-qPCR analysis of copy number of HCV core gene in total RNA extracted from cells at all concentrations of antiviral incubation",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,,HCV CG2a G4 sequence,"?Tm = 5.2 ºC, ligand moderately increased G4 thermal stabilization with or without ions","Ligand = 25 uM, RNA = 5 uM","20 mM Tris-HCl (pH = 7.2), with or without 100 mM KCl",Binding,Circular Dichroism,"melt study, measured with or without 100 mM KCl (physiological concentration of KCl)",Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,NARS RNA G4,fluorescence comparable to CG2a,"Ligand = 1 uM, RNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,BCL2 RNA G4,fluorescence comparable to CG2a,"Ligand = 1 uM, RNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,TERRA RNA G4,fluorescence comparable to CG2a,"Ligand = 1 uM, RNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,VEGF RNA G4,fluorescence comparable to CG2a,"Ligand = 1 uM, RNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,ZICI RNA G4,fluorescence comparable to CG2a,"Ligand = 1 uM, RNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,KRAS DNA G4,minor fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,cymc DNA G4,minor fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,G3T4 DNA G4,minor fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,PS2.M DNA G4,minor fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,T3TT DNA G4,negligible fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,TBA DNA G4,negligible fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,C,T95 RNA G4,negligible fluorescence,"Ligand = 1 uM, DNA = 5 uM","20 mM Tris-HCl, 10 mM KCl (pH = 7.2)",Binding,Fluorescence Spectroscopy,-,compared to target (CG2a),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0131,,CCN(CC)C1=CC=C(C=C1)C1=[N+](C)C2=CC=C(C)C=C2S1,ThT-NE,10.1021/jacs.8b10265,,HCV CG2a G4 sequence,"?Tm = 8.1 ºC, with KCl: no influence of ligand on spectra, without KCl: ligand improved parallel G4 formation","Ligand = 5 uM, RNA = 10 uM","20 mM Tris-HCl, with or without 100 mM KCl",Structure Determination,Circular Dichroism,measured with or without 100 mM KCl (physiological concentration of KCl),Ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,pri-miR-515 Drosha site,Kd = 12 ± 2.1 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,ligand enriched levels of miR-515 by 5-fold in the pulled down fraction,Ligand = 0.5 uM,On-Target Effect,Chem-CLIP,used Targaprimir-515/885- CA-Biotin; enrichment of miR-515 measured before and after pull-down using RT-qPCR,control compound lacking the RNA binding module (pulled down background RNA),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,adjacent to Drosha site in pri-miR-515,Kd = 7.5 ± 0.7 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,pulldown of miR-515 was competed off by ~50%,Ligand = 5 uM,On-Target Effect,C-Chem-CLIP,ligand incubated with RNA for 15 minutes before adding 0.5 uM Targaprimir-515/885- CA-Biotin to determine competition of parent compound (ligand),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,pri-miR-515 Drosha site and adjacent site,Kd = 15 ± 1.9 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,ligand decreased level of miR-515 with an IC50 of ~2 uM,"Ligand = 0.05, 0.5, 5 uM",Translational Activity,RT-qPCR,"following compound treatment, mature levels of miR-515 were measured",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C,DNA Hairpin,Kd = >100 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C,tRNA,Kd = >100 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C,pri-miR-515 Drosha site,dose-dependent pulldown of RNA,"Ligand = 0.05, 0.5, 5, 50 uM",DMEM growth medium,Binding,Chem-CLIP,"overnight (16 hr) incubation at 37C, derivative of Targaprimir-515/885 was used, Targaprimir-515/885- CA-Biotin","ligand free control, control compound lacking the
RNA-binding module (no pulldown)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,pri-miR-515 Drosha site,competed off pull-down of RNA,"Ligand = 0.5, 5, 50 uM",DMEM growth medium,Binding,C-Chem-CLIP,ligand incubated with RNA for 45 minutes before adding 0.5 uM Targaprimir-515/885- CA-Biotin to determine competition of parent compound (ligand),-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132A,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,Targaprimir-515/885,not self structured,NR,NR,Structure Determination,UV-Vis Thermal Melting,investigating ligand intramolecular structure,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,pri-miR-885 Drosha site,Kd = 9.0 ± 1.0 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,ligand enriched levels of miR-885 by 7-fold in the pulled down fraction,Ligand = 0.5 uM,On-Target Effect,Chem-CLIP,used Targaprimir-515/885- CA-Biotin; enrichment of miR-885 measured before and after pull-down using RT-qPCR,control compound lacking the RNA binding module (pulled down background RNA),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C,DNA Hairpin,Kd = >100 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,pulldown of miR-885 was competed off by ~50%,Ligand = 5 uM,On-Target Effect,C-Chem-CLIP,ligand incubated with RNA for 15 minutes before adding 0.5 uM Targaprimir-515/885- CA-Biotin to determine competition of parent compound (ligand),-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C ,tRNA,Kd = >100 uM,NR,NR,Binding,Fluorescence Spectroscopy,-,-,,MCF-7 Cells,ligand decreased level of miR-885 with an IC50 of ~2 uM,"Ligand = 0.05, 0.5, 5 uM",Translational Activity,RT-qPCR,"following compound treatment, mature levels of miR-885 were measured",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,C,pri-miR-885 Drosha site,dose-dependent pulldown of RNA,"Ligand = 0.05, 0.5, 5, 50 uM",DMEM growth medium,Binding,Chem-CLIP,"overnight (16 hr) incubation at 37C, derivative of Targaprimir-515/885 was used, Targaprimir-515/885- CA-Biotin","ligand free control, control compound lacking the
RNA-binding module (no pulldown)",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,pri-miR-885 Drosha site,competed off pull-down of RNA,"Ligand = 0.5, 5, 50 uM",DMEM growth medium,Binding,C-Chem-CLIP,ligand incubated with RNA for 45 minutes before adding 0.5 uM Targaprimir-515/885- CA-Biotin to determine competition of parent compound (ligand),ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0132B,,C[NH+]1CCN(CC1)C1=CC=C2NC(=NC2=C1)C1=CC=C2NC(=NC2=C1)C1=CC(=C(OCCCC(=O)NCCCN=[N+]=[N-])C(=C1)C(C)(C)C)C(C)(C)C,Targaprimir-515/885,10.1021/jacs.8b10558,,Targaprimir-515/885,not self structured,NR,NR,Structure Determination,UV-Vis Thermal Melting,investigating ligand intramolecular structure,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,Cos-7 Cells,"cell viability increased significantly in higher repeats (Q74, Q84), minor increase in lower repeats (Q23, Q28)",NR,Cytotoxicity,MTT,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84)",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,"minor changes, not indicative of binding",RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,?Tm = 7.6 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 3",ligand free control,C,GM07492 Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Kd = 0.028 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,,Cos-7 Cells,"polyQ aggregation inhibited in higher repeats (Q74, Q84), no changes in lower repeats (Q23, Q28)","Ligand = 25, 50, 100 uM",Protein Abundance,Fluorescence Microscopy,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84), treated for 12 hours with compound",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,Kd = 9.52 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,C,Cos-7 Cells,Minor reduction in aggregates,Ligand = 100 uM,Protein Abundance,Fluorescence Microscopy,Cells transfected with EGFP-CGGx99 plasmid containing a GG mismatch,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,ThT fluorescence increases upon binding with protein aggregates; ThT fluorescence decreased in the presence of compound,"Ligand = 25, 50, 100 uM",Translational Activity,Thioflavin T Fluorescence Assay,cells at 80% confluency were treated for 24 hours with compound then lysed an total protein was extracted. Total protein was stained with ThT dye (10 uM),"ligand free control, ThT control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,?Tm = 5.4 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,?Tm = 0.7 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 DNA,No significant reduction in band intensity,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,no change in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0133,,CS\C(=N/C1=CC=C(Cl)C=C1)N1CC=CC2=CC=CC=C12,CP2,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,compounds preferred binding with C4A5G6 triad with the lowest binding energy (-6.764 kcal/mole),-,-,In Silico,Docking,"CAG duplex RNA (PDB code:2MS5) used for docking, Autodock 4.0 as the software with RNA as a rigid body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,Cos-7 Cells,"cell viability increased significantly in higher repeats (Q74, Q84), minor increase in lower repeats (Q23, Q28)",NR,Cytotoxicity,MTT,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84)",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,"minor changes, not indicative of binding",RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,?Tm = 7.1 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 3",ligand free control,C,GM07492 Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Kd = 0.709 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,,Cos-7 Cells,"polyQ aggregation inhibited in higher repeats (Q74, Q84), no changes in lower repeats (Q23, Q28)","Ligand = 25, 50, 100 uM",Protein Abundance,Fluorescence Microscopy,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84), treated for 12 hours with compound",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,Kd = 30.3 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,C,Cos-7 Cells,Minor reduction in aggregates,Ligand = 100 uM,Protein Abundance,Fluorescence Microscopy,Cells transfected with EGFP-CGGx99 plasmid containing a GG mismatch,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,ThT fluorescence increases upon binding with protein aggregates; ThT fluorescence decreased in the presence of compound,"Ligand = 25, 50, 100 uM",Translational Activity,Thioflavin T Fluorescence Assay,cells at 80% confluency were treated for 24 hours with compound then lysed an total protein was extracted. Total protein was stained with ThT dye (10 uM),"ligand free control, ThT control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,?Tm = 5.8 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,?Tm = 1.0 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 DNA,No significant reduction in band intensity,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,no change in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0134,,FC1=CC2=C(SCC3=CC=CC=C3)C=NN=C2C=C1,CP6,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,compounds preferred binding with C4A5G6 triad with the lowest binding energy (-6.84 kcal/mole),-,-,In Silico,Docking,"CAG duplex RNA (PDB code:2MS5) used for docking, Autodock 4.0 as the software with RNA as a rigid body",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,Cos-7 Cells,"cell viability increased significantly in higher repeats (Q74, Q84), minor increase in lower repeats (Q23, Q28)",NR,Cytotoxicity,MTT,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84)",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,"minor changes, not indicative of binding",RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x20 RNA,?Tm = 8.4 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 3",ligand free control,C,GM07492 Cells,compounds showed very less cytotoxic effects in fibroblast cells from HD patient-derived cells ,NR,Cytotoxicity,MTT,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Kd = 0.011 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,,Cos-7 Cells,"polyQ aggregation inhibited in higher repeats (Q74, Q84), no changes in lower repeats (Q23, Q28)","Ligand = 25, 50, 100 uM",Protein Abundance,Fluorescence Microscopy,"Cells expressed expanded polyglutamine (HDQ23, HDQ74, ATXQ28, or ATXQ 84), treated for 12 hours with compound",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,Kd = 3.89 uM,NR,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Isothermal Titration Calorimetry ,"RNA used in the cell, compounds titrated in, molar ratio of RNA to compound ranged from 0 to 1.5",Myricetin positive control,C,Cos-7 Cells,Minor reduction in aggregates,Ligand = 100 uM,Protein Abundance,Fluorescence Microscopy,Cells transfected with EGFP-CGGx99 plasmid containing a GG mismatch,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,changes in CD spectra indicative of binding,RNA = 20 uM,"10 mM Na2HPO4 (pH = 7.2), 0.1 M NaCl, 50 mM EDTA",Binding,Circular Dichroism,"RNA titrated with increasing concentration of compounds, ligand concentration ranged from Drug/Nucleic Acid ratio 0-4",ligand free control,,GM04281 (HD patient-derived) Cells,ThT fluorescence increases upon binding with protein aggregates; ThT fluorescence decreased in the presence of compound,"Ligand = 25, 50, 100 uM",Translational Activity,Thioflavin T Fluorescence Assay,cells at 80% confluency were treated for 24 hours with compound then lysed an total protein was extracted. Total protein was stained with ThT dye (10 uM),"ligand free control, ThT control",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,?Tm = 6.1 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,?Tm = 0.2 ºC,NR,NR,Binding,UV Melting,"RNA heated from 25C to 95C, Drug/Nucleic Acid Ratio = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 DNA,Band intensity decreased,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 DNA,No significant reduction in band intensity,"Ligand = 0.03, 0.06, 0.12, 0.25, 0.50, 1.00 nM",-,Binding,PCR Stop Assay,-,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x1 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,(5'CAG/3'GAC)x6 RNA,Significant reduction in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,C,(5'CAG/3'GUC)x6 RNA,no change in mobility,"RNA = 5 uM, Ligand = 0 - 1000 uM",NR,Binding,Electrophoretic Mobility Shift Assay,RNA incubated with compound for 30 minutes at RT ,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,CP13 has specific binding affinity for CAG RNA,NR,NR,Binding,Nuclear Magnetic Resonance ,"1D H NMR, increasing concentration of ligand up to DN = 2",ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,CP13 has specific binding affinity for CAG RNA,NR,NR,Binding,Nuclear Magnetic Resonance ,"1D H NMR, increasing concentration of RNA up to 100 ligand:4 RNA",RNA free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,compounds preferred binding with C4A5G6 triad with the lowest binding energy (-7.43 kcal.mole),-,-,In Silico,Docking,"CAG duplex RNA (PDB code:2MS5) used for docking, Autodock 4.0 as the software with RNA as a rigid body",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0135,,CC1=CC2=CC=CC=C2N=C1C1=C(F)C=CC=C1,CP13,10.1038/s41598-019-53410-z,,5'r(CCGCAGCGG)3' containing one AA loop,"no NOEs between CP13 and RNA, could not elucidate solution structure of complex",NR,NR,Structure Determination,Nuclear Magnetic Resonance ,2D NOSEY NMR,ligand free control,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,C,NLuc reporter mRNA lacking any repeat element and translated using a canonical AUG start codon (AUG-NLuc),pIC50=4.81 (15.5 ?M),"Ligand = 8 -50 ?M, RNA = 0.6 nM","30% RRL (rabbit reticulocyte lysate), 10 ?M minus leucine amino acid mix, 10 ?M minus methionine amino acid mix, 0.5 mM magnesium acetate, 100 mM potassium chloride, 4 units of murine RNase inhibitor",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",-,,Primary cortical neurons from embryonic day 19–20 rats,High toxicity even at a dose well below IC50,Ligand =1 ?M,Cytotoxicity,Longitudinal Fluorescence Microscopy,-,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,"FXTAS-associated CGG repeats, +1CGGx100 RAN translation nanoluciferase (NLuc) reporter mRNA",pIC50=5.13 (7.41 ?M),"Ligand = 8 -50 ?M, RNA = 0.6 nM","30% RRL (rabbit reticulocyte lysate), 10 ?M minus leucine amino acid mix, 10 ?M minus methionine amino acid mix, 0.5 mM magnesium acetate, 100 mM potassium chloride, 4 units of murine RNase inhibitor",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",-,,HEK293 (ATCC CRL-1573) Cells,Selectively reduced +1CGG RAN translation,"Ligand = 0, 12.5, 25, 37.5, 50 ?M",Translational Activity,Reporter,-,AUG-Nluc and GA70-NLuc reporters,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,"FXTAS-associated CGG repeats, +2CGGx100 RAN translation nanoluciferase (NLuc) reporter mRNA (translation occurs in the +2 reading frame)",Dose-responsive decrease of RAN translation,"Ligand = 0, 6.25, 12.5, 25 ?M, RNA= 0.6 nM","30% RRL (rabbit reticulocyte lysate), 10 ?M minus leucine amino acid mix, 10 ?M minus methionine amino acid mix, 0.5 mM magnesium acetate, 100 mM potassium chloride, 4 units of murine RNase inhibitor",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",AUG-NLuc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,"C9ALS/FTD-associated GGGGCC repeats (GGGGCC70), for all three reading frames (GA, GP and GR)",Dose-responsive decrease of RAN translation,"Ligand = 0, 6.25, 12.5 ?M, RNA= 3 nM","30% RRL (rabbit reticulocyte lysate), 10?mM amino-acid mix minus methionine, 10?mM amino acid mix minus leucine, 0.5?mM MgOAc, 100?mM KCl, and 0.8?U?µL?1 Murine RNase Inhibitor (NEB)",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",AUG-NLuc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,"C9ALS/FTD-associated GGGGCC repeats (GGGGCC70), for all three reading frames (GA, GP and GR)",Dose-responsive decrease of RAN translation,"Ligand = 0, 12.5, 50 ?M, RNA= 50 ng","30% RRL (rabbit reticulocyte lysate), 10?mM amino-acid mix minus methionine, 10?mM amino acid mix minus leucine, 0.5?mM MgOAc, 100?mM KCl, and 0.8?U?µL?1 Murine RNase Inhibitor (NEB)",Activity,Translational Activity,Western Blot,AUG-NLuc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,"FXTAS-associated RAN CGG repeats (+1CGG100, +2CGG100) and AUG-initiated repeats (AUG +1CGG100, AUG +2CGG100)",Higher inhibitory effect on RAN repeats than AUG-initiated repeats,"Ligand = 0, 25, 50 ?M, RNA= 0.6 nM","30% RRL (rabbit reticulocyte lysate), 10 ?M minus leucine amino acid mix, 10 ?M minus methionine amino acid mix, 0.5 mM magnesium acetate, 100 mM potassium chloride, 4 units of murine RNase inhibitor",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",AUG-NLuc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,ACG-NLuc and CUG-NLuc,"No repeat-dependent, but better on non-AUG-initiated translation","Ligand = 0, 6.25, 12.5, 25 ?M, RNA= 0.6 nM","30% RRL (rabbit reticulocyte lysate), 10 ?M minus leucine amino acid mix, 10 ?M minus methionine amino acid mix, 0.5 mM magnesium acetate, 100 mM potassium chloride, 4 units of murine RNase inhibitor",Activity,Translational Activity,"In vitro translation assay, using RRL (rabbit reticulocyte lysate), the reporter gene was placed downstream of the target gene",AUG-NLuc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,CGG×16,CD spectrum shifted for CGG×16 only,"Ligand = 0, 50, 100 ?M, RNA=5 ?M","100 mM KCl, 10 mM Tris-HCl, and 0.1 mM EDTA",Binding,Circular Dichroism,,UUU×16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,GGGGCC×8,CD spectrum shifted,"Ligand = 0, 150 ?M, RNA=2.5 ?M",100 mM KCl or 100 mM NaCl with 10 mM Tris-HCl and 0.1 mM EDTA,Binding,Circular Dichroism,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0136,,COC1=CC2=NC(=NC(NC3CC[NH+](CC4=CC=CC=C4)CC3)=C2C=C1OC)N1CCC[NH+](C)CC1,BIX01294,10.1074/jbc.RA119.009951,,5' Irdye 800CW-labeled CGGx16 RNAs,Preferential dose-responsive band intensity,"Ligand = 0, 0.1, 0.4, 1.6, 6.4, 25.6 ?M, RNA=50 nM","100 mM KCl, 10 mM Tris-HCl, and 0.1 mM EDTA",Binding,Native Gel Electrophoresis,,UUUx16,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,5? biotin-labeled HOTAIR 36G46A wild type,"adding ADQ to the wild-type HOTAIR probe induced a moderate gel shift, indicating that ADQ directly bound HOTAIR",NR,-,Binding,Electrophoretic Mobility Shift Assay,"ADQ treatment increased signals of disassociation wild type HOTAIR probe with EZH2 protein. However, ADQ treatment markedly attenuated the increased percentage of the mutant HOTAIR probe, further confirming the computational results",-,,"U87, U87 EGFRvIII, and LN229 glioblastoma cells and MDA-MB-231 breast cancer cells",NLK luciferase activity increased 2-2.5 fold,NR,On-Target Effect,Luciferase,"NLK was proven to be a transcriptional target of HOTAIR. Thus, the NLK luciferase activity was then determined.",DMSO treatment,,BALB/c nude mice,"ADQ treatment induced reduced and redistribution of EZH2 signals from nucleus to cytoplasm and disassociation of HOTAIR, indicating that ADQ could efficiently interfere the HOTAIR/PRC2 interaction in vivo.",15 mg/kg by intraperitoneal injection every 2 days for 21 days,Localization,Fluorescence in situ hybridization,Comparatively studied the HOTAIR/PRC2 interaction through RNA in situ hybridization and immunofluorescence. Co-localization signals between Cy3 and FITC fluorescence in the nucleus and cytoplasm suggests that HOTAIR has a strong binding affinity with EZH2 in the control group,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,C,"5? biotin-labeled HOTAIR 36U46A, 36G46G, and 36U46G mutant probes",ADQ treatment markedly attenuated the increased percentage of the mutant HOTAIR probe compared to wt,NR,-,Binding,Electrophoretic Mobility Shift Assay,"ADQ treatment increased signals of disassociation wild type HOTAIR probe with EZH2 protein. However, ADQ treatment markedly attenuated the increased percentage of the mutant HOTAIR probe, further confirming the computational results",-,,"U87, U87 EGFRvIII, and LN229 glioblastoma cells and MDA-MB-231 breast cancer cells","NLK mRNA levels were
increased by 1.5–2.0 fold",NR,RNA Abundance,qRT-PCR,-,-,,BALB/c nude mice,"Immunohistochemistry staining showed increased NLK-positive cells in the ADQ, demonstrating that ADQ could effectively block the HOTAIR/EZH2 interaction and recruitment of EZH2 to target genes, thereby elevating the expression of NLK",15 mg/kg by intraperitoneal injection every 2 days for 21 days,Protein Abundance,Immunohistochemical Staining,NLK expressions were examined by immunohistochemistry in tumor sections,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,212–300 nt HOTAIR,ADQ binds to the 36G46A sequence of HOTAIR,N/A,-,In Silico,Docking,Conformation analysis and molecular docking model using the AutoDock program. Binding energy analysis revealed that 36G46A resulted in the strongest free energy and binding stability. A mutation in either sequence greatly reduced the binding energy.,-,,U87 and MDA-MB-231 cells,HOTAIR levels bound to EZH2 were reduced to 2-fold,NR,RNA Abundance,RNA Immunoprecipitation,RNA sample was extracted and determined by agarose gel electrophoresis and qPCR,-,,BALB/c nude mice,Significant reduction in tumor growth was detected in the ADQ-treated mice. Number and volume of metastatic nodules in the lung of mice injected with ADQ were significantly reduced. Lung metastasis in ADQ-treated mice was dramatically lower than that in control mice.,15 mg/kg by intraperitoneal injection every 2 days for 21 days,Tumor Burden,Tumor Size,"MDA-MB-231 cells transduced with luciferase lentivirus were injected into the mammary fat pads of each nude mouse. Twenty-one days after implantation, PBS or ADQ was administered every 2 days for 21 days. The mice were imaged for luciferase activity once per week. ADQ treatment resulted in similar cell growth and lung metastasis inhibition as that in the HOTAIR knockdown group. ",PBS treatment,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,Migratory activity of ADQ-treated cells was clearly reduced,NR,Cell Migration,Wound Healing,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,ADQ treatment decreased the number of invaded cells by 3- to 5-fold,NR,Cell Migration,Matrigel Invasion Assay,-,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,EZH2 binding was dramatically reduced after ADQ treatment.,NR,On-Target Effect,ChIRP-qPCR,"Analysis of co-purified genomic DNA by qPCR detected a reduced occupancy on the NLK promote after ADQ treatment, indicating that ADQ affected the binding of HOTAIR to the target gene",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,"U87 and MDA-MB-231 cells stably transfected with HOTAIR full-length (WT), 5? domain (5? 300-mer), and 5? domain with 36U46G mutation (mut 5? 300-mer) constructs","ADQ diminished the binding efficiency of the HOTAIR fragment in combination with EZH2 proteins in WT and 5? domain transfected cell, but did not affect the mutant type",NR,On-Target Effect,RNA Immunoprecipitation,EZH2 interacted with both the wild-type 36G46A and mutant 36U46G HOTAIR sequences,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,"U87 and MDA-MB-231 cells stably transfected with HOTAIR full-length (WT), 5? domain (5? 300-mer), and 5? domain with 36U46G mutation (mut 5? 300-mer) constructs","NLK luciferase activity was significantly enhanced in ADQ-treated WT and 5? domain cells, whereas ADQ exerted a minimal effect on 5? domain with 36U46G mutation cells",NR,On-Target Effect,Luciferase,"NLK was proven to be a transcriptional target of HOTAIR. Thus, the NLK luciferase activity was then determined.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,ChIP analysis detected a marked reduction in H3K27-mediated tri-methylation in the NLK promoter region in ADQ-treated cells,NR,On-Target Effect,ChIP-qPCR,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,reduced H3K27me3 expression and elevated NLK protein expression levels were detected in both ADQ-treated cell lines,NR,Protein Abundance,Western Blot,Previous study demonstrated that HOTAIR-mediated H3K27 tri-methylation was responsible for decreased NLK expression,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,U87 and MDA-MB-231 cells,Protein levels of nuclear ?-catenin were significantly decreased in ADQ-treated cells,NR,Protein Abundance,Western Blot,ADQ inhibits cell invasion and migration by blocking the ?-catenin signaling pathway,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,C,"U87, U87 EGFRvIII, and LN229 glioblastoma cells and MDA-MB-231 breast cancer cells","ADQ did not alter the expression of HOTAIR, indicating that this molecule does not directly regulate HOTAIR expression",NR,RNA Abundance,-,-,DMSO treatment,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0137,,[O-]C1=C(OC2=NC3=CC(=CC=C3NC12)[N+]([O-])=O)C1=CC=C(C=C1)C1OC2=[NH+]C3=C(NC2=C1[O-])C=CC(=C3)[N+]([O-])=O,ADQ,10.1186/s13148-019-0624-2,,,,,,,,,,,"U87VIII, U87, LN229, MDA-MB-231","90 upregulated and 64 downregulated mRNAs (fold change ? 2.0, P < 0.05) existed in ADQ-treated MDA-MB-231 cells",NR,RNA Abundance,mRNA microarray,"To further explore the distribution of DEGs, GO enrichment analysis was performed. A wide range of biological processes was affected. Importantly, “Negative regulation of Wnt signaling pathway” was the top-ranked biological process. The top 10 KEGG pathways in the dysregulated mRNAs included “cell adhesion molecule,” “cytokine-cytokine receptor interaction,” “ECM receptor interaction,” and “TGF-? signaling pathway.” Thus, we hypothesized that ADQ contributes to the inhibition of aggressive tumor behavior by inactivating cell adhesion molecules and the epithelial-to-mesenchymal transition (EMT), suggesting a tight link between ADQ and biological processes involving tumor migration and metastasis.",DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0138,,NC1=C(N=C2N(CC3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 9,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,EC50 = 1.16 ± 0.18 ?M,NR,Antiviral Activity,MTT,The antiviral activity of the target compounds against HIV-1 strain IIIB in MT-4 cells was performed using the MTT assay. EC50: concentration of compound required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity,WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0138,,NC1=C(N=C2N(CC3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 9,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,CC50 = 3.97 ± 0.70 ?M,NR,Cytotoxicity,MTT,"Mock-infected cells were used to assess the cytotoxic effects of the test compounds. CC50:
concentration of compound that reduces the viability of mock-infected cells by 50%",WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0139,,NC1=C(N=C2N(CCC3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 10,10.2174/1874104501913010016,,TAR/Tat complex,Ki = 1.72 ± 0.22 ?M,-," 10 mM Tris (pH = 7.5), 1 mM Mg(ClO4)2, 20 mM NaCl (TNMg), 0.01% Triton X-100",Binding,Fluorescence Quenching Assay,"The protocol envisages the use of TAR labelled with a quencher moiety (Q) and of Tat labelled with a fluorescent dye (D). The fluorophore emits efficiently when the peptide is free in solution, but its emission dramatically decreases when in close proximity to the quencher dabcyl molecule, that is, when the QD complex is formed.",-,,MT-4 Cells,EC50 ?0.18 ?M,NR,Antiviral Activity,MTT,The antiviral activity of the target compounds against HIV-1 strain IIIB in MT-4 cells was performed using the MTT assay. EC50: concentration of compound required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity,WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0139,,NC1=C(N=C2N(CCC3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 10,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,CC50 = 3.34 ± 1.47 ?M,NR,Cytotoxicity,MTT,"Mock-infected cells were used to assess the cytotoxic effects of the test compounds. CC50:
concentration of compound that reduces the viability of mock-infected cells by 50%",WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0140,,NC1=C(N=C2N(CC[NH+]3CCN(CC3)C3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 11,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,EC50 = 3.37 ± 1.62  ?M,NR,Antiviral Activity,MTT,The antiviral activity of the target compounds against HIV-1 strain IIIB in MT-4 cells was performed using the MTT assay. EC50: concentration of compound required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity,WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0140,,NC1=C(N=C2N(CC[NH+]3CCN(CC3)C3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 11,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,CC50 = 11.65 ± 1.17 ?M,NR,Cytotoxicity,MTT,"Mock-infected cells were used to assess the cytotoxic effects of the test compounds. CC50:
concentration of compound that reduces the viability of mock-infected cells by 50%",WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0141,,NC1=C(N=C2N(CCC[NH+]3CCN(CC3)C3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 12,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,EC50 ?0.67 ?M,NR,Antiviral Activity,MTT,The antiviral activity of the target compounds against HIV-1 strain IIIB in MT-4 cells was performed using the MTT assay. EC50: concentration of compound required to achieve 50% protection of MT-4 cells from HIV-1 induced cytopathogenicity,WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0141,,NC1=C(N=C2N(CCC[NH+]3CCN(CC3)C3=CC=CC=N3)C=C(C([O-])=O)C(=O)C2=C1)N1CCN(CC1)C1=NC2=CC=CC=C2S1,Compound 12,10.2174/1874104501913010016,,,,,,,,,,,MT-4 Cells,CC50 = 10.70 ± 7.76 ?M,NR,Cytotoxicity,MTT,"Mock-infected cells were used to assess the cytotoxic effects of the test compounds. CC50:
concentration of compound that reduces the viability of mock-infected cells by 50%",WM5,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,A hypochromic and a bathochromic shift in the peak at 262 nm. EC50 ~ 67 ± 3.5 ?M,"Ligand = 50-150 ?M, RNA = 2 ?M, [Mg2+] = 100 ?M","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates.,-, ,Huh 7 Cells,The effect on the translation efficiency of each compound was determined at much lower concentrations than their respective cytotoxicity concentrations,"Ligand = 0, 5, 7.5, 10, 20, 30 and 40 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,A hypochromic and a bathochromic shift in the peak at 262 nm. EC50 ~ 131 ± 11 ?M,"Ligand = 50-150 ?M, RNA = 2 ?M, [Mg2+] = 2 mM","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates. Plot of CD ellipticity at 262 nm was fitted for EC50.,-, ,HEK293 Cells,The effect on the translation efficiency of each compound was determined at much lower concentrations than their respective cytotoxicity concentrations,"Ligand = 0, 5, 7.5, 10, 20, 30 and 40 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,"The hypochromic shift of the peak at 262 nm reverted back when increasing concentrations of MgCl2 were added. At a higher concentration of 4d (100 mM), the MgCl2- induced restacking of RNA bases was not observed","Ligand = 50 ?M, RNA = 2 ?M, [Mg2+] = 0.5-5 mM","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates.,-, ,Huh 7 Cells,Decreased translation by ~58%,Ligand = 10 µM,Translational Activity,Reporter,"Cells were transfected with bicistronic plasmid, compounds were then added, the Luciferase activity was checked using Dual Luciferase assay substrate",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,HCV-IRES subdomain Iia,Gradual increase up to 10 Å and above between the termini residues of the IRES RNA docked with compound 4d was observed from the start to the end of the simulation (30 ns). A significant structural alteration along with the decrease in base stacking was observed in the post-simulation docked complex,-,-,In Silico,Molecular Docking and Molecular Dynamics,HCV IRES domain (PDB ID: 2NOK); The receptor was prepared using protein preparation wizard of Schrodinger suite. All the ligands were prepared using Ligprep wizard of Schrodinger suite. The docking was performed using rDock. The molecular dynamic simulation was carried out using GROMACSv4.5.3 simulation package.,-, ,Huh 7 Cells,Dose-dependently decreased translation,"Ligand = 0, 2, 5, 10, 15 µM",Translational Activity,Reporter,"Cells were transfected with bicistronic plasmid, compounds were then added, the Luciferase activity was checked using Dual Luciferase assay substrate",Bicistronic control (100%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,"Inhibits the production of viral replicon RNA by about 0.2-fold at 2 mM, reaching a maximum inhibition of about 0.6 fold at 10 mM","Ligand = 0, 2, 5, 10 µM",Replication Inhibition,RT-qPCR,"HCV-replicon cell line (Huh7
cells harboring HCV sub-genomic replicon RNA) was used. Changes in the HCV RNA were measured using RT-qPCR. GAPDH was used as an internal control.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,No significant inhibition of translation,"Ligand = 0, 2, 5, 10, 15 µM",Translational Activity,Reporter,Adenine 57 (A57) residue in the subdomain IIa was mutated to U. (A57U),A57U control (100%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0142,,CN(C)C1=CC=C(C=CC(=O)NC2=CC=C(CNC3=NC4=CC=C(C=C4N=C3NCCCN3CC[NH+](C)CC3)[N+]([O-])=O)C=C2)C=C1,4d,10.1039/c9cc06531h,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0143,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCCCN1CC[NH+](C)CC1)[N+]([O-])=O,3b,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,Decreased ellipticity at 262 nm. EC50 ~ 250 ± 5 ?M,"Ligand = 10-250 ?M, RNA = 2 ?M, [Mg2+] = 100 ?M","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates. Plot of CD ellipticity at 262 nm was fitted for EC50.,-, ,Huh 7 Cells,-,"Ligand = 0, 10, 20, 30, 40, 50 and 60 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0143,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCCCN1CC[NH+](C)CC1)[N+]([O-])=O,3b,10.1039/c9cc06531h,,HCV-IRES subdomain Iia,Docking region is similar to 4d,-,-,In Silico,Molecular Docking and Molecular Dynamics,HCV IRES domain (PDB ID: 2NOK); The receptor was prepared using protein preparation wizard of Schrodinger suite. All the ligands were prepared using Ligprep wizard of Schrodinger suite. The docking was performed using rDock.,-, ,HEK293 Cells,-,"Ligand = 0, 10, 20, 30, 40 and 50 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0143,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCCCN1CC[NH+](C)CC1)[N+]([O-])=O,3b,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,Decreased translation by ~40%,Ligand = 25 µM,Translational Activity,Reporter,"Cells were transfected with bicistronic plasmid, compounds were then added, the Luciferase activity was checked using Dual Luciferase assay substrate",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0143,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCCCN1CC[NH+](C)CC1)[N+]([O-])=O,3b,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,Dose-dependently decreased translation,"Ligand = 0, 10, 25 µM",Translational Activity,Reporter,Adenine 57 (A57) residue in the subdomain IIa was mutated to U. (A57U),A57U control (100%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0144,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCC1=CC=C(NC(=O)CCCC[C@H]2SCC3NC(=O)NC23)C=C1)[N+]([O-])=O,4a,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,Decreased ellipticity at 262 nm. EC50 ~ 87 ± 4 ?M,"Ligand = 25-150 ?M, RNA = 2 ?M, [Mg2+] = 100 ?M","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates. Plot of CD ellipticity at 262 nm was fitted for EC50.,-, ,Huh 7 Cells,-,"Ligand = 0, 10, 20, 30, 40, 50 and 60 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0144,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCC1=CC=C(NC(=O)CCCC[C@H]2SCC3NC(=O)NC23)C=C1)[N+]([O-])=O,4a,10.1039/c9cc06531h,,HCV-IRES subdomain Iia,Docking region is similar to 4d,-,-,In Silico,Molecular Docking and Molecular Dynamics,HCV IRES domain (PDB ID: 2NOK); The receptor was prepared using protein preparation wizard of Schrodinger suite. All the ligands were prepared using Ligprep wizard of Schrodinger suite. The docking was performed using rDock.,-, ,HEK293 Cells,-,"Ligand = 0, 10, 20, 30, 40 and 50 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0144,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCC1=CC=C(NC(=O)CCCC[C@H]2SCC3NC(=O)NC23)C=C1)[N+]([O-])=O,4a,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,Decreased translation by ~40%,Ligand = 15 µM,Translational Activity,Reporter,"Cells were transfected with bicistronic plasmid, compounds were then added, the Luciferase activity was checked using Dual Luciferase assay substrate",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0144,,C[NH+](C)CCCNC1=NC2=CC(=CC=C2N=C1NCC1=CC=C(NC(=O)CCCC[C@H]2SCC3NC(=O)NC23)C=C1)[N+]([O-])=O,4a,10.1039/c9cc06531h,,,,,,,,,,C,Huh 7 Cells,Dose-dependently decreased translation,"Ligand = 0, 5, 10, 15 µM",Translational Activity,Reporter,Adenine 57 (A57) residue in the subdomain IIa was mutated to U. (A57U),A57U control (100%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0145,,C[NH+]1CCN(CCCNC2=NC3=CC(=CC=C3N=C2NCC2=CC=C(NC(=O)CCCCC3SCC4NC(=O)NC34)C=C2)[N+]([O-])=O)CC1,4c,10.1039/c9cc06531h,,HCV-IRES subdomain IIa,Decreased ellipticity at 262 nm. EC50 ~ 74 ± 3.5 ?M,"Ligand = 10-150 ?M, RNA = 2 ?M, [Mg2+] = 100 ?M","10 mM HEPES buffer, 1% DMSO (pH = 7.0)",Binding,Circular Dichroism ,Annealed HCV IRES domain IIa RNA was mixed without and with increasing concentration of compounds and measured using a scan speed of 50 nm/min. Minimum of 2 accumulations were taken per sample concentrations and all data were done in triplicates. Plot of CD ellipticity at 262 nm was fitted for EC50.,-, ,Huh 7 Cells,-,"Ligand = 0, 20, 30, 40, 50 and 60 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0145,,C[NH+]1CCN(CCCNC2=NC3=CC(=CC=C3N=C2NCC2=CC=C(NC(=O)CCCCC3SCC4NC(=O)NC34)C=C2)[N+]([O-])=O)CC1,4c,10.1039/c9cc06531h,,,,,,,,,,,HEK293 Cells,-,"Ligand = 0, 20, 30, 40, 50 and 60 µM",Cytotoxicity ,MTT,"Huh 7 and HEK 293 cells were seeded in a 96 well plate in DMEM medium supplemented with 10 % FBS. Cells were incubated in a CO2 incubator at 37° C overnight. Compounds were treated keeping a final concentration of DMSO at around 0.5 % for 24 hours in the
incubator. MTT solution was added to each well and incubated for 3 hours in the CO2 incubator. Media was discarded and equal amounts of DMSO were added to each well and shaken at room temperature for 20 mins in dark. The plates were analyzed using a multiplate reader and absorbance was measured at 595 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0145,,C[NH+]1CCN(CCCNC2=NC3=CC(=CC=C3N=C2NCC2=CC=C(NC(=O)CCCCC3SCC4NC(=O)NC34)C=C2)[N+]([O-])=O)CC1,4c,10.1039/c9cc06531h,,,,,,,,,,,Huh 7 Cells,Decreased translation by ~67%,Ligand = 20 µM,Translational Activity,Reporter,"Cells were transfected with bicistronic plasmid, compounds were then added, the Luciferase activity was checked using Dual Luciferase assay substrate",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0145,,C[NH+]1CCN(CCCNC2=NC3=CC(=CC=C3N=C2NCC2=CC=C(NC(=O)CCCCC3SCC4NC(=O)NC34)C=C2)[N+]([O-])=O)CC1,4c,10.1039/c9cc06531h,,,,,,,,,,C,Huh 7 Cells,Dose-dependently decreased translation,"Ligand = 0, 5, 10, 20 µM",Translational Activity,Reporter,Adenine 57 (A57) residue in the subdomain IIa was mutated to U. (A57U),A57U control (100%),,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,Dose-dependent inhibition of Dicer processing,"Ligand = 0, 50, 100 µM",NR,Activity,Dicer Protection,Agarose gel shift,Control with no drug; Control with no Dicer,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,pre-miR-638,No significant change,Ligand = 5 µM; RNA = 1 µM,"2% DMSO, 0.25 mM Tris-HCl and 0.25 mM NaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,Minimal presence of ligand within nuclei,Ligand = 50 nM,Localization,Fluorescence Microscopy,Hoechst stained; Treatment for 24 Hr; Data indicate ligand does not induce cellular proliferation arrest via intercalating DNA. Also supports hypothesis that ligand most likely inhibits Dicer-mediated processing of pre-miRNA-21,DMSO control,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,?Tm = 3.38 °C,3 µM,"2% DMSO, (0.25mMTris-HCl and 0.25mMNaCl)",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Spermidine and methoctramine were used as a stabilizing or destabilizing control,,HCT-116 Cells,GI50 = 0.035 ± 0.003 µM,Ligand = 0 - 25 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand; Control with normal colon cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,5'SLA RNA fragment Dengue-II virus,No significant ?Tm -data not shown ,-,-,Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,C,Normal Colon Cells,GI50 ? 10µM,Ligand = 0 - 10 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,Lys3 tRNA,No significant change,Ligand = 5 µM; RNA = 1 µM,"2% DMSO, 0.25 mM Tris-HCl and 0.25 mM NaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,"55% reduction of cell number 24 h post treatment at 0.05 µM (p < 0.01), complete cell death at ?0.5 µM (p < 0.001)","Ligand = 0.005, 0.05, 0.5 µM",Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,stabilizing effects on pre-miR-21 structure in the presence of ligand consistent with DSF,ligand = 300 ?M; RN A = 30 µM,0.25 mM Tris-HCl (pH = 7.5) and 0.25 mM NaCl,Binding,Differential Scanning Calorimetry,"Two distinct thermal curves are observed after treatment with ligand, indicating the presence of two major species of pre-miR-21",Control with no ligand,,HCT-116 Cells,time-dependent increase in Pdcd4 and PTEN protein levels within 24 h post treatment,Ligand = 50 nM,Protein Abundance,Western Blot,"Cells cultured in 100 mm cell culture plates until 50-60% confluence before treatment; collected for time point studies at 0, 1, 4, 8, 16, 24, 36, 48, and 72 hours post-treatment",protein expression decreased by ~40% when treated with  miRNA-21 mimic and increased by 22%–58% when treated with miRNA-21 inhibitor 48 h post transfection,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,HIV TAR,No significant change,Ligand = 5 µM; RNA = 1 µM,"2% DMSO, 0.25 mM Tris-HCl and 0.25 mM NaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,rapidly reduced miR-21 levels by  80% (p < 0.001) within 2 h post treatment. less effective in downregulating the expression level of the other tested miRs (up to  30% reduction). miR-21 expression level gradually recovered up to 24 h post treatment. pre-miR-21 expression level did not significantly change up to 24 h post treatment,Ligand = 50 nM,RNA Abundance,RT-qPCR,"collected for time point studies at 0, 1, 4, 8, 16, 24, 36, 48, and 72 hours post-treatment; miRNAs  1246,  203a-3p,  200b-3p, and  361 expression levels were used to assess selectivity.",GAPDH and U6 snRNA were used as reference control genes,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,?Tm max = 3.1 °C,Ligand = 0- 20 µM; RNA = 1 µM,"2% DMSO, 0.25 mM Tris-HCl and 0.25 mM NaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,"miRNA-21 target genes PDCD4 and PTEN were upregulated 2-4 fold, 8-36 h post treatment",Ligand = 50 nM,RNA Abundance,RT-qPCR,"collected for time point studies at 0, 1, 4, 8, 16, 24, 36, 48, and 72 hours post-treatment",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,Kd = 0.41 ± 0.04 µM,Ligand = 0 - 10 µM; 1 µM RNA,0.25 mM Tris-HCl and 0.25 mM NaCl,Binding,Fluorescence-Based Titration (Intrinsic),Using the intrinsic fluorescence of ligands. Measured direct binding affinity (Kd),"Control with no ligand, Navitoclax was used as a control for these experiments as navitoclax and obatoclax have been shown to share a common molecular mechanism as BH3 mimetics in cells  Our results showed no significant interaction between pre-miR-21 and navitoclax",,HCT-116 Cells,28 of 41 predicted genes significantly differentiated from untreated control cells (p < 0.05),Ligand = 50 nM,RNA Abundance,NanoString,"NanoString Technologies; NanoString nCounter Human Pan-Cancer Pathway Panel assay kit employed to identify altered mRNAs with or without 50 nM treatment of ligand at time points: 0, 1, and 24 h post-treatment.",Control with no ligand (time point 0); 40 housekeeping genes used as internal controls,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,+Dicer ?Tm = -7.2 C; +Dicer+50 µM ligand ?Tm = -2.8 C; +Dicer+100 µM ligand ?Tm = -0.6 C,"Ligand = 0, 50, 100 µM; 1 µM RNA","2% DMSO, 0.25 mM Tris-HCl and 0.25 mM NaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,Purified Total RNA,does not quench fluorescence of ligand up to 48 h of incubation,"Ligand = 0, 12.5, 25, 50, and 100 nM",0.25 mM Tris-HCl and 0.25 mM NaCl,Off-Target Effect,Fluorescence Quenching,Total RNA (50 ng/µL),-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,Purified gDNA,does not quench fluorescence of ligand up to 48 h of incubation,"Ligand = 0, 12.5, 25, 50, and 100 nM",0.25 mM Tris-HCl and 0.25 mM NaCl,Off-Target Effect,Fluorescence Quenching,gDNA (25 ng/µL),-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0146,,CCCC[C@H]1CCCCCCC2=C1C=C(N2)C=C1N=CC(C2=CC=CN2)=C1OC,bPGN,10.1016/j.chembiol.2019.04.011,C,Plasmid DNA,does not quench fluorescence of ligand up to 48 h of incubation,"Ligand = 0, 12.5, 25, 50, and 100 nM",0.25 mM Tris-HCl and 0.25 mM NaCl,Off-Target Effect,Fluorescence Quenching,Plasmid DNA (50 ng/µL),-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0147,,COC1=C(C=NC1=CC1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1,Obatoclax,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,?Tm max = 3.2 °C,Ligand = 0- 20 µM; RNA = 1 µM,"2% DMSO, 0.25mMTris-HCl and 0.25mMNaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,GI50 = 0.10 ± 0.01 µM,Ligand = 0 - 25 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand; Control with normal colon cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0147,,COC1=C(C=NC1=CC1=C(C)C=C(C)N1)C1=CC2=CC=CC=C2N1,Obatoclax,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,Kd = 0.09 ± 0.02 µM,Ligand = 0 - 10 µM; 1 µM RNA,0.25 mM Tris-HCl and 0.25 mM NaCl,Binding,Fluorescence-Based Titration (Intrinsic),Using the intrinsic fluorescence of ligands. Measured direct binding affinity (Kd),"Control with no ligand, Navitoclax was used as a control for these experiments as navitoclax and obatoclax have been shown to share a common molecular mechanism as BH3 mimetics in cells  Our results showed no significant interaction between pre-miR-21 and navitoclax",C,Normal Colon Cells,GI50 ? 10µM,Ligand = 0 - 10 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0148,,CCCCCC1=C(C)NC(C=C2N=CC(C3=CC=CN3)=C2OC)=C1,Prodigiosin,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,?Tm max = 7.0 °C,Ligand = 0- 20 µM; RNA = 1 µM,"2% DMSO, 0.25mMTris-HCl and 0.25mMNaCl",Binding,Differential Scanning Fluorimetry,SYBR Green dye,Control with no ligand,,HCT-116 Cells,GI50 = 0.24 ± 0.04 µM,Ligand = 0 - 25 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand; Control with normal colon cells,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0148,,CCCCCC1=C(C)NC(C=C2N=CC(C3=CC=CN3)=C2OC)=C1,Prodigiosin,10.1016/j.chembiol.2019.04.011,,pre-miRNA-21,Kd = 0.16 ± 0.06 µM,Ligand = 0 - 10 µM; 1 µM RNA,0.25 mM Tris-HCl and 0.25 mM NaCl,Binding,Fluorescence-Based Titration (Intrinsic),Using the intrinsic fluorescence of ligands. Measured direct binding affinity (Kd),"Control with no ligand, Navitoclax was used as a control for these experiments as navitoclax and obatoclax have been shown to share a common molecular mechanism as BH3 mimetics in cells  Our results showed no significant interaction between pre-miR-21 and navitoclax",C,Normal Colon Cells,GI50 ? 10µM,Ligand = 0 - 10 µM,Proliferation,XTT cell-viability assay,Treatment for 24 hours,Control with no ligand,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N3,BRX1555,10.1021/acschembio.8b00533,,"165 ribD FMN Riboswitch Aptamer, B. subtilis ",EC50 = 1.7 ± 0.18 µM,"Ligand = 0.1 - 100 µM, 4-fold intervals",NR,Activity,Transcription Termination,,Compared to native ligand FMN,,C. difficile Strain MMx3581,MIC ? 8 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N2,BRX1555,10.1021/acschembio.8b00533,,"165 ribD FMN Riboswitch Aptamer, B. subtilis ",IC50 = 0.039 ± 0.007 µM,"Ligand = 0.26 nM - 20 µM, 5-fold intervals",NR,Binding,In-Line Probing,32P labeled RNA used; Utilized hydroxide ions and RNase T1; Apparent Kd was derived from quantifying RNA cleaved at each nucleotide position,Compared to native ligand FMN,,C. difficile Strain ATCC 700057,MIC = 8 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N4,BRX1555,10.1021/acschembio.8b00533,,Aptamer domain of the FMN riboswitch from F. nucleatum,Crystal structures confirmed the structural similarity that was suggested by in-line probing and SHAPE data. An unexpected aspect of these structures is how the various modifications are accommodated in the binding pocket,-,-,Structure Determination,X-Ray Crystallography,"Crystal structures of BRX1151, BRX1354, and BRX1555 bound to the aptamer domain of the FMN riboswitch from F. nucleatum were compared. Optimal crystallization conditions were found by mixing and matching the different FMN strands A and B, and by subjecting the
resulting complexes to a grid screen at room temperature.",-,,Streptococcus pneumoniae ATCC 49619,MIC = 16 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N5,BRX1555,10.1021/acschembio.8b00533,,,,,,,,,,,Staphylococcus epidermidis ATCC 12228,MIC = 0.5 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N6,BRX1555,10.1021/acschembio.8b00533,,,,,,,,,,,Staphylococcus aureus NRS384,MIC = 16 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N7,BRX1555,10.1021/acschembio.8b00533,,,,,,,,,,,Staphylococcus aureus NR4220,MIC ? 64 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0149,,CC1=CC2=C(C=C1C)N(CCCC1=CC=CC=C1)C1=NC(=O)[N-]C(=O)C1=N2,BRX1555,10.1021/acschembio.8b00533,,,,,,,,,,,Staphylococcus aureus ATCC 29213,MIC = 64 µg/mL,NR,Antimicrobial Activity,Microdilution,-,-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,SMA Type I Patient Fibroblasts,SMN protein EC1.5x = 87 nM,NR,Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),-,-,,C/C-allele SMA mouse,Dose dependent increase in SMN protein in quadriceps,"0, 1, 3, 10 mg/kg po",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),"SMN protein in vivo in adult C/C-allele mice (FVB.129(B6)- Smn1tm5(Smn1/SMN2)Mrph/J), the animals were treated daily for 10 days. One hour after the 10th dose, the mice were euthanized, and the brain and quadriceps were collected",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.6b00459,,,,,,,,,,,spinal motor neurons derived from SMA type I and II patient induced pluripotent stem cells ,maximal increase in SMN protein was similar in both cell types (60?80%),NR,Protein Abundance,Immunostaining and Confocal Fluorescence Microscopy,72 Hr treatment,Untreated cell control,,Neonatal SMN?7 SMA mouse,Dose dependent increase in SMN protein in quadriceps,"0, 0.3, 1, 3 mg/kg ip",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),"intraperitoneal (ip) injection once daily starting on postnatal day 3 (PND3) and continued through day 9 (PND9). One hour after the last dose, the level of the SMN protein was determined in the brain and quadriceps muscle",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.6b00459,,,,,,,,,,,Cynomolgus Monkey Induced Pluripotent Stem Cells (iPSCs),FOXM1b/c expression IC50 = 0.90 ?M,NR,RNA Abundance,RT-qPCR,-,-,,SMN?7 SMA mouse,Dose dependent increase in bodyweight with profound body weight gain when the study was terminated.,"0, 0.3, 1, 3 mg/kg ip postnatal day 3-23; 1, 3, and 10 mg/kg/day postnatal day 24 and after",Body Weight,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.6b00459,,,,,,,,,,,Human Induced Pluripotent Stem Cells (iPSCs),FOXM1b/c expression IC50 = 1.85 ?M,NR,RNA Abundance,RT-qPCR,-,-,,SMN?7 SMA mouse,"dose-dependent increase in survival beginning at the low dose. Approximately 80?90% of animals
survived beyond PND50/PND60","0, 0.3, 1, 3 mg/kg ip postnatal day 3-23; 1, 3, and 10 mg/kg/day postnatal day 24 and after",Lifespan,-,-,-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.8b00741,,,,,,,,,,,HEK293H Cells,SMN2 splicing EC1.5x = 23 nM,NR,RNA Splicing,RT-qPCR,SMN2 FL mRNA levels,-,,C/C-allele SMA mouse,Dose dependent increase in SMN protein in brain tissue,"0, 1, 3, 10 mg/kg po",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),"SMN protein in vivo in adult C/C-allele mice (FVB.129(B6)- Smn1tm5(Smn1/SMN2)Mrph/J), the animals were treated daily for 10 days. One hour after the 10th dose, the mice were euthanized, and the brain and quadriceps were collected",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0150,,CCC1=NC(C)=CN2N=C(C=C12)C1=CC(=O)N2C=C(C=C(C)C2=N1)C1CC[NH+](C)CC1,RG7800,10.1021/acs.jmedchem.8b00741,,,,,,,,,,C,SMA Type I Patient Fibroblasts,FOXM1a splicing EC50 = 247 ±60 nM; FOXM1b/c splicing EC50 = 352 nM ±49 nM,NR,RNA Splicing,RT-qPCR,FOXM1 FL mRNA levels,-,,Neonatal SMN?7 SMA mouse,Dose dependent increase in SMN protein in brain tissue,"0, 0.3, 1, 3 mg/kg ip",Protein Abundance,Homogeneous Time-Resolved Fluorescence (HTRF),"intraperitoneal (ip) injection once daily starting on postnatal day 3 (PND3) and continued through day 9 (PND9). One hour after the last dose, the level of the SMN protein was determined in the brain and quadriceps muscle",-,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,Mixture of RNAs,Preferentially binds: 5'UUA3'/3'A_U5'; 5'GAU3'/3'C_A5'; 5'GCU3'/3'C_A5'; and UUA3'/3'A_U5' internal bulges,Ligand = 2mM; RNA = 0.125 pmol/µL; Competitor oligonucleotides = 0.125 nmol/µL,"Screening Buffer 1 (SB1): 8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, 0.1 mM EDTA, and 40 µg/mL BSA; Screening Buffer 2 (SB2): SB1 without BSA",Binding ,Microarray,"2 mM compound spotted onto the microarray surface. Radioactively labeled RNA was mixed with competitor oligonucleotides. Nucleic acids were mixed together in a total volume of 400 µL, and BSA was added to 40 µg/mL.  Spots that bound RNA were mechanically removed them from the surface. RNA was subjected to RT-qPCR for identity.",-,,Huh-7.5 Cells,IC50 = 14 ± 1 µM,"Ligand = 0, 2.5, 5, 10, 20 µM",Antiviral Activity,Luciferase,"SGR-Neo_Rluc-JFH1-2A replicon cells. HCV stable subgenomic replicon cells (SGR-Rluc-Neo-[NS3-5B]-JFH1-2a with luciferase reporter).  24 hr post cell plating, the compound of interest was added. After 72 hr,  luciferase activity was measured.","Compared to DMSO, Compound 9 (non-binder) and 2'-C-methyladenosine triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'UUA3'/3'A_U5' ,Kd = 690 ± 47 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,C,Huh-7.5 Cells,CAMK4 is not expressed in Huh-7.5 cells; suggest mode of action is not due to general inhibition of kinases,Ligand = 20 µM,Off-Target Effect,RT-qPCR,SGR-Neo_Rluc-JFH1-2A replicon cells. mRNA expression levels measured for seven affected kinases,"Compared to untreated cells, and treatment with known inhibitors of kinases activity on HCV replication (CHK1 and AKT had inhibition).",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'GAU3'/3'C_A5',Kd = 600 ± 61 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,,Huh-7.5 Cells,8 inhibits cleavage induced by an ASO that overlaps with 8 binding site,Ligand = 10 µM; ASO = 100 nM,Off-Target Effect,qRT-PCR,SGR-Neo_Rluc-JFH1-2A replicon cells. Treatment with 8 for 24 hr. Total RNA  extracted using a Zymo Quick RNA mini-prep kit. RT carried out with qScript reverse transcriptase. qPCR was completed using Power SYBR PCR Master Mix.,"Compared to control ASO for downstream site that compound 8 does not bind, and untreated cells",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'GCU3'/3'C_A5' ,Kd = 450 ± 47 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,,Huh-7.5 Cells,8 inhibits cleavage induced by an ASO that overlaps with 8 binding site. ASO complementary to SL I and 8 have a synergistic effect on viral replication.,Ligand = 10 µM; ASO = 100 nM,Off-Target Effect,Dual Luciferase,SGR-Neo_Rluc-JFH1-2A replicon cells. Luminescence was measured.,Compared to control ASO for downstream site that compound 8 does not bind,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'UUA3'/3'A_U5' ,Kd = 530 ± 26 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'UCUAU3'/3'ACCA5' (non-binder),"Kd = 5,580 ± 440 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003, C,Fully paired RNA ,"Kd = >5,000 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, and 40 mg/mL BSA",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,HCV SL I and SL III (5'GUG3'/3'C_G5'),"Kd = 1,400 ± 160 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,HCV SL II (5'CUG3'/3'G_C5'),"Kd = 1,400 ± 211 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,HCV SL I (5'UAG3'/3'A_C5'),Kd = 849 ± 150 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'UUA3'/3'A_U5' ,Kd = 468 ± 245 nM,"Ligand = 1.25, 2.5, 5 µM","20 mM HEPES (pH = 7.5), 150 mM NaCl, and 5 mM KCl; 1x Kinetics Buffer (Forte Bio) and 0.05% DMSO",Binding ,Biolayer Interferometry,"Biotinylated RNA. Experimental parameters: baseline (120 s), loading (600 s), washing (120 s), association (1500 s), dissociation (1500 s). ",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'GCU3'/3'C_A5' ,Kd = 448 ± 224 nM,"Ligand = 1.25, 2.5, 5 µM","20 mM HEPES (pH = 7.5), 150 mM NaCl, and 5 mM KCl; 1x Kinetics Buffer (Forte Bio) and 0.05% DMSO",Binding ,Biolayer Interferometry,"Biotinylated RNA. Experimental parameters: baseline (120 s), loading (600 s), washing (120 s), association (1500 s), dissociation (1500 s). ",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,5'UCUAU3'/3'ACCA5',Kd = 1710 ± 224 nM,"Ligand = 1.25, 2.5, 5 µM","20 mM HEPES (pH = 7.5), 150 mM NaCl, and 5 mM KCl; 1x Kinetics Buffer (Forte Bio) and 0.05% DMSO",Binding ,Biolayer Interferometry,"Biotinylated RNA. Experimental parameters: baseline (120 s), loading (600 s), washing (120 s), association (1500 s), dissociation (1500 s). ",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,C,Fully paired RNA ,"Kd = >3,500 nM","Ligand = 1.25, 2.5, 5 µM","20 mM HEPES (pH = 7.5), 150 mM NaCl, and 5 mM KCl; 1x Kinetics Buffer (Forte Bio) and 0.05% DMSO",Binding ,Biolayer Interferometry,"Biotinylated RNA. Experimental parameters: baseline (120 s), loading (600 s), washing (120 s), association (1500 s), dissociation (1500 s). ",-,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,HCV SL I,Compound 8 inhibited ASO binding and cleavage of SL I (50% cleavage at 1 µM and above).,"Ligand = 0.1, 1, 5, and 10 µM; AS0 = 100 nM; RNA = 100 nM ",1x RNase H Reaction Buffer (New England BioLabs),Binding ,Competitive Binding,Anti-sense oligonucleotide mediated cleavage measured by polyacrylamide gel. 5'-32P Label on WT-SL I.,"Compared to untreated, and control ASO that binds a mutated SL I with base pairs, in absence and presence of 8",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,C,Mixture of Kinases,Affected seven kinases; average percent inhibition = 14 ± 3%; CAMK4 most inhibited,Ligand = 20 µM,NR,Off-Target Effect,Kinase Selectivity Profiling Assay,Luminescence readout. Timepoints of 24 and 72 hours. 22 kinases were studied.,Compared to staurosporine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0151,,O=C(NC1=CC=C(C=C1)C1=[NH+]CCN1)C1=CC(=CC(=C1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1)C(=O)NC1=CC=C(C=C1)C1=[NH+]CCN1,Compound 8,10.1016/j.chempr.2018.08.003,,Mixture of RNAs,5'UUA3'/3'A_U5' (Zobs = 13.6; Fitness score = 100); 5'GAU3'/3'C_A5' (Zobs = 11.8; Fitness score = 87); 5'GCU3'/3'C_A5' (Zobs = 10.8; Fitness score = 79); 5'UUA3'/3'A_U5' (Zobs = 9.5; Fitness score = 70); 5'UCUAU3'/3'ACCA5' ( Zobs = 6.1; Fitness Score = 45),Ligand = 2 mM,NR,RNA Abundance,RNAseq,"2 mM compound spotted onto the microarray surface. RNA sequences enriched for binding from microarray screen and analyzed via HiT-StARTS. The frequency of occurrence of a selected RNA in RNA-seq data was compared with the frequency of occurrence of the same RNA in RNA-seq analysis of the starting RNA library which gave value for Zobs. A large, positive Zobs indicates a strong preference for binding the motif. A Fitness Score is assigned by normalizing the Zobs values to the most statistically significant small molecule-RNA interaction to 100. ",-,C,Huh-7.5 Cells,No toxicity at 10 µM,Ligand = 10 µM,Cytotoxicity,WST-1,-,Compared to cells treated with DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0152,,O=C(NC1=CC(=CC=C1)C1=[NH+]CCN1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)NC1=CC=CC(=C1)C1=[NH+]CCN1,Compound 10,10.1016/j.chempr.2018.08.003,,Mixture of RNAs,No preferential binding data shown,Ligand = 2mM; RNA = 0.125 pmol/µL; Competitor oligonucleotides = 0.125 nmol/µL,"Screening Buffer 1 (SB1): 8 mM Na2HPO4 (pH = 7.0), 185 mM NaCl, 0.1 mM EDTA, and 40 µg/mL BSA; Screening Buffer 2 (SB2): SB1 without BSA",Binding ,Microarray,"2 mM compound spotted onto the microarray surface. Radioactively labeled RNA was mixed with competitor oligonucleotides. Nucleic acids were mixed together in a total volume of 400 µL, and BSA was added to 40 µg/mL.  Spots that bound RNA were mechanically removed them from the surface. RNA was subjected to RT-qPCR for identity.",-,,SGR-Neo_Rluc-JFH1-2A replicon cells in Huh-7.5,IC50 = 19 ± 2 µM,"Ligand = 0, 2.5, 5, 10, 20 µM",Antiviral Activity,Luciferase,"HCV stable subgenomic replicon cells (SGR-Rluc-Neo-[NS3-5B]-JFH1-2a with luciferase reporter).  24 hr post cell plating, the compound of interest was added. After 72 hr,  luciferase activity was measured.","Compared to DMSO, Compound 9 (non-binder) and 2'-C-methyladenosine triphosphate",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0152,,O=C(NC1=CC(=CC=C1)C1=[NH+]CCN1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)NC1=CC=CC(=C1)C1=[NH+]CCN1,Compound 10,10.1016/j.chempr.2018.08.003,,HCV SL I and SL III (5'GUG3'/3'C_G5'),"Kd = 3,350 ± 770 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),C,Huh-7.5 Cells,No toxicity at 10 µM,Ligand = 10 µM,Cytotoxicity,WST-1,-,Compared to cells treated with DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0152,,O=C(NC1=CC(=CC=C1)C1=[NH+]CCN1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)NC1=CC=CC(=C1)C1=[NH+]CCN1,Compound 10,10.1016/j.chempr.2018.08.003,,HCV SL II (5'CUG3'/3'G_C5'),"Kd = 7,100 ± 4,200 nM",NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0152,,O=C(NC1=CC(=CC=C1)C1=[NH+]CCN1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)NC1=CC=CC(=C1)C1=[NH+]CCN1,Compound 10,10.1016/j.chempr.2018.08.003,,HCV SL I (5'UAG3'/3'A_C5'),Kd = 460 ± 140 nM,NR,"20 mM HEPES (pH = 7.5), 150 mM NaCl, 5 mM KCl, 40 mg/mL BSA, and 1 mM MgCl2",Binding ,Fluorescence-Based Titration (Labeled RNA) ,5'-fluorescein labeled RNA. Ligand was prepared in serial dilutions (1:2) for concentration range tested.,Compared to compound 9 (non-binder),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0152,,O=C(NC1=CC(=CC=C1)C1=[NH+]CCN1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)NC1=CC=CC(=C1)C1=[NH+]CCN1,Compound 10,10.1016/j.chempr.2018.08.003,C,Mixture of Kinases,No kinases were significantly inhibited,Ligand = 20 µM,NR,Off-Target Effect,Kinase Selectivity Profiling Assay,Luminescence readout. Timepoints of 24 and 72 hours. 22 kinases were studied.,Compared to staurosporine,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,Inhibited migration of MM231 cells,Ligand = 10 µM,Cell Migration,Wound Healing Assay,Scratch assay to determine migration capacity of MM231 cells after treatment with 10 ?M linifanib.,"DMSO, anti-miR-10b, anti-miR-scrambled",,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,"Significantly decreased migration and invasion by 50% and 75%, respectively",Ligand = 10 µM,Cell Migration,Matrigel-based Migration and Invasion assay,"In the cell motility assay, 100 ?L of serum-free media containing 50,000 cells (MM231) were seeded onto the insert with 8.0 ?m porous membrane well either coated with gelatin (for migration assay) or Matrigel matrix containing collagen and laminin (for invasion assay), and 500 ?L of media with serum was added to the bottom well. Cells were left to migrate or invade for 24 hrs. The cells that migrated or invaded to the bottom of the well were fixed, stained and counted. For each well, five different fields were counted and the average number of cells was determined (AutoCAD).",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,Significant alteration was observed,Ligand = 10 µM,Cell Morphology,Microscopy,Morphological analysis of MCF7 cell line were performed after 24 and 48 hrs of treatment with 10 ?M linifanib.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,Significant alteration was observed,Ligand = 10 µM,Cell Morphology,Microscopy,Morphological analysis of MM231 cell line were performed after 24 and 48 hrs of treatment with 10 ?M linifanib.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,Morphological alteration was observed,Ligand = 10 µM,Cell Morphology,Microscopy,Morphological analysis of HepG2 cell line were performed after 24 and 48 hrs of treatment with 10 ?M linifanib.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,IC50 = 33.3 µM (after 24 hr treatment) and 11.7 µM (after 48 hr treatment),-,Cell Viability,MTT,"10,000 MCF7 and T47D cells were plated the evening prior to treatment in 96 well microculture plates. After cells became adherent, five different doses of the drugs were added to the supernatant of newly added media. The optical density (OD) was read at 570 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,T47D Cells,IC50 = 18.9 µM (after 24 hr treatment) and 39.5 µM (after 48 hr treatment),-,Cell Viability,MTT,"10,000 MCF7 and T47D cells were plated the evening prior to treatment in 96 well microculture plates. After cells became adherent, five different doses of the drugs were added to the supernatant of newly added media. The optical density (OD) was read at 570 nm",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,"Significantly inhibited
the colony formation capability of MCF7",Ligand = 10 µM,Colony Formation,Stereomicroscope,"500 MCF7 cells were added to 6-well plate. 24 hrs later, 10 ?M DMSO or linifanib was added to each well. Two weeks later, colonies were fixed with 4% paraformaldehyde, stained with crystal violet and counted using a stereomicroscope.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,"Significantly inhibited
the colony formation capability of MCF7",Ligand = 10 µM,Colony Formation,Stereomicroscope,"500 MM231 cells were added to 6-well plate. 24 hrs later, 10 ?M DMSO or linifanib was added to each well. Two weeks later, colonies were fixed with 4% paraformaldehyde, stained with crystal violet and counted using a stereomicroscope.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,"Significantly inhibited
the colony formation capability of HepG2",Ligand = 10 µM,Colony Formation,Stereomicroscope,"500 HepG2 cells were added to 6-well plate. 24 hrs later, 10 ?M DMSO or linifanib was added to each well. Two weeks later, colonies were fixed with 4% paraformaldehyde, stained with crystal violet and counted using a stereomicroscope.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,"Maximum miR-10b inhibition at 10 µM, both after 24 hr and 48 hr treatment","Ligand = 0.1, 1, 10, 30 µM",Inhibitory Potency,Reporter,MCF7 cells were treated with these compounds and luciferase gene translation level was detected after 24 and 48 hrs.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,T47D Cells,"Maximum miR-10b inhibition at 10 µM, both after 24 hr and 48 hr treatment","Ligand = 0.1, 1, 10, 30 µM",Inhibitory Potency,Reporter,MCF7 cells were treated with these compounds and luciferase gene translation level was detected after 24 and 48 hrs.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,"Significant cell death at 3 days after treatment, and almost completely eliminated all cells following day 4",Ligand = 10 µM,Proliferation,BrdU Cell Proliferation Assay,"2000 MCF7 cells were seeded to 96-well plate. After 24 hrs, 10 ?M DMSO or linifanib was added to each well. The optical density (OD) was read at 450/550 nm on a microplate
spectrophotometer, after one to seven days of the treatment.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,"Significant cell death at 3 days after treatment, and almost completely eliminated all cells following day 4",Ligand = 10 µM,Proliferation,BrdU Cell Proliferation Assay,"2000 MM231 cells were seeded to 96-well plate. After 24 hrs, 10 ?M DMSO or linifanib was added to each well. The optical density (OD) was read at 450/550 nm on a microplate
spectrophotometer, after one to seven days of the treatment.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,"Significant cell death at 2 days after treatment, and almost completely eliminated all cells following day 3",Ligand = 10 µM,Proliferation,BrdU Cell Proliferation Assay,"2000 HepG2 cells were seeded to 96-well plate. After 24 hrs, 10 ?M DMSO or linifanib was added to each well. The optical density (OD) was read at 450/550 nm on a microplate
spectrophotometer, after one to seven days of the treatment.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,Expression level of Dicer and Drosha were not significantly changed; Expression level of miR-10b downstream targets PTEN and HOXD10 were decreased.,Ligand = 10 µM,Protein Abundance,Western Blot,"Expression levels of Dicer, Drosha, HOXD10 and PTEN after treatment with 10 ?M linifanib for 24 and 48 hrs in breast cancer cell lines.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,"Expression level of VEGFR and PDGFR decreased, but p-VEGFR and p-PDGFR increased. Expression level of HOXD10 and PTEN decreased.",Ligand = 10 µM,Protein Abundance,Western Blot,"Does-escalation experiment, Linifanib = 10 µM, pre-miR-10b = 0, 5, 20, 80 nM.",-,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,Expression level of p-VEGFR and p-PDGFR increase mediated by linifanib.,"Ligand = 0, 5, 10 and 15 µM",Protein Abundance,Western Blot,"Rescue experiments by transferring increasing doses of pre-miR-10b (0, 5, 20, 80 nM) and then treated HepG2 with increasing doses of linifanib (0, 5, 10, 15 ?M) for 24 hrs.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MDA-MB-468 (MM468) Cells,Decreased expression level of miR-10b,Ligand = 10 µM,RNA Abundance,RT-qPCR,MM468 cells were treated with these compounds and miRNA expression level was detected after 48 hrs.,Normalized to 0 hr-treated group,,Female Nu/Nu mice,miR-10b expression levels were significantly reduced in mice treated with linifanib or with anti-miR-10b when compared to vehicle or scrambled treated mice,"Oral, 12 mg/kg/day",RNA Abundance,Fluorescence In Situ Hybridization,In Situ hybridization of fixed tumor tissues.,"Vehicle, anti-miR-Scrambled and anti-miR-10b. U6 as internal control",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,Decreased expression level of miR-10b,Ligand = 10 µM,RNA Abundance,RT-qPCR,MCF7 cells were treated with these compounds and miR-10b expression level was detected after 48 hrs.,-,,Female Nu/Nu mice,"A significant decrease in total tumor bioluminescence, when compared to vehicle or scrambled control. Similar efficacy to anti-miR-10b.","Oral, 12 mg/kg/day",Tumor Burden,Bioluminescent Imaging,In vivo orthotopic grafting experiments were performed by injecting MM231- FG12-Luc cells in 30 ?L of saline solution containing 50% (v/v) of Reduce Growth Hormone Matrigel (BD Bioscience) into the left fourth mammary fat pad of female Nu/Nu mice. In vivo imaging of tumors was performed using a Xenogen IVIS 100 optical in vivo imaging system.,"Vehicle, anti-miR-Scrambled and anti-miR-10b",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,C,MCF7 Cells,"No decreased expression level observed for the following miRNAs: miR-9, ?10a, ?21, ?155, ?181a, and ?181b",Ligand = 10 µM,RNA Abundance,RT-qPCR,MCF7 cells were treated with these compounds and miRNA expression level was detected after 48 hrs.,Normalized to 0 hr-treated group,,Female Nu/Nu mice,"A significant decrease in total tumor size/volume, when compared to vehicle or scrambled control. Similar efficacy to anti-miR-10b.","Oral, 12 mg/kg/day",Tumor Burden,Tumor size,In vivo orthotopic grafting experiments were performed by injecting MM231- FG12-Luc cells in 30 ?L of saline solution containing 50% (v/v) of Reduce Growth Hormone Matrigel (BD Bioscience) into the left fourth mammary fat pad of female Nu/Nu mice.,"Vehicle, anti-miR-Scrambled and anti-miR-10b",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MDA-MB-231 (MM231) Cells,Decreased expression level of miR-10b,Ligand = 10 µM,RNA Abundance,RT-qPCR,MM231 cells were treated with these compounds and miRNA expression level was detected after 48 hrs.,Normalized to 0 hr-treated group,,Female Nu/Nu mice,"A significant decrease in total tumor weight, when compared to vehicle or scrambled control. Similar efficacy to anti-miR-10b.","Oral, 12 mg/kg/day",Tumor Burden,Tumor mass,In vivo orthotopic grafting experiments were performed by injecting MM231- FG12-Luc cells in 30 ?L of saline solution containing 50% (v/v) of Reduce Growth Hormone Matrigel (BD Bioscience) into the left fourth mammary fat pad of female Nu/Nu mice.,"Vehicle, anti-miR-Scrambled and anti-miR-10b",,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,T47D Cells,Decreased expression level of miR-10b,Ligand = 10 µM,RNA Abundance,RT-qPCR,T47D cells were treated with these compounds and miRNA expression level was detected after 48 hrs.,Normalized to 0 hr-treated group,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,reduced ~50% mature miR-10b expression ,Ligand = 10 µM,RNA Abundance,RT-qPCR,"the miR-10b was overexpressed >1000X over
normal levels when compared to the empty vector",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,HepG2 Cells,"Increased expression level of pri-miR-10b and pre-miR-10b, but decreased expression level of mature miR-10b",Ligand = 10 µM,RNA Abundance,RT-qPCR,Measured after treatment with 10 ?M linifanib for 24 hrs.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,"Increased expression level of pri-miR-10b and pre-miR-10b, but decreased expression level of mature miR-10b",Ligand = 10 µM,Transcriptional Activity,RT-qPCR,Measured after treatment with 10 ?M linifanib for 24 hrs in breast cancer cell lines.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MM231 Cells,"Increased expression level of pri-miR-10b and pre-miR-10b, but decreased expression level of mature miR-10b",Ligand = 10 µM,Transcriptional Activity,RT-qPCR,Measured after treatment with 10 ?M linifanib for 24 hrs in breast cancer cell lines.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,T47D Cells,"Increased expression level of pri-miR-10b and pre-miR-10b, but decreased expression level of mature miR-10b",Ligand = 10 µM,Transcriptional Activity,RT-qPCR,Measured after treatment with 10 ?M linifanib for 24 hrs in breast cancer cell lines.,DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
R-BIND (SM) 0153,,CC1=CC(NC(=O)NC2=CC=C(C=C2)C(C=C)=C2CN[NH+]=C2N)=C(F)C=C1,Linifanib,10.1038/s41598-018-30989-3,,,,,,,,,,,MCF7 Cells,Expression level of Dicer and Drosha were not significantly changed; Expression level of miR-10b downstream targets PTEN and HOXD10 were decreased.,Ligand = 10 µM,Translational Activity,Western Blot,"Expression levels of Dicer, Drosha, HOXD10 and PTEN after treatment with 10 ?M linifanib for 24 and 48 hrs in breast cancer cell lines.",DMSO,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
